



US 20150160201A1

(19) **United States**

(12) **Patent Application Publication**

**Kane et al.**

(10) **Pub. No.: US 2015/0160201 A1**

(43) **Pub. Date: Jun. 11, 2015**

(54) **COMPOSITIONS AND METHODS FOR  
DETECTING UNSTABLE  
ARTERIOSCLEROTIC PLAQUES**

(71) Applicant: **The Regents of the University of  
California, Oakland, CA (US)**

(72) Inventors: **John P. Kane, Hillsborough, CA (US);  
Robert J. Chalkley, San Francisco, CA  
(US); Olga Miroshnychenko, Palo Alto,  
CA (US)**

(21) Appl. No.: **14/391,153**

(22) PCT Filed: **Mar. 6, 2013**

(86) PCT No.: **PCT/US13/29276**

§ 371 (c)(1),

(2) Date: **Oct. 7, 2014**

**Related U.S. Application Data**

(60) Provisional application No. 61/635,645, filed on Apr. 19, 2012.

**Publication Classification**

(51) **Int. Cl.**  
**G01N 33/53** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **G01N 33/5308** (2013.01); **G01N 2800/323**  
(2013.01)

(57) **ABSTRACT**

The present disclosure provides methods of detecting an unstable arteriosclerotic plaque in an individual, involving detecting in a biological sample from the individual an enzymatic cleavage product of a protein component of an arteriosclerotic plaque. The present disclosure provides methods of assessing the risk that an individual will develop an occlusive vascular event. The present disclosure further provides kits for carrying out a subject method.

**Figure 1A***Homo sapiens*

Alpha-1 (I) collagen (1464 aa)

GenBank AAB94054

```
1 mfsfvdlrll lllaatalit hgqeegqveg qdedippitc vqnglryhdr dvwkpepcrri
61 cvcdngkvlc ddvicdetkn cpgaevepege ccpcvcpdgse sptdqettgv eggkgtgpr
121 gprgpagppg rdgipgqpgl pppppppppp gppglggnfa pqlsygydek stggisvpvgp
181 mgpsgprglp gppgapppqg fqgppgpege pgasgpmgpr gpppppgkng ddgeagkpgr
241 pgergppgpq garglpgtag lpgmkghrgf sgldgakgda gpagpkgepg spgengapgg
301 mgprglpger grpgagppag argndgatga agpppgtgpq gppgfpagvg akgeagppgg
361 rgsegpqqvr gepppppag aagpagnpqa dgqpgakgan gapgiagapg fpgargpsgp
421 qppggppgpk gnsgepgapg skgdtgakge pppvgvqgpp gpageegkrg argepggtgl
481 ppppgerggp gsrqfpgadg vagpkgpape rgspgpagpk gspgeagrpg eaglpgakgl
541 tgspspsgpd gktgppppag qdgrppppp pgargqagvm gfpgpkaag epkagergv
601 ppppgavgpa gkdgeagaqg ppppagpage rgeqgpagsp gfqglpmpag ppgeagkpge
661 qgvpgdlgap gpsgargerg fpgergvqgp pppagprgan gapgndgakg dagapgapgs
721 qgapglqgmp gergaaglpq pkgdrgdagp kgadgsppgd gvrqltgpig ppppagapgd
781 kgesqpsgpa gptgargapg drgeppppp agfagppgad gppgakgepg dagakgdagp
841 pppagpagpp gpignvgapg akgargsagp pgatgfpгаа grvpppppsg nagppppppp
901 agkeggkgr getgpagrp evppppppp agekgsppad gpagapgtpg pqliagqrgv
961 vglpqrger gfpplpmpg epkqppsga sgerppppm gppglagppg esgregapga
1021 egspgrdgs gkgdrgetg pagppgapga pppagppvpa gksgrgetg pagpagpvgp
1081 vgargpagp gprgdkgetg eqqdrqikgh rgfsglqgpp gppgspegg psgasppagp
1141 rgppgsagap gkdglnglpq pigpppprgr tgdagpvqpp gppppppppp ppsagfdfsf
```

**Figure 1B**

1201 lpqppqekah dggryyradd anvvrdrdle vdttlkslsq qienirspg srknpartcr  
1261 dlkmchsdwk sgeywidpnq gcnldaikvf cnmetgetcv yptqpsvaqk nwyisknpkd  
1321 krhvwfgesm tdgfqfeygg qgsdpadvai qltflrlmst easqnityhc knsvaymdqg  
1381 tgnlkkalll kgsneieira egnsrftysv tvdgctshg awgktvieyk ttktsrlpii  
1441 dvaplvdgap dqefgfdvgp vcfl (SEQ ID NO:1)

**Figure 2A***Homo sapiens*

Alpha-1 (II) collagen

GenBank AAC41772 (1487 aa)

```
1  mirlgapqsl vlltllvaav lrcqqgdvqe agscvqdgqr yndkdvwkpe pcricvcdtg
61  tvlcddiice dvkdclspei pfgeccpicp tdlatasgqp gpkqkgepg dikdivgpkq
121 pppgqqpage qgprqdrqdk gekgapgprg rdgepgtpgn pppppppppp gppglggnfa
181 aqmaggfdek aggaqlgvmq gpmgpmgprg ppppagapgp qgfqgnpgep gepgvsqpmg
241 prppppppgk pgddgeagkp gkagergppg pqgargfpgt pglpgvkghr gypgldgakg
301 eagapgvkge sgspgengsp gpmgprglpg ergrtgpaga agargndgqp gpagppgpvg
361 pagppgfpga pgakgeagpt gargpegaqg prgepgtpgs pppagasgnp gtdgipgakg
421 sagapgiaga pgfpgprgpp gppgatgplg pkqqtgepgi agfkgeqgpk gepgpapqgq
481 apgpapeegk rgargepggv gpigppgerg apgnrgfpgq dglagpkgap gergpsqlag
541 pkgangdpgr pgepglpgar gltgrpgdag pqgkvpsga pgedgrpppp gppgarqcpq
601 vmgfpqpkga ngepgkagek glpgapglrg lpgkdgetga agppgpagpa gergeqgapg
661 psgfqglpqp ppppgeggkp gdqgvpeag apglvgprge rgfpgergsp gaqglqgprg
721 lpgtptgdgp kgasgpagpp gaqppglqg mpgergaagi agpkdrgdv gekgpegapq
781 kdggrgltgp igppgpagan gekgevgppg pagsagarga pgergetgpp gpagfagppg
841 adgqpqakge qgeagqkda gapppqpsg apgpqgptgv tgpkgargaq gppgatgfpq
901 aagrvgppgs ngnppppppp gpsgkdqpk argdsppgr agepglqgpa gppgekgepg
961 ddgppgaegp pppqglagqr givglpqrq ergfpglppp sgepgkqgap gasgdrppp
1021 pvpppgltgp agepgregsp gadpppgrdg aagvkgdrge tgavgapgap gppgsppag
1081 ptgkqdrge agaqqpmgps gpagargiqg ppprgdkge agepgerglk ghrqftglqg
1141 lppppppsgd qgasgpagps gppppppvg psgkdgangi pppppppr grsgetgpag
```

**Figure 2B**

1201 ppgnpgppgp pggppgpidm safaglgpre kgpdplqymr adqaagglrq hdaevdatlk  
1261 slnnqiesir spegrknpa rtrcdklch pewksgdywi dpnqgctlda mkvfcnmetg  
1321 etcvypnpan vpknwssk skekhiwfg etinggfhs ygddnlapnt anvqmtflrl  
1381 lstegsqnit yhcnsiayl deaagnlkka lliqgsndve iraeqnsrft ytalkdgctk  
1441 htgkwgktvi eyrsqktsrl piidiapmdi ggpeqefgvd igpvcl (SEQ ID NO:2)

**Figure 3A***Homo sapiens*

Alpha-1(III) collagen (1466 aa)

GenBank AAL13167

```
1 mmsfvqkgs w lllallhpti ilaqqeaveg gcshlgqsy a drdvwkpepc qicvcdsgsv
61 ldddiicddq eldcpnpeip fgceccavcpq pptaptrppn gggpqqpkgd pggpgipgrn
121 gdpqipggpg spgspggpgi cescptgpqn yspqydsydv ksgvavggla gypgpagppg
181 pggppgtsgh pgspgspgyq gppgepgqag psppppppga igpsgpagkd gesgrpgrpg
241 erglpggpgi kgpagipgfp gmkghrgfdg rngekgetga pglkgenglp gengapgpmg
301 prgapgergr pglpgaagar gndgargsdg qpppppppgt agfpgpsgak gevvpagspg
361 sngapgqrge pppqghagaq gpppppging spggkgemgp agipgapglm gargppgpag
421 angapglrgg agepgkngak gepgprgerg eagipgvpga kgedgkdgsp gepganglp
481 aagergapgf rgpagpngip gekgpagerg apgpagprga agepgrdgvp gpgmrgmpg
541 spggpgsdgk ppppgsqges grpppppsg prgqpgvmgf ppgkngdgap gkngerggpg
601 gpppgppgk ngetgpqgpp gptgpggdkg dtgppppqgl qglpgtggpp gengkpgepg
661 pkgdagapga pggkgdagap gergppglag apglrggagp ppgggkkaa gppppgaag
721 tpglqgmpge rgglgspgpk gdkgepggpg adgvpkgdgp rgptgpigpp gpagqpgdkg
781 eggapglpgi agprgspger getgppgpag fpgapqng epgkgergap gekgeggppg
841 vagppggsgp agppgpqgvk gergspgpg aagfpgargl ppppgsngp gpppgsgspg
901 kdppppagn tgapgspgvs gpkgdagqpg ekgspgaagg pgapplgia gitgarglag
961 ppgmpgprgs pppqgvkges gkpganglsg ergppppqgl pglagtag egrdgnpgsdg
1021 lpgrdgspgg kgdrngesp gapgapghpg pppvpgpagk sdrngesgpa gpagapgpag
1081 srgapppgp rgdkgetger gaagikghrg fpngpgapgs ppgagqgai gspgpagprg
1141 pvqpsgppgk dgtsghppi gppgprnrg ergsegspgh ppppppppp gapgpccgsv
```

**Figure 3B**

1201 gaaaiagigg ekaggfapyy gdepmdfkin tdeimtslks vngqieslis pdgsrknpar  
1261 ncrdlkfchp elksgewvd pnqgckldai kvfcnmetge tcisanplnv prkhwwtdss  
1321 aekkhvwfge smdggfqsy gnpelpedvl dvqlaflrll ssrasqnity hcknsiaymd  
1381 qasgnvkkal klmgsnegef kaegnskfty tvledgctkh tgewsktvfe yrtrkavrlp  
1441 ivdiapydig gpdqefgvdv gpvcfl (SEQ ID NO:3)

**Figure 4A***Homo sapiens*

Alpha-1 (IV) collagen (1669 aa)

GenBank AAA53098

```
1  mgprlsvwll llpaalllhe ehsraaakgg cagsgcgkcd chgvkgqkge rglpglqgvi
61  gfpqmqgpeg pggppgqkqd tgepglpgtk gtrgppgasg ypgnpglpgi pgqdppppp
121  gipgcngtkg ergplgppgl pgfagnpppp glpkmkgdpg eilghvpgml lkgergfpgi
181  pgtppppglp glqgpvpppg ftgppppppp ppppgekqgm glsfqgpkgd kgdqgvsgpp
241  gvppqaqvqe kgdfatkgek gqkgepgfqg mpgvgekgep gkpgprgkpg kdqdkgekgs
301  pgfpgepgyp gligrqppqg ekgeagpppp pgivigtgpl gekgergypp tpgprgeppp
361  kgfpglpqgp gppglpvpgg agapgfper gekdrgfpg tslpgpsgrd glppppgspg
421  ppqqpvytng ivecqppppg dqpppgipqg pgfigeigek gqkgesclie didgyrgppg
481  pggppgeigf pgqpgakgdr glpgrdvag vpgpqtgpl igqpgakgep gefyfdlrk
541  gdkgdpgfpg qpgmpgrags pgrdghppl gpkgspsvg lkgergpppg vgfpgsrgdt
601  gpppppygyp agpigdkgqa gfpggpspg lpgpkgepgk ivplppppga eglpgspgfp
661  gpqgdrfpg tprpplpge kgavqppig fpggpppkgv dglpdmgpp gtpgrpgfng
721  lpnppgvqgk kgepgvplp lkgplpplgi pgtppgekgsi gvpvppgehg aigppglqgi
781  rgeppppglp gsvgspgvpv igppgargpp gggpppglsg ppvikgekgep pffppldmpg
841  pkgdkgaqgl pgitgqslp glpqqqgapg ipgfpgskge mgvmgtppgp gspgpgvapg
901  lpgekghgfh pgspprgdp glkgdkdvg lpgkpgsmdk vdmgsmkqk gdqgekqgig
961  pigekgsrgd pgtpgvpgkd gqagppgqpg pkgdpgisgt pgapglpgpk gsvggmglp
1021  tpgekgyvpi pppqgspglp gdkgakgekq qagppgigip glrgekqdqg iagfpgspge
1081  kgekgsigip gmpgspglk spgsvgypgs pglpgekgek glppldgipg vkgeaglpgt
1141  pgptgpagqk gepgsdgipg sagekgepgl pgrgfpfpg akgdkskge vgfpglagsp
```

**Figure 4B**

1201 gipgskgeqg fmgppgpqgq pglpgspgha tegpkgdrgp qgqpglpglp gpmgppglpg  
1261 idgvkgdkgn pgwpgapgvv gpkgdpgfqg mpigggspgi tgskgdmgpp gvpqfagpkg  
1321 lpqlqgikgd qgdqgvpgak glpgpppppg pydiikgepg lpgpegppgl kglqglpgpk  
1381 gqqgvtglvg ipgppgipgf dgapqkqgem gpagptgprg fpqppgpdgl pgsmpgpgtp  
1441 svdhgflvtr hsqtidpqc psgtkilyhg ysllvqgne rahgqdlgta gsclrkfstm  
1501 pflfcninnv cnfasrndys ywlstpepmp msmapiitgen irpfisrcav ceapamvmav  
1561 hsqtiqippc psgwsslwig ysfvmhtsag aegsgqalas pgsccleefrs apfiechgrg  
1621 tcnyyanays fwlatierse mfkktptstl kagelrthvs rcqvcmrtr (SEQ ID NO:4)

**Figure 5***Homo sapiens*

Alpha-1 (VI) collagen (1028 aa)

GenBank NP\_001839

1 mraarallpl llqacwtaa q depetprava fqdcpvdlff vldtsesval rlkpygalvd  
61 kvksftrkfi dnldr dryrc drnlvwnaga lhysdeveii qgltrmpggr dalkssvdav  
121 kyfgkgtytd caikkgleql lvggshlken kylivvtdgh plegykepcg gledavneak  
181 hlgvkvfsva itpdhleprl siiatdhtyr rnftaadwgq srdaeeaisq tidtivdmik  
241 nnveqvccsf ecqpargppg lrgdpgfege rgkpglpgek geagdpgrpg dlgpvgyqgm  
301 kgekgsrgek gsrpgkgykg ekkgkrgidgv dgvgkemgyp glpgckgspg fdgiqgpppg  
361 kgdpgafglk gekgepgadg eagrpgssgp sgdegqpgep gppgekgeag degnpgpdga  
421 pgerggpger gprgtpgtrg prgdpgeagg qgdggregpv gvpgdpgeag pigpkgyrgd  
481 egppgsegar gapgpagppg dpglmgerge dgpagngteg fpgfpgypgn rgapgingtk  
541 gypglkgdeg eagdpddnn diaprgvka kgyrgpeppg gppghqppg pdeceildii  
601 mkmcscceck cgpidlflvl dsessiglqn feiakdfvfk vidrlsrdel vkfepggsya  
661 gvvqyshsqm gehvslrps irnvqelkea ikslqwmagg tftgealqyt rdqllppspn  
721 nrrialvitdg rsdtqrtdtp lnvlcspgiq vsvgikdvf dfipgsdqln viscqqlaps  
781 qgrpglslvk enyaelleda flknvtaqic idkkcpdytc pitfsspadi tilldgsasv  
841 gshnfdttkr fakrlaerfl tagrtdpahd vrvavvqysg tgqqrperas lqflqnytal  
901 asavdamdfi ndatdvndal gyvtrfyrea ssgaakrll lfsdgnscga tpaaiekavq  
961 eaqrageief vvvvgrgvne phirvlvtgk taeydvayge shlfrvpsyq allrgvfhqt  
1021 vsrkvalg (SEQ ID NO:5)

**Figure 6A***Homo sapiens*

Alpha-3 (VI) collagen (3177 aa)

GenBank NP\_04360

```
1 mrkhrhlpv avfcflfsgf ptthaqqqa dvkngaaadi iflvdsswti geehfqlvre
61 flydvvksla vgendfhfal vqfngnphte flntyrtkq evlshisnms yiggtnqtgk
121 gleyimqshl tkaagsragd gvpqvivvlt dgshkdglal psaelksadv nvfaigveda
181 degalkeias eplnmhmfnl enftslhdiv gnlvscvhss vsperagde tlkditaqds
241 adiiiflidgs nntgsvnfav ildflvnlle klpigtqqir vgvvqfsdep rtmfslدتys
301 tkaqvlgvak algfaggela niglaldfvv enhftraggs rveegvpqvl vlisagpssd
361 eirygvvalk qasvfsfglg aqaasraelq hiatddnlvf tvpefrsfgd lqekllpyiv
421 gvaqrhivlk pptivtqvie vnkrdivflv dgssalglan fnairdfiak viqrleigqd
481 liqvavaqya dtvrpefyfn thptkrevit avrkmkpldg salytsald fvrnnlftss
541 agyraaegip kllvlitggk sldeisqpaq elkrssimaf aignkgadqa eleeiafdss
601 lvfipaefra aplqgmipgl laplrtilsgt pevhsnkrdi iflldgsanv gktnfpyvrd
661 fvmnlvnsld igndnirvgl vqfsdtpvte fslntyqtks dilghlrqlq lqggsglntg
721 salsyvyanh fteaggsrir ehvpqlllll tagqsedsyl qaanaltrag iltfcvgasq
781 ankaeleqia fnpslvylmd dfsslpalpq qliqpltttyv sggveevpla qpeskrdilf
841 lfdgsanlvq qfpvvrdfly kiidelnvkp egtriavaqy sddvkvesrf dehqskpeil
901 nlvkrmkikt gkalnlgyal dyaqryifvk sagsriedgv lqflvllvag rssdrvdgpa
961 snlkqsgvvp fifqaknadp aeelqivlsp afileaeslp kigdlhpqiv nllksvhnga
1021 papvsgekdv vflldgsegv rsgfpllkef vqrvvesldv gqdrvravv qysdrtrpef
1081 ylnsymnkqd vvnavrqltl lggptpntga alefvlnil vssagsrite gvpqllivlt
1141 adrsgddvrn psvvvkrnga vpigigigna ditemqtisf ipdfavaipt frqlgtvqqv
```

**Figure 6B**

1201 iservtqltr eelsrlqpvl qplpspgvgg krdvvflidg sqsagpefqy vrtlierlvd  
1261 yldvgfdttr vaviqfsddp kvefllnabs skdevqnavq rlrpkggrqi nvgnaleys  
1321 rnifkrplgs rieegvpqfl vliissgksdd evddpavelk qfgvapftia rnadqeelvk  
1381 islspeyvfs vstfrelpsl eqklltpitt ltseqiqkll astrypppav esdaadivfl  
1441 idssegvrpd gfahirdfvs rivrrlnigp skvrvgvvqf sndvfpefyl ktyrsqapvl  
1501 dairrlrlrg gsplntgkal efvarnlfvk sagsriedgv pqhlvlvlvgg ksqddvsrfa  
1561 qvirssgivs lvggdrnidr telqtitndp rlvftvrefr elpnieerim nsfgpsaatp  
1621 appgvdtppp srpekkkadi vflldgsinf rrdsfqevlr fvseivdtyv edgdsiqvgl  
1681 vqynsdptde fflkdfstkr qiidainkvv ykggrhantk vglehrlvnh fvpeagsrld  
1741 qrvpqiafvi tggksvedaq dvslaltqrg vkvfavgvrn idseevgkia snsatafrvg  
1801 nvqelselse qvletlhdam hetlcpgvtd aakacnldvi lgfdgsrdqn vfvaqkgfes  
1861 kvdailnris qmhrvscsgg rsptvrsvv antpsgpvea fdfdeyqpem lekfrnmrsq  
1921 hpyvltedtl kvylnkfrqs spdsvkvvih ftdgadgda dlhrasenlr qegvralilv  
1981 glervvnlr lmhlefggrgf mydrplrlnl ldldyelaeg ldniaekacc gvpckcsgqr  
2041 gdrgpigsig pkgipgedgy rgyppgedgpp gergppgvng tqgfqgcpqg rgvkgsgf  
2101 gekgevgeig ldgldgedgd kglpgssgek gnpgrrgdkg prgekgergd vgirgdpgnp  
2161 gqdsqergpk getgdlgpmg vpgrdgvpvg pgetgknggf grrgppgakg nkggppgppf  
2221 egeqgtrgaq gpapagppg ligeqgisgp rgsggaagap gergrtgplg rkgepgepp  
2281 kggignrgpr getgddgrdg vgsegrrgkk gergfpgypp pkgnpgepgl ngttgpkgir  
2341 grrngsppg ivgqkgdpgy ppagpkgnr gdsidqcali qsikdkcpc ygplecpvfp  
2401 telafaldts egvnqdtfgr mrdvvlsvn dltiaesncp rgarvavvty nnevtteirf  
2461 adskrksvll dkiknlqval tskqqsleta msfvarntfk rvrngflmrk vavffsntpt

**Figure 6C**

2521 raspqlreav lklsdagitp lfltrqedrq linalqinnt avghalvlpa grdltdflen  
2581 vltchvcldi cnidpscgh swrpsfrdr aagsdvdidm afildsaett tlfqfnemkk  
2641 yiaylvqrld mspdpkasqh farvavvqha psesvdnasm ppvkvefslt dygskeklvd  
2701 flsrgmtqlq gtralgsaie ytienvfesa pnprdlkivv lmltgevpeg qleeaqrvil  
2761 qakckgyffv vlgigrkvni keyytfasep ndvffklvdk stelneepm rfgrollpsfv  
2821 ssenafylsp dirkqcdwfq gdqptknlvk fghkqvnvnp nvtssptsnp vtttkpvttt  
2881 kpvttttkpv ttttkpvtii nqpsvkpaaa kpapakpvaa kpvatkmatv rppvavkpat  
2941 aakpvaakpa avrppaaaaa kpvatkpevp rpqaakpaat kpattkpmvk msrevqvfei  
3001 tensaklhwe raepgpyfy dltvtsahdq slvlkqnlvt tdrviglla gqtyhvavvc  
3061 ylrsvraty hgsfstkksq pppqparsa ssstinlmvs teplaltetd icklpkdegt  
3121 crdfilkwy dntkscarf wyggcggnen kfgsqkecek vcapvlakpg visvmgt (SEQ  
ID NO:6)

**Figure 7A**

*Homo sapiens*  
Alpha-1 (XII) collagen (3063 aa)  
GenBank CAl19898

```
1 mrsrlppala algaalllss ieaevdppsd lnfkiident vhmwakpvd pivgyritvd
61 ptt dgptkef tlasattetl lselpetey vvtitsydev eesvpvigql tiqtgsstkp
121 vekkpgktei qkcsvsawtd lvflvdgsws vgrnnfkyil dfiaalvsaf digeektrvg
181 vvqyssdtrt efnlnqyyqr dellaaikki pykkgntmtg daidylvknf ftesagarvg
241 fpkvaiiitd gksqdeveip arelrnvge vflslgikaad akelkqiasf pslnhvfna
301 nfdaivdign eiisqvcsgv deqlgelvsg eevveppsnl iamevsskyv klnwnpsspsp
361 vtgykviltp mtagrqhal svqpqtntl vrdlsadtey qisvsamkqm tssepisime
421 ktqpmkvqve csrgvdikad ivflvdgsws igianfvkvr aflevlvksf eisprnvqis
481 lvqysrdpht eftlkkftkv ediieaintf pyrggstntg kamtyvreki fvpskgsrsn
541 vpkvmilitd gkssdafrdp aiklrnsdve ifavgvkdv rseleaiasp paethvftve
601 dfdafqrisf eltqsiclr ieqelaaikk ayvppkdlf sevtsygfkt nwspagenvf
661 syhitykeaa gddevtvvpe asstsvlss lkpetlylvn vtaeyedgfs iplageette
721 evkgaprnlk vtdettdsfk itwtqapgrv lryriiyrpv aggesrevtt ppnqrrtle
781 nlipdkyev svipeyfsqp gtpltgnaat eevrgnprdl rvsdpttstm klswsgapgk
841 vkqylvtytp vaggetqevt vrgdtntvl qglkegtqya lsvtalyasg agdalfgegt
901 tleergspqd lvtkditdts igaywtsapg mvrqyrvswk slyddvdtge knlpedaiht
961 mienlqpetk yrisvfatys sgegepltgd attelsqdsf tlkvdeeten tmrvtwkppap
1021 gkvvnrvvy rphgrgkqmv akvpptvtst vlkrlqpqt yditvlpik mgegklrqs
1081 gttasrfksp rnlktsdptm ssfrvtwepa pgevkykvt fhptgddrrl gelvvgpydn
1141 tvvleelrag ttykvvfgm fdggessplv qgemttlsdt tvmpilssgm ecltraeadi
```

**Figure 7B**

1201 vllvdgswsi granfrtvrs fisrivevfd igpkrvqial aqysgdprte wqlnahrddk  
1261 sllqavanlp ykgnntltgm alnfirqqnf rtqagmrpra rkigvlitdg ksqddveaps  
1321 kklkdegvel faigiknade velkmiatdp ddthaynvad feslsrivdd ltinlcnsvk  
1381 gpgdleapn lviserthrs frvswtppsd svdrykveyy pvsggkrqef yvsrmetstv  
1441 lkdlkpetey vvnvysvved eyseplkgte ktlpvvsvsl niydvqpttm hvqwqpvvga  
1501 tgyilsykp v kdteptrpke vrlgotvndm qltdlvpnte yavtvqavlh dltsepvtvr  
1561 evtlplprpq dlklrdvths tmrvfwepvp gkvrkyivry ktpeedvkev evdrsetsts  
1621 lkdlfsqtly tvsvsavhde gesppvtaqe ttrpvpaptn lkitevtseg frgtwdhgas  
1681 dvslyritwa pfgssdkmet ilngdentlv fenlnpntiy evsitaiypd esesddligs  
1741 ertlpilittq apksgprnlq vynatsnslt vkwdpasgrv qkyrityqps tgegneqttt  
1801 iggrqnsvgl qklkpdtpyt itvsslypdg eggrmtgrgk tkplntvrnl rvydpststl  
1861 nvrwdhaegn prqyklfyap aaggpeelvp ipgnntnyail rnlqpdtsyt vtvpvyteg  
1921 dggrrtsdtgr tlmrglarnv qvynptpnl dvrwdpapgp vlqyrvvysp vdgtprsesi  
1981 vvpgntrmvh lerlipdtly svnlvalysd gegnpspaqg rtlprsgprn lrvfgettns  
2041 lsvawdhadg pvqyriiys ptvgdpidey ttvpgrnnv ilqplqpdtp ykitviavye  
2101 dgdgghltgn grtvglppq nihisdewyt rfrvswdpsp spvlgykivy kpvgsnepme  
2161 afvgemtsyt lhnlnpstty dvnvyaqyds glsvpltdqg ttlylnvtdl ktyqigwdf  
2221 cvkwsphraa tsyrlklspa dgtrgqeitv rgsetshcft glspdtdygv tvfvqtpnle  
2281 gpgvsvkeht tvkpteapte pptpppppti ppardvckga kadivflda swsigddfn  
2341 kvvkfifntv ggfdeispag iqvsfvqysd evksefklnt yndkalalga lqniryrggn  
2401 trtgkaltfi kekvlwesg mrknvpkvlv vvtmgrsqde vkkaalviqq sgfsfvvvgv  
2461 advdynelan iaskpserhv fivddfesfe kiednlitfv cetatsscpl iyldgytspg

**Figure 7C**

2521 fkmleaynlt eknfasvqgv slesgsfpsy sayriqknaf vnqptadlhp nglppsytii  
2581 llfrllpetp sdpfaiwqit drdykpqvgv iadpssktlS ffnkdtgrgev qvtvfdteev  
2641 ktlfygsfhk vhivvtsksv kiyidcyeei ekdikeagni ttdgyeilgk llkgerksaa  
2701 fqiqsfdivc spvwtsrdrc cdipsrrdeg kcpafpnsct ctqdsvgppg ppppagppga  
2761 kgprgergis gaigppgprg digppgpqgp pppqgpngls ipgecgrqgm kgdagepglp  
2821 grtgtpglpg pppgmppgd rgftgkdgam gprppppppg spgspgvtgp sgkpgkpgdh  
2881 grpppsglkg ekgdrgdias qnmravarq vceqlisqgm nrfngmlnqi pndyqssrnq  
2941 pppppppppp gsagargepg pggprgfpgt pgmqpppger glpgekgerg tgssgprglp  
3001 gppppqgesr tgppgstgsr gpppppgrpg nsgirppppg pgycdssqca sipyngqgyp  
3061 gsg (SEQ ID NO:7)

**Figure 8A**

*Homo sapiens*

Alpha-1 (XIV) collagen (1796 aa)

GenBank AAI40894

1 mkifqrkmry wllppflaiv yfctivqgqv apptrlrynv ishdsiqisw kaprgkfggy  
61 kllvtptsgg ktnqlnlqnt atkaiiqglm pdqnytvqii aynkdkeskp aqqqfrikdl  
121 ekrkdpkprv kvvdrngsr psspeevkfv cqtpaiadiv ilvdgswsig rfnfrlvrhf  
181 lenlvtafdv gsektrigla qysgdpriew hlnafstkde vieavrnlpv kggntltgla  
241 lnyifensfk peagsrtgvs kigilitdgk sqddiippsr nlresgvelf aigvknadvn  
301 elqeiasepd sthvynvaef dlmhtvvesl trtlcsrvee qdreikasah aitgppteli  
361 tsevtarsfm vnwthapgnv ekyrvvyvpt rggkpdevvv dgtvsstvlk nlmslteyqi  
421 avfaiyahta seglrgtett lalpmasdll lydvtensmr vkwdavpgas gylilyaplt  
481 eglagdekem kigethtdie lsgllpntey tvtyamfge easdpvtgqe ttlalspprn  
541 lrismvgsns arltwdptsr qingyriyvyn nadgteinev evdpittfpl kgltplteyt  
601 iaifsiydeg qsepltgvtft teevpaqqyl eidevttdsf rvtwhplsad eglhklmwip  
661 vyggkteevv lkeeqdshvi eglepgteye vsllavlddg sesevvtavg ttldsfwtep  
721 attivpttsv tsvfqtgirn lvvgdettss lrvkwdisds dvqqfrvtym taqgdpeeev  
781 igtvmvpgsq nllllkpllp dteykvvtp iytdgegvsv sapgktpss gpqnlrvsee  
841 wynrlritwd ppsspvkgyr ivykpvsyvp ptletfvgad intilitnll sgmdynvkif  
901 asqasgfsda ltgmvktlfl gvtnlqakhv emtslcahwq vhrhatayrv vieslqdrqk  
961 qestvgggtt rhcfyglqpd seykisvytk lqeiegpsvs imektqslpt rpptfpptip  
1021 pakevckaak adlvfmdvgs wsigdenfnk iisflystvg alnkigtdgt qvamvqftdd  
1081 prtefklnay ktketlldai khisykggnt ktgkaikyvr dtlftaesgt rrgipkvivv  
1141 itdgrsqddv nkisremqld gysifaigva dadyselvs i gskpsarhvf fvdddfafkk

**Figure 8B**

1201 iedelitfvc etasatcpvv hkdgidlagf kmmemfglve kdfssvegvs mepgtfnvfp  
1261 cyqlhkdalv sqptrylhpe glpsdytisf lfrilpdtpg epfalweiln knsdplvgvi  
1321 ldnggkltly fnydqsgdfq tvtfegpeir kifygshfkl hivvsetlvk vvidckqvge  
1381 kamnasanit sdqvevlgkm vrsrgpggns apfqqlmfdi vcstswantd kccelpglrd  
1441 descpdlphs cscsetneva lgpagppgqp glrgpkqqqg epgpkgpdgp rgeiglpqpq  
1501 gppgpqgpgs lsiqgmpgmp gekgekgtg lpgpqqipgg vgsppgrdgsq gqrglpqkdq  
1561 ssgppppppp igipgtpgvp gitgsmgpgg algppgvpga kgergergdl qsqamvrsva  
1621 rqvceqliqs hmarytailn qipshsssir tvqpppgepg rpgspgapge qpppgtppfp  
1681 gnagvpgtpg ergltgikge kgnpgvgtqg prgppgpapq sgesrpgspg ppgspgprgp  
1741 pghlgvppqg qpsgqpgygd psscsaygvr aphpdqpeft pvqdeleame lwgpgv (SEQ  
ID NO:8)

**Figure 9A**

*Homo sapiens*  
 Alpha-1 (XV) collagen (1388 aa)  
 GenBank CAI17044

```

1  maprrnngqc wcllmlsvs tplpavtqtr gatetasqgh ldltqligvp lpssvsfvvtg
61  yggfpaysfg pganvgrpar tlipstffrd faisvvvkps strggvlfai tdafqkviyl
121 glrlsgvedg hqriillyte pgshvsqea afsvpmthr wnrfamivqg eevtllvnce
181 ehsripfqr sqalafessa gifmgngat glerftgslq qltvhpdprt peelcdpees
241 sasgetsglq eadgvaeile avtytqaspk eakvepintp ptpsspfedm elsgepvpeg
301 tlettmsii qhsspkqsg eilndtleqv hsvdgdpitd sgsagafld iaeknlaat
361 aaglaevpis tageaeassv ptggptlms tenpeegvtp gpdneerlaa taageaeala
421 smpgeveasg vaggeldism saqslgeeat vgpssedsit taaaatevsl stfedeeasg
481 vptdglaplt atmaperavt sgggdeedla aatteplit aggeesgspp pdgpplplpt
541 vaperwitpa qrehvgmkqg agpkgekda geelpgpppep sgpvptaga eaegsglgwg
601 sdvsgsgdvl vgseqlrqp pggppppglp gipgkpgtdv fmgppgspe dgpagegppp
661 gpegqpgvdg atglpgmkge kgargpngsv gekgdpgnrg lpgppgkkg agppgvmgppp
721 gppppppppg pgctmglgfe dtegsstql lnepklsrpt aaiglkgek drgpkgergm
781 dqasivgppg prgppghikv lsnslinith gfmnfsdipe lvppppgdgl pglpgfpgpr
841 gpkgdglpg fpglkgeqge kgepgailte diplerlmgk kgepgmhgap gpmgkpppg
901 hkgefglpgr pgrpglnglk gtkgdpgvim qpppglpopp gpppppgavi nikgaifpip
961 vrphckmpvd tahpgspeli tfhgkgek swglpgskge kgdqgaqppp gppldlaylr
1021 hflnnlkgen gdkgfkgek ekgdingsfl msgppglpgn pppagqkget vvgppppga
1081 pglppppfg rpgdppppp pppppppail gaavalpppp gppgppglpg srnlvtafsn
1141 mddmlqkahl viegtfiyrl dsteffirvr dgwklqlge lipipadspp ppalssnphq
    
```

**Figure 9B**

1201 llppppnpiiss anyekpalhl aalnmpfsgd iradfqcfcq araagllsty rafllsshlqd  
1261 lstivrkaer yslpivnlkg qvlfnnwdsi fsghggqfnm hipiysfdgr dimtdpswpq  
1321 kviwhgssph gvrlvdnyce awrtadtavt glasplstgk ildqkaysca nrlivlcien  
1381 sfmtdark (SEQ ID NO:9)

**Figure 10A***Homo sapiens*

Alpha-1 (XVIII) collagen (1751 aa)

GenBank NP\_569711

```
1 mapypcgchi llllfcclaa aranllnlw lwfnnedtsh aattipepgg plpvqptadt
61 tthvtprngs tepatapgsp eppselledg qdtptsaes dapeeniagv gaeilnvakg
121 irsfvqlwnd tvpteslara etlvletpvg plalagspst pqengttlwp srgipsspga
181 htteagtlpa ptpsppslgr pwapltgpsv pppssgrasl sllggappw gslqdpdsqg
241 lspaaaapsq qlqrpdvrlr tpllhlplvmg slgkhaapsa fssglpgals qvavttltrd
301 sgawvshvan svpgplanns allgadpeap agrclplpps lpvcghlgis rfwlphnlhh
361 esgeqvrage rawggllqth chpflawffc lllvppcgsv pppappppccq fcealqdacw
421 srlgggrlpv acaslptqed gycvligpaa eriseevgll qlldgppppq vtqtddpdvg
481 layvfqpdan sgqvaryhfp slffrdfsll fhirpategp gvlfaitdsa qamvllgvkl
541 sgvqdgghqdi sillytepgag qthtaasfrl pafvqgwithl alsvaggfva lyvdceefqr
601 mplarssrgl elepgaglfv aqaggadpdk fggviaelkv rrdpqvspmh cldeegddsd
661 gasgdsqsgl gdarellree tgaalkprlp apppvttppl aggsstedsr seeveeqttv
721 aslgaqtlpg sdsvstwdgs vrtpggrvke gglkgqkgep gvpqppgrag ppgspclpgp
781 pglpcpvsppl gpagpalqtv pppqpppppp grdgtpprdg epqdpgedgk pgdtpqgqfp
841 gtpgdvgpkg dkgdpgvger gppqpppppp ppgpsfrhdk ltfidmegsg fggdleadrg
901 prgfpqpppp pgvpglpgep grfgvnssdv ppgaglpqvp gregppgfpq lpgppppppgr
961 egppprtqgk gslgeagapq hkgskgappq agargesgla gapgpagppq pppppppppq
1021 glpagfddme gsggpfwsta rsadgpqppp glpqlkgdpg vpglpqakge vgadgvpqfp
1081 glpgregiag pqqpkdrgs rgekdpqkd gvgqpglpq pppqppvvyv seqdgsvlsv
1141 pgpegrpgfa gfpqpagpkq nlgskgers pppkgekgep gsifspdggg lgpqkqkqk
```

**Figure 10B**

1201 epgrfrgppgp ygrpgykgei gfpgrpgrpg mnglkgekge pgdaslgfgm rgmpgppppp  
1261 gpppppgtpv ydsnvfaess rpgppglpgn qppppkgak gevppppppg qfpfdflqle  
1321 aemkgekqdr gdagqkgerg epggggffgs slpppppppg prgyppgippg kgesirgppg  
1381 pppqgppgi gyegrqppg pppppppsf pgphrtisv pppppppppp gppgtmgass  
1441 gvrlwatrqa mlgqvhevpe gwlfvaeqe elyvrvqngf rkvqleartp lprgtdneva  
1501 alqppvvqlh dsnpyprrh phptarpwra ddilaspprl pepqypgap hhssyvhlrp  
1561 arptspahs hrdfqpvhlh valnsplsgg mrgirgadfq cfqcaravgl agtfracflss  
1621 rlqdlvisvr radraavpiv nkdelifps wealfsgseg plkpgarifs fdgkdvlrhp  
1681 twpcksvwhg sdpngrrlte sycetwrtea psatgqassl lggrllgqsa aschhayivl  
1741 ciensfmas k (SEQ ID NO:10)

**Figure 11**

*Homo sapiens*  
Alpha-1 (XIX) collagen (1142 aa)  
GenBank CA142716

```
1 mrltgpwklw lwmsifllpa stsvtvrckt eescpilrie ghqltydnin klevsgfdlg
61 dsfslrrafc esdkctcklg sallirdtik ifpklpeey svaamfrvrr nakkerwflw
121 qvlnqqnipq isivvdggkk vvefmfgate gdvlnyifrn relrplfdrq whklgisigs
181 qvislymdcn liarrqtdek dtvdfhgtrv iatrasdgkp vdielhqlki ycsanliaqe
241 tceeisdtkc peqdgfgnia sswvtahask mssylpakqe lkdqcqcipn kgeaglpgap
301 gspgqkghkg epgenglhga pgfpgqkgeq gfegskgetg ekgeqqekgd palaglngen
361 glkgdlgphg ppgpkgekgd tgppgppalp gslgiqqpgg ppgkegqrgr rgktgppgkp
421 gppppppppg iqgihqtlgg yynkdnkndr eheagglkgd kgetglpgfp gsvgpkqkqg
481 epgepftkge kgdrgepgvi gsqgvkgepg dpgpppligs pglkgqqgsa gsmgprgppg
541 dvglpgeghi pgkqgikgek gdpggiigpp glpgpkgeag ppgkslpgep gldgnpgapg
601 prgpkgergl pgvhgspgdi gpggigipgr tgaqgpapep giqgprglpg lpgtptpgn
661 dgvpgrdgkp glpgppgdpi alpllgdiga llknfcgncq asvpglksnk geeggagepg
721 kydsmarkgd igprgppgip gregpkgskg ergyppipge kgdeglqgip gipgapgptg
781 ppglmgrtgh pgptgakgek gsdgppgkpg pppppgipfn erngmsslyk ikggvnpvpsy
841 pppppppgpk gdpgpvgepg amglpglegf pgvkdrqpa gppgiagmsg kpgapppgv
901 pgepgergpv gdigfpgpeg psgkpgingk dgipgaqgim gkpgdrpkg ergdqgipgd
961 rgsqgergkp gltgmkgaig pmgppgnkgs mgspghqgpp gspgipgipa davsfeeikk
1021 yinqevlrif eermavflsq lklpaamlaa qaygrpppg kdglpppgd pppqgyrgqk
1081 gergepgigl pgspglppts alglpgsppa pppqpppps grcnpedcly pvshahqrtg
1141 gn (SEQ ID NO:11)
```

**Figure 12A**

*Homo sapiens*

Alpha-2 (I) collagen (1366 aa)

GenBank NP\_000080

```
1 mlsfvdtrtl lllavtlcla tcqslqeetv rkqpagdrqp rgergppgpp grdgedgptg
61 pppppppppp pglggnfaaq ydgkgvlgp gpmgmgprg ppgaagapgp qgfqgpapep
121 gepgqtgpag argpagppgk agedghpgkp grpgergvvg pqgargfpgt pglpgfkgir
181 ghnldgldkg qpgapgvkge pgapgenstp gqtgarglpq ergrvgapgp agargsdgsv
241 gpvpgapigp sagppgfpga pppkgeigav gnagpagpag prgevglpql sqpvpppnp
301 gangltgakg aaglpgvaga pglpgprgip gpvgaagatg arglvgeppp agskgesgnk
361 gepgsagppg ppppsgeegk rgngeagsa gpppppplrg spgsrglpqa dgragvmgpp
421 gsrqasgpag vrgpndagr pgepglmgpr glpgspgnig pagkegpvql ppidgrpppi
481 gpagargepg nigfpgkqp tgdpqkngdk ghaglagarg apgpdgnnga qppppppgvq
541 ggkgeqppp ppgfqglpqp sqpagevgkp gerghhgefz lpgpagprge rpppgeesaa
601 gptgpiqsrp psgppppdgn kgepgvvgav gtagpsgppg lpgergaagi pggkgekgep
661 glrgeignp rdgargapga vgapppagat gdrgeagaag pagpagprgs pgergevgpa
721 gpngfagpag aagppgakge rgakgpkgen gvvgtgppv aagpagppngl pppagsrgdg
781 gppgmtgfpq aagrtgppgp sgisgppgpp gpagkeglrg prgdqppvgr tgevavgppp
841 gfagekqpsg eagtagppgt pppqllgap gilglpqsrg erglpgvaga vgepgplgia
901 gppgargppg avgsppvnga pgeagrdgnp gndgppgrdg qpghkgergy pgnigpvvaa
961 gapgphgppv pagkhgnrge tgpsgpvqpa gavpprgpsg pqgirdkge pgekpprglp
1021 glkghnglqg lpgiaghhgd qgapgsvqpa gprgpagpsg pagkdgrtgh pgtvppagir
1081 gpqghqgpag pppppppppp pgvsggydf gydgdgyrad qprsapslrp kdyevdatlk
1141 slnnqietll tpegrknpa rtrdrlrlsh pewssgywi dppngctmda ikvycdfstg
```

**Figure 12B**

1201 etciraqpen ipaknwyrss kdkkhvwlge tinagsqfey nvegvtskem atqlafmrl1  
1261 anyasqnity hcknsiaymd eetgnlkkav ilqgsndvel vaegnsrfty tvlvdgcskk  
1321 tnewgktiie yktnkpsrlp fldiapldig gadqeffvdi gpvcfk (SEQ ID NO:12)

**Figure 13A**

*Homo sapiens*  
Fibronectin (2386 aa)  
GenBank P02751

1 mlrqppggl1 llavqclgta vpstgasksk rqaqqmvppq spvavsqskp gcydngkhyq  
61 inqwertyl gnalvctcyg gsergfnesc peaeetcfdk ytgntyrvgd tyerpkdsmi  
121 wdctcigagr grisctianr cheggqsyki gdtwrrphet ggymlcvcl gngkgewtck  
181 piaekcfdha agtsyvvget wekpyqgwm vdctclgegs gritctsrnr cndqdrtsy  
241 rigdtwskkd nrgnllqcic tgnrgewkc erhtsvqtts sgsgpftdvr aavyppqphp  
301 qpppyghcvt dsqvysvvgm qwlktqgnkq mlctclngv scqetavtqt yggnsngepc  
361 vlpftyngrt fyscttegrq dghlwcstts nyeqdqkysf ctdhtvlvqt rggnsngalc  
421 hpflynnhn ytdctsegrr dnmkwcgttq nydadqkfgf cpmaaheeic ttnegvmyri  
481 gdqwdkqhdn ghmmrctcvg nrgewtcia ysqrldqciv dditynvndt fhkrheeghm  
541 lnctcfqggr grwkcdpvdq cqdsetgtfy qigdswekyv hgvryqcycy grgigewhcg  
601 plqtypsssg pvevfitetp sqpnshpiqw napqpskishk yilrwrpkns vgrwkeatip  
661 ghlnsytikg lkpgvvyegq lisiqqyghq evtrfdfttt ststpvtstnt vtgettpfsp  
721 lvatsesvte itassfvvsw vsasdtvsgf rveyelseeg depqyldlps tatsvnipl  
781 lpgrkyivnv yqisedgeqs lilstsqtta pdappdttdv qvddtsivvr wsrpqapitg  
841 yrivyspsve gsstelnlpe tansvtlsdl qpgvqyniti yaveengest pvviqgettq  
901 tprsdvpsp rdlqfvevtd vkvtimwtp esavtgyrvd vipvnlpgeh gqrlpisrnt  
961 faevtqlspg vtyyfkvfav shgreskplt aqgttkldap tnlqfvnetd stvlvrwtp  
1021 raqitgyrlt vgltrrgqpr qynvgpsvsk yplrnlqpas eytvsivaik gngespkatg  
1081 vfttlqpgss ippyntevte ttivitwtpa prigfklqvr psqggeapre vtsdsgsivv  
1141 sgltpgveyv ytiqvlrdgq erdapivnkvtplspptnl hleanpdtgv ltvswerstt

Figure 13B

1201 pditgyritt tptngqqgns leevvhadqs sctfdnlspg leynvsvytv kddkesvpis  
1261 dtiipavppp tdlrftnigp dtmrvtwapp psidltnflv ryspvkneed vaelsispsd  
1321 navvltnlpp gteyvsvss vyeqhestpl rgrqktglds ptgidfsdit ansftvhwia  
1381 pratitgyri rhhpehfsgr predrvphsr nsitltnltp gteyvsvsiva lngreespll  
1441 igqqstvsdv prdlevvaat ptslliswda pavtvryyri tygetggensp vqeftvpgsk  
1501 statisglkp gvdytitvya vtgrgdspas skpisinyrt eidkpsqmqv tdvqdnsisv  
1561 kwlpssspvt gyrvtttpkn gpgptkktka gpdqtemtie glqptveyvv svyaqnpdge  
1621 sqplvqtavt nidrpkglaf tdvdvdsiki awespqqgvs ryrvtyspe dgihelpap  
1681 dgeedtaelq glrpgseytv svalhddme sqpligtqst aipaptdlkf tqvtptslsa  
1741 qwtppnvqlt gyrvrvtpke ktgpmkeinl apdsssvvvs glmvatkyev svyalkdtlt  
1801 srpaggvvt lenvspprra rvtatetti tiswrktet itgfqvdavp angqtpiqrt  
1861 ikpdvrsyti tglqpgtdyk ilytln dna rsspvidas taidapsnlr flattpnsll  
1921 vswqpprari tgyiikyekp gspprevvpr prpgvteati tglepgteyt iyvialknng  
1981 ksepligrkk tdelpqlvtl phpnlhgpei ldvpstvqkt pfvthpgydt gngiqlpqts  
2041 gqqpsvqqqm ifeehgfrtt tppttatpir hrprpyppnv geeiqighip redvdyhlyp

**Figure 13C**

2101 hgpplnfnas tqealsqtt iswapfgdts eyiischpvg tdeepqfrv pgtstsatlt  
2161 gltrgatynv ivealkdqr hkvreevvtv gnsvneqlnq ptddscfdpy tvshyavgde  
2221 wermesgfk llcqlgfgs ghfrcdssrw chdngvnyki gekwdrqgen gqmsctclg  
2281 ngkgefkdcp heatcyddgk tyhvgeqwk eylgaicsct cggqrgwrc dncrrpggep  
2341 spegttgqsy nqysqryhqr tntnvcpie cfmpldvqad redsre (SEQ ID NO:13)

**Figure 14A***Homo sapiens*

Fibrillin-1 (2871 aa)

GenBank NP\_000129

```
1 mrrgrlleia lgftvllasy tshgadanle agnvketras rakrrggggh dalkgpnvcg
61 srynayccpg wktlpggnqc ivpicrhscg dgfcsrpnmc tpcsgqiaps cgsrsiqhcn
121 ircmnggscs ddhclcqkgy igthcgqpvcs esgclnggrc vapnrcacty gftgppqcerd
181 yrtgpcftvi snqmcqqqls givctktlcc atvgrawghp cemcpaqqhp crrgfipnir
241 tgacqdvdec qaipglcqqg ncintvgsfe ckcpaghkln evsqkcedid ecstipgice
301 ggectntvss yfckcpggfy tspdgtrcid vrpqgyctal tngrcsnqlp qsitkmqccc
361 dagrcwspgv tvapemcpir atedfnklcs vpmvipgrpe ypppplpgpip pvlpvppgfp
421 pggqipvprp pveylypsre pprvlpvnvt dycqlvrylc qngrciptpg syrcecnkgf
481 qldlrgecid vdeceknpcg ggecinnggs ytcqcragyq stltrtecrd ideclqngri
541 cnngrcintd gsfhvcnag fhvtrdgknc edmdecsirn mclngmcine dgsfkcoickp
601 gfqlasdgrg ckdinecetp gicmngrcvn tdgsyrcecf pglavglldgr vcvdthmrst
661 cyggykrqgc ikplfgavtk secccastey afgepcqpcp aqnsaeyqal cssgpgmtsa
721 gsdinecald pdicpngice nlrqtykci c nsgyevdstg kncvdinecv lnsllcdngq
781 crntpgsfvc tcpkgfiykp dlktcedide cesspcingv cknspgsfic ecssestldp
841 tkticietik gtcwqtvidg rceiningat lksqccsslq aawgspctlc qvdpicgkgy
901 srikgtqced idecevfpgv cknglcvntr gsfkcqpcsg mtldatgric ldirletcfl
961 ryedeectlp iagrhrmdac ccsvgaawgt eeceecpmrn tpeyeelcpr gpgfatkeit
1021 ngkpfkfdin eckmipslct hgkcrntigs fkrcrdsgfa ldseernctd idecrispdl
1081 cgrgqcvntp gdfeckcdeg yesgfmnmkn cmdidecqrq pllcrggvch ntegsyrcec
1141 ppgghqlspni sacidinece lsahlcpngr cvnligkyqc acnpgyhstp drlfcvdide
```

Figure 14B

1201 csimnggcet fctnsegsye cscqpgfalm pdqrsctdid ecednprnid ggqctnipge  
1261 yrclcydgmf asedmktev d vnecdlnpni clsgtcentk gsfichcdmg ysgkkkgktgc  
1321 tdineceiga hncgkhavct ntagsfkesc spgwigdgik ctdldecnsng thmcsqhadc  
1381 kntmgsyrcl ckegytgdgf tctdldecse nlnlcgngqc lnapggyrce cdmgfvpsad  
1441 gkacedidec slpnicvfgt chnlpglfrc eceigyeldr sggncdvdne cldpttcisg  
1501 ncvntpgsyi cdcppdfeln ptrvgcvdtr sgnicyldirp rgdngdtacs neigvgvska  
1561 scccslgkaw gtpcemcpav ntseykilcp gggefrnpi tviledidec qelpglcqqg  
1621 kcintfgsfq crcptgyyln edtrvcddvn ecetpgicgp gtcyntvgny tcicppdymq  
1681 vnggnncmdm rrslycyrnyy adnqtcdgel lfnmtkkmcc csynigrawn kpceqcpips  
1741 tdefatlcgs qrpqfvidiy tglpvdidec reipgvceng vcinmvgsfr cecpvqffyn  
1801 dkllvcedid ecqngpvcqr naecintags yrcdckpgyr ftstgqcnr necqeipnic  
1861 shgqcidtvg sfyclchtgf ktnddqtmc l dinecerdac gngtcrntig sfncrcnhgf  
1921 ilshnndcid vdecasngn lcrngqcint vgsfqcqone gyevapdgrt cvdineclle  
1981 prkcapgtcq nldgsyrcic ppgyslqnek cedidecvee peicalgtcs ntegsfkclc  
2041 pegfslsssg rrcqdlrmsy cyakfeggkc sspksrnhs k qeccalkge gwgdpcelcp  
2101 tepdeafraqi cpygsgiivg pddsavdme ckepdvckhg qcintdgsyr cecpfgyila  
2161 gnecvdtdec svgnpcngt cknviggfec tceegfepgp mmtcedinec aqnpllcafr  
2221 cvntygsyec kcpvgyvlre drrmckdede ceegkhdcte kqmecknlig tymcicgpgy  
2281 qrrpdgegc v denecqtkpg icengrclnt rgsytcecmd gftaspnqde cldnregycf  
2341 tevlqnmqci gssnrnpv tk secccdggrg wgphceicpf ggtvafkklc phgrgfmtng

**Figure 14C**

2401 adideckvih dvrngecvn drgsyhck tgytpditgt scvdlnecnq apkpcnfick  
2461 ntegsyqcsc pkgylqedg rsckdldeca tkqhncqflc vntiggftck cppgftqhht  
2521 scidnnects dinlcsksgi cqntpgsftc ecqrgfsldq tgsscedvde cegnhrcqhg  
2581 cqniiggyrc scpqqylqhy qwnqcvdene clsahicgga schntlgsyk cmcpagfgye  
2641 qfsggcqdin ecgsaqapcs ygsnteggy lcgppgyfr igqghcvsgm gmgrgnpepp  
2701 vsgemddnsl speacyeck ngyprgrkr rstnetdasn iedqsetean vslaswdvek  
2761 taifafnish vsnkvrilel lpalttltnh nryliesgne dgffkingke gisyhftkk  
2821 kpvagtyslq isstplykkk elnqledkyd kdylsgelgd nlkmiqvll h (SEQ ID  
NO:14)

**Figure 15**

*Homo sapiens*

Dermatopontin (201 aa)

GenBank CAA 80487

```
1 mdlsllwvlm plvtmawggy gdygypyqgy hdysddgwn lnrqgfsyqc pggqvivavr
61 sifskkegsd rqwnyacmpt pqsigeptec wweeinragm ewyqtcsnng lvagfqsryf
121 esvldrewqf yccryskrcp yscwltteyp ghygeemdmf synydyirg atttfsaver
181 drqwkfimcr mteydcefan v (SEQ ID NO:15)
```

**Figure 16**

*Homo sapiens*

Metalloproteinase inhibitor-1 (207 aa)

GenBank NP\_003245

```
1 mapfeplasn illllwliap sractcvpph pqtafcnsdl virakfvgtg evnqttlyqr
61 yeikmtkmyk gfqalgdaad irfvytpame svogyfhrsh nrseefliag klqdgllhit
121 tcsfvapwns lsiaqrrgft ktyvtgceec tvfpclsipc klqsgthclw tdqllqgsek
181 gfqsrhlacl prepqlctwq slrsqia (SEQ ID NO:16)
```

**Figure 17**

*Homo sapiens*

Galectin-1 (135 aa)

GenBank NP\_003396

```
1 macglvasnl nlkpgeclrv rgevapdaks fvlnlgkdsn nlclhfnprf nahgdantiv
61 cnskdggawg teqreavfpf qpgsvaevci tfdqanltvk lpdgyefkfp nrlnleainy
121 maadgdfkik cvafd (SEQ ID NO:17)
```

**Figure 18**

*Homo sapiens*

Lumican (338 aa)

GenBank AAA85268

1 mslsaftlfl aliggtsgqy ydydfppsiy gqsspncape cncpesypsa mycdelklks  
61 vpmvppgiky lylnnqidh idekafenvt dlqwlildhn vlenskikgr vfsklkqlkk  
121 lhinhnnte svqplpksle dlqlthnkit klgsfeglvn ltfihlqhnr lkedavsaaaf  
181 kglksleyld lsfnqiarlp sglpvslltl yldnnkisni pdeyfkrfna lqylrlshne  
241 ladsgipgns fnvsslveld lsynklknip tvnenlenyy levnqlekfd iksfckilgp  
301 lsyskikhlr ldgnrisets lppdmyeclr vanevtln (SEQ ID NO:18)

**Figure 19**

*Homo sapiens*

Prolargin (382 aa)

GenBank AAC18782

1 mrsplcwllp llilasvaqg qprrrprpqt gpgrrrprpr rptpsfpqpd epaepdldpp  
61 plppgppsif pdcprecycp pdfpsalycd srnlrkvpvi pprihylylq nnfitelpve  
121 sfqnatglrw inldnnrirk idqrvleklp glvflymekn qleevpsalp rnleqlrlsq  
181 nhisrippgv fsklenllll dlqhnrlsdg vfkpdtfhgl knlmqlnlah nilrkmpprv  
241 ptaihqllyld snkietipng yksfpnlaf irlnynklt d rglpknsfni snllvlhlsh  
301 nrissvpain nrlehlylnn nsiekingtq icpndlvafh dfssdlenvp hlrylrl d gn  
361 ylkppipldl mmcfrllqsv vi (SEQ ID NO:19)

**Figure 20A**

*Homo sapiens*

Tenascin (2201 aa)

GenBank NP\_002151

1 mgamtqllag vflaflalat eggvlkkvir hkrqsgvnat lpeenqpvvf nhvyniklpv  
61 gsqcsvdles asgekdlapp sepsesfgeh tvdgenqivf thriniprra cgcaaapdvk  
121 ellsrleele nlvsslreqc tagagcclqp atgrldtrpf csgrgnfste gcgcvcepgw  
181 kgpncsepec pgnchlrgrc idgqcioddg ftgedcsqla cpsdcndqgk cvngvcicfe  
241 gyagadcsre icpvpcseeh gtcvdglcvc hdgfagddcn kplclnncyn rgrcvenecv  
301 cdegftgedc selicpndcf drgrcingtc yceegftged cgkptcpnac htqgrceegq  
361 cvcdegfagv dcsekrpad chnrgrcvdg rcecdgftg adcgelkcpn gcsghgrcvn  
421 gqcvcdegvt gedcsqlrcp ndchsrgrcv egkevcceqgf kgydcsmcsc pndchqhgrc  
481 vngmccvddg ytgedcrdrq cprdcsnrgl cvdgqcvced gftgpdcael scpndchqgg  
541 rcvngqevch egfmgkdcke qrcpsdchqg grcvdgqcic hegftgldeg qhscpsdcnn  
601 lgqcvsgrci cnegysgedc sevspkdlv vtevteetvn lawdnemrvt eylvytptth  
661 egglemqfrv pgdqtstiiq elepgveyfi rvfailenkk sipvsarvat ylpapeglkf  
721 ksiketsvev ewdpldiafe tweiifrnmn kedegaitks lrrpetsyrg tglapqgeye  
781 islhivkntt rgpglkrvtt trldapsqie vkdvtdttal itwfkplaei dgieltygik  
841 dvpgdrttid ltedenqysi gnlpdteye vslisrrgdm ssnpaketft tgldapnrlr  
901 rvsqtdnsit lewrngkaai dsyrikyapi sggdhaevdv pksqqattkt tltglrpgte  
961 ygigvsavke dkesnpatin aateldtpkd lqvsetaets ltllwktpa kfdryrlmys  
1021 lptgqwgvgvq lprnttsyvl rglepqqeyn vlltaekgrh kskparvka teqapelenl  
1081 tvtevgwdgl rlnwtaadqa yehfiiqvqe ankveaarnl tvpgslravd ipglkaatpy  
1141 tvsiygvigq yrtpvlsea stgetpnlge vvvaevgwda lklnwtapeg ayeyffiqvq

Figure 20B

1201 eadtveaaqn ltvpgglrst dlpglkaath ytitirgvtq dfsttplsve vlteevpdmg  
1261 nltvtevswd alrlnwttpd gtydqftiqv qeadqveeah nltvpgslrs meipglragt  
1321 pyvtvlhgev rghstrplav evvtedlpql gdlavsevgw dglrlnwtaa dnayehfviq  
1381 vqevnkveaa qnltlpgslr avdipgleaa tpyrvsiygv irgyrtpvls aeastakepe  
1441 ignlnvsdit pesfnlswma tdgifetfti eiidsnrllle tveynisgae rtahisglpp  
1501 stdfivylsg lapsirtkti satattealp llenltsidi npygftvswm asenafdsfl  
1561 vtvdsgkll dpqeftlsgt qrklelrgli tgigyevmvs gftqghqtkp lraeivteae  
1621 pevdnllvsd atpdgfrlsw tadegvfdnf vlkirdtkkq sepleitlla pertrditgl  
1681 reateyeiel ygiskgrsq tvsaiattam gspkevifsd itensatvsw raptaqvef  
1741 rityvpitgg tpsmvtvdgt ktqtrlvkli pgveylvsii amkgfeesep vsqsfittald  
1801 gpsglvtani tdsealarwq paiatvdsyv isytgekvpe itrvtvsgntv eyaltdlepa  
1861 teytlrifae kqpqsstit akfttdldsp rdltatevqs etalltwrpp rasvtgyllv  
1921 yesvdgtvke vivgpdttsty sladlspsth ytakiqalng plrsnmiqti fttigllypf  
1981 pkdcsqamln gdttsglyti ylngkaeal evfcdmtsdi ggwivflrrk ngrenfyqnw  
2041 kayaagfgdr reefwlgldn lnkitaqqgy elrvdlrdhg etafavydkf svgdaktryk  
2101 lkvegysgta gdsamayhngr sfstfdktd saidncalsy kgafwyrnch rvnlmgrygd  
2161 nnhsqgvnwf hwkqhehsiq faemklrpsn frnlegrrrkr a (SEQ ID NO:20)

**Figure 21**

*Homo sapiens*

Vitronectin (478 aa)

GenBank ADL14521

```
1 maplrplllil allawvalad qesckgrcte gfnvdkkcqc delcsyyqsc ctdytaeckp
61 qvtrrgdvftm pedeytvydd geeknnatvh eqvggpslts dlqaqskgnp eqtpvlkpee
121 eapapevgas kpegidsrpe tlhpgrpqqp aeeelcsgkp fdaftdlkng slfafrgqyc
181 yeldekavrp gypklirdvw giegpidaaf trincggkty lfkgsqywrp edgvldpdyp
241 rnisdgfdgi pdnvdaalal pahsysgrer vyffkgkqyw eyqfqhqpsq eecegsslsa
301 vfehfaammqr dswedifell fwgrtsagtr qpqfisrdwh gvpqqvdaam agriyisqma
361 prpslakkqr frhrnrkgyr sqrghsrgrn qnsrrpsrat wlslfssees nlgannyddy
421 rmdwlvpatc epiqsvfffs gdkyyrvnlr trrvdtvdpp yprsiacywl gcpapghl (SEQ
ID NO:21)
```

**Figure 22A**

*Homo sapiens*

Tenascin-X (4289 aa)

GenBank P22105

1 mmpaqyalts slvllvllst aragpfssrs nvtlpaprpp pqpqgghtvga gvgspssqly  
61 ehtveggekq vvfthrinlp pstgqgcppg teppvlasev qalrvrleil eelvkglkeq  
121 ctggccpasa qagtgqtdvr tlcslhgvfd lsrctcscep gwggptcsdp tdaeippssp  
181 psasgscpdd cndqgrevrg rcvcfpgytg pscgwpscpq dcqgrgrevq gvcvcragfs  
241 gpdcqsqrscp rgcsqrgrce ggrevcdpgy tgddcgmrsc prgcsqrgrc engrcvcnpg  
301 ytgedcgvrs cprgcsqrgr ckdgrvcvdp gytgedcgtr scpwdcgegq rcvdgrvcvw  
361 pgytgedcst rtcprdergr grcedgecic dtgysgddcg vrscpgdncq rgrcedgrcv  
421 cwpgytgtdc gsracprdcr grgrcengvc vonagysged cgvrscpgdc rgrgrcesgr  
481 cmcwpgytgr dcgtracpgd crgrgrcvdg rcvcnpgftg edcgsrrcpq dcrghglced  
541 gvcvcdagys gedcstrscp ggcrgrgqcl dgrvcvedgy sgedcgvrqc pndcsqhgvq  
601 qdgvccicweg yvsedcsirt cpsnchgrgr ceegrclcdp gytgptcatr mcpadcrgrg  
661 rcvqgvclch vgyggedcqq eeppasacpg gcgprelcra gqcvcvegfr gpdcaiqtcp  
721 gdcrggrgech dgscvckdgy agedogearv pssasaydqr glapggqeyqv tvralrgtsw  
781 glpasktitt midgpqdlrv vavtpttlel gwlrpqaevd rfvsyvsag nqrvrlevpp  
841 eadgtlltdl mpgveyvvtv taergravsy pasvrantee reeespprps lsqpprrpwg  
901 nltaelrfr gtvqdlrhl rahgyplran qtytsvarhi heylqrqvlq ssadgallvs  
961 ldglrgqfer vvlrwrpqpp aegpggeltv pgttrtvslp dlrggttyhv evhgvrageq  
1021 sksyafittt gpsttqgaga pllqqrpqel gelrvlgrde tgrlrvvwtq qpdtfayfql  
1081 rmrvpegpqa heevlpgdvr qalvpppppg tpyelslhgv ppggkpsdpi iyqgimdkde  
1141 ekpgkssgpp rlgeltvtdr tdslllrwt vpegefdsfv iqykdrdqap qvvpvegqqr

Figure 22B

1201 savitsldpg rkykfvlygf vgkkrhgplv aeakilpqsd pspgtpphlg nlwvtdptpd  
1261 slhlswtvpe gqfdtfmvqy rdrdgrpqv pvegpersfv vssldpdhky rftlfgiank  
1321 krygpltdag ttaperkeep prpeflegpl lgeltvtgvt pdsrlswtv aqgpfdsfmv  
1381 qykdaqqgpq avpvagdene vtvpgldpdr kykmnlyglr grqrvgpsv vaktapgedv  
1441 detpsptelg teapespeep llgeltvtgs spdslslfw vpqgs fdsft vqykdrdgrp  
1501 ravrvggkes evtvgglepg hkykmhlygl hegqrvgps avgvtapqqe etppatespl  
1561 eprlgeltvt dvtpnsvglw wtvpegqfds fivqykdkdg qqvvpvaad qrevtvynle  
1621 perkykmmy glhdgqrmgp lsvvvtapa teaskpplep rlgeltvtdi tpdsvglswt  
1681 vpegefdsfv vqykdrdgpq qvvpvaadqr evtipdleps rkykflfqi qdgkrrspvs  
1741 veaktvargd aspgaprlg elwvtdptpd srlswtvpe gqfdfsfvvqf kdkdgpqvvp  
1801 veghersvtv tpldagrkyr fllygllgkk rhgpltdagt tearsamddt gtkrppkprl  
1861 geelqvttvt qnsvglswtv pegqfdfsfv qykdrdgpq vvpvegslre vsvpglpah  
1921 rykllyglh hgkrvgpisa waitagreet etettaptp apephlgelt veeatshth  
1981 lswmvtegef dsfeiqytdr dgqlqmvrig gdrnditlsg lesdhrylvt lygfsdgkhv  
2041 gpvhvealtv peekpsepp tatpeppikp rlgeltvtda tpdslslswt vpegqfdhfl  
2101 vqyrngdgqp kavrvpgee gvtisglepd hkykmnlygf hggqrmgps vvgvtepsme  
2161 apepaeep11 geltvtgssp ds1slswtvp qgrfdfsftvq ykdrdgrpqv vrvggeesev  
2221 tvqglepgrk ykmhlyglhe grrvgpvsav gvtapeeesp daplaklrlg qmtvrditsd  
2281 slslswtvpe gqfdhflvqf kngdgqpkav rvpghedgvt isglepdhky kmnlygfhhg  
2341 qrvgpsav ltasteptp eppikprlee ltvtdatpds slswtvpeg qfdhflvqyk

Figure 22C

2401 ngdgqpkatr vpghedrvti sglepdnkyk mnlygfhggq rvgpvsaigv teeetpspte  
2461 psmeapeppe epllgeltvt gsspdslsls wtvpggrfds ftvqykdrdg rpqvrvvgge  
2521 esevtvGGLE pgrkykmhly glhegrrvvp vstvgvtapq edvdetpspt epgteapggp  
2581 eepllgeltv tgsspdsisl swtvpggrfd sftvqykdrd grpqavrvvg geskvtvrgl  
2641 epgrkykmhl yglhegrrlg pvsavgvted eaettqavpt mtpeppikpr lgeltmtdat  
2701 pdslsiswsv pegqfdhflv qyrngdgqpk avrvpghedg vtisglepdh kykmnlygfh  
2761 ggqrvgpisv igvteeetps ptelsteape ppeepllgel tvtgsspds slswtipqgh  
2821 fdsftvqyk rdgrpqvmrv rgeesevtvg glepgrkykm hlyglhegrr vgpvstvgvt  
2881 vptttpeppn kprlgeltvt datpdslsls wmvpegqfdh flvqyrngdg qpkvrvpgh  
2941 edgvtisgle pdhkykmnly gfhggqrvvp isvigvtee tpaptepste apeppeepll  
3001 geltvtgssp dslsiswsv qgrfdsftvq ykdrdgrpqv vrvrgeesev tvGGLEpgck  
3061 ykmhlyglhe qrvgpvsav gvtapkdeae ttqavptmp eppikprlge ltvtdatpds  
3121 lsismvpeg qfdhflvqyr ngdgqpkavr vpghedgvti sglepdhkyk mnlygfhggq  
3181 rvgpvsaigv teeetpspte psteapeape epllgeltvt gsspdslsls wtvpggrfds  
3241 ftvqykdrdg qpqvrvrge esevtvGGLE pgrkykmhly glhegrrvvp vstvgitapl  
3301 ptplpveprl gelavaavts dsvglswtva qgpfdsfvlv yrdaqqppa vpvsgdlrav  
3361 avsgldpark ykflfvlgn gkrhgvpvpe artapdkps prlgeltvtd atpdsvglsw  
3421 tvpegefdsf vvqykdkdgr lqvvpvaanq revtvqglep srkyrfllyg lsgrkrlgpi  
3481 sadsttable kelpphlgel tvaetsssl rlswtvaqgp fdfvqvyrtd tdgqpravpv  
3541 aadqrtvtve dlepgkkykf llyglggkr lgpvsalgmt apeedtpape lapeapeppe

**Figure 22D**

3601 eprlgvltvt dttpdsmrls wsvaqgpfds fvvqyedtnq qpqallvdgd qskilisgle  
3661 pstpyrflly glhegkrlgp lsaegttgla pagqtseesr prlsqslsvtd vttsslrlnw  
3721 eappgafdsf llrfgvpsps tlephprpll qrelmvpgr hsavlrldrs gtlysltlyg  
3781 lrqphkads i qgtartlspv lesprdlqfs eiretsakvn wmpppsrad fkvsyqladg  
3841 gepqsvqvdg qartqklqgl ipgaryevtv vsvrgfeese pltgflttvp dgptqlraln  
3901 ltegfavlhk kppqnpvdy dvqvtapgap plqaetpgsa vdyplhdlvl htnytavrg  
3961 lrqpnltspa sitfttglea prdleakevt prtalltwte ppvrpagyll sfhtpggqng  
4021 eillpggits hqllglfpst synarlqamw gqslppvst sfttgglrip fprdcgeemq  
4081 ngagasrtst iflgnrerp lnvfcdmetd gggwlvfqr mdgqtdfwr wedyahgfgn  
4141 isgefvlqne alhsltqagd ysmrvdlrag deavfaqyds fhvdsaaeyy rhllegyhgt  
4201 agdsmsyhs svfsardrdp nslliscavs yrgawwyrnc hyanlnglyg stvdhggvsw  
4261 yhwkgfefsv pftemklrpr nfrspaggg (SEQ ID NO:22)

**Figure 23A**

*Homo sapiens*

Collagen alpha-2(IV) (1712 amino acids)

GenBank NP\_001837

```
1 mgrdqravag palrrwlllg tvvtvgflaqs vlagvkkfdv pcggrdcsgg cqcypekqgr
61 gqpgpvpgqg yngppglqgf pglqqrkgdk gergapgvvtg pkgdvvgargv sgfpqadgip
121 ghpgqggprg rpgydgcngt qgdsqpgqpp gsegftgppg pqgpkgqkge pyalpkeerd
181 ryrgepgepg lvqfagppgr pghvqmqmpv gapgrppppg ppgpkqqaqn rglgfygvkg
241 ekgdvqppg ngipsdtlhp iiaptgvtfh pdqykgekgs egepgirgis lkgeegimgf
301 pglrgypqls gekgsppqkg srgldgyqgp dqprgpkgea gdpqppglpa ysphpslakg
361 argdpqfpga qgepgsqgep gdpqlpqpqp lsigdgdqrr glpgemgpkf figdpqipal
421 yggppgpdgk rgpppppqlp gppgpdgflf glkgakgrag fpqlpgspga rgpkgwkgda
481 gecrctegde aikglpqlpg pkgfaginge pgrkgdrqdp gqhgllpgfpg lkgvpgniga
541 ppgkqakqds rtittkgerg qpgvpgvpgm kgddgspgrd gldgfpqlpg ppgdgikgpp
601 gdpqypqipg tkgtppgemg pglglpqlkg qrgfpqdagl ppppgflgpp qpagtppqid
661 cdtvkkravg gdrqeaipqg ciggpqqlpg lpqpppqtga kglrgipgfa gadgppgprg
721 lpgdagregf ppppgfigpr gskgavqlpg pdgspqpiql pppdpppger qlpgevlgaq
781 pgprgdagvp gqplkqlpg drgppgfrgs qmpgmpgk gqpglpqpsg qpplypqpl
841 hgfpgapqge qplqlpqlpg reglpqdrqd pldtgapqv gmkglsqdrq dagftgeqgh
901 pgsqpfkqid gmpgtplkg drgspqmdgf qmpgplkgrp gfpqskgeag ffgipqlkgl
961 agepffkqsr gdpqppppp vilpkmkdik gekgdegpmg lkqylgakgi qmpgipqls
1021 gipqlpqrpg hikgvkqdig vpgipqlpqlpg pvagppgit gfpqfigsrg dkgapqragl
1081 ygeigatqdf gdigdtinlp grpqlkgerg ttgipqlkqf fgekgteddi gfpqitgvtg
1141 vqpppqlkqg tgfpltpqp gsqgelgrig lpqgkqddgw pqpqlpqlpg qlrgirqlhg
```

**Figure 23B**

1201 lpgtkgfpgs pgsdihgdpq fpgppgergd pgeantlpgp vgvpgqkqdq gapgergppg  
1261 spglqgfpqi tppsniqgap gdkgapgfig lkgyrgppgp pgsaalpgsk gdtgnpgapq  
1321 tpgtkgwagd sgpqgrpgvf glpgekprg eqgfmqntgp tgavqdrqpk gpkqdpqfpg  
1381 apgtvgapqi agipqkiavq pgtvqpqgrr gppgapgemq pggppqepgf rgapqkagpq  
1441 grggvsavpg frgdegpigh qgpigqegap grpgspglpg mpgrsvsigy llvkhsqtdq  
1501 epmcpvgmnk lwsyysllyf egqekahnqd lglagsclar fstmpflycn pgdvcyyasr  
1561 ndksywlstt aplpmmpvae deikpyisrc svceapaiai avhsqdvqip hcpagwrslw  
1621 igysflmhta agdeggqsl vspgscledf ratpfiecnq grgtchyyan kysfwlittip  
1681 eqsfqgspsa dtlkaqlirt hisrcqvcmk nl (SEQ ID NO:23)

**Figure 24A**

*Homo sapiens*

Collagen alpha-5(IV) (1691 amino acids)

GenBank AAF66217

```
1 mklrgvslaa glfllalslw gqpaeaaacy gcspgskcdc sgikgekger gfpgleghpg
61 lpgfpgpegp pgprgqkqdd gipgppgpkp irgppglpgf pgtpglpmp ghdgapppqg
121 ipgcngtkge rgfpgspgfp glqgppgppg ipgmkgpss iimsslpgpk gnpgyppppg
181 iqglpgptgi ppgigppgpp glmgppgppg lpgpkgnmgl nfqgpkgekq eqglqgpppg
241 pggiseqkrp idvefqkqdg glpgdrppg ppgirgppgp pgggekgekq qgepgkrqkp
301 gkdgengqpg ipglpgdpy pgeprdgek gqkqdtgppg ppglviprpg tgitigekgn
361 iglpplpgek gergfpqiag ppplpgppga avmgppppg fpgergqkd egppgisipg
421 pppldgppga pglpgppgpa ghippsdei ceppppppg spgdkglqge qgvkqdkgdt
481 cfncigtgis pppgqplpg lpgppgslgf pgqkgekqqa gatgpkglpg ipgapgapgf
541 pgskgpvgdi ltfpgmkqdk gelgspgag lpglpgtppg dglpglpgp gepggitfkq
601 ergppgnpgl pglpqnigpm gppgfppgp vgekqiaggva gnpqppgip pkgdppqtit
661 qpgkpglpgn pgrdgdvlp gdpplpgppg lpgipgskqe pgipgiglp ppgpkgfpgi
721 ppppgapgtg griglegppg ppgfpgpkqe pgfalppppg ppplpgfkga lpgkqdrqfp
781 gpppppgrtg ldglpgpkgd vgpngppgm pppplpgigv qppppppgip gpigqplhg
841 ipgekqdpdp pglpvpppg ergspgipga ppgipppgsp glpgkagasg fpgtkgemgm
901 mgpppppppl gipgrsgvpg lkgddglqgq pglpgptgek gskgeplpg ppgpmdpnl1
961 gskgekgepg lpgipgvsgp kgyqglpgdp gqplsgqpg lpgppgpkgn pglpgqplli
1021 gppglkgtig dmgfppqgv egppgspgv gqpgspglpg qkqdkqdpqi ssiglpplpg
1081 pkgeplpgy pgnpgikgsv gdpplpglpg tpgakqppgl pfpptppp gpkgispppg
1141 nplpgppegp vqggghppqg pppgekqkpg qdqipppagp kgeppqpgf nppppplpl
```

**Figure 24B**

1201 sqqkqdgqlp gipgnpqlpg pkgepgfhgf pgvqgppgpp gspgpalegp kgnpgpqqpp  
1261 grpgptgfgq lpgpegppgl pgnngikgek gnpgqplpg lpglkgdqqp pglqgnpgrp  
1321 glngmkgdpg lpgvpgfpgm kgpsgvpgsa gpegepglig ppqppglpgp sqqsiikgd  
1381 agppgipqqp glkglpgpqq pqlpgptgp pqpgrnglp gfdgaggrkg dpqlpgqpgt  
1441 rgldgppgpd glqgppgppg tssvahgfli trhsqtdap qcpqgtlqvy egfsllyvqg  
1501 nkrahgqdlg tagsclrrfs tmpfmcnin nvcnfasrnd ysywlstpep mpmsmqplkg  
1561 qsiqpfisrc avceapavvi avhsqtiqip hcpqgwdsiw igysfmmhts agaegsqgal  
1621 aspgsclief rsapfiechg rgtcnnyans ysfwlatvdv sdmfskpqse tlkagdlrtr  
1681 isrcqvcmk r t (SEQ ID NO:24)

**Figure 25**

*Homo sapiens*

Elastin (730 amino acids)

GenBank AAA52382

```
1 magltaaapr pgvlllllsl lhpsrpggvp gaipggvpgg vfyppaglg lgggalgpgg
61 kplkpvpggl agaglgaglg afpavtffga lvpggvadaa aaykaakaga glggvpgvvgg
121 lgvsgavvp qpgagvkpgk vpgvglpgvy pggvlpgarf pggvglpgvp tgagvkpkap
181 gvggafagip gvgpfggpqp gvplgypika pklpggyglp yttgklpygy gpggvagaag
241 kagyptgtgv gpqaaaaaaaa kaaakfgaga agvlpvgvga gvpgvpgaip giggiagvgt
301 paaaaaaaa akaakygaaa glvpggpgfg pggvvgvpgag vpgvvgvpgag ipvvpgagip
361 gaavpgvvsp eaaakaaaka akygarpgvg vggitygvg aggfpgfgvg vggipgvagv
421 psvggvpgvg gvpvggispe aqaaaaakaa kygvgtpaaa aakaaakaaq fallnlaglv
481 pggv vapvgv vglapgvv pggv vapvgv vapgigpggv aaaaksaakv
541 aakaqlraaa glgagipglg vgvvpglgv gagvpglgv agvpfggavp galaaakaak
601 ygaavpgvlg glgalggvgi pggvvgagpa aaaaaakaaa kaaqfglvga aglgglgvvg
661 lgvpgvgglg gippaaaaka akygaaglgg vlggagqfpl ggvaarpfgf lspifpggac
721 lgkacgrkrk (SEQ ID NO:25)
```

## COMPOSITIONS AND METHODS FOR DETECTING UNSTABLE ARTERIOSCLEROTIC PLAQUES

### CROSS-REFERENCE

**[0001]** This application claims the benefit of U.S. Provisional Patent Application No. 61/635,645, filed Apr. 19, 2012, which application is incorporated herein by reference in its entirety.

### STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

**[0002]** This invention was made with government support under Grant No. P41 RR001614 awarded by the National Institutes of Health, National Center for Research Resources. The government has certain rights in the invention.

### INTRODUCTION

**[0003]** Cardiovascular disease (CVD) is the general term for heart and blood vessel diseases, including atherosclerosis, coronary artery disease, cerebrovascular disease, aorto-iliac disease, and peripheral vascular disease. Individuals with CVD may develop a number of complications, such as myocardial infarction, stroke, angina pectoris, transient ischemic attacks, congestive heart failure, aortic aneurysm, and death.

**[0004]** Arterial plaque instability is a critical element in occlusive vascular disease events, including myocardial ischemia, myocardial infarction, stroke, and peripheral arterial disease. As plaques become unstable, they erode or rupture, exposing prothrombotic stimuli to the blood, which in turn initiates thrombi.

**[0005]** Levels of the acute phase reactant C-reactive protein (CRP) have been used to estimate an individual's risk of developing a cardiovascular disorder. However, CRP may be found in the blood of individuals with inflammation due to causes other than CVD; as such, the value of CRP as a diagnostic or prognostic tool is limited.

**[0006]** There is a need in the art for methods of determining an individual's risk of developing an occlusive vascular event.

### LITERATURE

**[0007]** U.S. Patent Publication No. 2010/0323377; Libby et al. (2010) *Circ. J.* 74:213; Galis et al. (1994) *J. Clin. Invest.* 94:2493; Skølt-Arkil et al. (2010) *Assay and Drug Development Technologies* 8:542; Barascuk et al. (2010) *BMC Cardiovasc. Dis.* 10:19; Libby (2006) *Arterioscler. Thromb. Vasc. Biol.* 26:2181.

### SUMMARY

**[0008]** The present disclosure provides methods of detecting an unstable arteriosclerotic plaque in an individual, involving detecting in a biological sample from the individual an enzymatic cleavage product of a protein component of an arteriosclerotic plaque. The present disclosure provides methods of assessing the risk that an individual will develop an occlusive vascular event. The present disclosure further provides kits for carrying out a subject method.

**[0009]** In a first embodiment, the present disclosure provides a method for detecting an unstable arteriosclerotic plaque in an individual, the method comprising detecting in a biological sample from the individual an enzymatic cleavage product of a protein component of an arteriosclerotic plaque.

In some cases, the protein component is not collagen type III, elastin, decorin, biglycan, versican, apolipoprotein E, C-reactive protein, or lumican.

**[0010]** In the first embodiment of a subject method, the protein can be a structural protein, e.g., a non-enzymatic protein. In some cases, in the first and/or the second embodiment of a subject method, the individual is asymptomatic with respect to an arterial occlusive event and/or is an apparently healthy human subject. In some cases, in any of the above embodiments of a subject method, the individual has experienced one or more typical symptoms of cardiovascular disease. In some cases, in any of the above embodiments of a subject method, the individual has experienced an atypical symptom of cardiovascular disease. In any of the above embodiments, the biological sample is blood; or is a blood fraction (e.g., serum or plasma). In any of the above embodiments, level of the one or more enzymatic cleavage products is determined by an immunological method. In any of the above embodiments, the protein component is fibrillin, vitronectin, fibronectin, tenascin, prolargin, dermatopontin, vascular collagen, metalloproteinase inhibitor-1, galectin-1, or tenascin-X. For example, the collagen can be collagen alpha-1 (I) chain, collagen alpha-1 (II) chain, collagen alpha-1 (IV) chain, collagen alpha-1 (VI) chain, collagen alpha-1 (XII), collagen alpha-1 (XIV) chain, collagen alpha-1 (XV) chain, collagen alpha-1 (XVIII), collagen alpha-1 (XIX); collagen alpha-2 (I) chain, collagen alpha-3 (VI), collagen alpha-2 (IV), or collagen alpha-5 (IV). In any of the above embodiments, the enzymatic cleavage product has a molecular weight in a range of from about 0.5 kDa to about 50 kDa; for example, the enzymatic cleavage product can have a length in a range of from about 5 amino acids to about 500 amino acids.

**[0011]** In any of the above embodiments of a subject method for detecting an unstable arteriosclerotic plaque in an individual, the detecting step can comprise processing the enzymatic cleavage product in vitro. For example, in some cases, the processing comprises trypsin digestion.

**[0012]** In any of the above embodiments of a subject method for detecting an unstable arteriosclerotic plaque in an individual, the enzymatic cleavage product can be a cleavage product of a matrix metalloproteinase (MMP). For example, in some cases, the MMP is secreted by a macrophage. For example, in some cases, the MMP is MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, or MMP13.

**[0013]** In some cases, the enzymatic cleavage product is a cleavage product of a cathepsin.

**[0014]** In any of the above embodiments of a subject method for detecting an unstable arteriosclerotic plaque in an individual, the method can further comprise generating a report providing an indication of the risk that the individual will experience an occlusive vascular event.

**[0015]** In a second embodiment, the present disclosure provides a method for determining a risk that an individual will develop an occlusive vascular event, the method comprising determining the level, in a biological sample from the individual, of an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, wherein a level of the enzymatic cleavage product that is higher than a normal control level indicates risk of developing an occlusive vascular event. For example, the protein component can be fibrillin, vitronectin, fibronectin, tenascin, prolargin, dermatopontin, vascular collagen, metalloproteinase inhibitor-1, galectin-1,

or tenascin-X. In some cases, the level of the one or more enzymatic cleavage products is determined by an immunological method. In some cases, the protein component is not collagen type III, elastin, decorin, biglycan, versican, apolipoprotein E, C-reactive protein, or lumican.

**[0016]** In any of the above embodiments of a subject method for determining a risk that an individual will develop an occlusive vascular event, the biological sample can be blood, serum, or plasma. In any of the above embodiments of a subject method for determining a risk that an individual will develop an occlusive vascular event, the subject can be an apparently healthy human subject. In any of the above embodiments of a subject method for determining a risk that an individual will develop an occlusive vascular event, the individual can be one who does not have a history of having an occlusive vascular event.

**[0017]** In a third embodiment, the present disclosure provides a kit for detecting an unstable arteriosclerotic plaque in an individual, the kit comprising: a) a binding reagent that specifically binds an enzymatic cleavage product of a protein component of an arteriosclerotic plaque; and b) a control that provides for quantitation of the enzymatic product. In some cases, the protein component is not collagen type III, elastin, decorin, biglycan, versican, apolipoprotein E, C-reactive protein, or lumican.

**[0018]** In some embodiments of a subject kit, the reagent that specifically binds an enzymatic cleavage product of a protein component of an arteriosclerotic plaque is an antibody. For example, the antibody can be a monoclonal antibody, or an antigen-binding fragment. In some embodiments of a subject kit, the antibody is immobilized on an insoluble support. In some embodiments of a subject kit, the antibody comprises a detectable label; in some of these embodiments, the kit further comprises one or more reagents for developing a detectable label.

**[0019]** In a fourth embodiment, the present disclosure provides an assay device for use in detecting, in a liquid biological sample obtained from an individual, an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, the device comprising a matrix defining an axial flow path, the matrix comprising: i) a sample receiving zone at an upstream end of the flow path that receives the liquid sample; ii) one or more test zones positioned within the flow path and downstream from the sample receiving zone, each of said one or more test zones comprising an antibody specific for an enzymatic cleavage product of a protein component of an arteriosclerotic plaque immobilized in each of said test zones, wherein each of said immobilized antibodies is capable of binding different enzymatic cleavage product present in said liquid sample, to form an immobilized antibody/enzymatic cleavage product complex; and iii) one or more control zones positioned within the flow path and downstream from the sample receiving zone. In some embodiments, the protein component is not collagen type III, elastin, decorin, biglycan, versican, apolipoprotein E, C-reactive protein, or lumican.

**[0020]** In some embodiments of a subject assay device, the one or more control zones are positioned between the test zones when two or more test zones are present. In some embodiments of a subject assay device, wherein the test zones and control zones are positioned in an alternating format within the flow path beginning with a test zone positioned upstream of any control zone. In some embodiments of a subject assay device, the assay device further comprises a label zone positioned upstream of a test zone, wherein the

label zone comprises a labeled antibody specific for an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, wherein the labeled antibody is capable of binding an enzymatic cleavage product present in an immobilized antibody/enzymatic cleavage product complex to form a labeled immobilized antibody/enzymatic cleavage product complex, and wherein the labeled antibody is mobilizable in the presence of the liquid sample.

**[0021]** In some embodiments of a subject assay device that include a labeled antibody, the labeled antibody comprises a label component selected from the group consisting of a chemiluminescent agent, a particulate label, a colorimetric agent, an energy transfer agent, an enzyme, a fluorescent agent, and a radioisotope. In some embodiments of a subject assay device, the matrix is positioned within a housing comprising a support and optionally a cover, wherein the housing contains an application aperture and one or more observation ports. In any of the embodiments of a subject assay device, the device can be a test strip or a dipstick assay device. In any of the embodiments of a subject assay device, the liquid sample can be blood, serum, or plasma.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0022]** FIGS. 1A-B provide an amino acid sequence of alpha-1 collagen (type I).

**[0023]** FIGS. 2A-B provide an amino acid sequence of alpha-1 collagen (type II).

**[0024]** FIGS. 3A-B provide an amino acid sequence of alpha-1 collagen (type III).

**[0025]** FIGS. 4A-B provide an amino acid sequence of alpha-1 collagen (type IV).

**[0026]** FIG. 5 provides an amino acid sequence of alpha-1 collagen (type VI).

**[0027]** FIGS. 6A-C provide an amino acid sequence of alpha-3 collagen (type VI).

**[0028]** FIGS. 7A-C provide an amino acid sequence of alpha-1 collagen (type XII).

**[0029]** FIGS. 8A-B provide an amino acid sequence of alpha-1 collagen (type XIV).

**[0030]** FIGS. 9A-B provide an amino acid sequence of alpha-1 collagen (type XV).

**[0031]** FIGS. 10A-B provide an amino acid sequence of alpha-1 collagen (type XVIII).

**[0032]** FIG. 11 provides an amino acid sequence of alpha-1 collagen (type XIX).

**[0033]** FIGS. 12A-B provide an amino acid sequence of alpha-2 collagen (type I).

**[0034]** FIGS. 13A-C provide an amino acid sequence of fibronectin.

**[0035]** FIGS. 14A-C provide an amino acid sequence of fibrillin-1.

**[0036]** FIG. 15 provides an amino acid sequence of dermatopontin.

**[0037]** FIG. 16 provides an amino acid sequence of metalloproteinase inhibitor-1.

**[0038]** FIG. 17 provides an amino acid sequence of galectin-1.

**[0039]** FIG. 18 provides an amino acid sequence of lumican.

**[0040]** FIG. 19 provides an amino acid sequence of prolarigin.

**[0041]** FIGS. 20A and B provide an amino acid sequence of tenascin.

[0042] FIG. 21 provides an amino acid sequence of vitronectin.

[0043] FIGS. 22A-D provide an amino acid sequence of tenascin-X.

[0044] FIGS. 23A and 23B provide an amino acid sequence of collagen alpha-2(IV).

[0045] FIGS. 24A and 24B provide an amino acid sequence of collagen alpha-5(IV).

[0046] FIG. 25 provides an amino acid sequence of elastin.

#### DEFINITIONS

[0047] The terms “polypeptide,” “peptide” and “protein”, used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. The term includes fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusions with heterologous and homologous leader sequences, with or without N-terminal methionine residues; immunologically tagged proteins; and the like. NH<sub>2</sub> refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxyl group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature, *J. Biol. Chem.*, 243 (1969), 3552-59 is used.

[0048] A “biological sample” encompasses a variety of sample types obtained from an individual and can be used in a diagnostic or monitoring assay. The definition encompasses blood, blood products, and other liquid samples of biological origin; and solid tissue samples such as a biopsy specimen. The definition includes biological samples obtained via catheter during or as a result of coronary angiogram; and biological samples obtained during catheterization of a carotid artery, a femoral artery, or the aorta. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as peptides (e.g., enzymatic cleavage products of an arteriosclerotic plaque). The term “biological sample” encompasses a clinical sample, and also includes serum, plasma, biological fluid, and tissue samples. Enzymatic cleavage products of an arteriosclerotic plaque present in a biological sample can be eluted, monomerized, solubilized, etc., or otherwise treated in order to render the enzymatic cleavage products in a physical state suitable for analysis. Enzymatic cleavage products of an arteriosclerotic plaque present in a biological sample can be purified from the liquid sample, e.g., using immunoaffinity methods. For example, magnetic beads comprising an antibody specific for a given enzymatic cleavage product can be used to enrich the cleavage product from a biological sample.

[0049] The terms “individual,” “subject,” “host,” and “patient,” used interchangeably herein, refer to a mammal, including, e.g., humans and non-human primates.

[0050] “Conservative amino acid substitution” refers to a substitution of one amino acid residue for another sharing chemical and physical properties of the amino acid side chain (e.g., charge, size, hydrophobicity/hydrophilicity). “Conservative substitutions” are intended to include substitution within the following groups of amino acid residues: gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr. Guidance for such substitutions can be drawn from alignments of amino acid sequences of polypeptides.

[0051] “Isolated” refers to an entity of interest that is in an environment different from that in which the compound may naturally occur. “Isolated” is meant to include compounds that are within samples that are substantially enriched for the compound of interest and/or in which the compound of interest is partially or substantially purified.

[0052] By “purified” is meant a compound of interest (e.g., a polypeptide) has been separated from components that accompany it in nature. “Purified” can also be used to refer to a compound of interest separated from components that can accompany it during manufacture (e.g., in chemical synthesis). In some embodiments, a compound is substantially pure when it is at least 50% to 60%, by weight, free from organic molecules with which it is naturally associated or with which it is associated during manufacture. In some embodiments, the preparation is at least 75%, at least 90%, at least 95%, or at least 99%, by weight, of the compound of interest. A substantially pure compound can be obtained, for example, by extraction from a natural source (e.g., bacteria), by chemically synthesizing a compound, or by a combination of purification and chemical modification. A substantially pure compound can also be obtained by, for example, enriching a sample that contains the compound. Purity can be measured by any appropriate method, e.g., chromatography, mass spectroscopy, high performance liquid chromatography analysis, etc.

[0053] “Axial flow” as used herein refers to lateral, vertical or transverse flow through a particular matrix or material comprising one or more test and/or control zones. The type of flow contemplated in a particular device, assay or method varies according to the structure of the device. Without being bound by theory, lateral, vertical or transverse flow may refer to flow of a fluid sample from the point of fluid contact on one end or side of a particular matrix (the upstream or proximal end) to an area downstream (or distal) of this contact. The downstream area may be on the same side or on the opposite side of the matrix from the point of fluid contact. For example, in vertical flow devices of the present invention, axial flow may progress vertically from and through a first member (top to bottom) to a second member and from there on to an absorbent medium. By way of further example, and as will be appreciated by those of skill in the art, in a vertical flow device configured, for example, as a dipstick, a fluid sample may flow literally up the device, in which case however, the point of first contact of the fluid sample to the device is nonetheless considered the upstream (i.e., proximal) end and the point of termination of flow the downstream (i.e., distal) end.

[0054] As used herein the terms “upstream” and “downstream” refer to the direction of fluid sample flow subsequent to contact of the fluid sample with a representative device of the present disclosure, wherein, under normal operating conditions, the fluid sample flow direction runs from an upstream position to a downstream position. For example, when fluid sample is initially contacted with the sample receiving zone, the fluid sample then flows downstream through the label zone and so forth.

[0055] Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

**[0056]** Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

**[0057]** Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

**[0058]** It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an enzymatic cleavage product” includes a plurality of such enzymatic cleavage products and reference to “the protease secreted by an inflammatory cell” includes reference to one or more such proteases and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

**[0059]** It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the invention are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed, to the extent that such combinations embrace subject matter that are, for example, compounds that are stable compounds (i.e., compounds that can be made, isolated, characterized, and tested for biological activity). In addition, all sub-combinations of the various embodiments and elements thereof (e.g., elements of the chemical groups listed in the embodiments describing such variables) are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.

**[0060]** The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

## DETAILED DESCRIPTION

**[0061]** The present disclosure provides methods of detecting an unstable arteriosclerotic plaque in an individual, the methods generally involving detecting in a biological sample from the individual an enzymatic cleavage product of a protein component of an arteriosclerotic plaque. The present disclosure provides methods of assessing the risk that an individual will develop an occlusive vascular event. The present disclosure further provides kits for carrying out a subject method.

**[0062]** Stable arteriosclerotic plaques can comprise extracellular matrix (ECM) components. Under certain circumstances, inflammatory cells secrete enzymes that can break down a protein component of an arteriosclerotic plaque. As plaques become unstable, they erode or rupture, exposing prothrombotic stimuli to the blood, which in turn initiates thrombi. Thus, arterial plaque instability is a critical element in occlusive vascular disease events, including myocardial ischemia, myocardial infarction, stroke, and peripheral arterial disease. A hallmark of an unstable arteriosclerotic plaque (also referred to as an “unstable atherosclerotic plaque”) is the presence in an arteriosclerotic plaque of inflammatory cells, which cells secrete enzymes that proteolytically cleave protein components of the plaque, thereby destabilizing the plaque. The present disclosure provides methods of detecting an unstable arteriosclerotic plaque. Detection of an unstable arteriosclerotic plaque can provide an indication of an individual’s risk of developing an occlusive vascular event. Thus, the present disclosure provides methods of determining a risk that an individual will develop an occlusive vascular event. Based on detection an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, a physician or other qualified medical personnel can determine whether appropriate medical intervention is advised, e.g., in order to reduce the risk that an occlusive vascular event will actually occur.

### Methods of Detecting an Unstable Arteriosclerotic Plaque

**[0063]** The present disclosure provides methods of detecting an unstable arteriosclerotic plaque in an individual, the methods generally involving detecting in a biological sample from the individual an enzymatic cleavage product of a protein component of an arteriosclerotic plaque. The enzymatic cleavage products are generated in vivo by enzymes produced by cells in the vasculature.

**[0064]** Protein components of an arteriosclerotic plaque include non-enzymatic proteins. Protein components of an arteriosclerotic plaque include structural proteins.

**[0065]** Enzymatic cleavage products of a protein component of an arteriosclerotic plaque include cleavage products generated by an enzyme produced by a cell in the vasculature (e.g., cleavage products generated in vivo in the vasculature by enzyme(s) produced by a cell (e.g., an inflammatory cell) in the vasculature). Enzymatic cleavage products include unmodified polypeptides and covalently modified polypeptides. Covalently modified polypeptides include polypeptides comprising a covalently linked chemical adduct. For example, a covalently modified polypeptide can include a covalently linked Schiff base modification, such as a fatty aldehyde, a malondialdehyde, and the like.

### Enzymes

**[0066]** An enzymatic cleavage product of a protein component of an arteriosclerotic plaque can be a cleavage product of

an acid protease, a serine protease, a cysteine protease, an aspartic acid protease, a matrix metalloprotease (MMP), and the like. The enzymes are produced in vivo by a cell (e.g., an inflammatory cell) in the vasculature.

**[0067]** Proteolytic cleavage enzymes that may be present in the artery wall, and that can give rise to an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, include, but are not limited to, acid proteases, serine proteases (e.g., elastase-like serine proteases; chymotrypsin-like serine proteases; cysteine proteases; aspartic acid proteases; MMPs; an ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin Motifs) protease (e.g., any one of ADAMTS-1 through ADAMTS-20); and the like. Proteolytic cleavage enzymes that may be present in the artery wall, and that can give rise to an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, include, but are not limited to, cathepsins (e.g., cathepsin K, cathepsin S, cathepsin L, cathepsin B, cathepsin D, cathepsin H, and cystatin C); chymase; tryptase; macrophage metalloproteases; aggrecanases; protease-3; granzymes (e.g., granzyme A, granzyme B, granzyme H, granzyme K, etc.); and the like.

**[0068]** In some instances, an enzymatic cleavage product of a protein component of an arteriosclerotic plaque is a cleavage product of a matrix metalloproteinase (MMP), where MMPs include, e.g., secreted MMPs such as MMP1 (interstitial collagenase); MMP2 (72-kDa gelatinase, or gelatinase-A); MMP3 (stromelysin-1); MMP7 (matrilysin); MMP8 (neutrophil collagenase); MMP9 (92-kDa gelatinase or gelatinase-B); MMP10 (stromelysin-2); MMP11 (stromelysin-3); MMP12 (macrophage metalloprotease); MMP13 (collagenase-3); and MMP16. An enzymatic cleavage product of a protein component of an arteriosclerotic plaque can also be a cleavage product of a cathepsin. In some instances, cleavage products of a cathepsin are specifically excluded.

**[0069]** Enzymes that produce an enzymatic cleavage product of a protein component of an arteriosclerotic plaque can be produced by (e.g., secreted by) inflammatory cells, e.g., macrophages, neutrophils, monocytes, or transformed smooth muscle cells. Thus, in some embodiments, a subject method generally involves detecting in a biological sample from the individual an enzymatic cleavage product (e.g., an in vivo-generated enzymatic cleavage product) of a protein component of an arteriosclerotic plaque, where the enzymatic cleavage product is a product of cleavage by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature.

**[0070]** An enzymatic cleavage product of a protein component of an arteriosclerotic plaque can have a signature structure characteristic of cleavage by an enzyme(s) produced by an inflammatory cell in the vasculature.

#### Enzymatic Cleavage Products

**[0071]** Enzymatic cleavage products of a protein component of an arteriosclerotic plaque include enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by an inflammatory cell in the vasculature) of vascular collagen (where vascular collagen encompasses, e.g., collagen alpha-1 (I) chain; collagen alpha-1 (II) chain; collagen alpha-1 (III) chain; collagen alpha-1 (IV) chain; collagen alpha-1 (VI) chain; collagen alpha-1 (XII); collagen alpha-1 (XIV) chain; collagen alpha-1 (XV) chain; collagen alpha-1 (XVIII); collagen alpha-1 (XIX); collagen alpha-2 (I) chain; collagen alpha-3 (VI); collagen alpha-2 (IV); and collagen alpha-5 (IV)); fibrillin-1; fibronectin; vitronectin; met-

alloproteinase inhibitor 1; dermatopontin; galectin-1; prolargin; tenascin; and tenascin-X. Enzymatic cleavage products of a protein component of an arteriosclerotic plaque can also include enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by an inflammatory cell in the vasculature) of collagen type III, elastin, decorin, biglycan, versican, apolipoprotein E, C-reactive protein, or lumican. In some embodiments, enzymatic cleavage products of one or more of collagen type III, elastin, decorin, biglycan, versican, apolipoprotein E, C-reactive protein, and lumican are specifically excluded. Amino acid sequences of such proteins are known in the art. Exemplary sequences are provided in FIGS. 1-24.

**[0072]** Enzymatic cleavage products to be detected according to a method of the present disclosure can include cleavage products of all, or a subset of, the above-listed proteins. For example, enzymatic cleavage products of a protein component of an arteriosclerotic plaque can include enzymatic cleavage products of all 23, or a subset of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22, of the following set of proteins: 1) fibrillin (fibrillin-1); 2) vitronectin; 3) fibronectin; 4) tenascin; 5) prolargin; 6) dermatopontin; 7) collagen alpha-1 (I) chain; 8) collagen alpha-1 (II) chain; 9) collagen alpha-1 (III) chain; 10) collagen alpha-1 (IV) chain; 11) collagen alpha-1 (VI) chain; 12) collagen alpha-1 (XII); 13) collagen alpha-1 (XIV) chain; 14) collagen alpha-1 (XV) chain; 15) collagen alpha-1 (XVIII); 16) collagen alpha-1 (XIX); 17) collagen alpha-2 (I) chain; 18) collagen alpha-3 (VI); 19) collagen alpha-2 (IV); 20) collagen alpha-5 (IV); 21) metalloproteinase inhibitor 1; 22) galectin-1; and 23) tenascin-X. As an example, enzymatic cleavage products of a protein component of an arteriosclerotic plaque can include enzymatic cleavage products of: collagen alpha-1 (I) chain; collagen alpha-1 (II) chain; collagen alpha-1 (IV) chain; collagen alpha-1 (VI) chain; collagen alpha-1 (XII); collagen alpha-1 (XIV) chain; collagen alpha-1 (XV) chain; collagen alpha-1 (XVIII); collagen alpha-1 (XIX); collagen alpha-2 (I) chain; collagen alpha-3 (VI); collagen alpha-2 (IV); collagen alpha-5 (IV); fibrillin-1; fibronectin; vitronectin; metalloproteinase inhibitor 1; dermatopontin; galectin-1; prolargin; tenascin; and tenascin-X.

**[0073]** Enzymatic cleavage products of one or more of the above-listed proteins can in certain instances be specifically excluded. For example, in some instances, an enzymatic cleavage product of collagen type III is specifically excluded. In some instances, an enzymatic cleavage product of lumican is specifically excluded. In some instances, an enzymatic cleavage product of elastin is specifically excluded. In some instances, an enzymatic cleavage product of one or more of versican, perlecan, decorin, and biglycan is specifically excluded. In some instances, an enzymatic cleavage product of versican, perlecan, decorin, and biglycan is specifically excluded. In some instances, an enzymatic cleavage product of C-reactive protein (CRP) is specifically excluded. In some instances, an enzymatic cleavage product of apolipoprotein-E is specifically excluded.

**[0074]** Enzymatic cleavage products of a protein component of an arteriosclerotic plaque can have a size in a range of from about 0.5 kDa to about 50 kDa, e.g., from about 0.5 kDa to about 1 kDa, from about 1 kDa to about 1.5 kDa, from about 1.5 kDa to about 2 kDa, from about 2 kDa to about 5 kDa, from about 5 kDa to about 7.5 kDa, from about 7.5 kDa to about 10 kDa, from about 10 kDa to about 15 kDa, from about 15 kDa to about 20 kDa, from about 20 kDa to about 25

kDa, from about 25 kDa to about 30 kDa, from about 30 kDa to about 35 kDa, from about 35 kDa to about 40 kDa, from about 40 kDa to about 45 kDa, or from about 45 kDa to about 50 kDa.

**[0075]** An enzymatic cleavage product of a protein component of an arteriosclerotic plaque can have a length of from about 5 amino acids to about 500 amino acids, e.g., from about 5 amino acids (aa) to about 10 aa, from about 10 aa to about 15 aa, from about 15 aa to about 20 aa, from about 20 aa to about 25 aa, from about 25 aa to about 30 aa, from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa to about 50 aa, from about 50 aa to about 75 aa, from about 75 aa to about 100 aa, from about 100 aa to about 150 aa, from about 150 aa to about 200 aa, from about 200 aa to about 250 aa, from about 250 aa to about 300 aa, from about 300 aa to about 350 aa, from about 350 aa to about 400 aa, from about 400 aa to about 450 aa, or from about 450 aa to about 500 aa.

#### Collagens

**[0076]** Collagens are extracellular matrix proteins and have a triple-helical domain as their common structural element. Each collagen molecule includes three polypeptides referred to as alpha chains. For example, the basic structural unit of collagen VI is a heterotrimer of the alpha-1(VI), alpha-2(VI), and alpha-3(VI) chains.

**[0077]** Vascular collagens that are structural components of arteriosclerotic plaques include collagen alpha-1 (I) chain; collagen alpha-1 (II) chain; collagen alpha-1 (III) chain; collagen alpha-1 (IV) chain; collagen alpha-1 (VI) chain; collagen alpha-1 (XII); collagen alpha-1 (XIV) chain; collagen alpha-1 (XV) chain; collagen alpha-1 (XVIII); collagen alpha-1 (XIX); collagen alpha-2 (I) chain; and collagen alpha-3 (VI). Vascular collagen is present in the vasculature.

**[0078]** Exemplary amino acid sequences of collagen alpha-1 (I) chain; collagen alpha-1 (II) chain; collagen alpha-1 (III) chain; collagen alpha-1 (IV) chain; collagen alpha-1 (VI) chain; collagen alpha-1 (XII); collagen alpha-1 (XIV) chain; collagen alpha-1 (XV) chain; collagen alpha-1 (XVIII); collagen alpha-1 (XIX); collagen alpha-2 (I) chain; and collagen alpha-3 (VI) are provided in FIGS. 1-12. Exemplary amino acid sequences of collagen alpha-2 (IV) and collagen alpha-5 (IV) are provided in FIGS. 23 and 24.

**[0079]** An enzymatic cleavage product of a vascular collagen component of an arteriosclerotic plaque can be an enzymatic cleavage product of a collagen polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a collagen polypeptide depicted in one of FIGS. 1-12, 23, and 24. An enzymatic cleavage product of a vascular collagen component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a collagen polypeptide depicted in one of FIGS. 1-12, 23, and 24.

#### Collagen Alpha-1(I) Proteolytic Fragments

**[0080]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(I) chain, listed in sequence order, include:

TGGISVPGPMGPPSGPR;	(SEQ ID NO: 26)
GLPGPPGAPGPQG;	(SEQ ID NO: 27)
GLPGPPGAPGPQGF;	(SEQ ID NO: 28)
PGEPEPEGASGPMGPRGPPGPPGK;	(SEQ ID NO: 29)
GASGPMGPRGPPGPPGK;	(SEQ ID NO: 30)
KPGRPGERGPPGPQGAR;	(SEQ ID NO: 31)
GPPGPQGARGLPGTAGLPGM;	(SEQ ID NO: 32)
AGPQGP;	(SEQ ID NO: 33)
GAPGIAGAPGPPGAR;	(SEQ ID NO: 34)
PGIAGAPGPPGARGPSGPQGGPPGPK;	(SEQ ID NO: 35)
IAGAPGPPGARGPSGPQGGPPGPK;	(SEQ ID NO: 36)
GFPGARGPSGPQGGPPGPK;	(SEQ ID NO: 37)
GPSGPQGGP;	(SEQ ID NO: 38)
GDTGAKGEP;	(SEQ ID NO: 39)
VQGPPEGAGEEGK;	(SEQ ID NO: 40)
GEPGPTGLPGPPG;	(SEQ ID NO: 41)
GEPGPTGLPGPPGERGGPGS;	(SEQ ID NO: 42)
TGLPGPPGER;	(SEQ ID NO: 43)
LPGPPGER;	(SEQ ID NO: 44)
AGPKGPAGER;	(SEQ ID NO: 45)
GSPGPAGPKGSPGEAGRPGEAG;	(SEQ ID NO: 46)
PGEAGRPGEAGLPGAKGLTGSPGSPGPDGK;	(SEQ ID NO: 47)
LTGSPGSPGPDGK;	(SEQ ID NO: 48)
TGPPGPAGQDGRPGPPGPPGARG;	(SEQ ID NO: 49)
PGAVGPAGKDGEAGAQQPPGPAGPAGER;	(SEQ ID NO: 50)
GEAGAQQPPGPAGPAGER;	(SEQ ID NO: 51)

-continued

EAGAQGPPGPAGPAGER; (SEQ ID NO: 52)

VQGPPGPAGPR; (SEQ ID NO: 53)

QGPPGPAGPR\*; (SEQ ID NO: 54)

GPPGPAGPR; (SEQ ID NO: 55)

ANGAPGNDGAKGDAGAPGAPGSGQAPGLQGMPGER; (SEQ ID NO: 56)

LQGMPGER\*; (SEQ ID NO: 57)

LTGPIGPPGPAGAPGDK; (SEQ ID NO: 58)

IGPPGPAGAPGDK; (SEQ ID NO: 59)

KGESGSPGPAGPTGAR; (SEQ ID NO: 60)

PGDRGEPGPPGPAGFAGPPGADGQPGAK; (SEQ ID NO: 61)

GEPGPPGPAGF; (SEQ ID NO: 62)

FAGPPGADGQPGAK\*; (SEQ ID NO: 63)

AGPPGADGQPGAK\*; (SEQ ID NO: 64)

RVGPPGPSGNAGPPGPPGPAGK; (SEQ ID NO: 65)

VGPPGPSGNAGPPGPPGPAGKEGG; (SEQ ID NO: 66)

EVGPPGPPGAGEKGS PGADGPAGAPGTPGPGIAGQR; (SEQ ID NO: 67)

PGPPGPAGEKGS PGADGPAGAPGTPGPGIAGQR; (SEQ ID NO: 68)

GSPGADGPAGAPGTPGPQG; (SEQ ID NO: 69)

GPAGAPGTPGPGIAGQR; (SEQ ID NO: 70)

VVGLPGQR; (SEQ ID NO: 71)

LAGPPGESGR; (SEQ ID NO: 72)

ETGPAGPPGAPGAPGAPGVPVGPAGKSGDR; (SEQ ID NO: 73)

RGETGPAGPAGVPVGPAG; (SEQ ID NO: 74)

PAGVPVGPAG; (SEQ ID NO: 75)

PVGPVGPAG; (SEQ ID NO: 76)

SPGEQGPSGASGPAGPR; (SEQ ID NO: 77)

-continued

PGEQGPSGASGPAGPR; (SEQ ID NO: 78)

GPSGASGPAGPR; (SEQ ID NO: 79)

ASGPAGPR; (SEQ ID NO: 80)

GPPGSAGAPGKD; (SEQ ID NO: 81)

PPGSAGAPGKDGLNGLPGPIGPPGPR; (SEQ ID NO: 82)

and

LPQPPQEK\*; (SEQ ID NO: 83)

**[0081]** and naturally-occurring variants of any of the foregoing.

Collagen Alpha-2(I) Proteolytic Fragments

**[0082]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-2(I) chain, listed in sequence order, include:

GLMGPRGPPGAAGAPGPGQGFQGPAGEPEGPGQTGPAGAR; (SEQ ID NO: 84)

FQGPAGEPEGPGQTGPAGAR; (SEQ ID NO: 85)

QGPAGEPEGPGQTGPAGAR; (SEQ ID NO: 86)

EDGHPGKPRPGERGVVGPQGAR; (SEQ ID NO: 87)

PAGARGSDGSVGPVGPAGPIGSAGPPGFPGAPGPK; (SEQ ID NO: 88)

DGSVGPVGPAGPIGSAGPPGFPGAPGPK; (SEQ ID NO: 89)

PGAPGPKGEIGAVGNAGPAGPAGPR; (SEQ ID NO: 90)

GPAGPAGPR; (SEQ ID NO: 91)

PAGPAGPR; (SEQ ID NO: 92)

RGEVGLPGLSGPVPVGNPANGLTGAK; (SEQ ID NO: 93)

GAPGLPGPR; (SEQ ID NO: 94)

PNGEAGSAGPPGPPGLR; (SEQ ID NO: 95)

GPRGLPGSPGNIGPAGK; (SEQ ID NO: 96)

GRPGPIGPAGAR; (SEQ ID NO: 97)

GPSGPPGPDG; (SEQ ID NO: 98)

-continued

(SEQ ID NO: 99)  
GPSPPGPDGNKGEVVGAVGTAGPS;  
  
(SEQ ID NO: 100)  
GPSGLPGER;  
  
(SEQ ID NO: 101)  
GAVGAPGATGDRGEAGAAGPAGPAGPR;  
  
(SEQ ID NO: 102)  
VGAPGATGDRGEAGAAGPAGPAGPR;  
  
(SEQ ID NO: 103)  
PGPAGATGDRGEAGAAGPAGPAGPR;  
  
(SEQ ID NO: 104)  
NGVVGPTGPGAAGPAGPPGAGSR;  
  
(SEQ ID NO: 105)  
GPPGAGSR;  
  
(SEQ ID NO: 106)  
PGPAGSRGDGPPGMTGPGAAGR;  
  
(SEQ ID NO: 107)  
GDGPPGTMGFPAAAGRTGPPGSGISGPPGPPGA;  
  
(SEQ ID NO: 108)  
ISGPPGPPGAGK;  
  
(SEQ ID NO: 109)  
GPSGEAGTAGPPGTPGQGL;  
  
(SEQ ID NO: 110)  
PGILGLPGSR;  
  
(SEQ ID NO: 111)  
IAGPPGAR;  
  
(SEQ ID NO: 112)  
PGNIGPVAAGAPGPHGVPAGKHGNR;  
  
(SEQ ID NO: 113)  
VGPAGAVGPR;  
  
(SEQ ID NO: 114)  
QGAPGVSVPAGPR;  
  
(SEQ ID NO: 115)  
GPAGPSGPAGK;  
and  
  
(SEQ ID NO: 116)  
GTVGPAGIR,

**[0083]** and naturally-occurring variants of any of the foregoing.

Collagen Alpha-1(III) Proteolytic Fragments

**[0084]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(III) chain, listed in sequence order, include:

(SEQ ID NO: 117)  
GPQGPKGDPGPPGIPGR;  
  
(SEQ ID NO: 118)  
PGTSGHPGSPGPGYQPPGEPGQAGPSGPPGPPGAIGPSGPAGK;  
  
(SEQ ID NO: 119)  
GLPGLPGIKGPAG;

-continued

(SEQ ID NO: 120)  
GEVGPAGSPGNSGAPGQRGEPPGQGHAG;  
  
(SEQ ID NO: 121)  
GEPGPGHAGAQGPPPPGINGSPPGKEMGPAGIPG;  
  
(SEQ ID NO: 122)  
GEMGPAGIPGAPGLMGARGPPGAG;  
  
(SEQ ID NO: 123)  
GIPGAPGLMGAR;  
  
(SEQ ID NO: 124)  
GAPGLMGARGPPGAGANGAPGLR;  
  
(SEQ ID NO: 125)  
PAGERGAPGAPGPR;  
  
(SEQ ID NO: 126)  
GAPGAPGPRGAAGEP;  
  
(SEQ ID NO: 127)  
GEPGRDGVPGPGMR;  
  
(SEQ ID NO: 128)  
DGKPPGSGQGESGRPPGPPSGPR;  
  
(SEQ ID NO: 129)  
GKPPGSGQGESGRPPGPPSGPR;  
  
(SEQ ID NO: 130)  
GRPGPPGPPSGPR;  
  
(SEQ ID NO: 131)  
GPPGPPSGPR;  
  
(SEQ ID NO: 132)  
QGPPKNGETGPQGPPTGPGGDK;  
  
(SEQ ID NO: 133)  
GDAGAPGERGP;  
  
(SEQ ID NO: 134)  
LQGMPPGER;  
  
(SEQ ID NO: 135)  
GEGGPPGVAGPPGSGPAGPPGPGQGV;  
  
(SEQ ID NO: 136)  
GNSGPPGPPGSPGKDGPPGAGNTGAPGSPGVSPPGK;  
  
(SEQ ID NO: 137)  
NGNPPGPPGSPGSPGK;  
  
(SEQ ID NO: 138)  
GSPGAQGGP;  
  
(SEQ ID NO: 139)  
GNPGLDGLPGR;  
  
(SEQ ID NO: 140)  
ENSGPAGPAGPHGPPGPPGVPAGK;  
  
(SEQ ID NO: 141)  
PGAPGAPGHPGPPGVPAGK;  
  
(SEQ ID NO: 142)  
RGESGPAGPAGPAGPAGSR;  
  
(SEQ ID NO: 143)  
GESGPAGPAGAP;  
  
(SEQ ID NO: 144)  
PGAPGSPGAGQQAIGSPGAPGPR;  
  
(SEQ ID NO: 145)  
GQQAIGSPGAPPRGPPGPPGK;

-continued

(SEQ ID NO: 146)  
 QGAIGSPGPAGPR;  
 and

(SEQ ID NO: 147)  
 GSEGSPPGHFGQPGPPGAPGPCCGVGAATAIGIGGEKAGGFAPYYG,

**[0085]** and naturally-occurring variants of any of the foregoing.

#### Collagen Alpha-1(II) Proteolytic Fragments

**[0086]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(II) chain, listed in sequence order, include:

(SEQ ID NO: 148)  
 GPQGFQGNPGEPEPGVSGPMGPRPPGPKPGDDGEGKPKG;

(SEQ ID NO: 149)  
 GAAGARGNDGQPGPAGPPGVPAGGPGFPAGGAPGAK;

(SEQ ID NO: 150)  
 AAGARGNDGQPGPAGPPGVPAGGPGFPAGGAPGAK;

(SEQ ID NO: 151)  
 PGAKGSAGAPGIAGAPGFPGPR;

(SEQ ID NO: 152)  
 GPRGPPGPGQATGPLGPK;

(SEQ ID NO: 153)  
 DGLAGPK;

(SEQ ID NO: 154)  
 PQGKVGPSGAPGEDGRPPGPGQGAR;

(SEQ ID NO: 155)  
 GFPGPKGANGEPGK;

(SEQ ID NO: 156)  
 GLPGPPGPPGEGGKPGDQGVPEAGAPGLVGPR;

(SEQ ID NO: 157)  
 GPPGEGGKPGDQGVPEAGAPGLVGPR;

(SEQ ID NO: 158)  
 LQGMPGER;

(SEQ ID NO: 159)  
 GRGLTGPIPPGAPAGANGEK;

(SEQ ID NO: 160)  
 GLTGPIGPPGAPAGANGEKGEVGP;

(SEQ ID NO: 161)  
 GLTGPIGPPGAPAGANGEKGEVGPAGSAG;

(SEQ ID NO: 162)  
 LTTGPIGPPGAPAGANGEKGEVGPAGSAGAR;

(SEQ ID NO: 163)  
 TGTGPIGPPGAPAGANGEKGEVGPAGSAGAR;

(SEQ ID NO: 164)  
 FAGPPGADGQPGAK\*;

(SEQ ID NO: 165)  
 AGPPGADGQPGAK\*;

(SEQ ID NO: 166)  
 SGPPGRAGEPGLQGPAGPPGKEK;

-continued

(SEQ ID NO: 167)  
 GPPGRAGEPGLQGPAGPPGKEK;

(SEQ ID NO: 168)  
 PPGLTGPAEPGREGSPGADGPPGR;  
 and

(SEQ ID NO: 169)  
 PPGIDMSAFAGLGPKEK,

**[0087]** and naturally-occurring variants of any of the foregoing.

#### Collagen Alpha-1(XIV) Proteolytic Fragments

**[0088]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(XIV) chain, listed in sequence order, include:

(SEQ ID NO: 170)  
 IEWHLNAP;

(SEQ ID NO: 171)  
 AITGPPELITSEVTAR;

(SEQ ID NO: 172)  
 AIYAHTASEGLR;

(SEQ ID NO: 173)  
 LYDVTENSMR;

(SEQ ID NO: 174)  
 YLILYAPLTEGLAGDEKEMK;

(SEQ ID NO: 175)  
 YAPLTEGLAGDEK;

(SEQ ID NO: 176)  
 HVEMTSLCAH;

(SEQ ID NO: 177)  
 SIQGMPPGMPGKEKGEK;

(SEQ ID NO: 178)  
 QVCEQLIQSH;  
 and

(SEQ ID NO: 179)  
 EPGRPGSPGAPGEQGGPPGTPGFPGNAGVPGTPGER;

**[0089]** and naturally-occurring variants of any of the foregoing.

#### Collagen Alpha-1(XII) Proteolytic Fragments

**[0090]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(XII) chain, listed in sequence order, include:

(SEQ ID NO: 180)  
 GGSTNTGKAMTYVRE;

(SEQ ID NO: 181)  
 PKVMILITDGK;

(SEQ ID NO: 182)  
 PDDTHAYNVADFESLSR;

-continued

SVVEDEYSEPLK; (SEQ ID NO: 183)  
 SETSTSLKD; (SEQ ID NO: 184)  
 LKPDTPYITVSSLYPDGEGGRMTG; (SEQ ID NO: 185)  
 PGPAGPGAK; (SEQ ID NO: 186)  
 GRTGTPGLPGPPGMPGPPGDR; (SEQ ID NO: 187)  
 TPGLPGPPGMPGPPGDRGFTGK; (SEQ ID NO: 188)  
 GFPPTPMQGGPPGERLPGEK; (SEQ ID NO: 189)  
 QGPPGER; (SEQ ID NO: 190)  
 and  
 PRGLPGPPGQGESR, (SEQ ID NO: 191)

**[0091]** and naturally-occurring variants of any of the foregoing.

Collagen Alpha-1(XVIII) Proteolytic Fragments

**[0092]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(XVIII) chain, listed in sequence order, include:

PPSLGRPWAPLTGSPVPPSSGR; (SEQ ID NO: 192)  
 PGEDGKPGDTGPQGFPTPGDVGPKGDK; (SEQ ID NO: 193)  
 PGLPGEPEGR; (SEQ ID NO: 194)  
 GREGPPGFPLPGPPGPPGR; (SEQ ID NO: 195)  
 QDGSVLSVPGPEGRPGFAGFPAGPKGNLGSK; (SEQ ID NO: 196)  
 AESSRPGPPGLPGNQGPPGPK; (SEQ ID NO: 197)  
 GPPGPKGAK; (SEQ ID NO: 198)  
 PGPPGPPGTMGASSGVR; (SEQ ID NO: 199)  
 RLPEPQYPGAPHSSSYVHLRPARPTSPPAHSR; (SEQ ID NO: 200)  
 LPEPQYPGAPHSSSY; (SEQ ID NO: 201)  
 NSPLSGGMR; (SEQ ID NO: 202)  
 and  
 PSLGRPWAPLTGSPVPPSSER, (SEQ ID NO: 203)

**[0093]** and naturally-occurring variants of any of the foregoing.

Collagen Alpha-2(IV) Proteolytic Fragments

**[0094]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-2(IV) chain, listed in sequence order, include:

GARGVSGFPADGIPGHPGQGGPR; (SEQ ID NO: 204)  
 GGPKGLPGLPGPPGPTGAK; (SEQ ID NO: 205)  
 GPPGLHGFPGAPQEGPLGIPGREGLPGDR; (SEQ ID NO: 206)  
 APGRPGSPGLPGMPGR; (SEQ ID NO: 207)  
 LYCNPGDVCCYASR; (SEQ ID NO: 208)  
 and  
 LMHTAAGDEGGQSLVSPGSCLEDFR, (SEQ ID NO: 209)

**[0095]** and naturally-occurring variants of any of the foregoing.

Collagen Alpha-1(IV) Proteolytic Fragments

**[0096]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(IV) chain, listed in sequence order, include:

**[0097]** and naturally-occurring variants of any of the foregoing.

EPGPPGLPGSVGSPGVPGIGPPGAR; (SEQ ID NO: 210)  
 PGVPGIGPPGARGPPGQGGPGLSGPPGIK; (SEQ ID NO: 211)  
 PPGGQGGPGLSGPPGIKGEK; (SEQ ID NO: 212)  
 DPGFQGMPIGGSPGITGSK; (SEQ ID NO: 213)  
 KGQQGVTGLVGIPGPPGIPGFDGAPGQK; (SEQ ID NO: 214)  
 SLLYVQGNR; (SEQ ID NO: 215)  
 LFCNINNVCFASR; (SEQ ID NO: 216)  
 VMHTSAGAEGSQALASPGSCLEEFR; (SEQ ID NO: 217)  
 RSAPFIECHGR; (SEQ ID NO: 218)  
 SFWLATIER; (SEQ ID NO: 219)  
 and  
 WLATIER, (SEQ ID NO: 220)

**[0098]** and naturally-occurring variants of any of the foregoing.

## Collagen Alpha-5(IV) Proteolytic Fragments

**[0099]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-5(IV) chain, listed in sequence order, include:

DGIPGPPGPK; (SEQ ID NO: 221)

KGPNPGYPGPPGIQGLPGPTGIPGPIGPPGPPGLMGPGLPGPK; (SEQ ID NO: 222)

PHIPPSDEICEPGPPGPPGSPGDK; (SEQ ID NO: 223)

GLPGLPGPPGSLGFPGQK; (SEQ ID NO: 224)

PKGEPGGITFK; (SEQ ID NO: 225)

TPGRIGLEGPPGPPGFPGPK; (SEQ ID NO: 226)

GPPGRTGLDGLPGPK; (SEQ ID NO: 227)

APGPIGPPGSPGLPGK; (SEQ ID NO: 228)

KGEPGLPGPPGMPDNLGSK; (SEQ ID NO: 229)

PGEPGPVGGGGHPGQPPGPK; (SEQ ID NO: 230)

PALEGPKGNPGPQPPGRPGPTGFQGLPGEGPPGLPGNGGIK; (SEQ ID NO: 231)

and

PPGPPGLPGPSGQSIIK, (SEQ ID NO: 232)

**[0100]** and naturally-occurring variants of any of the foregoing.

## Collagen Alpha-1(XV) Proteolytic Fragments

**[0101]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(XV) chain, listed in sequence order, include:

VDGATGLPGMK; (SEQ ID NO: 233)

KGQAGPPGVMGPPGPPGPPGCTMGLGFED; (SEQ ID NO: 234)

KLQLGELIPIPADSPPPP; (SEQ ID NO: 235)

AWRTADTAVTGLASPLSTGK; (SEQ ID NO: 236)

and

AVTGLASPLSTGKILDQK, (SEQ ID NO: 237)

**[0102]** and naturally-occurring variants of any of the foregoing.

## Collagen Alpha-3(VI) Proteolytic Fragments

**[0103]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-3(VI) chain, listed in sequence order, include:

GVEDADEGALKEIASEPLNMHMFNLENFTSLHDI VGNLVSCVHSSVSPER; (SEQ ID NO: 238)

NNLFTSSAGYR; (SEQ ID NO: 239)

AAPLQGMPLGLLAPLR; (SEQ ID NO: 240)

and

IGDLHPQIVN, (SEQ ID NO: 241)

**[0104]** and naturally-occurring variants thereof.

## Collagen Alpha-1(VI) Proteolytic Fragments

**[0105]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(VI) chain, listed in sequence order, include:

GPQGDQGR; (SEQ ID NO: 242)

TDPAHDVR; (SEQ ID NO: 243)

FSDGNSQGATPAAIEK; (SEQ ID NO: 244)

QVNEPHIR; (SEQ ID NO: 245)

and

GVFHQTVSR, (SEQ ID NO: 246)

**[0106]** and naturally-occurring variants thereof.

## Collagen Alpha-1(XIX) Proteolytic Fragments

**[0107]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of a Collagen alpha-1(XIX) chain, include, e.g., NPGAPGPR (SEQ ID NO:355), and naturally-occurring variants thereof.

## Fibronectin

**[0108]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of fibronectin. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a fibronectin polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a fibronectin polypeptide depicted in FIGS. 13A-C. An enzymatic cleavage product of a fibronectin component of an arteriosclerotic plaque can be an enzymatic

cleavage product of a naturally-occurring variant (polymorphism) of a fibronectin polypeptide depicted in FIGS. 13A-C.

[0109] Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of fibronectin, listed in sequence order, include:

- GPGLLLLAVQCLGTAVPSTGASK; (SEQ ID NO: 247)
- ALVCTCYGGSR; (SEQ ID NO: 248)
- ISCTIANR; (SEQ ID NO: 327)
- MVDCTCLGEGSGR; (SEQ ID NO: 249)
- AAHEEICTTNEGVMYR; (SEQ ID NO: 250)
- SHPIQWNAPQPSHISK; (SEQ ID NO: 251)
- VVSWVSASDTVSGFR; (SEQ ID NO: 252)
- SDTVSPRDLQFVEVTDVK; (SEQ ID NO: 253)
- VDVIPVNLPGEHGQR; (SEQ ID NO: 254)
- VFAVSHGRESKPLTAQQTTK; (SEQ ID NO: 255)
- LGVRPSQGGEAPR; (SEQ ID NO: 256)
- DAPIVNKVVTPLSPTNLH; (SEQ ID NO: 257)
- TPDITGYR; (SEQ ID NO: 258)
- PGTEYVVSSSVYEQHESTPLR; (SEQ ID NO: 259)
- TGLDSPTGIDFSDITANSFTVH; (SEQ ID NO: 260)
- TVHWIAPR; (SEQ ID NO: 261)
- SPVQEFTVPGSK; (SEQ ID NO: 262)
- VVSVYAQNPSGESQLVQTAVTNIDRPK; (SEQ ID NO: 263)
- RPGSEYTVSVVALHDDMESQLIGTQSTAIAPPTDLK; (SEQ ID NO: 264)
- YEVSVYALK; (SEQ ID NO: 265)
- IYLYTLNDNAR; (SEQ ID NO: 266)
- SLLVSWQPPR; (SEQ ID NO: 267)
- YEKPGSPPR; (SEQ ID NO: 268)

- continued

- TPFVTHPG; (SEQ ID NO: 269)
  - TPFVTHPGYDT; (SEQ ID NO: 270)
  - TPFVTHPGYDTGNGIQLPGTSGQQPSVGQQM; (SEQ ID NO: 271)
  - QDTSEYIISCHPVGTDDEEPLQFR; (SEQ ID NO: 272)
  - VPGTSTSATLTGLTRGATYNIIVEALK; (SEQ ID NO: 273)
  - VREEVTVGN; (SEQ ID NO: 274)
  - SVNEGLNQPTDDSCDPYTVSHYAVGDEWER; (SEQ ID NO: 275)
  - and
  - LGFGSGHFR; (SEQ ID NO: 276)
- [0110] and naturally-occurring variants of any of the foregoing.
- Fibrillin**
- [0111] An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of fibrillin, e.g., fibrillin-1. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a fibrillin-1 polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a fibrillin-1 polypeptide depicted in FIGS. 14A-C. An enzymatic cleavage product of a fibrillin-1 component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a fibrillin-1 polypeptide depicted in FIGS. 14A-C.
- [0112] Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of fibrillin, listed in sequence order, include:
- ACEDIDECSLPNICVFGTCHNLPLGLFR; (SEQ ID NO: 277)
  - TGLPVDIDECR; (SEQ ID NO: 278)
  - PVDIDECR; (SEQ ID NO: 279)
  - EIPGVCNGVCINHVGSFR; (SEQ ID NO: 280)
  - EIPGVCENGVCINMVGSR; (SEQ ID NO: 281)
  - LLVCEDIDECQNGPVCQR; (SEQ ID NO: 282)
  - TCVDINECLLEPR; (SEQ ID NO: 283)
  - GEGWGDPCELCPTPEDEAFR; (SEQ ID NO: 284)
  - and

[0113] and naturally-occurring variants thereof.

## Vitronectin

**[0114]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of vitronectin. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a vitronectin polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a vitronectin polypeptide depicted in FIG. 21. An enzymatic cleavage product of a vitronectin component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a vitronectin polypeptide depicted in FIG. 21.

**[0115]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of vitronectin, listed in sequence order, include:

CTDYTAECKPQVTR;	(SEQ ID NO: 285)
IYISGMAPRPS;	(SEQ ID NO: 286)
TCEPIQSVFFFSGDK;	(SEQ ID NO: 287)
SIAQYWLGCAPAGH;	(SEQ ID NO: 288)
and	
WLGCPAPGHL,	(SEQ ID NO: 289)

**[0116]** and naturally-occurring variants of any of the foregoing.

## Metalloproteinase Inhibitor-1

**[0117]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of metalloproteinase inhibitor-1. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a metalloproteinase inhibitor-1 polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a metalloproteinase inhibitor-1 polypeptide depicted in FIG. 16. An enzymatic cleavage product of a metalloproteinase inhibitor-1 component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a metalloproteinase inhibitor-1 polypeptide depicted in FIG. 16.

**[0118]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of metalloproteinase inhibitor-1, listed in sequence order, include:

CNSDLVIR;	(SEQ ID NO: 290)
LQDGLLHITTC;	(SEQ ID NO: 291)
and	
SFVAPWNSLSLAQR,	(SEQ ID NO: 292)

**[0119]** and naturally-occurring variants of any of the foregoing.

## Dermatopontin

**[0120]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of dermatopontin. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a dermatopontin polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a dermatopontin polypeptide depicted in FIG. 15. An enzymatic cleavage product of a dermatopontin component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a dermatopontin polypeptide depicted in FIG. 15.

**[0121]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of dermatopontin, listed in sequence order, include:

SDDGWNLNR;	(SEQ ID NO: 293)
SYQCPQGQVIVAVR;	(SEQ ID NO: 294)
SLGEPTECWWEINR;	(SEQ ID NO: 295)
and	
SNNGLVAGFQSR,	(SEQ ID NO: 296)

**[0122]** and naturally-occurring variants of any of the foregoing.

## Galectin-1

**[0123]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of galectin-1. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a galectin-1 polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a galectin-1 polypeptide depicted in FIG. 17. An enzymatic cleavage product of a galectin-1 component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a galectin-1 polypeptide depicted in FIG. 17.

**[0124]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of galectin-1, listed in sequence order, include:

VASNLNLPKGECLR;	(SEQ ID NO: 297)
GDANTIVCNSK;	(SEQ ID NO: 298)
and	
MAADGDFK,	(SEQ ID NO: 299)

**[0125]** and naturally-occurring variants of any of the foregoing.

Lumican

**[0126]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of lumican. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a lumican polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a lumican polypeptide depicted in FIG. 18. An enzymatic cleavage product of a lumican component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a lumican polypeptide depicted in FIG. 18. In some cases, an enzymatic cleavage product of lumican is specifically excluded.

**[0127]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of lumican, listed in sequence order, include:

- CAPECNCPESYPSAMYCDELK; (SEQ ID NO: 300)
- RNNQIDHIDEK; (SEQ ID NO: 301)
- NNQIDHIDE; (SEQ ID NO: 302)
- ILDHNLLENSK; (SEQ ID NO: 303)
- SLEDLQLTH; (SEQ ID NO: 304)
- IHLQHNR; (SEQ ID NO: 305)
- and
- CKILGPLSYSK; (SEQ ID NO: 306)

**[0128]** and naturally-occurring variants of any of the foregoing.

Prolargin

**[0129]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of prolargin. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a prolargin polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a prolargin polypeptide depicted in FIG. 19. An enzymatic cleavage product of a prolargin component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a prolargin polypeptide depicted in FIG. 19.

**[0130]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of prolargin, listed in sequence order, include:

- EVPSALPR; (SEQ ID NO: 307)
- RLSQNHISR; (SEQ ID NO: 308)

-continued

- RLSQNHISRIPPVFSK; (SEQ ID NO: 309)
- LSDGVFKPDT; (SEQ ID NO: 310)
- NLAHNILR; (SEQ ID NO: 311)
- LAHNILR; (SEQ ID NO: 312)
- LDSNKIETIPNGYFKSFPNLAFIR; (SEQ ID NO: 313)
- IETIPNGYFKSFPNLA; (SEQ ID NO: 314)
- SFPNLAFIRLNLYN; (SEQ ID NO: 315)
- LMNNSIEK; (SEQ ID NO: 316)
- and
- DLVAFHDFSSDLENVPHLR; (SEQ ID NO: 317)

**[0131]** and naturally-occurring variants of any of the foregoing.

Tenascin

**[0132]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of tenascin. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a tenascin polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a tenascin polypeptide depicted in FIGS. 20A and 20B. An enzymatic cleavage product of a tenascin component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a tenascin polypeptide depicted in FIGS. 20A and 20B.

**[0133]** Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of tenascin, listed in sequence order, include:

- ELEPGVEYFIR; (SEQ ID NO: 318)
- TVSIYGVIQGYR; (SEQ ID NO: 319)
- TVTLLHGEVR; (SEQ ID NO: 320)
- and
- FRITYVPITGGTPSMVTVDTGK; (SEQ ID NO: 321)

**[0134]** and naturally-occurring variants of any of the foregoing.

Tenascin-X

**[0135]** An enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic

cleavage product of tenascin-X. For example, an enzymatic cleavage product of a structural component of an arteriosclerotic plaque includes an enzymatic cleavage product of a tenascin-X polypeptide having at least about 98%, at least about 99%, or 100%, amino acid sequence identity with an amino acid sequence of a tenascin-X polypeptide depicted in FIGS. 22A-D. An enzymatic cleavage product of a tenascin-X component of an arteriosclerotic plaque can be an enzymatic cleavage product of a naturally-occurring variant (polymorphism) of a tenascin-X polypeptide depicted in FIGS. 22A-D.

[0136] Non-limiting examples of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) of tenascin-X, listed in sequence order, include:

(SEQ ID NO: 322)  
WRPQPPAEGPGGELTVPGTTRTVS;  
  
(SEQ ID NO: 323)  
FDSFTVQYK;  
  
(SEQ ID NO: 324)  
GEESEVTVGGLEPGR;  
  
(SEQ ID NO: 325)  
EPPNKPR;  
and  
  
(SEQ ID NO: 326)  
GFESEPLTGFLTTPDGPTQ,

[0137] and naturally-occurring variants of any of the foregoing.

[0138] In some embodiments, any one or more of the above-listed fragments is specifically excluded.

Panels

[0139] The present disclosure provides a panel of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature). The panel can include 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, or more than 50, of the above-described enzymatic cleavage products. Thus, the panel can include 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, or more than 50, different enzymatic cleavage products (peptides), selected from the above-described enzymatic cleavage products. Enzymatic cleavage products in the panel can be purified.

[0140] As one non-limiting example, a subject peptide panel includes:

[0141] 1) one or more fibrillin fragments selected from:

(SEQ ID NO: 277)  
ACEDIDECSLPNICVFGTCHNLPGLFR;  
  
(SEQ ID NO: 278)  
TGLPVDIDECR;  
  
(SEQ ID NO: 279)  
PVDIDECR;  
  
(SEQ ID NO: 280)  
EIPGVCNGVCINHVGSFR;  
  
(SEQ ID NO: 281)  
EIPGVCENGVCINMVGSR;

-continued

(SEQ ID NO: 282)  
LLVCEIDIDECQNGPVCQR;  
  
(SEQ ID NO: 283)  
TCVDINECLLEPR;  
  
(SEQ ID NO: 284)  
GEGWGDPCELCPTEPDEAFR;  
and

[0142] and naturally-occurring variants thereof;

[0143] 2) one or more vitronectin fragments selected from:

(SEQ ID NO: 285)  
CTDYTAECKPQVTR;  
  
(SEQ ID NO: 286)  
IYISGMAPRPS;  
  
(SEQ ID NO: 287)  
TCEPIQSVFFFS GDK;  
  
(SEQ ID NO: 288)  
SIAQYWLGC PAPGH;  
and  
  
(SEQ ID NO: 289)  
WLGCPAPGHL,

[0144] and naturally-occurring variants of any of the foregoing;

[0145] 3) one or more fibronectin fragments selected from:

(SEQ ID NO: 247)  
GPGLLLLAVQCLGTAVPSTGASK;  
  
(SEQ ID NO: 248)  
ALVCTCYGGSR;  
  
(SEQ ID NO: 327)  
ISCTIANR;  
  
(SEQ ID NO: 249)  
MVDCTCLGEGSGR;  
  
(SEQ ID NO: 250)  
AAHEEICTTNEGVMYR;  
  
(SEQ ID NO: 251)  
SHPIQWNAPQPSHISK;  
  
(SEQ ID NO: 252)  
VVSWSASDTVSGFR;  
  
(SEQ ID NO: 253)  
SDTVPSPRDLQFVEVTDVK;  
  
(SEQ ID NO: 254)  
VDVIPVNLPGHEGQR;  
  
(SEQ ID NO: 255)  
VFAVSHGRESKPLTAQQTTK;  
  
(SEQ ID NO: 256)  
LGV RPSQGGEAPR;  
  
(SEQ ID NO: 257)  
DAPIV NKVV TPLSPPTNLH;  
  
(SEQ ID NO: 258)  
TPDITGYR;

-continued

PGTEYVSVSSVYEQHESTPLR; (SEQ ID NO: 259)  
 TGLDSPTGIDFSDITANSFTVH; (SEQ ID NO: 260)  
 TVHWIAPR; (SEQ ID NO: 261)  
 SPVQEFVPGSK; (SEQ ID NO: 262)  
 VVSVYAQNPSGESQPLVQTAVTNIDRPK; (SEQ ID NO: 263)  
 RPGSEYTVSVVALHDDMESQPLIGTQSTAIAPATDLK; (SEQ ID NO: 264)  
 YEVSVYALK; (SEQ ID NO: 265)  
 IYLYTLNDNAR; (SEQ ID NO: 266)  
 SLLVSWQPPR; (SEQ ID NO: 267)  
 YEKPGSPPR; (SEQ ID NO: 268)  
 TPFVTHPG; (SEQ ID NO: 269)  
 TPFVTHPGYDT; (SEQ ID NO: 270)  
 TPFVTHPGYDTGNGIQLPGTSGQQPSVGQQM; (SEQ ID NO: 271)  
 QDTSEYIISCHPVGTDDEEPLQFR; (SEQ ID NO: 272)  
 VPGTSTSATLTGLTRGATYNIIVEALK; (SEQ ID NO: 273)  
 VREEVTVGN; (SEQ ID NO: 274)  
 SVNEGLNQPTDDSCFDPPYTVSHYAVGDEWER; (SEQ ID NO: 275)  
 and  
 LGFGSGHFR; (SEQ ID NO: 276)

[0146] and naturally-occurring variants of any of the foregoing.

[0147] A subject panel can further include:

[0148] 4) one or more tenascin peptides selected from:

ELEPGVEYFIR; (SEQ ID NO: 318)  
 TVSIYGVIQGYR; (SEQ ID NO: 319)  
 TVTLHGEVR; (SEQ ID NO: 320)  
 and  
 FRITYVPITGGTPSMVTVDGTK; (SEQ ID NO: 321)

[0149] and naturally-occurring variants of any of the foregoing;

[0150] 5) one or more prolargin peptides selected from:

EVPSALPR; (SEQ ID NO: 307)  
 RLSQNHISR; (SEQ ID NO: 308)  
 RLSQNHISRIPPGVFSK; (SEQ ID NO: 309)  
 LSDGVFKPDT; (SEQ ID NO: 310)  
 NLAHNILR; (SEQ ID NO: 311)  
 LAHNILR; (SEQ ID NO: 312)  
 LDSNKIETIPNGYFKSFPNLAFIR; (SEQ ID NO: 313)  
 IETIPNGYFKSFPNLA; (SEQ ID NO: 314)  
 SFPNLAFIRLNYN; (SEQ ID NO: 315)  
 LMNNSIEK; (SEQ ID NO: 316)  
 and  
 DLVAFHDFSSDLENVPHLR; (SEQ ID NO: 317)

[0151] and naturally-occurring variants of any of the foregoing; and

[0152] 6) one or more dermatopontin peptides selected from:

SDDGWVNLNR; (SEQ ID NO: 293)  
 SYQCPQGQVIVAVR; (SEQ ID NO: 294)  
 SLGEPTECWEEINR; (SEQ ID NO: 295)  
 and  
 SNNGLVAGFQSR; (SEQ ID NO: 296)

[0153] and naturally-occurring variants of any of the foregoing.

[0154] A subject method can involve detecting peptides present in a subject panel. In some embodiments, a subject panel can serve as a control.

[0155] In some embodiments, the enzymatic cleavage products of a subject panel are immobilized on an insoluble support. In some embodiments, the enzymatic cleavage products of a subject panel are detectably labeled.

Further Processing In Vitro

[0156] In some cases, an enzymatic cleavage product generated in the vasculature (e.g., in vivo) is further processed in vitro. In vitro processing of an in vivo-generated enzymatic cleavage product can include enzymatic digestion in vitro. Thus, in some cases, an enzymatic cleavage product generated in the vasculature (e.g., in vivo) is further cleaved enzymatically, e.g., in vitro. Such in vitro cleavage of a cleavage

product produced in vivo may be undertaken in order to characterize an in vivo-generated cleavage product. As an example, an enzymatic cleavage product of a structural component of an unstable arteriosclerotic plaque, generated by an enzyme produced by an inflammatory cell in the vasculature, may be subjected to trypsin digestion or other enzymatic digestion in vitro before the cleavage product is analyzed by mass spectrometry (MS). In vitro enzymatic cleavage can include trypsinization.

**[0157]** Non-limiting examples of trypsin cleavage products of an enzymatic cleavage products of a collagen alpha-1 (VI) component of an arteriosclerotic plaque include:

- 1) (SEQ ID NO: 328)  
LFSDBGNSQGATPAAIEKA;
- 2) (SEQ ID NO: 329)  
RGVVFHQTVSRK;
- 3) (SEQ ID NO: 330)  
RQVNEPHIRV;  
and
- 4) (SEQ ID NO: 331)  
RTDPAHDVRV,

**[0158]** and naturally-occurring variants of any of the foregoing.

**[0159]** A non-limiting example of enzymatic cleavage products of a collagen alpha-3(VI) component of an arteriosclerotic plaque include: IGDLPQIVN (SEQ ID NO:241).

**[0160]** Non-limiting examples of enzymatic cleavage products of fibronectin include, e.g.:

- 1) (SEQ ID NO: 332)  
DAPIVNK;
- 2) (SEQ ID NO: 333)  
SEPLIGR;
- 3) (SEQ ID NO: 334)  
ATITGYR;
- 4) (SEQ ID NO: 335)  
AQITGYR;
- 5) (SEQ ID NO: 336)  
SDTVPSPR;
- 6) (SEQ ID NO: 337)  
VFAVSHGR;
- 7) (SEQ ID NO: 338)  
ISCTIANRC;
- 8) (SEQ ID NO: 339)  
PLTAQQTTK;
- 9) (SEQ ID NO: 340)  
YEVSUYALK;

-continued

- 10) (SEQ ID NO: 341)  
QYNVGPSPVSK;
- 11) (SEQ ID NO: 342)  
GATYNIIVEALK;
- 12) (SEQ ID NO: 343)  
DLQFVEVTDVK;
- 13) (SEQ ID NO: 344)  
LGVRRPSQGGEAPR;
- 14) (SEQ ID NO: 345)  
IYLYTLNDNAR;
- 15) (SEQ ID NO: 346)  
VPGTSTSATLTGLTR;  
and
- 16) (SEQ ID NO: 347)  
VDVIPVNLPGEHGQR,

**[0161]** and naturally-occurring variants thereof.

**[0162]** Non-limiting examples of enzymatic cleavage products of fibrillin-1 include, e.g.:

- 1) (SEQ ID NO: 348)  
KACEDIDECSLPNICVFGTCHNLPGLFRC;
- 2) (SEQ ID NO: 349)  
YTGLPVDIDECRE;
- 3) (SEQ ID NO: 350)  
LPVDIDECRE;
- 4) (SEQ ID NO: 351)  
REIPGVCENGVCINMVGSPRC;
- 5) (SEQ ID NO: 352)  
KLLVCEDIDECQNGPVCQRN;
- 6) (SEQ ID NO: 353)  
RTCVDINECLLEPRK;  
and
- 7) (SEQ ID NO: 354)  
KGEWGDPCELCPTPEDEAFRQ,

**[0163]** and naturally-occurring variants thereof.

#### Detection Methods

**[0164]** An enzymatic cleavage product of a protein component of an arteriosclerotic plaque can be detected using any known method, where suitable methods include, e.g., immunological methods, gel electrophoresis methods, chromatographic methods, and mass spectrometric methods.

#### Immunological Methods

**[0165]** Suitable immunological methods include, e.g., enzyme-linked immunosorbent assay (ELISA), radioimmu-

noassay (RIA), and an immunofixation assay. Immunological assays involve use of antibody specific for an enzymatic cleavage product of a protein component of an arteriosclerotic plaque. In some instances, the primary antibody used in an immunological assay is an antibody specific for an epitope that is exposed upon cleavage of a protein component of an arteriosclerotic plaque, e.g., an epitope that is not accessible to the antibody in the protein in its uncleaved state. For example, an immunological assay can involve use of antibody specific for an epitope that is exposed upon cleavage of a protein component of an arteriosclerotic plaque, e.g., an epitope comprising the newly-formed carboxyl-terminus or amino-terminus of an enzymatic cleavage product of a protein component of an arteriosclerotic plaque. For example, an enzyme(s) produced by an inflammatory cell in the vasculature can proteolytically cleave a protein component of an arteriosclerotic plaque; and the cleavage product would then present epitope(s) (e.g., linear epitopes; conformational epitopes) not presented by the uncleaved protein component, where such epitopes could include the C-terminal amino acids of the cleavage product, or the N-terminal amino acids of the cleavage product.

**[0166]** In some instances, the antibody used in an immunological assay is immobilized on an insoluble (e.g., a solid) support. Suitable supports are well known in the art and comprise, inter alia, commercially available column materials, polystyrene beads, latex beads, magnetic beads, colloid metal particles, glass and/or silicon chips and surfaces, nitrocellulose strips, nylon membranes, sheets, duracytes, wells of reaction trays (e.g., multi-well plates), test strips, plastic tubes, etc. A solid support can comprise any of a variety of substances, including, e.g., glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amylose, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. Suitable methods for immobilizing an antibody onto a solid support are well known and include, but are not limited to ionic, hydrophobic, covalent interactions and the like. Solid supports can be soluble or insoluble, e.g., in aqueous solution. In some embodiments, a suitable solid support is generally insoluble in an aqueous solution.

**[0167]** In some instances, antibody used in an immunological assay comprises a detectable label. Suitable detectable labels include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Suitable include, but are not limited to, magnetic beads (e.g. Dynabeads™), fluorescent dyes (e.g., fluorescein isothiocyanate, texas red, rhodamine, a green fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, and the like), radiolabels (e.g., <sup>3</sup>H, <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, or <sup>32</sup>P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase, luciferase, and others commonly used in an enzyme-linked immunosorbent assay (ELISA)), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g. multistyrene, multipropylene, latex, etc.) beads.

#### Mass Spectrometric Methods

**[0168]** In some cases, a detection method provides size information about an enzymatic cleavage product. Detection methods that provide size information include, e.g., gel electrophoresis methods, and the like. In some cases, a detection method provides size information about an enzymatic cleavage product; and also involves use of an antibody specific for the enzymatic cleavage product.

**[0169]** In some instances, identification of cleavage products is carried out using mass spectrometry. For example, as discussed above, an in vivo-generated enzymatic cleavage product can be subjected to enzymatic digestion in vitro using a specific protease (e.g. trypsin), followed by detection and/or quantitation, of specific peptide products of the in vivo-generated enzymatic cleavage product. Mass spectrometric detection approaches include detection of peptide masses, detection of masses of fragments formed in the mass spectrometer, or a combination of the foregoing (e.g. Selective Reaction Monitoring).

#### Controls

**[0170]** Levels of an enzymatic cleavage product of a protein component of an arteriosclerotic plaque present in a biological sample obtained from a test subject are compared to a normal control value(s) or range of normal control values. The control value can be based on levels of the enzymatic cleavage product in comparable samples (e.g., blood, plasma, or serum sample, or other biological sample) obtained from a control population, e.g., the general population or a select population of human subjects. For example, the select population may be comprised of apparently healthy subjects, e.g., individuals who have not previously had any signs or symptoms of cardiovascular disease. Apparently healthy individuals also generally do not otherwise exhibit symptoms of disease. In other words, such individuals, if examined by a medical professional, would be characterized as healthy and free of symptoms of disease.

**[0171]** The control value can take a variety of forms. The control value can be a single cut-off value, such as a median or mean. A normal control value can be a normal control range. The control value can be established based on comparative groups such as where the risk in one defined group is double the risk in another defined group. The control values can be divided equally (or unequally) into groups, such as a low risk group, a medium risk group and a high-risk group, or into quadrants, the lowest quadrant being individuals with the lowest risk the highest quadrant being individuals with the highest risk, and the test subject's risk of having CVD can be based upon which group his or her test value falls.

#### Biological Samples

**[0172]** Suitable biological samples useful for predicting or monitoring cardiovascular disease in a subject or for assessing the effect of therapeutic agents on subjects with cardiovascular disease include, but are not limited to, whole blood samples, and blood fractions (also referred to as "blood products"), where suitable blood fractions include, but are not limited to, serum and plasma. The biological sample can be fresh blood or stored blood (e.g. in a blood bank) or blood fractions. The biological sample can be a blood sample expressly obtained for an assay of the present disclosure or a blood sample obtained for another purpose which can be subsampled for an assay of the present disclosure. A suitable biological sample can also be a biological sample obtained via catheter during or as a result of coronary angiogram. A suitable biological sample can also be a biological sample obtained during catheterization of a carotid artery.

**[0173]** In one embodiment, the biological sample is whole blood. Whole blood can be obtained from the subject using standard clinical procedures. In another embodiment, the biological sample is plasma. Plasma can be obtained from whole

blood samples by centrifugation of anti-coagulated blood. Such process provides a buffy coat of white cell components and a supernatant of the plasma. In another embodiment, the biological sample is serum.

**[0174]** The sample can be pretreated as necessary by dilution in an appropriate buffer solution, heparinized, concentrated if desired, or fractionated by any number of methods including but not limited to ultracentrifugation, fractionation by fast performance liquid chromatography (FPLC), or precipitation. Any of a number of standard aqueous buffer solutions, employing one of a variety of buffers, such as phosphate, Tris, or the like, at physiological pH can be used.

#### Subjects

**[0175]** Subjects to be tested using a method of the present disclosure include individuals who have experienced one or more typical symptoms of cardiovascular disease; individuals who have experienced an atypical symptom of cardiovascular disease; smokers; non-smokers; individuals who have a body mass index greater than about 25 kg/m<sup>2</sup>, or greater than about 30 kg/m<sup>2</sup>; individuals aged 50 years or older; and apparently healthy individuals. An individual can be male or female. In some instances, the individual is a female who has experienced an atypical symptom of cardiovascular disease, e.g., a symptom not normally associated with cardiovascular disease. In some instances, the individual has a disorder or disease involving a pathological process that pre-disposes the individual to a vascular occlusive event, where such pre-disposing diseases include, but are not limited to, systemic lupus erythematosus. In some instances, the individual does not have a history of having an occlusive vascular event.

**[0176]** In some cases, the individual has a disorder of lipid metabolism that can lead to plaque formation, where such disorders include, e.g., familial hypercholesterolemia; familial combined hyperlipidemia; high-density lipoprotein (HDL) deficiency; and other primary and secondary causes of dyslipidemia.

#### Methods of Assessing Risk of an Occlusive Vascular Event

**[0177]** The present disclosure provides methods of determining a risk that an individual will develop an occlusive vascular event. The methods generally involve determining the level, in a biological sample from the individual, of an in vivo-generated enzymatic cleavage product of a protein component of an arteriosclerotic plaque. A level of the enzymatic cleavage product that is higher than a normal control level indicates risk of developing or experiencing an occlusive vascular event.

**[0178]** In some embodiments, a subject method for determining a risk that an individual will develop an occlusive vascular event comprises: a) assaying the level, in a biological sample from the individual, of an enzymatic cleavage product of a protein component of an arteriosclerotic plaque; and b) identifying the individual as being at risk of developing an occlusive vascular event when the level of the enzymatic cleavage product is higher than a normal control level. In some cases, as discussed below, a subject method for determining a risk that an individual will develop an occlusive vascular event further comprises outputting a report indicating a risk assessment based on said identifying to facilitate a treatment decision by a clinician.

**[0179]** Individuals to be subjected to a risk assessment method of the present disclosure include individuals who

have experienced one or more typical symptoms of cardiovascular disease; individuals who have experienced an atypical symptom of cardiovascular disease; smokers; non-smokers; individuals who have a body mass index greater than about 25 kg/m<sup>2</sup>, or greater than about 30 kg/m<sup>2</sup>; individuals aged 50 years and older; and apparently healthy individuals. An individual can be male or female. In some instances, the individual is a female who has experienced an atypical symptom of cardiovascular disease, e.g., a symptom not normally associated with cardiovascular disease. In some instances, the individual is not otherwise known to be at an elevated risk of having an occlusive vascular event. In some instances, the individual does not have a history of having an occlusive vascular event. In some instances, the individual has a disease or disorder that predisposes the individual to having an occlusive vascular event. In some cases, the individual has a disorder of lipid metabolism that can lead to plaque formation, where such disorders include, e.g., familial hypercholesterolemia; familial combined hyperlipidemia; high-density lipoprotein (HDL) deficiency; and other primary and secondary causes of dyslipidemia.

**[0180]** Suitable biological samples are as described above, and include, but are not limited to, blood; a blood product, such as serum or plasma; a biological sample obtained from a catheter during or as a result of coronary angiogram; and biological samples obtained during catheterization of a carotid artery.

**[0181]** Enzymatic cleavage products of a protein component of an arteriosclerotic plaque, and suitable methods of detecting same, are as described above. Suitable normal controls are as described above.

**[0182]** Occlusive vascular disease events include, but are not limited to, peripheral artery disease, arterial thrombosis, arterial occlusion, occlusive coronary arteriosclerosis, etc.

#### Generating a Report

**[0183]** In some embodiments, a subject method of determining a risk that an individual will develop an occlusive vascular event further involves generating a report. Such a report can include information such as a predicted risk that the patient will experience an occlusive vascular event; a recommendation regarding further evaluation; a recommendation regarding therapeutic drug and/or device intervention; and the like.

**[0184]** For example, the methods disclosed herein can further include a step of generating or outputting a report providing the results of a subject risk assessment, which report can be provided in the form of an electronic medium (e.g., an electronic display on a computer monitor), or in the form of a tangible medium (e.g., a report printed on paper or other tangible medium). An assessment as to the likelihood can be referred to as a "risk report" or, simply, "risk score." A person or entity that prepares a report ("report generator") may also perform steps such as sample gathering, sample processing, and the like. Alternatively, an entity other than the report generator can perform steps such as sample gathering, sample processing, and the like. A risk assessment report can be provided to a user. A "user" can be a health professional (e.g., a clinician, a laboratory technician, a physician (e.g., a cardiologist), etc.).

#### Further Evaluation

**[0185]** Based on detection an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, and/or

based on a report (as described above), a physician or other qualified medical personnel can determine whether further evaluation of the test subject (the patient) is required. Further evaluation can include, e.g., angiogram; electrocardiogram; an echocardiogram; a test for blood (or blood product, such as plasma or serum) triglyceride levels; a test for blood (or blood product, such as plasma or serum) low density lipoprotein levels; a test for blood (or blood product, such as plasma or serum) high density lipoprotein levels; and the like.

#### Therapeutic Intervention

**[0186]** Based on detection of an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, and/or based on a report (as described above), a physician or other qualified medical personnel can determine whether appropriate therapeutic intervention is advised, e.g., in order to reduce the risk that an occlusive vascular event will actually occur. Thus, in some embodiments, a subject method comprises detecting an unstable arteriosclerotic plaque in an individual (where the detection method comprises detecting in a biological sample from the individual an enzymatic cleavage product of a protein component of an arteriosclerotic plaque); and administering to the individual a therapeutic intervention for reducing an arteriosclerotic plaque.

**[0187]** Therapeutic intervention includes drug-based therapeutic intervention, device-based therapeutic intervention, and surgical intervention. Drug-based therapeutic intervention includes, an anti-inflammatory agent, an antithrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, and an angiotensin system inhibitor.

**[0188]** Device-based therapeutic intervention includes, e.g., installation of an intravascular stent; balloon angioplasty; and the like. Surgical intervention includes, e.g., arterial bypass surgery.

#### Kits and Assay Devices

**[0189]** The present disclosure provides a kit for carrying out a method of the present disclosure, e.g., a method of detecting, in a biological sample obtained from an individual, an enzymatic cleavage product of a protein component of an arteriosclerotic plaque. The present disclosure further provides an assay device for carrying out a method of the present disclosure, e.g., a method of detecting, in a biological sample obtained from an individual, an enzymatic cleavage product of a protein component of an arteriosclerotic plaque.

#### Kits

**[0190]** A subject kit can include: a) a binding reagent that specifically binds an enzymatic cleavage product of a protein component of an arteriosclerotic plaque; and b) a control that provides for quantitation of the enzymatic cleavage product.

**[0191]** In some embodiments, a subject kit includes standard enzymatic cleavage products of a protein component of an arteriosclerotic plaque, where the enzymatic cleavage product is of greater than 90% purity, greater than 95% purity, greater than 98% purity, or greater than 99% purity. The standard enzymatic cleavage product can be prepared synthetically, e.g., by incubating a protein component of an arte-

riosclerotic plaque with an enzyme (e.g., an enzyme that is secreted by an inflammatory cell, as described above); and isolating a fragment that corresponds to a fragment that is produced by an unstable arteriosclerotic plaque. The standard enzymatic cleavage product can be prepared synthetically, e.g., using standard chemical methods for peptide synthesis. Thus, in some embodiments, a subject kit includes purified enzymatic cleavage products of a protein component of an arteriosclerotic plaque, where the purified enzymatic cleavage products are suitable for generating a standard curve, e.g., for quantitating an enzymatic cleavage product of a protein component of an arteriosclerotic plaque detected in a test biological sample from a test individual.

**[0192]** In some embodiments, a subject kit includes a panel of purified enzymatic cleavage products of a protein component of an arteriosclerotic plaque, where the purified enzymatic cleavage products are suitable for generating a standard curve, e.g., for quantitating an enzymatic cleavage product of a protein component of an arteriosclerotic plaque detected in a test biological sample from a test individual.

**[0193]** A panel of enzymatic cleavage products (enzymatic cleavage products generated by an enzyme produced by a cell (e.g., an inflammatory cell) in the vasculature) suitable for inclusion in a subject kit can include 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, or more than 50, of the above-described enzymatic cleavage products.

**[0194]** As one non-limiting example, a suitable peptide panel includes:

**[0195]** 1) one or more fibrillin fragments selected from:

(SEQ ID NO: 277)  
ACEDIDECSLPNICVFGTCHNLPGLFR;  
(SEQ ID NO: 278)  
TGLPVDIDECR;  
(SEQ ID NO: 279)  
PVDIDECR;  
(SEQ ID NO: 280)  
EIPGVCNGVCINHVGSFR;  
(SEQ ID NO: 281)  
EIPGVCENGVCINMVGSFR;  
(SEQ ID NO: 282)  
LLVCEDIDECQNGPVCQR;  
(SEQ ID NO: 283)  
TCVDINECLLEPR;  
(SEQ ID NO: 284)  
GEGWDPCELCPTPEDEAFR;  
and

**[0196]** and naturally-occurring variants thereof;

**[0197]** 2) one or more vitronectin fragments selected from:

(SEQ ID NO: 285)  
CTDYTAECKPQVTR;  
(SEQ ID NO: 286)  
IYISGMAPRPS;  
(SEQ ID NO: 287)  
TCEPIQSVFFFS GDK;

-continued

(SEQ ID NO: 288)

SIAQYWLGCPCAPGH;  
and

(SEQ ID NO: 289)

WLGCPCAPGHL,

**[0198]** and naturally-occurring variants of any of the foregoing;

**[0199]** 3) one or more fibronectin fragments selected from:

(SEQ ID NO: 247)

GPGLLLLAVQCCLGTAVPSTGASK;

(SEQ ID NO: 248)

ALVCTCYGGSR;

(SEQ ID NO: 327)

ISCTIANR;

(SEQ ID NO: 249)

MVDCTCLGEGSGR;

(SEQ ID NO: 250)

AAHEEICTTNEGVMYR;

(SEQ ID NO: 251)

SHPIQWNAPQPSHISK;

(SEQ ID NO: 252)

VVSWVSASDTVSGFR;

(SEQ ID NO: 253)

SDTVPSPRDLQFVEVTDVK;

(SEQ ID NO: 254)

VDVIPVNLPGHEGQR;

(SEQ ID NO: 255)

VFAVSHGRESKPLTAQQTK;

(SEQ ID NO: 256)

LGVRPSQGGEAPR;

(SEQ ID NO: 257)

DAPIVNKVVTPSPPTNLH;

(SEQ ID NO: 258)

TPDITGYR;

(SEQ ID NO: 259)

PGTEYVSVSSVYEQHESTPLR;

(SEQ ID NO: 260)

TGLDSPTGIDFSDITANSFTVH;

(SEQ ID NO: 261)

TVHWIAPR;

(SEQ ID NO: 262)

SPVQEFVPGSK;

(SEQ ID NO: 263)

VVSVYAQNPSGESQPLVQTAVTNIDRPF;

(SEQ ID NO: 264)

RPGEYTVSVVALHDDMESQPLIGTQSTAIAPTDLK;

(SEQ ID NO: 265)

YEVSVYALK;

(SEQ ID NO: 266)

IYLYTLNDNAR;

(SEQ ID NO: 267)

SLLVSWQPPR;

-continued

(SEQ ID NO: 268)

YEKPGSPPR;

(SEQ ID NO: 269)

TPFVTHPG;

(SEQ ID NO: 270)

TPFVTHPGYDT;

(SEQ ID NO: 271)

TPFVTHPGYDTGNGIQLPGTSGQQPSVGQQM;

(SEQ ID NO: 272)

QDTSEYIISCHPVGTDEEPLQFR;

(SEQ ID NO: 273)

VPGTSTSATLTGLTRGATYNIIVEALK;

(SEQ ID NO: 274)

VREEVTVGN;

(SEQ ID NO: 275)

SVNEGLNQPTDDSCFPYTVSHYAVGDEWER;  
and

(SEQ ID NO: 276)

LGFGSGHFR,

**[0200]** and naturally-occurring variants of any of the foregoing.

**[0201]** A subject panel can further include:

**[0202]** 4) one or more tenascin peptides selected from:

(SEQ ID NO: 318)

ELEPGVEYFIR;

(SEQ ID NO: 319)

TVSIYGVIQGYR;

(SEQ ID NO: 320)

TVTLHGVEVR;  
and

(SEQ ID NO: 321)

FRITYVPITGGTSPMVTVDGTK,

**[0203]** and naturally-occurring variants of any of the foregoing;

**[0204]** 5) one or more prolargin peptides selected from:

(SEQ ID NO: 307)

EVPSALPR;

(SEQ ID NO: 308)

RLSQNHISR;

(SEQ ID NO: 309)

RLSQNHISRIPPVFSK;

(SEQ ID NO: 310)

LSDGVFKPDT;

(SEQ ID NO: 311)

NLAHNILR;

(SEQ ID NO: 312)

LAHNILR;

(SEQ ID NO: 313)

LDSNKIETIPNGYFKSPNLAIFIR;

-continued

IETIPNGYFKSFPNLA; (SEQ ID NO: 314)  
 SFPNLAFIRLNLYN; (SEQ ID NO: 315)  
 LNNNSIEK; (SEQ ID NO: 316)  
 and  
 DLVAFHDFSSDLENVPHLR, (SEQ ID NO: 317)

[0205] and naturally-occurring variants of any of the foregoing; and

[0206] 6) one or more dermatopontin peptides selected from:

SDDGWVNLNR; (SEQ ID NO: 293)  
 SYQCPQGQVIVAVR; (SEQ ID NO: 294)  
 SLGEPTECWEEINR; (SEQ ID NO: 295)  
 and  
 SNNGLVAGFQSR, (SEQ ID NO: 296)

[0207] and naturally-occurring variants of any of the foregoing.

[0208] In some cases, the reagent that specifically binds an enzymatic cleavage product of a protein component of an arteriosclerotic plaque is an antibody. Suitable antibodies include monoclonal antibodies, and antigen-binding fragments (e.g., a Fv, scFv, Fab, F(ab')<sub>2</sub>, or Fab' fragment). Where the binding reagent is an antibody, the antibody can be immobilized on an insoluble support (e.g., a test strip, a well of a multi-well plate, beads, etc.). Where the binding reagent is an antibody, the antibody can comprise a detectable label. Where the antibody comprises a detectable label, a subject kit can include one or more reagents for developing the detectable label. A labeled antibody can comprise a label such as a chemiluminescent agent, a particulate label, a colorimetric agent, an energy transfer agent, an enzyme, a fluorescent agent, or a radioisotope.

[0209] In some cases, a subject kit includes a plurality of antibodies, where each member of the plurality is specific for a different enzymatic cleavage product of a protein component of an arteriosclerotic plaque. For example, the plurality of antibodies can include individual member antibodies, each of which is specific for a different enzymatic cleavage product of a protein component of an arteriosclerotic plaque present in a panel of such enzymatic cleavage products.

[0210] A suitable antibody includes an antibody specific for an epitope that is exposed upon cleavage of a protein component of an arteriosclerotic plaque, e.g., an epitope comprising the newly-formed carboxyl-terminus or amino-terminus of an enzymatic cleavage product of a protein component of an arteriosclerotic plaque. For example, an enzyme(s) produced by an inflammatory cell in the vasculature can proteolytically cleave a protein component of an arteriosclerotic plaque; and the cleavage product would then present epitope (s) (e.g., linear epitopes; conformational epitopes) not presented by the uncleaved protein component, where such

epitopes could include the C-terminal amino acids of the cleavage product, or the N-terminal amino acids of the cleavage product.

[0211] Other optional components of the kit include: a buffer; a protease inhibitor; a detectable label; etc. The various components of the kit may be present in separate containers or certain compatible components may be pre-combined into a single container, as desired.

[0212] In addition to above-mentioned components, a subject kit can include instructions for using the components of the kit to practice a subject method. The instructions for practicing a subject method are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. compact disc-read only memory (CD-ROM), digital versatile disk (DVD), diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

#### Assay Device

[0213] The present disclosure further provides an assay device for use in detecting, in a liquid biological sample obtained from an individual, an enzymatic cleavage product of an arteriosclerotic plaque. The device can include a matrix defining an axial flow path. The matrix can comprise: i) a sample receiving zone at an upstream end of the flow path that receives the liquid sample; ii) one or more test zones positioned within the flow path and downstream from the sample receiving zone, each of the one or more test zones comprising an antibody specific for an enzymatic cleavage product of an arteriosclerotic plaque in each of the test zones, where each of the immobilized antibodies is capable of binding a different enzymatic cleavage product present in the liquid sample, to form an immobilized enzymatic cleavage product; and iii) one or more control zones positioned within the flow path and downstream from the sample receiving zone, where the one or more control zones can include positive and/or negative controls. The test zones and control zones can be positioned in an alternating format within the flow path beginning with a test zone positioned upstream of any control zone.

[0214] In using such an assay device, in some embodiments, a labeled antibody specific for an enzymatic cleavage product of an arteriosclerotic plaque can first be mixed with a liquid sample before the liquid sample is applied to the sample receiving zone of the device, where such mixing results in a labeled antibody/enzymatic cleavage product complex. In these embodiments, the liquid sample comprising the labeled antibody/enzymatic cleavage product complex is applied to the sample receiving zone of the assay device. The liquid sample flows along the device until the liquid sample reaches a test zone. Antibody present in the test

zone binds an enzymatic cleavage product present in the labeled antibody/enzymatic cleavage product complex; and can then be detected.

**[0215]** The assay device can further include a label zone comprising a labeled antibody specific for an enzymatic cleavage product of an arteriosclerotic plaque, where the labeled antibody is capable of binding a cleavage product present in an immobilized cleavage product complex, to form a labeled enzymatic cleavage product complex, where the labeled antibody is mobilizable in the presence of liquid sample. In using such an assay device, a liquid sample comprising an enzymatic cleavage product of an arteriosclerotic plaque is applied to the sample receiving zone of the device; antibody present in the label zone binds the enzymatic cleavage product, forming labeled antibody/enzymatic cleavage product complex, which, like the labeled antibody, is mobilizable; and the labeled antibody/enzymatic cleavage product complex flows along the device until the liquid sample reaches a test zone. Antibody present in the test zone binds an enzymatic cleavage product present in the labeled antibody/enzymatic cleavage product complex; and can then be detected.

**[0216]** The labeled antibody can comprise a label such as a chemiluminescent agent, a particulate label, a colorimetric agent, an energy transfer agent, an enzyme, a fluorescent agent, or a radioisotope.

**[0217]** Control zones include positive control zones and negative control zones.

**[0218]** The matrix is generally an insoluble support, where suitable insoluble supports include, but are not limited to, polyvinylidene difluoride (PVDF), cellulose, nitrocellulose, nylon, and the like. The matrix can be flexible, or can be relatively inflexible. The matrix can be positioned within a housing comprising a support and optionally a cover, where the housing contains an application aperture and one or more observation ports. The assay device can be in any of a variety of formats, e.g., a test strip, a dipstick; etc.

EXAMPLES

**[0219]** The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations may be used, e.g., bp, base pair(s); kb, kilobase(s); pl, picoliter(s); s or sec, second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); kb, kilobase(s); bp, base pair(s); nt, nucleotide(s); i.m., intramuscular(ly); i.p., intraperitoneal(ly); s.c., subcutaneous(ly); and the like.

Example 1

Identification of Enzymatic Cleavage Products in Unstable Arteriosclerotic Plaques

**[0220]** Arteriosclerotic plaques that appeared unstable by visual inspection were incubated in buffer. Proteins released

from the plaque into the buffer, including any enzymatic cleavage products, were isolated. To facilitate mass spectrometry analysis, the isolated enzymatic cleavage products were trypsinized. The trypsinization products were then subjected to mass spectrometry analysis.

**[0221]** Enzymatic cleavage products that were not solely the result of trypsin digestion (non-tryptic peptides) were identified. Examples of non-tryptic fragments of proteins present in the plaque are listed below. These represent in vivo-generated enzymatic cleavage products from the arteriosclerotic plaques. The peptides are listed in sequence order within each protein. Peptides denoted with an asterisk were detected in more than one protein.

Collagen alpha-1(I) chain fragments	(SEQ ID NO: 26)
TGGISVPGPMGPGS	
GLPGPPGAPGPGQ	(SEQ ID NO: 27)
GLPGPPGAPGPGQF	(SEQ ID NO: 28)
PGEPEGASGPMGPRGPPGPPGK	(SEQ ID NO: 29)
GASGPMGPRGPPGPPGK	(SEQ ID NO: 30)
KPGRPGERGPPGPGGAR	(SEQ ID NO: 31)
GPPGPQGARGLPGTAGLPGM	(SEQ ID NO: 32)
AGPQGPR	(SEQ ID NO: 33)
GAPGIAGAPGPPGAR	(SEQ ID NO: 34)
PGIAGAPGPPGARGPSGPGQGGPPGPK	(SEQ ID NO: 35)
IAGAPGPPGARGPSGPGQGGPPGPK	(SEQ ID NO: 36)
GFPGARGPSGPGQGGPPGPK	(SEQ ID NO: 37)
GPSGPGQGG	(SEQ ID NO: 38)
GDTGAKGEP	(SEQ ID NO: 39)
VQGGPPGAGEGK	(SEQ ID NO: 40)
GEPGPTGLPGPPG	(SEQ ID NO: 41)
GEPGPTGLPGPPGERGGPGS	(SEQ ID NO: 42)
TGLPGPPGER	(SEQ ID NO: 43)
LPGPPGER	(SEQ ID NO: 44)
AGPKGAGER	(SEQ ID NO: 45)

-continued	-continued
GSPGPAGPKGSPGEAGRPEAG	(SEQ ID NO: 46) LAGPPGESGR (SEQ ID NO: 72)
PEAGRPEAGLPGAKGLTGSPPGPDGK	(SEQ ID NO: 47) ETGPAGPPGAPGAPGAPVGPAGKSGDR (SEQ ID NO: 73)
LTGSPGSPGPDGK	(SEQ ID NO: 48) RGETGPAGPAGVGPVGAR (SEQ ID NO: 74)
TGPPGAGQDRPGPPPPGARG	(SEQ ID NO: 49) PAGVGPVGAR (SEQ ID NO: 75)
PGAVGPAGKDGEAGAQPPGPAGPAGER	(SEQ ID NO: 50) PVGPVGAR (SEQ ID NO: 76)
GEAGAQGPPGPAGPAGER	(SEQ ID NO: 51) SPGEQGPSGASGPAGPR (SEQ ID NO: 77)
EAGAQGPPGPAGPAGER	(SEQ ID NO: 52) PGEQGPSGASGPAGPR (SEQ ID NO: 78)
VQGPPGPAGPR	(SEQ ID NO: 53) GPSGASGPAGPR (SEQ ID NO: 79)
QGPPGPAGPR*	(SEQ ID NO: 54) ASGPAGPR (SEQ ID NO: 80)
GPPGPAGPR	(SEQ ID NO: 55) GPPGSAGAPGKD (SEQ ID NO: 81)
ANGAPGNDGAKGDAGAPGAPGSQGAPGLQMPGER	(SEQ ID NO: 56) PPGSAGAPGKDLNGLPGPIGPPGPR (SEQ ID NO: 82)
LQGMPPER*	(SEQ ID NO: 57) and LP QPPQEK* (SEQ ID NO: 83)
LTGPIGPPGPAGAPGDK	(SEQ ID NO: 58) Collagen alpha-2(I) chain fragments (SEQ ID NO: 84)
IGPPGPAGAPGDK	(SEQ ID NO: 59) GLMGPRGPPGAAGAPGQGFQGPAGEPGEPGQTGPAGAR (SEQ ID NO: 85)
KGESGPSGPAGPTGAR	(SEQ ID NO: 60) FQGPAGEPGEPGQTGPAGAR (SEQ ID NO: 86)
PGDRGEPGPPGAGFAGPPGADGQPGAK	(SEQ ID NO: 61) QGPAGEPGEPGQTGPAGAR (SEQ ID NO: 87)
GEPGPPGAGF	(SEQ ID NO: 62) EDGHPGKPRPGERGVVGPQGAR (SEQ ID NO: 88)
FAGPPGADGQPGAK*	(SEQ ID NO: 63) PAGARGSDGSVGPVGPAGPIGSAGPPGFPGAPGPK (SEQ ID NO: 89)
AGPPGADGQPGAK*	(SEQ ID NO: 64) DGSVGPVGPAGPIGSAGPPGFPGAPGPK (SEQ ID NO: 90)
RVGPPGPSGNAGPPGPPGAGK	(SEQ ID NO: 65) PGAPGPKGEIGAVGNAGPAGPAGPR (SEQ ID NO: 91)
VGPPGPSGNAGPPGPPGAGKEGG	(SEQ ID NO: 66) GPAGPAGPR (SEQ ID NO: 92)
EVGPPGPPGAGEKGSFGADGPAGAPGTPGPQGIAGQR	(SEQ ID NO: 67) PAGPAGPR (SEQ ID NO: 93)
PGPPGAGEKGSFGADGPAGAPGTPGPQGIAGQR	(SEQ ID NO: 68) RGEVGLPGLSGPVGPPGNPGANGLTGAK (SEQ ID NO: 94)
GSPGADGPAGAPGTPGPQG	(SEQ ID NO: 69) GAPGLPGR (SEQ ID NO: 95)
GPAGAPGTPGPQGIAGQR	(SEQ ID NO: 70) PNGEAGSAGPPGPPGLR (SEQ ID NO: 96)
VVGLPGQR	(SEQ ID NO: 71) GPRGLPGSPGNIGPAGK

-continued	(SEQ ID NO: 97)	-continued	(SEQ ID NO: 123)
GRPGPIGPAGAR		GIPGAPGLMGAR	
	(SEQ ID NO: 98)		(SEQ ID NO: 124)
GPSGPPGPDG		GAPGLMGARGPPGPAGANGAPGLR	
	(SEQ ID NO: 99)		(SEQ ID NO: 125)
GPSGPPGPDGNKGEPEGVVGAVGTAGPS		PAGERGAPGPAGPR	
	(SEQ ID NO: 100)		(SEQ ID NO: 126)
GPSGLPGER		GAPGPAGPRGAAGEP	
	(SEQ ID NO: 101)		(SEQ ID NO: 127)
GAVGAPGAGATGDRGEAGAAGPAGPAGPR		GEPGRDGVPGGPGMR	
	(SEQ ID NO: 102)		(SEQ ID NO: 128)
VGAPGPAGATGDRGEAGAAGPAGPAGPR		DGKPGPPGSQGESGRPGPPGPGSGPR	
	(SEQ ID NO: 103)		(SEQ ID NO: 129)
PGPAGATGDRGEAGAAGPAGPAGPR		GKPGPPGSQGESGRPGPPGPGSGPR	
	(SEQ ID NO: 104)		(SEQ ID NO: 130)
NGVVGPTGPVGAAGPAGPNGPPGPAGSR		GRPGPPGPGSGPR	
	(SEQ ID NO: 105)		(SEQ ID NO: 131)
GPPGPAGSR		GPPGPGSGPR	
	(SEQ ID NO: 106)		(SEQ ID NO: 132)
PGPAGSRGDGGPPGMTGFPGAAGR		QGPPGKNGETGPQGGPPTGPGGDK	
	(SEQ ID NO: 107)		(SEQ ID NO: 133)
GDGGPPMTGFPGAAGRTGPPGPGSGISGPPGPPGPA		GDAGAPGERGP	
	(SEQ ID NO: 108)		(SEQ ID NO: 134)
ISGPPGPPGPAGK		LQGMPPER	
	(SEQ ID NO: 109)		(SEQ ID NO: 135)
GPSGEAGTAGPPGTPGPQGL		GEGGPPGVAGPPGGSGPAGPPGPQGV	
	(SEQ ID NO: 110)		(SEQ ID NO: 136)
PGILGLPGSR		GSNGNPGPPGSPGSPGKDGPPGPAGNTGAPGSPGVSQPK	
	(SEQ ID NO: 111)		(SEQ ID NO: 137)
IAGPPGAR		NGNPGPPGSPGSPGK	
	(SEQ ID NO: 112)		(SEQ ID NO: 138)
PGNIGPVGAAGAPGPHGVPVGPAGKHGMR		GSPGAQGPP	
	(SEQ ID NO: 113)		(SEQ ID NO: 139)
VGPAGAVGPR		GPNPGSDGLPGR	
	(SEQ ID NO: 114)		(SEQ ID NO: 140)
QGAPGSVGPAGPR		ENGSFGAPGAPGHGPPGPPGVGPAGK	
	(SEQ ID NO: 115)		(SEQ ID NO: 141)
GPAGPSGPAGKD		PGAPGAPGHGPPGPPGVGPAGK	
	(SEQ ID NO: 116)		(SEQ ID NO: 142)
GTVGPAGIR		RGESGPAGPAGAPGPAGSR	
	(SEQ ID NO: 117)		(SEQ ID NO: 143)
Collagen alpha-1(III) chain fragments		GESGPAGPAGAP	
GPQGPKGDGPPGPIGR			(SEQ ID NO: 144)
	(SEQ ID NO: 118)	PGAPGSPGPAQQGAIGSPGPAGPR	
PGTSGHPGSPGSPGYQGPPGEPGQAGPSGPPGPPGAIGPSGPAGK			(SEQ ID NO: 145)
	(SEQ ID NO: 119)	GQQGAIGSPGPAGPRGPVGPSPGPGK	
GLPGPPGIKGPAG			(SEQ ID NO: 146)
	(SEQ ID NO: 120)	QGAIKSPGPAGPR	
GEVGPAGSPGNSGAPGQRGEPGPQGHAG		and	
	(SEQ ID NO: 121)		(SEQ ID NO: 147)
GEPGPQGHAGAQQGPPGPPGINGSPPGKGMGPAGIPG		GSESGPHGQPPGPPGAPGPCCGVGAATAIGIGKEKAGGFAPYYG	
	(SEQ ID NO: 122)		
GEMGPAGIPGAPGLMGARGPPGPAG			

-continued	-continued	
Collagen alpha-1(II)chain fragments	LYDVTENSMR	(SEQ ID NO: 173)
(SEQ ID NO: 148)		
GPQGFQGNPGEPEGVSGPMGPRGPPGPKPGDDGEAGKPGK	YLILYAPLTEGLAGDEKEMK	(SEQ ID NO: 174)
(SEQ ID NO: 149)		
GAAGARGNDGQPGFAGPPGVPVGPAGGPGFPGAPGAK	YAPLTEGLAGDEK	(SEQ ID NO: 175)
(SEQ ID NO: 150)		
AAGARGNDGQPGFAGPPGVPVGPAGGPGFPGAPGAK	HVEMTSLCAH	(SEQ ID NO: 176)
(SEQ ID NO: 151)		
PGAKGSAGAPGIAGAPGFPGPR	SIQGMGMPGKGEK	(SEQ ID NO: 177)
(SEQ ID NO: 152)		
GPRGPPGQGGATGPLGPK	QVCEQLIQSH	(SEQ ID NO: 178)
(SEQ ID NO: 153)		
DGLAGPK	EPGRFGSPGAPGEQGGPPGTPGFPGNAGVPGTPGER	(SEQ ID NO: 179)
(SEQ ID NO: 154)		
PQKVGSPGAPGEDGRPGPPGQGAR	Collagen alpha-1(XII)chain fragments	(SEQ ID NO: 180)
(SEQ ID NO: 155)	GGSTNTGKAMTYVRE	
GFPGPKGANGEPGK	(SEQ ID NO: 181)	
(SEQ ID NO: 156)	PKVMILITDGK	
GLPGLPPGPPGEGGKPGDQGVPGGAGAPGLVGPR	(SEQ ID NO: 182)	
(SEQ ID NO: 157)	PDDTHAYNVADFESLSR	
GPPGEGGKPGDQGVPGGAGAPGLVGPR	(SEQ ID NO: 183)	
(SEQ ID NO: 158)	SVVEDEYSEPLK	
LQGMPPER	(SEQ ID NO: 184)	
(SEQ ID NO: 159)	SETSTSLKD	
GRGLTGPIGPPGAPANGEK	(SEQ ID NO: 185)	
(SEQ ID NO: 160)	LKPDTPYTITVSSLYPDGEGGRMTG	
GLTGPIGPPGAPANGEKGEVGGPP	(SEQ ID NO: 186)	
(SEQ ID NO: 161)	PGPAGGPGAK	
GLTGPIGPPGAPANGEKGEVGGPPGAGSAG	(SEQ ID NO: 187)	
(SEQ ID NO: 162)	GRTGTPLGPPGPMGPPGDR	
LTGPIGPPGAPANGEKGEVGGPPGAGSAGAR	(SEQ ID NO: 188)	
(SEQ ID NO: 163)	TPGLPGPPGPMGPPGDRGFTGK	
TGPIGPPGAPANGEKGEVGGPPGAGSAGAR	(SEQ ID NO: 189)	
(SEQ ID NO: 164)	GFPPTGPMQGGPPGERGLPGEK	
FAGPPGADGQPGAK*	(SEQ ID NO: 190)	
(SEQ ID NO: 165)	QGPPGER	
AGPPGADGQPGAK*	(SEQ ID NO: 191)	
(SEQ ID NO: 166)	PRGLPGPPGQGESR	
SGPPGRAGEPGLQGPAGPPGEK	Collagen alpha-1(XVIII)chain fragments	(SEQ ID NO: 192)
(SEQ ID NO: 167)	PPSLGRPWAPLTGSPVPPSSGR	
GPPGRAGEPGLQGPAGPPGEK	(SEQ ID NO: 193)	
(SEQ ID NO: 168)	PGEDGKPGDTGPGFPGTPGDVGPKGDK	
PPGLTGPAEPGREGSPGADGPPGR	(SEQ ID NO: 194)	
(SEQ ID NO: 169)	PGLGPEPGR	
PGPIDMSAFAGLGPRES	(SEQ ID NO: 195)	
Collagen alpha-1(XIV)chain fragments	GREGPPGPPGLPGPPGPPGR	
(SEQ ID NO: 170)		
IEWHLNAF	(SEQ ID NO: 196)	
(SEQ ID NO: 171)	QDGSVLSVPGPEGRPGFAGFPAGPKGNLGSK	
AITGPTELTITSEVTAR	(SEQ ID NO: 197)	
(SEQ ID NO: 172)	AESSRPGPPGLPGNQGPPGPK	
AIYAHTASEGLR		

-continued	-continued
GPPGPKGAK (SEQ ID NO: 198)	PHIPPSDEICEPGPPGPPGSPGDK (SEQ ID NO: 223)
PGPPGPPGTMGASSGVR (SEQ ID NO: 199)	GLPGLPGPPGSLGFPQK (SEQ ID NO: 224)
RLPEPQYPYGPAPHHSSVHLRPARPTSPPAHSR (SEQ ID NO: 200)	PKGEPGGITFK (SEQ ID NO: 225)
LPEPQYPYGPAPHHSSY (SEQ ID NO: 201)	TPGRIGLEGPPGPPGPPGPK (SEQ ID NO: 226)
NSPLSGGMR (SEQ ID NO: 202)	GPPGRTGLDGLPGPK (SEQ ID NO: 227)
PSLGRPWAPLTGPSVPPSSER (SEQ ID NO: 203)	APGPIGPPGSPGLPGK (SEQ ID NO: 228)
Collagen alpha-2(IV)chain fragments (SEQ ID NO: 204)	KGEPGLPGPPGMDPNLLGSK (SEQ ID NO: 229)
GARGVSGFPGADGIPGHGQGGPR (SEQ ID NO: 205)	PGEPGVGGGHPGQPPGPEK (SEQ ID NO: 230)
GGPKGLPGLPGPPGPTGAK (SEQ ID NO: 206)	PALEGPKGNPGQPPGRPGPTGFQGLPGPEGPPGLPGNGGIK (SEQ ID NO: 231)
GPPGLHGFPGAPGQEGPLGLPGIPGREGLPGDR (SEQ ID NO: 207)	GPPGPPGLPGPSQSIIK (SEQ ID NO: 232)
APGRPGSPGLPGMPGR (SEQ ID NO: 208)	Collagen alpha-1(XV)chain fragments (SEQ ID NO: 233)
LYCNPGDVCYYASR (SEQ ID NO: 209)	VDGATGLPGMK (SEQ ID NO: 234)
LMHTAAGDEGGQSLVSPGSCLEDFR (SEQ ID NO: 210)	KGQAGPPGVMGPPGPPGPPGPGCTMGLGFED (SEQ ID NO: 235)
Collagen alpha-1(IV)chain fragments (SEQ ID NO: 211)	KLQLGELIPIPADSPPPP (SEQ ID NO: 236)
EPGPPGLPGSVGSPGVPGIPPGAR (SEQ ID NO: 212)	AWRTADTAVTGLASPLSTGK (SEQ ID NO: 237)
PGVPGIGPPGARGPPGQGGPGLSGPPGIK (SEQ ID NO: 213)	AVTGLASPLSTGKILDQK (SEQ ID NO: 238)
PPGGQGGPGLSGPPGIKGEK (SEQ ID NO: 214)	Collagen alpha-3(VI)chain fragments (SEQ ID NO: 241)
DPGFQGMPIGGSPGITGSK (SEQ ID NO: 215)	GVEDADEGALKEIASEPLNMHMFNLENFTSLHDIVGNLNVSCVHSSVSPER (SEQ ID NO: 242)
KGQQGVTGLVGIPIGPPGIPGFDGAPGQK (SEQ ID NO: 216)	IGDLHPQIVN (SEQ ID NO: 244)
SLLYVQGNR (SEQ ID NO: 217)	Collagen alpha-1(VI)chain fragments (SEQ ID NO: 247)
LFCNINNVCFASR (SEQ ID NO: 218)	GPQGDQGR (SEQ ID NO: 248)
VMHTSAGAEGSQALASPGSCLEEFR (SEQ ID NO: 219)	FSDGNSQGATPAAIEK (SEQ ID NO: 355)
RSAPFIECHGR (SEQ ID NO: 220)	Collagen alpha-1(XIX)chain fragment (SEQ ID NO: 247)
SFWLATIER (SEQ ID NO: 221)	NPGAPGPR (SEQ ID NO: 247)
WLATIER (SEQ ID NO: 222)	Fibronectin fragments (SEQ ID NO: 248)
Collagen alpha-5(IV)chain fragments (SEQ ID NO: 223)	GPGLLLLAVQCLGTAVPSTGASK (SEQ ID NO: 327)
DGIPGPPGPK (SEQ ID NO: 224)	ALVCTCYGGSR (SEQ ID NO: 249)
(SEQ ID NO: 225)	ISCTIANR (SEQ ID NO: 249)
(SEQ ID NO: 226)	MVDCTCLGEGSGR (SEQ ID NO: 249)
(SEQ ID NO: 227)	
(SEQ ID NO: 228)	
(SEQ ID NO: 229)	
(SEQ ID NO: 230)	
(SEQ ID NO: 231)	
(SEQ ID NO: 232)	
(SEQ ID NO: 233)	
(SEQ ID NO: 234)	
(SEQ ID NO: 235)	
(SEQ ID NO: 236)	
(SEQ ID NO: 237)	
(SEQ ID NO: 238)	
(SEQ ID NO: 239)	
(SEQ ID NO: 240)	
(SEQ ID NO: 241)	
(SEQ ID NO: 242)	
(SEQ ID NO: 243)	
(SEQ ID NO: 244)	
(SEQ ID NO: 245)	
(SEQ ID NO: 246)	
(SEQ ID NO: 247)	
(SEQ ID NO: 248)	
(SEQ ID NO: 249)	
(SEQ ID NO: 250)	
(SEQ ID NO: 251)	
(SEQ ID NO: 252)	
(SEQ ID NO: 253)	
(SEQ ID NO: 254)	
(SEQ ID NO: 255)	
(SEQ ID NO: 256)	
(SEQ ID NO: 257)	
(SEQ ID NO: 258)	
(SEQ ID NO: 259)	
(SEQ ID NO: 260)	
(SEQ ID NO: 261)	
(SEQ ID NO: 262)	
(SEQ ID NO: 263)	
(SEQ ID NO: 264)	
(SEQ ID NO: 265)	
(SEQ ID NO: 266)	
(SEQ ID NO: 267)	
(SEQ ID NO: 268)	
(SEQ ID NO: 269)	
(SEQ ID NO: 270)	
(SEQ ID NO: 271)	
(SEQ ID NO: 272)	
(SEQ ID NO: 273)	
(SEQ ID NO: 274)	
(SEQ ID NO: 275)	
(SEQ ID NO: 276)	
(SEQ ID NO: 277)	
(SEQ ID NO: 278)	
(SEQ ID NO: 279)	
(SEQ ID NO: 280)	
(SEQ ID NO: 281)	
(SEQ ID NO: 282)	
(SEQ ID NO: 283)	
(SEQ ID NO: 284)	
(SEQ ID NO: 285)	
(SEQ ID NO: 286)	
(SEQ ID NO: 287)	
(SEQ ID NO: 288)	
(SEQ ID NO: 289)	
(SEQ ID NO: 290)	
(SEQ ID NO: 291)	
(SEQ ID NO: 292)	
(SEQ ID NO: 293)	
(SEQ ID NO: 294)	
(SEQ ID NO: 295)	
(SEQ ID NO: 296)	
(SEQ ID NO: 297)	
(SEQ ID NO: 298)	
(SEQ ID NO: 299)	
(SEQ ID NO: 300)	

-continued	(SEQ ID NO: 250)	-continued	(SEQ ID NO: 275)
AAHEEICTTNEGVMYR		SVNEGLNQPTDDSCFDPYTVSHYAVGDEWER	
	(SEQ ID NO: 251)		(SEQ ID NO: 276)
SHPIQWNAPQPSHISK		LGFGSGHFR	
	(SEQ ID NO: 252)	Fibrillin fragments	(SEQ ID NO: 278)
VVSWVSASDTVSGFR		TGLPVDIDECR	
	(SEQ ID NO: 253)		(SEQ ID NO: 279)
SDTVPSPRDLQFVEVTDVK		PVDIDECR	
	(SEQ ID NO: 254)	Vitronectin fragments	(SEQ ID NO: 285)
VDVIPVNLPGEHGQR		CTDYTAECKPQVTR	
	(SEQ ID NO: 255)		(SEQ ID NO: 286)
VFAVSHGRESKPLTAQQTTK		IYISGMAPRPS	
	(SEQ ID NO: 256)		(SEQ ID NO: 287)
LGVRPSQGGEAPR		TCEPIQSVFFFSGDK	
	(SEQ ID NO: 257)		(SEQ ID NO: 288)
DAPIVNKVVTPSPPTNLH		SIAQYWLGC PAPGH	
	(SEQ ID NO: 258)		(SEQ ID NO: 289)
TPDITGYR		WLGCPAPGHL	
	(SEQ ID NO: 259)	Metalloproteinase inhibitor 1 fragments	(SEQ ID NO: 290)
PGTEYVVSVSVEQHESTPLR		CNSDLVIR	
	(SEQ ID NO: 260)		(SEQ ID NO: 291)
TGLDSPTGIDFSIDITANSFTVH		LQDGLLHITTC	
	(SEQ ID NO: 261)		(SEQ ID NO: 292)
TVHWIAPR		SFVAPWNSLSLAQR	
	(SEQ ID NO: 262)	Dermatopontin fragments	(SEQ ID NO: 293)
SPVQEFTVPGSK		SDDGWVNLNR	
	(SEQ ID NO: 263)		(SEQ ID NO: 294)
VVSVYAQNPSGESQPLVQTAVTNIDRPK		SYQCPQGQVIVAVR	
	(SEQ ID NO: 264)		(SEQ ID NO: 295)
RPGSEYTVSVVALHDDMESQPLIGTQSTAI PAPTDLK		SLGEPTECWEEINR	
	(SEQ ID NO: 265)		(SEQ ID NO: 296)
YEVSVYALK		SNNGLVAGFQSR	
	(SEQ ID NO: 266)	Galectin-1 fragments	(SEQ ID NO: 297)
IYLYTLNDNAR		VASNLNKPGECLR	
	(SEQ ID NO: 267)		(SEQ ID NO: 298)
SLLVSWQPPR		GDANTIVCNSK	
	(SEQ ID NO: 268)		(SEQ ID NO: 299)
YEKPGSPPR		MAADGDFK	
	(SEQ ID NO: 269)	Lumican fragments	(SEQ ID NO: 300)
TPFVTHPG		CAPECNCPEPSYPSAMYCDELK	
	(SEQ ID NO: 270)		(SEQ ID NO: 301)
TPFVTHPGYDT		RNNQIDHIDEK	
	(SEQ ID NO: 271)		(SEQ ID NO: 302)
TPFVTHPGYDTGNGIQLPGTSGQQPSVGQQM		NNQIDHIDE	
	(SEQ ID NO: 272)		(SEQ ID NO: 303)
QDTSEYIISCHPVGTDEEPLQFR		ILDHNLLENSK	
	(SEQ ID NO: 273)		(SEQ ID NO: 304)
VPGTSTSATLTGLTRGATYNIIVEALK		SLEDLQLTH	
	(SEQ ID NO: 274)		
VREEVTVGN			

-continued		-continued	
IHLQHNR	(SEQ ID NO: 305)	TVTLHGEVR	(SEQ ID NO: 320)
CKILGPLSYSK	(SEQ ID NO: 306)	FRITYVPITGGTPSMVTVDTGK	(SEQ ID NO: 321)
Prolargin fragments		Tenascin-X fragments	(SEQ ID NO: 322)
EVPSALPR	(SEQ ID NO: 307)	WRPQPPAEGPGGELTVPGTTRTVS	(SEQ ID NO: 323)
RLSQNHISR	(SEQ ID NO: 308)	FDSFTVQYK	(SEQ ID NO: 324)
RLSQNHISRIPPGVFSK	(SEQ ID NO: 309)	GESEVTVGGLEPGR	(SEQ ID NO: 325)
LSDGVFKPDT	(SEQ ID NO: 310)	EPPNKPR	(SEQ ID NO: 326)
NLAHNILR	(SEQ ID NO: 311)	GFESEPLTGFLTTVPDGPTQ	
LAHNILR	(SEQ ID NO: 312)	<p><b>Example 2</b>                  Detecting Enzymatic Cleavage Products of an                  Arteriosclerotic Plaque</p>	
LDSNKIETIPNGYFKSFPNLAFIR	(SEQ ID NO: 313)	<p><b>[0222]</b> Blood is drawn into tubes containing buffered ethylenediamine tetraacetic acid (EDTA). Plasma is separated by centrifugation. Target protein fragments are monomerized by addition of 0.005% Tween 20 in 0.005 M phosphate buffer, pH 7.4.</p>	
IETIPNGYFKSFPNLA	(SEQ ID NO: 314)	<p><b>[0223]</b> Target peptide fragments are quantitated by ELISA using monovalent antibodies. Synthetic peptides are used as standards. The contents of target peptides are reported in mass units per mL.</p>	
SFPNLAFIRLNYN	(SEQ ID NO: 315)	<p><b>[0224]</b> While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.</p>	
LMNNSIEK	(SEQ ID NO: 316)		
DLVAFHDFSSDLENVPHLR	(SEQ ID NO: 317)		
Tenascin fragments			
ELEPGVEYFIR	(SEQ ID NO: 318)		
TVSIYGVIQGYR	(SEQ ID NO: 319)		

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 355

<210> SEQ ID NO 1

<211> LENGTH: 1464

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

Met Phe Ser Phe Val Asp Leu Arg Leu Leu Leu Leu Ala Ala Thr  
 1 5 10 15

Ala Leu Leu Thr His Gly Gln Glu Glu Gly Gln Val Glu Gly Gln Asp  
 20 25 30

Glu Asp Ile Pro Pro Ile Thr Cys Val Gln Asn Gly Leu Arg Tyr His  
 35 40 45

Asp Arg Asp Val Trp Lys Pro Glu Pro Cys Arg Ile Cys Val Cys Asp  
 50 55 60

Asn Gly Lys Val Leu Cys Asp Asp Val Ile Cys Asp Glu Thr Lys Asn  
 65 70 75 80

-continued

---

Cys Pro Gly Ala Glu Val Pro Glu Gly Glu Cys Cys Pro Val Cys Pro  
 85 90 95  
 Asp Gly Ser Glu Ser Pro Thr Asp Gln Glu Thr Thr Gly Val Glu Gly  
 100 105 110  
 Pro Lys Gly Asp Thr Gly Pro Arg Gly Pro Arg Gly Pro Ala Gly Pro  
 115 120 125  
 Pro Gly Arg Asp Gly Ile Pro Gly Gln Pro Gly Leu Pro Gly Pro Pro  
 130 135 140  
 Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala  
 145 150 155 160  
 Pro Gln Leu Ser Tyr Gly Tyr Asp Glu Lys Ser Thr Gly Gly Ile Ser  
 165 170 175  
 Val Pro Gly Pro Met Gly Pro Ser Gly Pro Arg Gly Leu Pro Gly Pro  
 180 185 190  
 Pro Gly Ala Pro Gly Pro Gln Gly Phe Gln Gly Pro Pro Gly Glu Pro  
 195 200 205  
 Gly Glu Pro Gly Ala Ser Gly Pro Met Gly Pro Arg Gly Pro Pro Gly  
 210 215 220  
 Pro Pro Gly Lys Asn Gly Asp Asp Gly Glu Ala Gly Lys Pro Gly Arg  
 225 230 235 240  
 Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Leu Pro  
 245 250 255  
 Gly Thr Ala Gly Leu Pro Gly Met Lys Gly His Arg Gly Phe Ser Gly  
 260 265 270  
 Leu Asp Gly Ala Lys Gly Asp Ala Gly Pro Ala Gly Pro Lys Gly Glu  
 275 280 285  
 Pro Gly Ser Pro Gly Glu Asn Gly Ala Pro Gly Gln Met Gly Pro Arg  
 290 295 300  
 Gly Leu Pro Gly Glu Arg Gly Arg Pro Gly Ala Pro Gly Pro Ala Gly  
 305 310 315 320  
 Ala Arg Gly Asn Asp Gly Ala Thr Gly Ala Ala Gly Pro Pro Gly Pro  
 325 330 335  
 Thr Gly Pro Ala Gly Pro Pro Gly Phe Pro Gly Ala Val Gly Ala Lys  
 340 345 350  
 Gly Glu Ala Gly Pro Gln Gly Pro Arg Gly Ser Glu Gly Pro Gln Gly  
 355 360 365  
 Val Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Ala Ala Gly Pro  
 370 375 380  
 Ala Gly Asn Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Ala Asn  
 385 390 395 400  
 Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly Phe Pro Gly Ala Arg Gly  
 405 410 415  
 Pro Ser Gly Pro Gln Gly Pro Gly Gly Pro Pro Gly Pro Lys Gly Asn  
 420 425 430  
 Ser Gly Glu Pro Gly Ala Pro Gly Ser Lys Gly Asp Thr Gly Ala Lys  
 435 440 445  
 Gly Glu Pro Gly Pro Val Gly Val Gln Gly Pro Pro Gly Pro Ala Gly  
 450 455 460  
 Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu Pro Gly Pro Thr Gly Leu  
 465 470 475 480

-continued

---

Pro Gly Pro Pro Gly Glu Arg Gly Gly Pro Gly Ser Arg Gly Phe Pro  
 485 490 495

Gly Ala Asp Gly Val Ala Gly Pro Lys Gly Pro Ala Gly Glu Arg Gly  
 500 505 510

Ser Pro Gly Pro Ala Gly Pro Lys Gly Ser Pro Gly Glu Ala Gly Arg  
 515 520 525

Pro Gly Glu Ala Gly Leu Pro Gly Ala Lys Gly Leu Thr Gly Ser Pro  
 530 535 540

Gly Ser Pro Gly Pro Asp Gly Lys Thr Gly Pro Pro Gly Pro Ala Gly  
 545 550 555 560

Gln Asp Gly Arg Pro Gly Pro Pro Gly Pro Pro Gly Ala Arg Gly Gln  
 565 570 575

Ala Gly Val Met Gly Phe Pro Gly Pro Lys Gly Ala Ala Gly Glu Pro  
 580 585 590

Gly Lys Ala Gly Glu Arg Gly Val Pro Gly Pro Pro Gly Ala Val Gly  
 595 600 605

Pro Ala Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Pro Gly Pro  
 610 615 620

Ala Gly Pro Ala Gly Glu Arg Gly Glu Gln Gly Pro Ala Gly Ser Pro  
 625 630 635 640

Gly Phe Gln Gly Leu Pro Gly Pro Ala Gly Pro Pro Gly Glu Ala Gly  
 645 650 655

Lys Pro Gly Glu Gln Gly Val Pro Gly Asp Leu Gly Ala Pro Gly Pro  
 660 665 670

Ser Gly Ala Arg Gly Glu Arg Gly Phe Pro Gly Glu Arg Gly Val Gln  
 675 680 685

Gly Pro Pro Gly Pro Ala Gly Pro Arg Gly Ala Asn Gly Ala Pro Gly  
 690 695 700

Asn Asp Gly Ala Lys Gly Asp Ala Gly Ala Pro Gly Ala Pro Gly Ser  
 705 710 715 720

Gln Gly Ala Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Ala Ala  
 725 730 735

Gly Leu Pro Gly Pro Lys Gly Asp Arg Gly Asp Ala Gly Pro Lys Gly  
 740 745 750

Ala Asp Gly Ser Pro Gly Lys Asp Gly Val Arg Gly Leu Thr Gly Pro  
 755 760 765

Ile Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly Asp Lys Gly Glu Ser  
 770 775 780

Gly Pro Ser Gly Pro Ala Gly Pro Thr Gly Ala Arg Gly Ala Pro Gly  
 785 790 795 800

Asp Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Phe Ala Gly Pro  
 805 810 815

Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Glu Pro Gly Asp Ala  
 820 825 830

Gly Ala Lys Gly Asp Ala Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly  
 835 840 845

Pro Pro Gly Pro Ile Gly Asn Val Gly Ala Pro Gly Ala Lys Gly Ala  
 850 855 860

Arg Gly Ser Ala Gly Pro Pro Gly Ala Thr Gly Phe Pro Gly Ala Ala  
 865 870 875 880

Gly Arg Val Gly Pro Pro Gly Pro Ser Gly Asn Ala Gly Pro Pro Gly

-continued

885				890				895							
Pro	Pro	Gly	Pro	Ala	Gly	Lys	Glu	Gly	Gly	Lys	Gly	Pro	Arg	Gly	Glu
		900					905							910	
Thr	Gly	Pro	Ala	Gly	Arg	Pro	Gly	Glu	Val	Gly	Pro	Pro	Gly	Pro	Pro
		915					920							925	
Gly	Pro	Ala	Gly	Glu	Lys	Gly	Ser	Pro	Gly	Ala	Asp	Gly	Pro	Ala	Gly
		930				935					940				
Ala	Pro	Gly	Thr	Pro	Gly	Pro	Gln	Gly	Ile	Ala	Gly	Gln	Arg	Gly	Val
		945			950					955					960
Val	Gly	Leu	Pro	Gly	Gln	Arg	Gly	Glu	Arg	Gly	Phe	Pro	Gly	Leu	Pro
			965						970					975	
Gly	Pro	Ser	Gly	Glu	Pro	Gly	Lys	Gln	Gly	Pro	Ser	Gly	Ala	Ser	Gly
			980						985					990	
Glu	Arg	Gly	Pro	Pro	Gly	Pro	Met	Gly	Pro	Pro	Gly	Leu	Ala	Gly	Pro
			995				1000							1005	
Pro	Gly	Glu	Ser	Gly	Arg	Glu	Gly	Ala	Pro	Gly	Ala	Glu	Gly	Ser	
		1010				1015								1020	
Pro	Gly	Arg	Asp	Gly	Ser	Pro	Gly	Ala	Lys	Gly	Asp	Arg	Gly	Glu	
		1025				1030					1035				
Thr	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Ala	Pro	Gly	Ala	Pro	Gly	Ala	
		1040				1045								1050	
Pro	Gly	Pro	Val	Gly	Pro	Ala	Gly	Lys	Ser	Gly	Asp	Arg	Gly	Glu	
		1055				1060					1065				
Thr	Gly	Pro	Ala	Gly	Pro	Ala	Gly	Pro	Val	Gly	Pro	Val	Gly	Ala	
		1070				1075								1080	
Arg	Gly	Pro	Ala	Gly	Pro	Gln	Gly	Pro	Arg	Gly	Asp	Lys	Gly	Glu	
		1085				1090					1095				
Thr	Gly	Glu	Gln	Gly	Asp	Arg	Gly	Ile	Lys	Gly	His	Arg	Gly	Phe	
		1100				1105								1110	
Ser	Gly	Leu	Gln	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Ser	Pro	Gly	Glu	
		1115				1120								1125	
Gln	Gly	Pro	Ser	Gly	Ala	Ser	Gly	Pro	Ala	Gly	Pro	Arg	Gly	Pro	
		1130				1135								1140	
Pro	Gly	Ser	Ala	Gly	Ala	Pro	Gly	Lys	Asp	Gly	Leu	Asn	Gly	Leu	
		1145				1150								1155	
Pro	Gly	Pro	Ile	Gly	Pro	Pro	Gly	Pro	Arg	Gly	Arg	Thr	Gly	Asp	
		1160				1165								1170	
Ala	Gly	Pro	Val	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	
		1175				1180								1185	
Pro	Gly	Pro	Pro	Ser	Ala	Gly	Phe	Asp	Phe	Ser	Phe	Leu	Pro	Gln	
		1190				1195								1200	
Pro	Pro	Gln	Glu	Lys	Ala	His	Asp	Gly	Gly	Arg	Tyr	Tyr	Arg	Ala	
		1205				1210								1215	
Asp	Asp	Ala	Asn	Val	Val	Arg	Asp	Arg	Asp	Leu	Glu	Val	Asp	Thr	
		1220				1225								1230	
Thr	Leu	Lys	Ser	Leu	Ser	Gln	Gln	Ile	Glu	Asn	Ile	Arg	Ser	Pro	
		1235				1240								1245	
Glu	Gly	Ser	Arg	Lys	Asn	Pro	Ala	Arg	Thr	Cys	Arg	Asp	Leu	Lys	
		1250				1255								1260	
Met	Cys	His	Ser	Asp	Trp	Lys	Ser	Gly	Glu	Tyr	Trp	Ile	Asp	Pro	
		1265				1270								1275	

-continued

---

Asn Gln Gly Cys Asn Leu Asp Ala Ile Lys Val Phe Cys Asn Met  
 1280 1285 1290  
 Glu Thr Gly Glu Thr Cys Val Tyr Pro Thr Gln Pro Ser Val Ala  
 1295 1300 1305  
 Gln Lys Asn Trp Tyr Ile Ser Lys Asn Pro Lys Asp Lys Arg His  
 1310 1315 1320  
 Val Trp Phe Gly Glu Ser Met Thr Asp Gly Phe Gln Phe Glu Tyr  
 1325 1330 1335  
 Gly Gly Gln Gly Ser Asp Pro Ala Asp Val Ala Ile Gln Leu Thr  
 1340 1345 1350  
 Phe Leu Arg Leu Met Ser Thr Glu Ala Ser Gln Asn Ile Thr Tyr  
 1355 1360 1365  
 His Cys Lys Asn Ser Val Ala Tyr Met Asp Gln Gln Thr Gly Asn  
 1370 1375 1380  
 Leu Lys Lys Ala Leu Leu Leu Lys Gly Ser Asn Glu Ile Glu Ile  
 1385 1390 1395  
 Arg Ala Glu Gly Asn Ser Arg Phe Thr Tyr Ser Val Thr Val Asp  
 1400 1405 1410  
 Gly Cys Thr Ser His Thr Gly Ala Trp Gly Lys Thr Val Ile Glu  
 1415 1420 1425  
 Tyr Lys Thr Thr Lys Thr Ser Arg Leu Pro Ile Ile Asp Val Ala  
 1430 1435 1440  
 Pro Leu Asp Val Gly Ala Pro Asp Gln Glu Phe Gly Phe Asp Val  
 1445 1450 1455  
 Gly Pro Val Cys Phe Leu  
 1460

&lt;210&gt; SEQ ID NO 2

&lt;211&gt; LENGTH: 1487

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 2

Met Ile Arg Leu Gly Ala Pro Gln Ser Leu Val Leu Leu Thr Leu Leu  
 1 5 10 15  
 Val Ala Ala Val Leu Arg Cys Gln Gly Gln Asp Val Gln Glu Ala Gly  
 20 25 30  
 Ser Cys Val Gln Asp Gly Gln Arg Tyr Asn Asp Lys Asp Val Trp Lys  
 35 40 45  
 Pro Glu Pro Cys Arg Ile Cys Val Cys Asp Thr Gly Thr Val Leu Cys  
 50 55 60  
 Asp Asp Ile Ile Cys Glu Asp Val Lys Asp Cys Leu Ser Pro Glu Ile  
 65 70 75 80  
 Pro Phe Gly Glu Cys Cys Pro Ile Cys Pro Thr Asp Leu Ala Thr Ala  
 85 90 95  
 Ser Gly Gln Pro Gly Pro Lys Gly Gln Lys Gly Glu Pro Gly Asp Ile  
 100 105 110  
 Lys Asp Ile Val Gly Pro Lys Gly Pro Pro Gly Pro Gln Gly Pro Ala  
 115 120 125  
 Gly Glu Gln Gly Pro Arg Gly Asp Arg Gly Asp Lys Gly Glu Lys Gly  
 130 135 140  
 Ala Pro Gly Pro Arg Gly Arg Asp Gly Glu Pro Gly Thr Pro Gly Asn

-continued

---

145	150	155	160
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly	165	170	175
Gly Asn Phe Ala Ala Gln Met Ala Gly Gly Phe Asp Glu Lys Ala Gly	180	185	190
Gly Ala Gln Leu Gly Val Met Gln Gly Pro Met Gly Pro Met Gly Pro	195	200	205
Arg Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly Pro Gln Gly Phe Gln	210	215	220
Gly Asn Pro Gly Glu Pro Gly Glu Pro Gly Val Ser Gly Pro Met Gly	225	230	240
Pro Arg Gly Pro Pro Gly Pro Pro Gly Lys Pro Gly Asp Asp Gly Glu	245	250	255
Ala Gly Lys Pro Gly Lys Ala Gly Glu Arg Gly Pro Pro Gly Pro Gln	260	265	270
Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Val Lys Gly	275	280	285
His Arg Gly Tyr Pro Gly Leu Asp Gly Ala Lys Gly Glu Ala Gly Ala	290	295	300
Pro Gly Val Lys Gly Glu Ser Gly Ser Pro Gly Glu Asn Gly Ser Pro	305	310	320
Gly Pro Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly Arg Thr Gly	325	330	335
Pro Ala Gly Ala Ala Gly Ala Arg Gly Asn Asp Gly Gln Pro Gly Pro	340	345	350
Ala Gly Pro Pro Gly Pro Val Gly Pro Ala Gly Gly Pro Gly Phe Pro	355	360	365
Gly Ala Pro Gly Ala Lys Gly Glu Ala Gly Pro Thr Gly Ala Arg Gly	370	375	380
Pro Glu Gly Ala Gln Gly Pro Arg Gly Glu Pro Gly Thr Pro Gly Ser	385	390	400
Pro Gly Pro Ala Gly Ala Ser Gly Asn Pro Gly Thr Asp Gly Ile Pro	405	410	415
Gly Ala Lys Gly Ser Ala Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly	420	425	430
Phe Pro Gly Pro Arg Gly Pro Pro Gly Pro Gln Gly Ala Thr Gly Pro	435	440	445
Leu Gly Pro Lys Gly Gln Thr Gly Glu Pro Gly Ile Ala Gly Phe Lys	450	455	460
Gly Glu Gln Gly Pro Lys Gly Glu Pro Gly Pro Ala Gly Pro Gln Gly	465	470	480
Ala Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu	485	490	495
Pro Gly Gly Val Gly Pro Ile Gly Pro Pro Gly Glu Arg Gly Ala Pro	500	505	510
Gly Asn Arg Gly Phe Pro Gly Gln Asp Gly Leu Ala Gly Pro Lys Gly	515	520	525
Ala Pro Gly Glu Arg Gly Pro Ser Gly Leu Ala Gly Pro Lys Gly Ala	530	535	540
Asn Gly Asp Pro Gly Arg Pro Gly Glu Pro Gly Leu Pro Gly Ala Arg	545	550	555
			560



-continued

---

Asp Asp Gly Pro Ser Gly Ala Glu Gly Pro Pro Gly Pro Gln Gly Leu  
                                   965                                  970                                  975

Ala Gly Gln Arg Gly Ile Val Gly Leu Pro Gly Gln Arg Gly Glu Arg  
                                   980                                  985                                  990

Gly Phe Pro Gly Leu Pro Gly Pro Ser Gly Glu Pro Gly Lys Gln Gly  
                                   995                                  1000                                  1005

Ala Pro Gly Ala Ser Gly Asp Arg Gly Pro Pro Gly Pro Val Gly  
   1010                                  1015                                  1020

Pro Pro Gly Leu Thr Gly Pro Ala Gly Glu Pro Gly Arg Glu Gly  
   1025                                  1030                                  1035

Ser Pro Gly Ala Asp Gly Pro Pro Gly Arg Asp Gly Ala Ala Gly  
   1040                                  1045                                  1050

Val Lys Gly Asp Arg Gly Glu Thr Gly Ala Val Gly Ala Pro Gly  
   1055                                  1060                                  1065

Ala Pro Gly Pro Pro Gly Ser Pro Gly Pro Ala Gly Pro Thr Gly  
   1070                                  1075                                  1080

Lys Gln Gly Asp Arg Gly Glu Ala Gly Ala Gln Gly Pro Met Gly  
   1085                                  1090                                  1095

Pro Ser Gly Pro Ala Gly Ala Arg Gly Ile Gln Gly Pro Gln Gly  
   1100                                  1105                                  1110

Pro Arg Gly Asp Lys Gly Glu Ala Gly Glu Pro Gly Glu Arg Gly  
   1115                                  1120                                  1125

Leu Lys Gly His Arg Gly Phe Thr Gly Leu Gln Gly Leu Pro Gly  
   1130                                  1135                                  1140

Pro Pro Gly Pro Ser Gly Asp Gln Gly Ala Ser Gly Pro Ala Gly  
   1145                                  1150                                  1155

Pro Ser Gly Pro Arg Gly Pro Pro Gly Pro Val Gly Pro Ser Gly  
   1160                                  1165                                  1170

Lys Asp Gly Ala Asn Gly Ile Pro Gly Pro Ile Gly Pro Pro Gly  
   1175                                  1180                                  1185

Pro Arg Gly Arg Ser Gly Glu Thr Gly Pro Ala Gly Pro Pro Gly  
   1190                                  1195                                  1200

Asn Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Gly Ile  
   1205                                  1210                                  1215

Asp Met Ser Ala Phe Ala Gly Leu Gly Pro Arg Glu Lys Gly Pro  
   1220                                  1225                                  1230

Asp Pro Leu Gln Tyr Met Arg Ala Asp Gln Ala Ala Gly Gly Leu  
   1235                                  1240                                  1245

Arg Gln His Asp Ala Glu Val Asp Ala Thr Leu Lys Ser Leu Asn  
   1250                                  1255                                  1260

Asn Gln Ile Glu Ser Ile Arg Ser Pro Glu Gly Ser Arg Lys Asn  
   1265                                  1270                                  1275

Pro Ala Arg Thr Cys Arg Asp Leu Lys Leu Cys His Pro Glu Trp  
   1280                                  1285                                  1290

Lys Ser Gly Asp Tyr Trp Ile Asp Pro Asn Gln Gly Cys Thr Leu  
   1295                                  1300                                  1305

Asp Ala Met Lys Val Phe Cys Asn Met Glu Thr Gly Glu Thr Cys  
   1310                                  1315                                  1320

Val Tyr Pro Asn Pro Ala Asn Val Pro Lys Lys Asn Trp Trp Ser  
   1325                                  1330                                  1335

Ser Lys Ser Lys Glu Lys Lys His Ile Trp Phe Gly Glu Thr Ile

-continued

1340	1345	1350
Asn Gly Gly Phe His Phe Ser Tyr Gly Asp Asp Asn Leu Ala Pro		
1355	1360	1365
Asn Thr Ala Asn Val Gln Met Thr Phe Leu Arg Leu Leu Ser Thr		
1370	1375	1380
Glu Gly Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala		
1385	1390	1395
Tyr Leu Asp Glu Ala Ala Gly Asn Leu Lys Lys Ala Leu Leu Ile		
1400	1405	1410
Gln Gly Ser Asn Asp Val Glu Ile Arg Ala Glu Gly Asn Ser Arg		
1415	1420	1425
Phe Thr Tyr Thr Ala Leu Lys Asp Gly Cys Thr Lys His Thr Gly		
1430	1435	1440
Lys Trp Gly Lys Thr Val Ile Glu Tyr Arg Ser Gln Lys Thr Ser		
1445	1450	1455
Arg Leu Pro Ile Ile Asp Ile Ala Pro Met Asp Ile Gly Gly Pro		
1460	1465	1470
Glu Gln Glu Phe Gly Val Asp Ile Gly Pro Val Cys Phe Leu		
1475	1480	1485

<210> SEQ ID NO 3  
 <211> LENGTH: 1466  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

Met Met Ser Phe Val Gln Lys Gly Ser Trp Leu Leu Leu Ala Leu Leu		
1	5	10 15
His Pro Thr Ile Ile Leu Ala Gln Gln Glu Ala Val Glu Gly Gly Cys		
	20	25 30
Ser His Leu Gly Gln Ser Tyr Ala Asp Arg Asp Val Trp Lys Pro Glu		
	35	40 45
Pro Cys Gln Ile Cys Val Cys Asp Ser Gly Ser Val Leu Cys Asp Asp		
	50	55 60
Ile Ile Cys Asp Asp Gln Glu Leu Asp Cys Pro Asn Pro Glu Ile Pro		
65	70	75 80
Phe Gly Glu Cys Cys Ala Val Cys Pro Gln Pro Pro Thr Ala Pro Thr		
	85	90 95
Arg Pro Pro Asn Gly Gln Gly Pro Gln Gly Pro Lys Gly Asp Pro Gly		
	100	105 110
Pro Pro Gly Ile Pro Gly Arg Asn Gly Asp Pro Gly Ile Pro Gly Gln		
	115	120 125
Pro Gly Ser Pro Gly Ser Pro Gly Pro Pro Gly Ile Cys Glu Ser Cys		
	130	135 140
Pro Thr Gly Pro Gln Asn Tyr Ser Pro Gln Tyr Asp Ser Tyr Asp Val		
145	150	155 160
Lys Ser Gly Val Ala Val Gly Gly Leu Ala Gly Tyr Pro Gly Pro Ala		
	165	170 175
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Thr Ser Gly His Pro Gly		
	180	185 190
Ser Pro Gly Ser Pro Gly Tyr Gln Gly Pro Pro Gly Glu Pro Gly Gln		
	195	200 205

-continued

---

Ala	Gly	Pro	Ser	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Ala	Ile	Gly	Pro	Ser
210						215					220				
Gly	Pro	Ala	Gly	Lys	Asp	Gly	Glu	Ser	Gly	Arg	Pro	Gly	Arg	Pro	Gly
225					230					235					240
Glu	Arg	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Ile	Lys	Gly	Pro	Ala	Gly	Ile
			245						250					255	
Pro	Gly	Phe	Pro	Gly	Met	Lys	Gly	His	Arg	Gly	Phe	Asp	Gly	Arg	Asn
		260						265					270		
Gly	Glu	Lys	Gly	Glu	Thr	Gly	Ala	Pro	Gly	Leu	Lys	Gly	Glu	Asn	Gly
		275					280					285			
Leu	Pro	Gly	Glu	Asn	Gly	Ala	Pro	Gly	Pro	Met	Gly	Pro	Arg	Gly	Ala
	290					295					300				
Pro	Gly	Glu	Arg	Gly	Arg	Pro	Gly	Leu	Pro	Gly	Ala	Ala	Gly	Ala	Arg
305					310					315					320
Gly	Asn	Asp	Gly	Ala	Arg	Gly	Ser	Asp	Gly	Gln	Pro	Gly	Pro	Pro	Gly
			325						330					335	
Pro	Pro	Gly	Thr	Ala	Gly	Phe	Pro	Gly	Ser	Pro	Gly	Ala	Lys	Gly	Glu
			340					345					350		
Val	Gly	Pro	Ala	Gly	Ser	Pro	Gly	Ser	Asn	Gly	Ala	Pro	Gly	Gln	Arg
		355					360					365			
Gly	Glu	Pro	Gly	Pro	Gln	Gly	His	Ala	Gly	Ala	Gln	Gly	Pro	Pro	Gly
	370					375					380				
Pro	Pro	Gly	Ile	Asn	Gly	Ser	Pro	Gly	Gly	Lys	Gly	Glu	Met	Gly	Pro
385					390					395					400
Ala	Gly	Ile	Pro	Gly	Ala	Pro	Gly	Leu	Met	Gly	Ala	Arg	Gly	Pro	Pro
			405					410						415	
Gly	Pro	Ala	Gly	Ala	Asn	Gly	Ala	Pro	Gly	Leu	Arg	Gly	Gly	Ala	Gly
		420					425						430		
Glu	Pro	Gly	Lys	Asn	Gly	Ala	Lys	Gly	Glu	Pro	Gly	Pro	Arg	Gly	Glu
		435				440						445			
Arg	Gly	Glu	Ala	Gly	Ile	Pro	Gly	Val	Pro	Gly	Ala	Lys	Gly	Glu	Asp
	450					455					460				
Gly	Lys	Asp	Gly	Ser	Pro	Gly	Glu	Pro	Gly	Ala	Asn	Gly	Leu	Pro	Gly
465					470					475					480
Ala	Ala	Gly	Glu	Arg	Gly	Ala	Pro	Gly	Phe	Arg	Gly	Pro	Ala	Gly	Pro
			485						490					495	
Asn	Gly	Ile	Pro	Gly	Glu	Lys	Gly	Pro	Ala	Gly	Glu	Arg	Gly	Ala	Pro
		500						505						510	
Gly	Pro	Ala	Gly	Pro	Arg	Gly	Ala	Ala	Gly	Glu	Pro	Gly	Arg	Asp	Gly
		515					520						525		
Val	Pro	Gly	Gly	Pro	Gly	Met	Arg	Gly	Met	Pro	Gly	Ser	Pro	Gly	Gly
	530					535						540			
Pro	Gly	Ser	Asp	Gly	Lys	Pro	Gly	Pro	Pro	Gly	Ser	Gln	Gly	Glu	Ser
545					550					555					560
Gly	Arg	Pro	Gly	Pro	Pro	Gly	Pro	Ser	Gly	Pro	Arg	Gly	Gln	Pro	Gly
			565					570						575	
Val	Met	Gly	Phe	Pro	Gly	Pro	Lys	Gly	Asn	Asp	Gly	Ala	Pro	Gly	Lys
			580					585					590		
Asn	Gly	Glu	Arg	Gly	Gly	Pro	Gly	Gly	Pro	Gly	Pro	Gln	Gly	Pro	Pro
		595					600					605			
Gly	Lys	Asn	Gly	Glu	Thr	Gly	Pro	Gln	Gly	Pro	Pro	Gly	Pro	Thr	Gly

-continued

610	615	620
Pro Gly Gly Asp Lys Gly Asp Thr Gly Pro Pro Gly Pro Gln Gly Leu 625 630 635 640		
Gln Gly Leu Pro Gly Thr Gly Gly Pro Pro Gly Glu Asn Gly Lys Pro 645 650 655		
Gly Glu Pro Gly Pro Lys Gly Asp Ala Gly Ala Pro Gly Ala Pro Gly 660 665 670		
Gly Lys Gly Asp Ala Gly Ala Pro Gly Glu Arg Gly Pro Pro Gly Leu 675 680 685		
Ala Gly Ala Pro Gly Leu Arg Gly Gly Ala Gly Pro Pro Gly Pro Glu 690 695 700		
Gly Gly Lys Gly Ala Ala Gly Pro Pro Gly Pro Pro Gly Ala Ala Gly 705 710 715 720		
Thr Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Gly Leu Gly Ser 725 730 735		
Pro Gly Pro Lys Gly Asp Lys Gly Glu Pro Gly Gly Pro Gly Ala Asp 740 745 750		
Gly Val Pro Gly Lys Asp Gly Pro Arg Gly Pro Thr Gly Pro Ile Gly 755 760 765		
Pro Pro Gly Pro Ala Gly Gln Pro Gly Asp Lys Gly Glu Gly Gly Ala 770 775 780		
Pro Gly Leu Pro Gly Ile Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg 785 790 795 800		
Gly Glu Thr Gly Pro Pro Gly Pro Ala Gly Phe Pro Gly Ala Pro Gly 805 810 815		
Gln Asn Gly Glu Pro Gly Gly Lys Gly Glu Arg Gly Ala Pro Gly Glu 820 825 830		
Lys Gly Glu Gly Gly Pro Pro Gly Val Ala Gly Pro Pro Gly Gly Ser 835 840 845		
Gly Pro Ala Gly Pro Pro Gly Pro Gln Gly Val Lys Gly Glu Arg Gly 850 855 860		
Ser Pro Gly Gly Pro Gly Ala Ala Gly Phe Pro Gly Ala Arg Gly Leu 865 870 875 880		
Pro Gly Pro Pro Gly Ser Asn Gly Asn Pro Gly Pro Pro Gly Pro Ser 885 890 895		
Gly Ser Pro Gly Lys Asp Gly Pro Pro Gly Pro Ala Gly Asn Thr Gly 900 905 910		
Ala Pro Gly Ser Pro Gly Val Ser Gly Pro Lys Gly Asp Ala Gly Gln 915 920 925		
Pro Gly Glu Lys Gly Ser Pro Gly Ala Gln Gly Pro Pro Gly Ala Pro 930 935 940		
Gly Pro Leu Gly Ile Ala Gly Ile Thr Gly Ala Arg Gly Leu Ala Gly 945 950 955 960		
Pro Pro Gly Met Pro Gly Pro Arg Gly Ser Pro Gly Pro Gln Gly Val 965 970 975		
Lys Gly Glu Ser Gly Lys Pro Gly Ala Asn Gly Leu Ser Gly Glu Arg 980 985 990		
Gly Pro Pro Gly Pro Gln Gly Leu Pro Gly Leu Ala Gly Thr Ala Gly 995 1000 1005		
Glu Pro Gly Arg Asp Gly Asn Pro Gly Ser Asp Gly Leu Pro Gly 1010 1015 1020		

-continued

---

Arg Asp 1025	Gly Ser Pro Gly 1030	Gly Lys Gly Asp Arg Gly 1035	Glu Asn Gly
Ser Pro 1040	Gly Ala Pro Gly 1045	Ala Pro Gly His Pro Gly 1050	Pro Pro Gly
Pro Val 1055	Gly Pro Ala Gly 1060	Lys Ser Gly Asp Arg Gly 1065	Glu Ser Gly
Pro Ala 1070	Gly Pro Ala Gly 1075	Ala Pro Gly Pro Ala Gly 1080	Ser Arg Gly
Ala Pro 1085	Gly Pro Gln Gly 1090	Pro Arg Gly Asp Lys Gly 1095	Glu Thr Gly
Glu Arg 1100	Gly Ala Ala Gly 1105	Ile Lys Gly His Arg Gly 1110	Phe Pro Gly
Asn Pro 1115	Gly Ala Pro Gly 1120	Ser Pro Gly Pro Ala Gly 1125	Gln Gln Gly
Ala Ile 1130	Gly Ser Pro Gly 1135	Pro Ala Gly Pro Arg Gly 1140	Pro Val Gly
Pro Ser 1145	Gly Pro Pro Gly 1150	Lys Asp Gly Thr Ser Gly 1155	His Pro Gly
Pro Ile 1160	Gly Pro Pro Gly 1165	Pro Arg Gly Asn Arg Gly 1170	Glu Arg Gly
Ser Glu 1175	Gly Ser Pro Gly 1180	His Pro Gly Gln Pro Gly 1185	Pro Pro Gly
Pro Pro 1190	Gly Ala Pro Gly 1195	Pro Cys Cys Gly Gly Val 1200	Gly Ala Ala
Ala Ile 1205	Ala Gly Ile Gly 1210	Gly Glu Lys Ala Gly Gly 1215	Phe Ala Pro
Tyr Tyr 1220	Gly Asp Glu Pro 1225	Met Asp Phe Lys Ile Asn 1230	Thr Asp Glu
Ile Met 1235	Thr Ser Leu Lys 1240	Ser Val Asn Gly Gln Ile 1245	Glu Ser Leu
Ile Ser 1250	Pro Asp Gly Ser 1255	Arg Lys Asn Pro Ala Arg 1260	Asn Cys Arg
Asp Leu 1265	Lys Phe Cys His 1270	Pro Glu Leu Lys Ser Gly 1275	Glu Tyr Trp
Val Asp 1280	Pro Asn Gln Gly 1285	Cys Lys Leu Asp Ala Ile 1290	Lys Val Phe
Cys Asn 1295	Met Glu Thr Gly 1300	Glu Thr Cys Ile Ser Ala 1305	Asn Pro Leu
Asn Val 1310	Pro Arg Lys His 1315	Trp Trp Thr Asp Ser Ser 1320	Ala Glu Lys
Lys His 1325	Val Trp Phe Gly 1330	Glu Ser Met Asp Gly Gly 1335	Phe Gln Phe
Ser Tyr 1340	Gly Asn Pro Glu 1345	Leu Pro Glu Asp Val Leu 1350	Asp Val Gln
Leu Ala 1355	Phe Leu Arg Leu 1360	Leu Ser Ser Arg Ala Ser 1365	Gln Asn Ile
Thr Tyr 1370	His Cys Lys Asn 1375	Ser Ile Ala Tyr Met Asp 1380	Gln Ala Ser
Gly Asn 1385	Val Lys Lys Ala 1390	Leu Lys Leu Met Gly Ser 1395	Asn Glu Gly

-continued

---

Glu Phe Lys Ala Glu Gly Asn Ser Lys Phe Thr Tyr Thr Val Leu  
 1400 1405 1410

Glu Asp Gly Cys Thr Lys His Thr Gly Glu Trp Ser Lys Thr Val  
 1415 1420 1425

Phe Glu Tyr Arg Thr Arg Lys Ala Val Arg Leu Pro Ile Val Asp  
 1430 1435 1440

Ile Ala Pro Tyr Asp Ile Gly Gly Pro Asp Gln Glu Phe Gly Val  
 1445 1450 1455

Asp Val Gly Pro Val Cys Phe Leu  
 1460 1465

<210> SEQ ID NO 4  
 <211> LENGTH: 1669  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Met Gly Pro Arg Leu Ser Val Trp Leu Leu Leu Leu Pro Ala Ala Leu  
 1 5 10 15

Leu Leu His Glu Glu His Ser Arg Ala Ala Ala Lys Gly Gly Cys Ala  
 20 25 30

Gly Ser Gly Cys Gly Lys Cys Asp Cys His Gly Val Lys Gly Gln Lys  
 35 40 45

Gly Glu Arg Gly Leu Pro Gly Leu Gln Gly Val Ile Gly Phe Pro Gly  
 50 55 60

Met Gln Gly Pro Glu Gly Pro Gln Gly Pro Pro Gly Gln Lys Gly Asp  
 65 70 75 80

Thr Gly Glu Pro Gly Leu Pro Gly Thr Lys Gly Thr Arg Gly Pro Pro  
 85 90 95

Gly Ala Ser Gly Tyr Pro Gly Asn Pro Gly Leu Pro Gly Ile Pro Gly  
 100 105 110

Gln Asp Gly Pro Pro Gly Pro Pro Gly Ile Pro Gly Cys Asn Gly Thr  
 115 120 125

Lys Gly Glu Arg Gly Pro Leu Gly Pro Pro Gly Leu Pro Gly Phe Ala  
 130 135 140

Gly Asn Pro Gly Pro Pro Gly Leu Pro Gly Met Lys Gly Asp Pro Gly  
 145 150 155 160

Glu Ile Leu Gly His Val Pro Gly Met Leu Leu Lys Gly Glu Arg Gly  
 165 170 175

Phe Pro Gly Ile Pro Gly Thr Pro Gly Pro Pro Gly Leu Pro Gly Leu  
 180 185 190

Gln Gly Pro Val Gly Pro Pro Gly Phe Thr Gly Pro Pro Gly Pro Pro  
 195 200 205

Gly Pro Pro Gly Pro Pro Gly Glu Lys Gly Gln Met Gly Leu Ser Phe  
 210 215 220

Gln Gly Pro Lys Gly Asp Lys Gly Asp Gln Gly Val Ser Gly Pro Pro  
 225 230 235 240

Gly Val Pro Gly Gln Ala Gln Val Gln Glu Lys Gly Asp Phe Ala Thr  
 245 250 255

Lys Gly Glu Lys Gly Gln Lys Gly Glu Pro Gly Phe Gln Gly Met Pro  
 260 265 270

Gly Val Gly Glu Lys Gly Glu Pro Gly Lys Pro Gly Pro Arg Gly Lys  
 275 280 285

-continued

---

Pro Gly Lys Asp Gly Asp Lys Gly Glu Lys Gly Ser Pro Gly Phe Pro  
 290 295 300

Gly Glu Pro Gly Tyr Pro Gly Leu Ile Gly Arg Gln Gly Pro Gln Gly  
 305 310 315 320

Glu Lys Gly Glu Ala Gly Pro Pro Gly Pro Pro Gly Ile Val Ile Gly  
 325 330 335

Thr Gly Pro Leu Gly Glu Lys Gly Glu Arg Gly Tyr Pro Gly Thr Pro  
 340 345 350

Gly Pro Arg Gly Glu Pro Gly Pro Lys Gly Phe Pro Gly Leu Pro Gly  
 355 360 365

Gln Pro Gly Pro Pro Gly Leu Pro Val Pro Gly Gln Ala Gly Ala Pro  
 370 375 380

Gly Phe Pro Gly Glu Arg Gly Glu Lys Gly Asp Arg Gly Phe Pro Gly  
 385 390 395 400

Thr Ser Leu Pro Gly Pro Ser Gly Arg Asp Gly Leu Pro Gly Pro Pro  
 405 410 415

Gly Ser Pro Gly Pro Pro Gly Gln Pro Gly Tyr Thr Asn Gly Ile Val  
 420 425 430

Glu Cys Gln Pro Gly Pro Pro Gly Asp Gln Gly Pro Pro Gly Ile Pro  
 435 440 445

Gly Gln Pro Gly Phe Ile Gly Glu Ile Gly Glu Lys Gly Gln Lys Gly  
 450 455 460

Glu Ser Cys Leu Ile Cys Asp Ile Asp Gly Tyr Arg Gly Pro Pro Gly  
 465 470 475 480

Pro Gln Gly Pro Pro Gly Glu Ile Gly Phe Pro Gly Gln Pro Gly Ala  
 485 490 495

Lys Gly Asp Arg Gly Leu Pro Gly Arg Asp Gly Val Ala Gly Val Pro  
 500 505 510

Gly Pro Gln Gly Thr Pro Gly Leu Ile Gly Gln Pro Gly Ala Lys Gly  
 515 520 525

Glu Pro Gly Glu Phe Tyr Phe Asp Leu Arg Leu Lys Gly Asp Lys Gly  
 530 535 540

Asp Pro Gly Phe Pro Gly Gln Pro Gly Met Pro Gly Arg Ala Gly Ser  
 545 550 555 560

Pro Gly Arg Asp Gly His Pro Gly Leu Pro Gly Pro Lys Gly Ser Pro  
 565 570 575

Gly Ser Val Gly Leu Lys Gly Glu Arg Gly Pro Pro Gly Gly Val Gly  
 580 585 590

Phe Pro Gly Ser Arg Gly Asp Thr Gly Pro Pro Gly Pro Pro Gly Tyr  
 595 600 605

Gly Pro Ala Gly Pro Ile Gly Asp Lys Gly Gln Ala Gly Phe Pro Gly  
 610 615 620

Gly Pro Gly Ser Pro Gly Leu Pro Gly Pro Lys Gly Glu Pro Gly Lys  
 625 630 635 640

Ile Val Pro Leu Pro Gly Pro Pro Gly Ala Glu Gly Leu Pro Gly Ser  
 645 650 655

Pro Gly Phe Pro Gly Pro Gln Gly Asp Arg Gly Phe Pro Gly Thr Pro  
 660 665 670

Gly Arg Pro Gly Leu Pro Gly Glu Lys Gly Ala Val Gly Gln Pro Gly  
 675 680 685

-continued

---

Ile	Gly	Phe	Pro	Gly	Pro	Pro	Gly	Pro	Lys	Gly	Val	Asp	Gly	Leu	Pro
690						695					700				
Gly	Asp	Met	Gly	Pro	Pro	Gly	Thr	Pro	Gly	Arg	Pro	Gly	Phe	Asn	Gly
705					710					715					720
Leu	Pro	Gly	Asn	Pro	Gly	Val	Gln	Gly	Gln	Lys	Gly	Glu	Pro	Gly	Val
			725						730						735
Gly	Leu	Pro	Gly	Leu	Lys	Gly	Leu	Pro	Gly	Leu	Pro	Gly	Ile	Pro	Gly
			740					745						750	
Thr	Pro	Gly	Glu	Lys	Gly	Ser	Ile	Gly	Val	Pro	Gly	Val	Pro	Gly	Glu
		755					760					765			
His	Gly	Ala	Ile	Gly	Pro	Pro	Gly	Leu	Gln	Gly	Ile	Arg	Gly	Glu	Pro
	770					775						780			
Gly	Pro	Pro	Gly	Leu	Pro	Gly	Ser	Val	Gly	Ser	Pro	Gly	Val	Pro	Gly
785					790					795					800
Ile	Gly	Pro	Pro	Gly	Ala	Arg	Gly	Pro	Pro	Gly	Gly	Gln	Gly	Pro	Pro
				805					810					815	
Gly	Leu	Ser	Gly	Pro	Pro	Gly	Ile	Lys	Gly	Glu	Lys	Gly	Phe	Pro	Gly
			820						825					830	
Phe	Pro	Gly	Leu	Asp	Met	Pro	Gly	Pro	Lys	Gly	Asp	Lys	Gly	Ala	Gln
		835						840					845		
Gly	Leu	Pro	Gly	Ile	Thr	Gly	Gln	Ser	Gly	Leu	Pro	Gly	Leu	Pro	Gly
	850						855					860			
Gln	Gln	Gly	Ala	Pro	Gly	Ile	Pro	Gly	Phe	Pro	Gly	Ser	Lys	Gly	Glu
865						870					875				880
Met	Gly	Val	Met	Gly	Thr	Pro	Gly	Gln	Pro	Gly	Ser	Pro	Gly	Pro	Val
				885					890						895
Gly	Ala	Pro	Gly	Leu	Pro	Gly	Glu	Lys	Gly	Asp	His	Gly	Phe	Pro	Gly
			900						905					910	
Ser	Ser	Gly	Pro	Arg	Gly	Asp	Pro	Gly	Leu	Lys	Gly	Asp	Lys	Gly	Asp
		915					920						925		
Val	Gly	Leu	Pro	Gly	Lys	Pro	Gly	Ser	Met	Asp	Lys	Val	Asp	Met	Gly
	930						935						940		
Ser	Met	Lys	Gly	Gln	Lys	Gly	Asp	Gln	Gly	Glu	Lys	Gly	Gln	Ile	Gly
	945					950					955				960
Pro	Ile	Gly	Glu	Lys	Gly	Ser	Arg	Gly	Asp	Pro	Gly	Thr	Pro	Gly	Val
				965						970					975
Pro	Gly	Lys	Asp	Gly	Gln	Ala	Gly	Gln	Pro	Gly	Gln	Pro	Gly	Pro	Lys
			980							985					990
Gly	Asp	Pro	Gly	Ile	Ser	Gly	Thr	Pro	Gly	Ala	Pro	Gly	Leu	Pro	Gly
		995						1000							1005
Pro	Lys	Gly	Ser	Val	Gly	Gly	Met	Gly	Leu	Pro	Gly	Thr	Pro	Gly	
	1010													1020	
Glu	Lys	Gly	Val	Pro	Gly	Ile	Pro	Gly	Pro	Gln	Gly	Ser	Pro	Gly	
	1025													1035	
Leu	Pro	Gly	Asp	Lys	Gly	Ala	Lys	Gly	Glu	Lys	Gly	Gln	Ala	Gly	
	1040													1050	
Pro	Pro	Gly	Ile	Gly	Ile	Pro	Gly	Leu	Arg	Gly	Glu	Lys	Gly	Asp	
	1055													1065	
Gln	Gly	Ile	Ala	Gly	Phe	Pro	Gly	Ser	Pro	Gly	Glu	Lys	Gly	Glu	
	1070													1080	
Lys	Gly	Ser	Ile	Gly	Ile	Pro	Gly	Met	Pro	Gly	Ser	Pro	Gly	Leu	

-continued

---

1085	1090	1095
Lys Gly Ser Pro Gly Ser	Val Gly Tyr Pro Gly Ser	Pro Gly Leu
1100	1105	1110
Pro Gly Glu Lys Gly Asp	Lys Gly Leu Pro Gly Leu	Asp Gly Ile
1115	1120	1125
Pro Gly Val Lys Gly Glu	Ala Gly Leu Pro Gly Thr	Pro Gly Pro
1130	1135	1140
Thr Gly Pro Ala Gly Gln	Lys Gly Glu Pro Gly Ser	Asp Gly Ile
1145	1150	1155
Pro Gly Ser Ala Gly Glu	Lys Gly Glu Pro Gly Leu	Pro Gly Arg
1160	1165	1170
Gly Phe Pro Gly Phe Pro	Gly Ala Lys Gly Asp Lys	Gly Ser Lys
1175	1180	1185
Gly Glu Val Gly Phe Pro	Gly Leu Ala Gly Ser Pro	Gly Ile Pro
1190	1195	1200
Gly Ser Lys Gly Glu Gln	Gly Phe Met Gly Pro Pro	Gly Pro Gln
1205	1210	1215
Gly Gln Pro Gly Leu Pro	Gly Ser Pro Gly His Ala	Thr Glu Gly
1220	1225	1230
Pro Lys Gly Asp Arg Gly	Pro Gln Gly Gln Pro Gly	Leu Pro Gly
1235	1240	1245
Leu Pro Gly Pro Met Gly	Pro Pro Gly Leu Pro Gly	Ile Asp Gly
1250	1255	1260
Val Lys Gly Asp Lys Gly	Asn Pro Gly Trp Pro Gly	Ala Pro Gly
1265	1270	1275
Val Pro Gly Pro Lys Gly	Asp Pro Gly Phe Gln Gly	Met Pro Gly
1280	1285	1290
Ile Gly Gly Ser Pro Gly	Ile Thr Gly Ser Lys Gly	Asp Met Gly
1295	1300	1305
Pro Pro Gly Val Pro Gly	Phe Gln Gly Pro Lys Gly	Leu Pro Gly
1310	1315	1320
Leu Gln Gly Ile Lys Gly	Asp Gln Gly Asp Gln Gly	Val Pro Gly
1325	1330	1335
Ala Lys Gly Leu Pro Gly	Pro Pro Gly Pro Pro Gly	Pro Tyr Asp
1340	1345	1350
Ile Ile Lys Gly Glu Pro	Gly Leu Pro Gly Pro Glu	Gly Pro Pro
1355	1360	1365
Gly Leu Lys Gly Leu Gln	Gly Leu Pro Gly Pro Lys	Gly Gln Gln
1370	1375	1380
Gly Val Thr Gly Leu Val	Gly Ile Pro Gly Pro Pro	Gly Ile Pro
1385	1390	1395
Gly Phe Asp Gly Ala Pro	Gly Gln Lys Gly Glu Met	Gly Pro Ala
1400	1405	1410
Gly Pro Thr Gly Pro Arg	Gly Phe Pro Gly Pro Pro	Gly Pro Asp
1415	1420	1425
Gly Leu Pro Gly Ser Met	Gly Pro Pro Gly Thr Pro	Ser Val Asp
1430	1435	1440
His Gly Phe Leu Val Thr	Arg His Ser Gln Thr Ile	Asp Asp Pro
1445	1450	1455
Gln Cys Pro Ser Gly Thr	Lys Ile Leu Tyr His Gly	Tyr Ser Leu
1460	1465	1470

-continued

---

Leu Tyr Val Gln Gly Asn Glu Arg Ala His Gly Gln Asp Leu Gly  
 1475 1480 1485  
 Thr Ala Gly Ser Cys Leu Arg Lys Phe Ser Thr Met Pro Phe Leu  
 1490 1495 1500  
 Phe Cys Asn Ile Asn Asn Val Cys Asn Phe Ala Ser Arg Asn Asp  
 1505 1510 1515  
 Tyr Ser Tyr Trp Leu Ser Thr Pro Glu Pro Met Pro Met Ser Met  
 1520 1525 1530  
 Ala Pro Ile Thr Gly Glu Asn Ile Arg Pro Phe Ile Ser Arg Cys  
 1535 1540 1545  
 Ala Val Cys Glu Ala Pro Ala Met Val Met Ala Val His Ser Gln  
 1550 1555 1560  
 Thr Ile Gln Ile Pro Pro Cys Pro Ser Gly Trp Ser Ser Leu Trp  
 1565 1570 1575  
 Ile Gly Tyr Ser Phe Val Met His Thr Ser Ala Gly Ala Glu Gly  
 1580 1585 1590  
 Ser Gly Gln Ala Leu Ala Ser Pro Gly Ser Cys Leu Glu Glu Phe  
 1595 1600 1605  
 Arg Ser Ala Pro Phe Ile Glu Cys His Gly Arg Gly Thr Cys Asn  
 1610 1615 1620  
 Tyr Tyr Ala Asn Ala Tyr Ser Phe Trp Leu Ala Thr Ile Glu Arg  
 1625 1630 1635  
 Ser Glu Met Phe Lys Lys Pro Thr Pro Ser Thr Leu Lys Ala Gly  
 1640 1645 1650  
 Glu Leu Arg Thr His Val Ser Arg Cys Gln Val Cys Met Arg Arg  
 1655 1660 1665

Thr

<210> SEQ ID NO 5  
 <211> LENGTH: 1028  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 5

Met Arg Ala Ala Arg Ala Leu Leu Pro Leu Leu Leu Gln Ala Cys Trp  
 1 5 10 15  
 Thr Ala Ala Gln Asp Glu Pro Glu Thr Pro Arg Ala Val Ala Phe Gln  
 20 25 30  
 Asp Cys Pro Val Asp Leu Phe Phe Val Leu Asp Thr Ser Glu Ser Val  
 35 40 45  
 Ala Leu Arg Leu Lys Pro Tyr Gly Ala Leu Val Asp Lys Val Lys Ser  
 50 55 60  
 Phe Thr Lys Arg Phe Ile Asp Asn Leu Arg Asp Arg Tyr Tyr Arg Cys  
 65 70 75 80  
 Asp Arg Asn Leu Val Trp Asn Ala Gly Ala Leu His Tyr Ser Asp Glu  
 85 90 95  
 Val Glu Ile Ile Gln Gly Leu Thr Arg Met Pro Gly Gly Arg Asp Ala  
 100 105 110  
 Leu Lys Ser Ser Val Asp Ala Val Lys Tyr Phe Gly Lys Gly Thr Tyr  
 115 120 125  
 Thr Asp Cys Ala Ile Lys Lys Gly Leu Glu Gln Leu Leu Val Gly Gly  
 130 135 140

-continued

---

Ser His Leu Lys Glu Asn Lys Tyr Leu Ile Val Val Thr Asp Gly His  
 145 150 155 160

Pro Leu Glu Gly Tyr Lys Glu Pro Cys Gly Gly Leu Glu Asp Ala Val  
 165 170 175

Asn Glu Ala Lys His Leu Gly Val Lys Val Phe Ser Val Ala Ile Thr  
 180 185 190

Pro Asp His Leu Glu Pro Arg Leu Ser Ile Ile Ala Thr Asp His Thr  
 195 200 205

Tyr Arg Arg Asn Phe Thr Ala Ala Asp Trp Gly Gln Ser Arg Asp Ala  
 210 215 220

Glu Glu Ala Ile Ser Gln Thr Ile Asp Thr Ile Val Asp Met Ile Lys  
 225 230 235 240

Asn Asn Val Glu Gln Val Cys Cys Ser Phe Glu Cys Gln Pro Ala Arg  
 245 250 255

Gly Pro Pro Gly Leu Arg Gly Asp Pro Gly Phe Glu Gly Glu Arg Gly  
 260 265 270

Lys Pro Gly Leu Pro Gly Glu Lys Gly Glu Ala Gly Asp Pro Gly Arg  
 275 280 285

Pro Gly Asp Leu Gly Pro Val Gly Tyr Gln Gly Met Lys Gly Glu Lys  
 290 295 300

Gly Ser Arg Gly Glu Lys Gly Ser Arg Gly Pro Lys Gly Tyr Lys Gly  
 305 310 315 320

Glu Lys Gly Lys Arg Gly Ile Asp Gly Val Asp Gly Val Lys Gly Glu  
 325 330 335

Met Gly Tyr Pro Gly Leu Pro Gly Cys Lys Gly Ser Pro Gly Phe Asp  
 340 345 350

Gly Ile Gln Gly Pro Pro Gly Pro Lys Gly Asp Pro Gly Ala Phe Gly  
 355 360 365

Leu Lys Gly Glu Lys Gly Glu Pro Gly Ala Asp Gly Glu Ala Gly Arg  
 370 375 380

Pro Gly Ser Ser Gly Pro Ser Gly Asp Glu Gly Gln Pro Gly Glu Pro  
 385 390 395 400

Gly Pro Pro Gly Glu Lys Gly Glu Ala Gly Asp Glu Gly Asn Pro Gly  
 405 410 415

Pro Asp Gly Ala Pro Gly Glu Arg Gly Gly Pro Gly Glu Arg Gly Pro  
 420 425 430

Arg Gly Thr Pro Gly Thr Arg Gly Pro Arg Gly Asp Pro Gly Glu Ala  
 435 440 445

Gly Pro Gln Gly Asp Gln Gly Arg Glu Gly Pro Val Gly Val Pro Gly  
 450 455 460

Asp Pro Gly Glu Ala Gly Pro Ile Gly Pro Lys Gly Tyr Arg Gly Asp  
 465 470 475 480

Glu Gly Pro Pro Gly Ser Glu Gly Ala Arg Gly Ala Pro Gly Pro Ala  
 485 490 495

Gly Pro Pro Gly Asp Pro Gly Leu Met Gly Glu Arg Gly Glu Asp Gly  
 500 505 510

Pro Ala Gly Asn Gly Thr Glu Gly Phe Pro Gly Phe Pro Gly Tyr Pro  
 515 520 525

Gly Asn Arg Gly Ala Pro Gly Ile Asn Gly Thr Lys Gly Tyr Pro Gly  
 530 535 540

-continued

---

Leu Lys Gly Asp Glu Gly Glu Ala Gly Asp Pro Gly Asp Asp Asn Asn  
 545 550 555 560  
 Asp Ile Ala Pro Arg Gly Val Lys Gly Ala Lys Gly Tyr Arg Gly Pro  
 565 570 575  
 Glu Gly Pro Gln Gly Pro Pro Gly His Gln Gly Pro Pro Gly Pro Asp  
 580 585 590  
 Glu Cys Glu Ile Leu Asp Ile Ile Met Lys Met Cys Ser Cys Cys Glu  
 595 600 605  
 Cys Lys Cys Gly Pro Ile Asp Leu Leu Phe Val Leu Asp Ser Ser Glu  
 610 615 620  
 Ser Ile Gly Leu Gln Asn Phe Glu Ile Ala Lys Asp Phe Val Val Lys  
 625 630 635 640  
 Val Ile Asp Arg Leu Ser Arg Asp Glu Leu Val Lys Phe Glu Pro Gly  
 645 650 655  
 Gln Ser Tyr Ala Gly Val Val Gln Tyr Ser His Ser Gln Met Gln Glu  
 660 665 670  
 His Val Ser Leu Arg Ser Pro Ser Ile Arg Asn Val Gln Glu Leu Lys  
 675 680 685  
 Glu Ala Ile Lys Ser Leu Gln Trp Met Ala Gly Gly Thr Phe Thr Gly  
 690 695 700  
 Glu Ala Leu Gln Tyr Thr Arg Asp Gln Leu Leu Pro Pro Ser Pro Asn  
 705 710 715 720  
 Asn Arg Ile Ala Leu Val Ile Thr Asp Gly Arg Ser Asp Thr Gln Arg  
 725 730 735  
 Asp Thr Thr Pro Leu Asn Val Leu Cys Ser Pro Gly Ile Gln Val Val  
 740 745 750  
 Ser Val Gly Ile Lys Asp Val Phe Asp Phe Ile Pro Gly Ser Asp Gln  
 755 760 765  
 Leu Asn Val Ile Ser Cys Gln Gly Leu Ala Pro Ser Gln Gly Arg Pro  
 770 775 780  
 Gly Leu Ser Leu Val Lys Glu Asn Tyr Ala Glu Leu Leu Glu Asp Ala  
 785 790 795 800  
 Phe Leu Lys Asn Val Thr Ala Gln Ile Cys Ile Asp Lys Lys Cys Pro  
 805 810 815  
 Asp Tyr Thr Cys Pro Ile Thr Phe Ser Ser Pro Ala Asp Ile Thr Ile  
 820 825 830  
 Leu Leu Asp Gly Ser Ala Ser Val Gly Ser His Asn Phe Asp Thr Thr  
 835 840 845  
 Lys Arg Phe Ala Lys Arg Leu Ala Glu Arg Phe Leu Thr Ala Gly Arg  
 850 855 860  
 Thr Asp Pro Ala His Asp Val Arg Val Ala Val Val Gln Tyr Ser Gly  
 865 870 875 880  
 Thr Gly Gln Gln Arg Pro Glu Arg Ala Ser Leu Gln Phe Leu Gln Asn  
 885 890 895  
 Tyr Thr Ala Leu Ala Ser Ala Val Asp Ala Met Asp Phe Ile Asn Asp  
 900 905 910  
 Ala Thr Asp Val Asn Asp Ala Leu Gly Tyr Val Thr Arg Phe Tyr Arg  
 915 920 925  
 Glu Ala Ser Ser Gly Ala Ala Lys Lys Arg Leu Leu Leu Phe Ser Asp  
 930 935 940  
 Gly Asn Ser Gln Gly Ala Thr Pro Ala Ala Ile Glu Lys Ala Val Gln

-continued

---

```

945                950                955                960
Glu Ala Gln Arg Ala Gly Ile Glu Ile Phe Val Val Val Val Gly Arg
          965                970                975
Gln Val Asn Glu Pro His Ile Arg Val Leu Val Thr Gly Lys Thr Ala
          980                985                990
Glu Tyr Asp Val Ala Tyr Gly Glu Ser His Leu Phe Arg Val Pro Ser
          995                1000                1005
Tyr Gln Ala Leu Leu Arg Gly Val Phe His Gln Thr Val Ser Arg
          1010                1015                1020
Lys Val Ala Leu Gly
          1025

<210> SEQ ID NO 6
<211> LENGTH: 3177
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6
Met Arg Lys His Arg His Leu Pro Leu Val Ala Val Phe Cys Leu Phe
1          5          10          15
Leu Ser Gly Phe Pro Thr Thr His Ala Gln Gln Gln Gln Ala Asp Val
          20          25          30
Lys Asn Gly Ala Ala Ala Asp Ile Ile Phe Leu Val Asp Ser Ser Trp
          35          40          45
Thr Ile Gly Glu Glu His Phe Gln Leu Val Arg Glu Phe Leu Tyr Asp
          50          55          60
Val Val Lys Ser Leu Ala Val Gly Glu Asn Asp Phe His Phe Ala Leu
          65          70          75          80
Val Gln Phe Asn Gly Asn Pro His Thr Glu Phe Leu Leu Asn Thr Tyr
          85          90          95
Arg Thr Lys Gln Glu Val Leu Ser His Ile Ser Asn Met Ser Tyr Ile
          100         105         110
Gly Gly Thr Asn Gln Thr Gly Lys Gly Leu Glu Tyr Ile Met Gln Ser
          115         120         125
His Leu Thr Lys Ala Ala Gly Ser Arg Ala Gly Asp Gly Val Pro Gln
          130         135         140
Val Ile Val Val Leu Thr Asp Gly His Ser Lys Asp Gly Leu Ala Leu
          145         150         155         160
Pro Ser Ala Glu Leu Lys Ser Ala Asp Val Asn Val Phe Ala Ile Gly
          165         170         175
Val Glu Asp Ala Asp Glu Gly Ala Leu Lys Glu Ile Ala Ser Glu Pro
          180         185         190
Leu Asn Met His Met Phe Asn Leu Glu Asn Phe Thr Ser Leu His Asp
          195         200         205
Ile Val Gly Asn Leu Val Ser Cys Val His Ser Ser Val Ser Pro Glu
          210         215         220
Arg Ala Gly Asp Thr Glu Thr Leu Lys Asp Ile Thr Ala Gln Asp Ser
          225         230         235         240
Ala Asp Ile Ile Phe Leu Ile Asp Gly Ser Asn Asn Thr Gly Ser Val
          245         250         255
Asn Phe Ala Val Ile Leu Asp Phe Leu Val Asn Leu Leu Glu Lys Leu
          260         265         270

```

-continued

---

Pro Ile Gly Thr Gln Gln Ile Arg Val Gly Val Val Gln Phe Ser Asp  
 275 280 285

Glu Pro Arg Thr Met Phe Ser Leu Asp Thr Tyr Ser Thr Lys Ala Gln  
 290 295 300

Val Leu Gly Ala Val Lys Ala Leu Gly Phe Ala Gly Gly Glu Leu Ala  
 305 310 315 320

Asn Ile Gly Leu Ala Leu Asp Phe Val Val Glu Asn His Phe Thr Arg  
 325 330 335

Ala Gly Gly Ser Arg Val Glu Glu Gly Val Pro Gln Val Leu Val Leu  
 340 345 350

Ile Ser Ala Gly Pro Ser Ser Asp Glu Ile Arg Tyr Gly Val Val Ala  
 355 360 365

Leu Lys Gln Ala Ser Val Phe Ser Phe Gly Leu Gly Ala Gln Ala Ala  
 370 375 380

Ser Arg Ala Glu Leu Gln His Ile Ala Thr Asp Asp Asn Leu Val Phe  
 385 390 395 400

Thr Val Pro Glu Phe Arg Ser Phe Gly Asp Leu Gln Glu Lys Leu Leu  
 405 410 415

Pro Tyr Ile Val Gly Val Ala Gln Arg His Ile Val Leu Lys Pro Pro  
 420 425 430

Thr Ile Val Thr Gln Val Ile Glu Val Asn Lys Arg Asp Ile Val Phe  
 435 440 445

Leu Val Asp Gly Ser Ser Ala Leu Gly Leu Ala Asn Phe Asn Ala Ile  
 450 455 460

Arg Asp Phe Ile Ala Lys Val Ile Gln Arg Leu Glu Ile Gly Gln Asp  
 465 470 475 480

Leu Ile Gln Val Ala Val Ala Gln Tyr Ala Asp Thr Val Arg Pro Glu  
 485 490 495

Phe Tyr Phe Asn Thr His Pro Thr Lys Arg Glu Val Ile Thr Ala Val  
 500 505 510

Arg Lys Met Lys Pro Leu Asp Gly Ser Ala Leu Tyr Thr Gly Ser Ala  
 515 520 525

Leu Asp Phe Val Arg Asn Asn Leu Phe Thr Ser Ser Ala Gly Tyr Arg  
 530 535 540

Ala Ala Glu Gly Ile Pro Lys Leu Leu Val Leu Ile Thr Gly Gly Lys  
 545 550 555 560

Ser Leu Asp Glu Ile Ser Gln Pro Ala Gln Glu Leu Lys Arg Ser Ser  
 565 570 575

Ile Met Ala Phe Ala Ile Gly Asn Lys Gly Ala Asp Gln Ala Glu Leu  
 580 585 590

Glu Glu Ile Ala Phe Asp Ser Ser Leu Val Phe Ile Pro Ala Glu Phe  
 595 600 605

Arg Ala Ala Pro Leu Gln Gly Met Leu Pro Gly Leu Leu Ala Pro Leu  
 610 615 620

Arg Thr Leu Ser Gly Thr Pro Glu Val His Ser Asn Lys Arg Asp Ile  
 625 630 635 640

Ile Phe Leu Leu Asp Gly Ser Ala Asn Val Gly Lys Thr Asn Phe Pro  
 645 650 655

Tyr Val Arg Asp Phe Val Met Asn Leu Val Asn Ser Leu Asp Ile Gly  
 660 665 670

Asn Asp Asn Ile Arg Val Gly Leu Val Gln Phe Ser Asp Thr Pro Val

-continued

675				680				685							
Thr	Glu	Phe	Ser	Leu	Asn	Thr	Tyr	Gln	Thr	Lys	Ser	Asp	Ile	Leu	Gly
690						695					700				
His	Leu	Arg	Gln	Leu	Gln	Leu	Gln	Gly	Gly	Ser	Gly	Leu	Asn	Thr	Gly
705					710					715					720
Ser	Ala	Leu	Ser	Tyr	Val	Tyr	Ala	Asn	His	Phe	Thr	Glu	Ala	Gly	Gly
				725					730					735	
Ser	Arg	Ile	Arg	Glu	His	Val	Pro	Gln	Leu	Leu	Leu	Leu	Leu	Thr	Ala
				740					745					750	
Gly	Gln	Ser	Glu	Asp	Ser	Tyr	Leu	Gln	Ala	Ala	Asn	Ala	Leu	Thr	Arg
		755					760						765		
Ala	Gly	Ile	Leu	Thr	Phe	Cys	Val	Gly	Ala	Ser	Gln	Ala	Asn	Lys	Ala
	770					775					780				
Glu	Leu	Glu	Gln	Ile	Ala	Phe	Asn	Pro	Ser	Leu	Val	Tyr	Leu	Met	Asp
785					790					795					800
Asp	Phe	Ser	Ser	Leu	Pro	Ala	Leu	Pro	Gln	Gln	Leu	Ile	Gln	Pro	Leu
				805					810					815	
Thr	Thr	Tyr	Val	Ser	Gly	Gly	Val	Glu	Glu	Val	Pro	Leu	Ala	Gln	Pro
				820					825					830	
Glu	Ser	Lys	Arg	Asp	Ile	Leu	Phe	Leu	Phe	Asp	Gly	Ser	Ala	Asn	Leu
		835				840						845			
Val	Gly	Gln	Phe	Pro	Val	Val	Arg	Asp	Phe	Leu	Tyr	Lys	Ile	Ile	Asp
	850					855						860			
Glu	Leu	Asn	Val	Lys	Pro	Glu	Gly	Thr	Arg	Ile	Ala	Val	Ala	Gln	Tyr
865					870					875					880
Ser	Asp	Asp	Val	Lys	Val	Glu	Ser	Arg	Phe	Asp	Glu	His	Gln	Ser	Lys
				885					890					895	
Pro	Glu	Ile	Leu	Asn	Leu	Val	Lys	Arg	Met	Lys	Ile	Lys	Thr	Gly	Lys
				900					905					910	
Ala	Leu	Asn	Leu	Gly	Tyr	Ala	Leu	Asp	Tyr	Ala	Gln	Arg	Tyr	Ile	Phe
		915					920						925		
Val	Lys	Ser	Ala	Gly	Ser	Arg	Ile	Glu	Asp	Gly	Val	Leu	Gln	Phe	Leu
	930					935					940				
Val	Leu	Leu	Val	Ala	Gly	Arg	Ser	Ser	Asp	Arg	Val	Asp	Gly	Pro	Ala
945					950					955					960
Ser	Asn	Leu	Lys	Gln	Ser	Gly	Val	Val	Pro	Phe	Ile	Phe	Gln	Ala	Lys
				965					970					975	
Asn	Ala	Asp	Pro	Ala	Glu	Leu	Glu	Gln	Ile	Val	Leu	Ser	Pro	Ala	Phe
				980					985					990	
Ile	Leu	Ala	Ala	Glu	Ser	Leu	Pro	Lys	Ile	Gly	Asp	Leu	His	Pro	Gln
		995					1000							1005	
Ile	Val	Asn	Leu	Leu	Lys	Ser	Val	His	Asn	Gly	Ala	Pro	Ala	Pro	
	1010					1015							1020		
Val	Ser	Gly	Glu	Lys	Asp	Val	Val	Phe	Leu	Leu	Asp	Gly	Ser	Glu	
	1025					1030							1035		
Gly	Val	Arg	Ser	Gly	Phe	Pro	Leu	Leu	Lys	Glu	Phe	Val	Gln	Arg	
	1040					1045							1050		
Val	Val	Glu	Ser	Leu	Asp	Val	Gly	Gln	Asp	Arg	Val	Arg	Val	Ala	
	1055					1060							1065		
Val	Val	Gln	Tyr	Ser	Asp	Arg	Thr	Arg	Pro	Glu	Phe	Tyr	Leu	Asn	
	1070					1075							1080		

-continued

---

Ser	Tyr	Met	Asn	Lys	Gln	Asp	Val	Val	Asn	Ala	Val	Arg	Gln	Leu
1085						1090					1095			
Thr	Leu	Leu	Gly	Gly	Pro	Thr	Pro	Asn	Thr	Gly	Ala	Ala	Leu	Glu
1100						1105					1110			
Phe	Val	Leu	Arg	Asn	Ile	Leu	Val	Ser	Ser	Ala	Gly	Ser	Arg	Ile
1115						1120					1125			
Thr	Glu	Gly	Val	Pro	Gln	Leu	Leu	Ile	Val	Leu	Thr	Ala	Asp	Arg
1130						1135					1140			
Ser	Gly	Asp	Asp	Val	Arg	Asn	Pro	Ser	Val	Val	Val	Lys	Arg	Gly
1145						1150					1155			
Gly	Ala	Val	Pro	Ile	Gly	Ile	Gly	Ile	Gly	Asn	Ala	Asp	Ile	Thr
1160						1165					1170			
Glu	Met	Gln	Thr	Ile	Ser	Phe	Ile	Pro	Asp	Phe	Ala	Val	Ala	Ile
1175						1180					1185			
Pro	Thr	Phe	Arg	Gln	Leu	Gly	Thr	Val	Gln	Gln	Val	Ile	Ser	Glu
1190						1195					1200			
Arg	Val	Thr	Gln	Leu	Thr	Arg	Glu	Glu	Leu	Ser	Arg	Leu	Gln	Pro
1205						1210					1215			
Val	Leu	Gln	Pro	Leu	Pro	Ser	Pro	Gly	Val	Gly	Gly	Lys	Arg	Asp
1220						1225					1230			
Val	Val	Phe	Leu	Ile	Asp	Gly	Ser	Gln	Ser	Ala	Gly	Pro	Glu	Phe
1235						1240					1245			
Gln	Tyr	Val	Arg	Thr	Leu	Ile	Glu	Arg	Leu	Val	Asp	Tyr	Leu	Asp
1250						1255					1260			
Val	Gly	Phe	Asp	Thr	Thr	Arg	Val	Ala	Val	Ile	Gln	Phe	Ser	Asp
1265						1270					1275			
Asp	Pro	Lys	Val	Glu	Phe	Leu	Leu	Asn	Ala	His	Ser	Ser	Lys	Asp
1280						1285					1290			
Glu	Val	Gln	Asn	Ala	Val	Gln	Arg	Leu	Arg	Pro	Lys	Gly	Gly	Arg
1295						1300					1305			
Gln	Ile	Asn	Val	Gly	Asn	Ala	Leu	Glu	Tyr	Val	Ser	Arg	Asn	Ile
1310						1315					1320			
Phe	Lys	Arg	Pro	Leu	Gly	Ser	Arg	Ile	Glu	Glu	Gly	Val	Pro	Gln
1325						1330					1335			
Phe	Leu	Val	Leu	Ile	Ser	Ser	Gly	Lys	Ser	Asp	Asp	Glu	Val	Asp
1340						1345					1350			
Asp	Pro	Ala	Val	Glu	Leu	Lys	Gln	Phe	Gly	Val	Ala	Pro	Phe	Thr
1355						1360					1365			
Ile	Ala	Arg	Asn	Ala	Asp	Gln	Glu	Glu	Leu	Val	Lys	Ile	Ser	Leu
1370						1375					1380			
Ser	Pro	Glu	Tyr	Val	Phe	Ser	Val	Ser	Thr	Phe	Arg	Glu	Leu	Pro
1385						1390					1395			
Ser	Leu	Glu	Gln	Lys	Leu	Leu	Thr	Pro	Ile	Thr	Thr	Leu	Thr	Ser
1400						1405					1410			
Glu	Gln	Ile	Gln	Lys	Leu	Leu	Ala	Ser	Thr	Arg	Tyr	Pro	Pro	Pro
1415						1420					1425			
Ala	Val	Glu	Ser	Asp	Ala	Ala	Asp	Ile	Val	Phe	Leu	Ile	Asp	Ser
1430						1435					1440			
Ser	Glu	Gly	Val	Arg	Pro	Asp	Gly	Phe	Ala	His	Ile	Arg	Asp	Phe
1445						1450					1455			

-continued

---

Val	Ser	Arg	Ile	Val	Arg	Arg	Leu	Asn	Ile	Gly	Pro	Ser	Lys	Val
1460						1465					1470			
Arg	Val	Gly	Val	Val	Gln	Phe	Ser	Asn	Asp	Val	Phe	Pro	Glu	Phe
1475						1480					1485			
Tyr	Leu	Lys	Thr	Tyr	Arg	Ser	Gln	Ala	Pro	Val	Leu	Asp	Ala	Ile
1490						1495					1500			
Arg	Arg	Leu	Arg	Leu	Arg	Gly	Gly	Ser	Pro	Leu	Asn	Thr	Gly	Lys
1505						1510					1515			
Ala	Leu	Glu	Phe	Val	Ala	Arg	Asn	Leu	Phe	Val	Lys	Ser	Ala	Gly
1520						1525					1530			
Ser	Arg	Ile	Glu	Asp	Gly	Val	Pro	Gln	His	Leu	Val	Leu	Val	Leu
1535						1540					1545			
Gly	Gly	Lys	Ser	Gln	Asp	Asp	Val	Ser	Arg	Phe	Ala	Gln	Val	Ile
1550						1555					1560			
Arg	Ser	Ser	Gly	Ile	Val	Ser	Leu	Gly	Val	Gly	Asp	Arg	Asn	Ile
1565						1570					1575			
Asp	Arg	Thr	Glu	Leu	Gln	Thr	Ile	Thr	Asn	Asp	Pro	Arg	Leu	Val
1580						1585					1590			
Phe	Thr	Val	Arg	Glu	Phe	Arg	Glu	Leu	Pro	Asn	Ile	Glu	Glu	Arg
1595						1600					1605			
Ile	Met	Asn	Ser	Phe	Gly	Pro	Ser	Ala	Ala	Thr	Pro	Ala	Pro	Pro
1610						1615					1620			
Gly	Val	Asp	Thr	Pro	Pro	Pro	Ser	Arg	Pro	Glu	Lys	Lys	Lys	Ala
1625						1630					1635			
Asp	Ile	Val	Phe	Leu	Leu	Asp	Gly	Ser	Ile	Asn	Phe	Arg	Arg	Asp
1640						1645					1650			
Ser	Phe	Gln	Glu	Val	Leu	Arg	Phe	Val	Ser	Glu	Ile	Val	Asp	Thr
1655						1660					1665			
Val	Tyr	Glu	Asp	Gly	Asp	Ser	Ile	Gln	Val	Gly	Leu	Val	Gln	Tyr
1670						1675					1680			
Asn	Ser	Asp	Pro	Thr	Asp	Glu	Phe	Phe	Leu	Lys	Asp	Phe	Ser	Thr
1685						1690					1695			
Lys	Arg	Gln	Ile	Ile	Asp	Ala	Ile	Asn	Lys	Val	Val	Tyr	Lys	Gly
1700						1705					1710			
Gly	Arg	His	Ala	Asn	Thr	Lys	Val	Gly	Leu	Glu	His	Leu	Arg	Val
1715						1720					1725			
Asn	His	Phe	Val	Pro	Glu	Ala	Gly	Ser	Arg	Leu	Asp	Gln	Arg	Val
1730						1735					1740			
Pro	Gln	Ile	Ala	Phe	Val	Ile	Thr	Gly	Gly	Lys	Ser	Val	Glu	Asp
1745						1750					1755			
Ala	Gln	Asp	Val	Ser	Leu	Ala	Leu	Thr	Gln	Arg	Gly	Val	Lys	Val
1760						1765					1770			
Phe	Ala	Val	Gly	Val	Arg	Asn	Ile	Asp	Ser	Glu	Glu	Val	Gly	Lys
1775						1780					1785			
Ile	Ala	Ser	Asn	Ser	Ala	Thr	Ala	Phe	Arg	Val	Gly	Asn	Val	Gln
1790						1795					1800			
Glu	Leu	Ser	Glu	Leu	Ser	Glu	Gln	Val	Leu	Glu	Thr	Leu	His	Asp
1805						1810					1815			
Ala	Met	His	Glu	Thr	Leu	Cys	Pro	Gly	Val	Thr	Asp	Ala	Ala	Lys
1820						1825					1830			
Ala	Cys	Asn	Leu	Asp	Val	Ile	Leu	Gly	Phe	Asp	Gly	Ser	Arg	Asp

-continued

---

1835	1840	1845
Gln Asn Val Phe Val Ala	Gln Lys Gly Phe Glu Ser	Lys Val Asp
1850	1855	1860
Ala Ile Leu Asn Arg Ile	Ser Gln Met His Arg Val	Ser Cys Ser
1865	1870	1875
Gly Gly Arg Ser Pro Thr	Val Arg Val Ser Val Val	Ala Asn Thr
1880	1885	1890
Pro Ser Gly Pro Val Glu	Ala Phe Asp Phe Asp Glu	Tyr Gln Pro
1895	1900	1905
Glu Met Leu Glu Lys Phe	Arg Asn Met Arg Ser Gln	His Pro Tyr
1910	1915	1920
Val Leu Thr Glu Asp Thr	Leu Lys Val Tyr Leu Asn	Lys Phe Arg
1925	1930	1935
Gln Ser Ser Pro Asp Ser	Val Lys Val Val Ile His	Phe Thr Asp
1940	1945	1950
Gly Ala Asp Gly Asp Leu	Ala Asp Leu His Arg Ala	Ser Glu Asn
1955	1960	1965
Leu Arg Gln Glu Gly Val	Arg Ala Leu Ile Leu Val	Gly Leu Glu
1970	1975	1980
Arg Val Val Asn Leu Glu	Arg Leu Met His Leu Glu	Phe Gly Arg
1985	1990	1995
Gly Phe Met Tyr Asp Arg	Pro Leu Arg Leu Asn Leu	Leu Asp Leu
2000	2005	2010
Asp Tyr Glu Leu Ala Glu	Gln Leu Asp Asn Ile Ala	Glu Lys Ala
2015	2020	2025
Cys Cys Gly Val Pro Cys	Lys Cys Ser Gly Gln Arg	Gly Asp Arg
2030	2035	2040
Gly Pro Ile Gly Ser Ile	Gly Pro Lys Gly Ile Pro	Gly Glu Asp
2045	2050	2055
Gly Tyr Arg Gly Tyr Pro	Gly Asp Glu Gly Gly Pro	Gly Glu Arg
2060	2065	2070
Gly Pro Pro Gly Val Asn	Gly Thr Gln Gly Phe Gln	Gly Cys Pro
2075	2080	2085
Gly Gln Arg Gly Val Lys	Gly Ser Arg Gly Phe Pro	Gly Glu Lys
2090	2095	2100
Gly Glu Val Gly Glu Ile	Gly Leu Asp Gly Leu Asp	Gly Glu Asp
2105	2110	2115
Gly Asp Lys Gly Leu Pro	Gly Ser Ser Gly Glu Lys	Gly Asn Pro
2120	2125	2130
Gly Arg Arg Gly Asp Lys	Gly Pro Arg Gly Glu Lys	Gly Glu Arg
2135	2140	2145
Gly Asp Val Gly Ile Arg	Gly Asp Pro Gly Asn Pro	Gly Gln Asp
2150	2155	2160
Ser Gln Glu Arg Gly Pro	Lys Gly Glu Thr Gly Asp	Leu Gly Pro
2165	2170	2175
Met Gly Val Pro Gly Arg	Asp Gly Val Pro Gly Gly	Pro Gly Glu
2180	2185	2190
Thr Gly Lys Asn Gly Gly	Phe Gly Arg Arg Gly Pro	Pro Gly Ala
2195	2200	2205
Lys Gly Asn Lys Gly Gly	Pro Gly Gln Pro Gly Phe	Glu Gly Glu
2210	2215	2220

-continued

---

Gln Gly Thr Arg Gly Ala	Gln Gly Pro Ala Gly Pro	Ala Gly Pro
2225	2230	2235
Pro Gly Leu Ile Gly Glu	Gln Gly Ile Ser Gly Pro	Arg Gly Ser
2240	2245	2250
Gly Gly Ala Ala Gly Ala	Pro Gly Glu Arg Gly Arg	Thr Gly Pro
2255	2260	2265
Leu Gly Arg Lys Gly Glu	Pro Gly Glu Pro Gly Pro	Lys Gly Gly
2270	2275	2280
Ile Gly Asn Arg Gly Pro	Arg Gly Glu Thr Gly Asp	Asp Gly Arg
2285	2290	2295
Asp Gly Val Gly Ser Glu	Gly Arg Arg Gly Lys Lys	Gly Glu Arg
2300	2305	2310
Gly Phe Pro Gly Tyr Pro	Gly Pro Lys Gly Asn Pro	Gly Glu Pro
2315	2320	2325
Gly Leu Asn Gly Thr Thr	Gly Pro Lys Gly Ile Arg	Gly Arg Arg
2330	2335	2340
Gly Asn Ser Gly Pro Pro	Gly Ile Val Gly Gln Lys	Gly Asp Pro
2345	2350	2355
Gly Tyr Pro Gly Pro Ala	Gly Pro Lys Gly Asn Arg	Gly Asp Ser
2360	2365	2370
Ile Asp Gln Cys Ala Leu	Ile Gln Ser Ile Lys Asp	Lys Cys Pro
2375	2380	2385
Cys Cys Tyr Gly Pro Leu	Glu Cys Pro Val Phe Pro	Thr Glu Leu
2390	2395	2400
Ala Phe Ala Leu Asp Thr	Ser Glu Gly Val Asn Gln	Asp Thr Phe
2405	2410	2415
Gly Arg Met Arg Asp Val	Val Leu Ser Ile Val Asn	Asp Leu Thr
2420	2425	2430
Ile Ala Glu Ser Asn Cys	Pro Arg Gly Ala Arg Val	Ala Val Val
2435	2440	2445
Thr Tyr Asn Asn Glu Val	Thr Thr Glu Ile Arg Phe	Ala Asp Ser
2450	2455	2460
Lys Arg Lys Ser Val Leu	Leu Asp Lys Ile Lys Asn	Leu Gln Val
2465	2470	2475
Ala Leu Thr Ser Lys Gln	Gln Ser Leu Glu Thr Ala	Met Ser Phe
2480	2485	2490
Val Ala Arg Asn Thr Phe	Lys Arg Val Arg Asn Gly	Phe Leu Met
2495	2500	2505
Arg Lys Val Ala Val Phe	Phe Ser Asn Thr Pro Thr	Arg Ala Ser
2510	2515	2520
Pro Gln Leu Arg Glu Ala	Val Leu Lys Leu Ser Asp	Ala Gly Ile
2525	2530	2535
Thr Pro Leu Phe Leu Thr	Arg Gln Glu Asp Arg Gln	Leu Ile Asn
2540	2545	2550
Ala Leu Gln Ile Asn Asn	Thr Ala Val Gly His Ala	Leu Val Leu
2555	2560	2565
Pro Ala Gly Arg Asp Leu	Thr Asp Phe Leu Glu Asn	Val Leu Thr
2570	2575	2580
Cys His Val Cys Leu Asp	Ile Cys Asn Ile Asp Pro	Ser Cys Gly
2585	2590	2595

-continued

---

Phe Gly	Ser Trp Arg Pro	Ser	Phe Arg Asp Arg Arg	Ala Ala Gly
2600		2605		2610
Ser Asp	Val Asp Ile Asp	Met	Ala Phe Ile Leu Asp	Ser Ala Glu
2615		2620		2625
Thr Thr	Thr Leu Phe Gln	Phe	Asn Glu Met Lys Lys	Tyr Ile Ala
2630		2635		2640
Tyr Leu	Val Arg Gln Leu	Asp	Met Ser Pro Asp Pro	Lys Ala Ser
2645		2650		2655
Gln His	Phe Ala Arg Val	Ala	Val Val Gln His Ala	Pro Ser Glu
2660		2665		2670
Ser Val	Asp Asn Ala Ser	Met	Pro Pro Val Lys Val	Glu Phe Ser
2675		2680		2685
Leu Thr	Asp Tyr Gly Ser	Lys	Glu Lys Leu Val Asp	Phe Leu Ser
2690		2695		2700
Arg Gly	Met Thr Gln Leu	Gln	Gly Thr Arg Ala Leu	Gly Ser Ala
2705		2710		2715
Ile Glu	Tyr Thr Ile Glu	Asn	Val Phe Glu Ser Ala	Pro Asn Pro
2720		2725		2730
Arg Asp	Leu Lys Ile Val	Val	Leu Met Leu Thr Gly	Glu Val Pro
2735		2740		2745
Glu Gln	Gln Leu Glu Glu	Ala	Gln Arg Val Ile Leu	Gln Ala Lys
2750		2755		2760
Cys Lys	Gly Tyr Phe Phe	Val	Val Leu Gly Ile Gly	Arg Lys Val
2765		2770		2775
Asn Ile	Lys Glu Val Tyr	Thr	Phe Ala Ser Glu Pro	Asn Asp Val
2780		2785		2790
Phe Phe	Lys Leu Val Asp	Lys	Ser Thr Glu Leu Asn	Glu Glu Pro
2795		2800		2805
Leu Met	Arg Phe Gly Arg	Leu	Leu Pro Ser Phe Val	Ser Ser Glu
2810		2815		2820
Asn Ala	Phe Tyr Leu Ser	Pro	Asp Ile Arg Lys Gln	Cys Asp Trp
2825		2830		2835
Phe Gln	Gly Asp Gln Pro	Thr	Lys Asn Leu Val Lys	Phe Gly His
2840		2845		2850
Lys Gln	Val Asn Val Pro	Asn	Asn Val Thr Ser Ser	Pro Thr Ser
2855		2860		2865
Asn Pro	Val Thr Thr Thr	Lys	Pro Val Thr Thr Thr	Lys Pro Val
2870		2875		2880
Thr Thr	Thr Thr Lys Pro	Val	Thr Thr Thr Thr Lys	Pro Val Thr
2885		2890		2895
Ile Ile	Asn Gln Pro Ser	Val	Lys Pro Ala Ala Ala	Lys Pro Ala
2900		2905		2910
Pro Ala	Lys Pro Val Ala	Ala	Lys Pro Val Ala Thr	Lys Met Ala
2915		2920		2925
Thr Val	Arg Pro Pro Val	Ala	Val Lys Pro Ala Thr	Ala Ala Lys
2930		2935		2940
Pro Val	Ala Ala Lys Pro	Ala	Ala Val Arg Pro Pro	Ala Ala Ala
2945		2950		2955
Ala Ala	Lys Pro Val Ala	Thr	Lys Pro Glu Val Pro	Arg Pro Gln
2960		2965		2970
Ala Ala	Lys Pro Ala Ala	Thr	Lys Pro Ala Thr Thr	Lys Pro Met

-continued

---

2975	2980	2985
Val Lys Met Ser Arg Glu	Val Gln Val Phe Glu Ile	Thr Glu Asn
2990	2995	3000
Ser Ala Lys Leu His Trp	Glu Arg Ala Glu Pro	Pro Gly Pro Tyr
3005	3010	3015
Phe Tyr Asp Leu Thr Val	Thr Ser Ala His Asp	Gln Ser Leu Val
3020	3025	3030
Leu Lys Gln Asn Leu Thr	Val Thr Asp Arg Val	Ile Gly Gly Leu
3035	3040	3045
Leu Ala Gly Gln Thr Tyr	His Val Ala Val Val	Cys Tyr Leu Arg
3050	3055	3060
Ser Gln Val Arg Ala Thr	Tyr His Gly Ser Phe	Ser Thr Lys Lys
3065	3070	3075
Ser Gln Pro Pro Pro Pro	Gln Pro Ala Arg Ser	Ala Ser Ser Ser
3080	3085	3090
Thr Ile Asn Leu Met Val	Ser Thr Glu Pro Leu	Ala Leu Thr Glu
3095	3100	3105
Thr Asp Ile Cys Lys Leu	Pro Lys Asp Glu Gly	Thr Cys Arg Asp
3110	3115	3120
Phe Ile Leu Lys Trp Tyr	Tyr Asp Pro Asn Thr	Lys Ser Cys Ala
3125	3130	3135
Arg Phe Trp Tyr Gly Gly	Cys Gly Gly Asn Glu	Asn Lys Phe Gly
3140	3145	3150
Ser Gln Lys Glu Cys Glu	Lys Val Cys Ala Pro	Val Leu Ala Lys
3155	3160	3165
Pro Gly Val Ile Ser Val	Met Gly Thr	
3170	3175	

&lt;210&gt; SEQ ID NO 7

&lt;211&gt; LENGTH: 3063

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 7

Met Arg Ser Arg Leu Pro Pro	Ala Leu Ala Ala Leu Gly	Ala Ala Leu
1	5	10 15
Leu Leu Ser Ser Ile Glu Ala	Glu Val Asp Pro Pro Ser	Asp Leu Asn
	20	25 30
Phe Lys Ile Ile Asp Glu Asn	Thr Val His Met Ser Trp	Ala Lys Pro
	35	40 45
Val Asp Pro Ile Val Gly Tyr	Arg Ile Thr Val Asp Pro	Thr Thr Asp
	50	55 60
Gly Pro Thr Lys Glu Phe Thr	Leu Ser Ala Ser Thr Thr	Glu Thr Leu
	65	70 75 80
Leu Ser Glu Leu Val Pro Glu	Thr Glu Tyr Val Val Thr	Ile Thr Ser
	85	90 95
Tyr Asp Glu Val Glu Glu Ser	Val Pro Val Ile Gly Gln	Leu Thr Ile
	100	105 110
Gln Thr Gly Ser Ser Thr Lys	Pro Val Glu Lys Lys Pro	Gly Lys Thr
	115	120 125
Glu Ile Gln Lys Cys Ser Val	Ser Ala Trp Thr Asp Leu	Val Phe Leu
	130	135 140

-continued

---

Val	Asp	Gly	Ser	Trp	Ser	Val	Gly	Arg	Asn	Asn	Phe	Lys	Tyr	Ile	Leu
145					150					155					160
Asp	Phe	Ile	Ala	Ala	Leu	Val	Ser	Ala	Phe	Asp	Ile	Gly	Glu	Glu	Lys
			165						170						175
Thr	Arg	Val	Gly	Val	Val	Gln	Tyr	Ser	Ser	Asp	Thr	Arg	Thr	Glu	Phe
			180						185					190	
Asn	Leu	Asn	Gln	Tyr	Tyr	Gln	Arg	Asp	Glu	Leu	Leu	Ala	Ala	Ile	Lys
		195					200						205		
Lys	Ile	Pro	Tyr	Lys	Gly	Gly	Asn	Thr	Met	Thr	Gly	Asp	Ala	Ile	Asp
	210					215					220				
Tyr	Leu	Val	Lys	Asn	Thr	Phe	Thr	Glu	Ser	Ala	Gly	Ala	Arg	Val	Gly
	225					230				235					240
Phe	Pro	Lys	Val	Ala	Ile	Ile	Ile	Thr	Asp	Gly	Lys	Ser	Gln	Asp	Glu
				245					250						255
Val	Glu	Ile	Pro	Ala	Arg	Glu	Leu	Arg	Asn	Val	Gly	Val	Glu	Val	Phe
				260					265					270	
Ser	Leu	Gly	Ile	Lys	Ala	Ala	Asp	Ala	Lys	Glu	Leu	Lys	Gln	Ile	Ala
		275						280							285
Ser	Thr	Pro	Ser	Leu	Asn	His	Val	Phe	Asn	Val	Ala	Asn	Phe	Asp	Ala
		290					295					300			
Ile	Val	Asp	Ile	Gln	Asn	Glu	Ile	Ile	Ser	Gln	Val	Cys	Ser	Gly	Val
	305				310						315				320
Asp	Glu	Gln	Leu	Gly	Glu	Leu	Val	Ser	Gly	Glu	Glu	Val	Val	Glu	Pro
				325						330					335
Pro	Ser	Asn	Leu	Ile	Ala	Met	Glu	Val	Ser	Ser	Lys	Tyr	Val	Lys	Leu
			340						345					350	
Asn	Trp	Asn	Pro	Ser	Pro	Ser	Pro	Val	Thr	Gly	Tyr	Lys	Val	Ile	Leu
		355					360						365		
Thr	Pro	Met	Thr	Ala	Gly	Ser	Arg	Gln	His	Ala	Leu	Ser	Val	Gly	Pro
		370				375						380			
Gln	Thr	Thr	Thr	Leu	Ser	Val	Arg	Asp	Leu	Ser	Ala	Asp	Thr	Glu	Tyr
	385					390					395				400
Gln	Ile	Ser	Val	Ser	Ala	Met	Lys	Gly	Met	Thr	Ser	Ser	Glu	Pro	Ile
				405					410						415
Ser	Ile	Met	Glu	Lys	Thr	Gln	Pro	Met	Lys	Val	Gln	Val	Glu	Cys	Ser
			420						425					430	
Arg	Gly	Val	Asp	Ile	Lys	Ala	Asp	Ile	Val	Phe	Leu	Val	Asp	Gly	Ser
		435						440						445	
Tyr	Ser	Ile	Gly	Ile	Ala	Asn	Phe	Val	Lys	Val	Arg	Ala	Phe	Leu	Glu
	450					455						460			
Val	Leu	Val	Lys	Ser	Phe	Glu	Ile	Ser	Pro	Asn	Arg	Val	Gln	Ile	Ser
	465					470					475				480
Leu	Val	Gln	Tyr	Ser	Arg	Asp	Pro	His	Thr	Glu	Phe	Thr	Leu	Lys	Lys
			485						490						495
Phe	Thr	Lys	Val	Glu	Asp	Ile	Ile	Glu	Ala	Ile	Asn	Thr	Phe	Pro	Tyr
			500						505					510	
Arg	Gly	Gly	Ser	Thr	Asn	Thr	Gly	Lys	Ala	Met	Thr	Tyr	Val	Arg	Glu
		515						520					525		
Lys	Ile	Phe	Val	Pro	Ser	Lys	Gly	Ser	Arg	Ser	Asn	Val	Pro	Lys	Val
	530						535					540			
Met	Ile	Leu	Ile	Thr	Asp	Gly	Lys	Ser	Ser	Asp	Ala	Phe	Arg	Asp	Pro

-continued

---

545	550	555	560
Ala Ile Lys Leu Arg Asn Ser Asp Val Glu Ile Phe Ala Val Gly Val	565	570	575
Lys Asp Ala Val Arg Ser Glu Leu Glu Ala Ile Ala Ser Pro Pro Ala	580	585	590
Glu Thr His Val Phe Thr Val Glu Asp Phe Asp Ala Phe Gln Arg Ile	595	600	605
Ser Phe Glu Leu Thr Gln Ser Ile Cys Leu Arg Ile Glu Gln Glu Leu	610	615	620
Ala Ala Ile Lys Lys Lys Ala Tyr Val Pro Pro Lys Asp Leu Ser Phe	625	630	640
Ser Glu Val Thr Ser Tyr Gly Phe Lys Thr Asn Trp Ser Pro Ala Gly	645	650	655
Glu Asn Val Phe Ser Tyr His Ile Thr Tyr Lys Glu Ala Ala Gly Asp	660	665	670
Asp Glu Val Thr Val Val Glu Pro Ala Ser Ser Thr Ser Val Val Leu	675	680	685
Ser Ser Leu Lys Pro Glu Thr Leu Tyr Leu Val Asn Val Thr Ala Glu	690	695	700
Tyr Glu Asp Gly Phe Ser Ile Pro Leu Ala Gly Glu Glu Thr Thr Glu	705	710	720
Glu Val Lys Gly Ala Pro Arg Asn Leu Lys Val Thr Asp Glu Thr Thr	725	730	735
Asp Ser Phe Lys Ile Thr Trp Thr Gln Ala Pro Gly Arg Val Leu Arg	740	745	750
Tyr Arg Ile Ile Tyr Arg Pro Val Ala Gly Gly Glu Ser Arg Glu Val	755	760	765
Thr Thr Pro Pro Asn Gln Arg Arg Arg Thr Leu Glu Asn Leu Ile Pro	770	775	780
Asp Thr Lys Tyr Glu Val Ser Val Ile Pro Glu Tyr Phe Ser Gly Pro	785	790	800
Gly Thr Pro Leu Thr Gly Asn Ala Ala Thr Glu Glu Val Arg Gly Asn	805	810	815
Pro Arg Asp Leu Arg Val Ser Asp Pro Thr Thr Ser Thr Met Lys Leu	820	825	830
Ser Trp Ser Gly Ala Pro Gly Lys Val Lys Gln Tyr Leu Val Thr Tyr	835	840	845
Thr Pro Val Ala Gly Gly Glu Thr Gln Glu Val Thr Val Arg Gly Asp	850	855	860
Thr Thr Asn Thr Val Leu Gln Gly Leu Lys Glu Gly Thr Gln Tyr Ala	865	870	880
Leu Ser Val Thr Ala Leu Tyr Ala Ser Gly Ala Gly Asp Ala Leu Phe	885	890	895
Gly Glu Gly Thr Thr Leu Glu Glu Arg Gly Ser Pro Gln Asp Leu Val	900	905	910
Thr Lys Asp Ile Thr Asp Thr Ser Ile Gly Ala Tyr Trp Thr Ser Ala	915	920	925
Pro Gly Met Val Arg Gly Tyr Arg Val Ser Trp Lys Ser Leu Tyr Asp	930	935	940
Asp Val Asp Thr Gly Glu Lys Asn Leu Pro Glu Asp Ala Ile His Thr	945	950	955
			960

-continued

---

Met Ile Glu Asn Leu Gln Pro Glu Thr Lys Tyr Arg Ile Ser Val Phe  
965 970 975

Ala Thr Tyr Ser Ser Gly Glu Gly Glu Pro Leu Thr Gly Asp Ala Thr  
980 985 990

Thr Glu Leu Ser Gln Asp Ser Lys Thr Leu Lys Val Asp Glu Glu Thr  
995 1000 1005

Glu Asn Thr Met Arg Val Thr Trp Lys Pro Ala Pro Gly Lys Val  
1010 1015 1020

Val Asn Tyr Arg Val Val Tyr Arg Pro His Gly Arg Gly Lys Gln  
1025 1030 1035

Met Val Ala Lys Val Pro Pro Thr Val Thr Ser Thr Val Leu Lys  
1040 1045 1050

Arg Leu Gln Pro Gln Thr Thr Tyr Asp Ile Thr Val Leu Pro Ile  
1055 1060 1065

Tyr Lys Met Gly Glu Gly Lys Leu Arg Gln Gly Ser Gly Thr Thr  
1070 1075 1080

Ala Ser Arg Phe Lys Ser Pro Arg Asn Leu Lys Thr Ser Asp Pro  
1085 1090 1095

Thr Met Ser Ser Phe Arg Val Thr Trp Glu Pro Ala Pro Gly Glu  
1100 1105 1110

Val Lys Gly Tyr Lys Val Thr Phe His Pro Thr Gly Asp Asp Arg  
1115 1120 1125

Arg Leu Gly Glu Leu Val Val Gly Pro Tyr Asp Asn Thr Val Val  
1130 1135 1140

Leu Glu Glu Leu Arg Ala Gly Thr Thr Tyr Lys Val Asn Val Phe  
1145 1150 1155

Gly Met Phe Asp Gly Gly Glu Ser Ser Pro Leu Val Gly Gln Glu  
1160 1165 1170

Met Thr Thr Leu Ser Asp Thr Thr Val Met Pro Ile Leu Ser Ser  
1175 1180 1185

Gly Met Glu Cys Leu Thr Arg Ala Glu Ala Asp Ile Val Leu Leu  
1190 1195 1200

Val Asp Gly Ser Trp Ser Ile Gly Arg Ala Asn Phe Arg Thr Val  
1205 1210 1215

Arg Ser Phe Ile Ser Arg Ile Val Glu Val Phe Asp Ile Gly Pro  
1220 1225 1230

Lys Arg Val Gln Ile Ala Leu Ala Gln Tyr Ser Gly Asp Pro Arg  
1235 1240 1245

Thr Glu Trp Gln Leu Asn Ala His Arg Asp Lys Lys Ser Leu Leu  
1250 1255 1260

Gln Ala Val Ala Asn Leu Pro Tyr Lys Gly Gly Asn Thr Leu Thr  
1265 1270 1275

Gly Met Ala Leu Asn Phe Ile Arg Gln Gln Asn Phe Arg Thr Gln  
1280 1285 1290

Ala Gly Met Arg Pro Arg Ala Arg Lys Ile Gly Val Leu Ile Thr  
1295 1300 1305

Asp Gly Lys Ser Gln Asp Asp Val Glu Ala Pro Ser Lys Lys Leu  
1310 1315 1320

Lys Asp Glu Gly Val Glu Leu Phe Ala Ile Gly Ile Lys Asn Ala  
1325 1330 1335

-continued

---

Asp	Glu	Val	Glu	Leu	Lys	Met	Ile	Ala	Thr	Asp	Pro	Asp	Asp	Thr
1340						1345					1350			
His	Ala	Tyr	Asn	Val	Ala	Asp	Phe	Glu	Ser	Leu	Ser	Arg	Ile	Val
1355						1360					1365			
Asp	Asp	Leu	Thr	Ile	Asn	Leu	Cys	Asn	Ser	Val	Lys	Gly	Pro	Gly
1370						1375					1380			
Asp	Leu	Glu	Ala	Pro	Ser	Asn	Leu	Val	Ile	Ser	Glu	Arg	Thr	His
1385						1390					1395			
Arg	Ser	Phe	Arg	Val	Ser	Trp	Thr	Pro	Pro	Ser	Asp	Ser	Val	Asp
1400						1405					1410			
Arg	Tyr	Lys	Val	Glu	Tyr	Tyr	Pro	Val	Ser	Gly	Gly	Lys	Arg	Gln
1415						1420					1425			
Glu	Phe	Tyr	Val	Ser	Arg	Met	Glu	Thr	Ser	Thr	Val	Leu	Lys	Asp
1430						1435					1440			
Leu	Lys	Pro	Glu	Thr	Glu	Tyr	Val	Val	Asn	Val	Tyr	Ser	Val	Val
1445						1450					1455			
Glu	Asp	Glu	Tyr	Ser	Glu	Pro	Leu	Lys	Gly	Thr	Glu	Lys	Thr	Leu
1460						1465					1470			
Pro	Val	Pro	Val	Val	Ser	Leu	Asn	Ile	Tyr	Asp	Val	Gly	Pro	Thr
1475						1480					1485			
Thr	Met	His	Val	Gln	Trp	Gln	Pro	Val	Gly	Gly	Ala	Thr	Gly	Tyr
1490						1495					1500			
Ile	Leu	Ser	Tyr	Lys	Pro	Val	Lys	Asp	Thr	Glu	Pro	Thr	Arg	Pro
1505						1510					1515			
Lys	Glu	Val	Arg	Leu	Gly	Pro	Thr	Val	Asn	Asp	Met	Gln	Leu	Thr
1520						1525					1530			
Asp	Leu	Val	Pro	Asn	Thr	Glu	Tyr	Ala	Val	Thr	Val	Gln	Ala	Val
1535						1540					1545			
Leu	His	Asp	Leu	Thr	Ser	Glu	Pro	Val	Thr	Val	Arg	Glu	Val	Thr
1550						1555					1560			
Leu	Pro	Leu	Pro	Arg	Pro	Gln	Asp	Leu	Lys	Leu	Arg	Asp	Val	Thr
1565						1570					1575			
His	Ser	Thr	Met	Asn	Val	Phe	Trp	Glu	Pro	Val	Pro	Gly	Lys	Val
1580						1585					1590			
Arg	Lys	Tyr	Ile	Val	Arg	Tyr	Lys	Thr	Pro	Glu	Glu	Asp	Val	Lys
1595						1600					1605			
Glu	Val	Glu	Val	Asp	Arg	Ser	Glu	Thr	Ser	Thr	Ser	Leu	Lys	Asp
1610						1615					1620			
Leu	Phe	Ser	Gln	Thr	Leu	Tyr	Thr	Val	Ser	Val	Ser	Ala	Val	His
1625						1630					1635			
Asp	Glu	Gly	Glu	Ser	Pro	Pro	Val	Thr	Ala	Gln	Glu	Thr	Thr	Arg
1640						1645					1650			
Pro	Val	Pro	Ala	Pro	Thr	Asn	Leu	Lys	Ile	Thr	Glu	Val	Thr	Ser
1655						1660					1665			
Glu	Gly	Phe	Arg	Gly	Thr	Trp	Asp	His	Gly	Ala	Ser	Asp	Val	Ser
1670						1675					1680			
Leu	Tyr	Arg	Ile	Thr	Trp	Ala	Pro	Phe	Gly	Ser	Ser	Asp	Lys	Met
1685						1690					1695			
Glu	Thr	Ile	Leu	Asn	Gly	Asp	Glu	Asn	Thr	Leu	Val	Phe	Glu	Asn
1700						1705					1710			
Leu	Asn	Pro	Asn	Thr	Ile	Tyr	Glu	Val	Ser	Ile	Thr	Ala	Ile	Tyr

-continued

---

1715		1720		1725
Pro Asp	Glu Ser Glu Ser	Asp Asp Leu Ile Gly Ser	Glu Arg Thr	
1730		1735	1740	
Leu Pro	Ile Leu Thr Thr	Gln Ala Pro Lys Ser Gly	Pro Arg Asn	
1745		1750	1755	
Leu Gln	Val Tyr Asn Ala Thr	Ser Asn Ser Leu Thr	Val Lys Trp	
1760		1765	1770	
Asp Pro	Ala Ser Gly Arg Val	Gln Lys Tyr Arg Ile	Thr Tyr Gln	
1775		1780	1785	
Pro Ser	Thr Gly Glu Gly Asn	Glu Gln Thr Thr Thr	Ile Gly Gly	
1790		1795	1800	
Arg Gln	Asn Ser Val Val Leu	Gln Lys Leu Lys Pro	Asp Thr Pro	
1805		1810	1815	
Tyr Thr	Ile Thr Val Ser Ser	Leu Tyr Pro Asp Gly	Glu Gly Gly	
1820		1825	1830	
Arg Met	Thr Gly Arg Gly Lys	Thr Lys Pro Leu Asn	Thr Val Arg	
1835		1840	1845	
Asn Leu	Arg Val Tyr Asp Pro	Ser Thr Ser Thr Leu	Asn Val Arg	
1850		1855	1860	
Trp Asp	His Ala Glu Gly Asn	Pro Arg Gln Tyr Lys	Leu Phe Tyr	
1865		1870	1875	
Ala Pro	Ala Ala Gly Gly Pro	Glu Glu Leu Val Pro	Ile Pro Gly	
1880		1885	1890	
Asn Thr	Asn Tyr Ala Ile Leu	Arg Asn Leu Gln Pro	Asp Thr Ser	
1895		1900	1905	
Tyr Thr	Val Thr Val Val Pro	Val Tyr Thr Glu Gly	Asp Gly Gly	
1910		1915	1920	
Arg Thr	Ser Asp Thr Gly Arg	Thr Leu Met Arg Gly	Leu Ala Arg	
1925		1930	1935	
Asn Val	Gln Val Tyr Asn Pro	Thr Pro Asn Ser Leu	Asp Val Arg	
1940		1945	1950	
Trp Asp	Pro Ala Pro Gly Pro	Val Leu Gln Tyr Arg	Val Val Tyr	
1955		1960	1965	
Ser Pro	Val Asp Gly Thr Arg	Pro Ser Glu Ser Ile	Val Val Pro	
1970		1975	1980	
Gly Asn	Thr Arg Met Val His	Leu Glu Arg Leu Ile	Pro Asp Thr	
1985		1990	1995	
Leu Tyr	Ser Val Asn Leu Val	Ala Leu Tyr Ser Asp	Gly Glu Gly	
2000		2005	2010	
Asn Pro	Ser Pro Ala Gln Gly	Arg Thr Leu Pro Arg	Ser Gly Pro	
2015		2020	2025	
Arg Asn	Leu Arg Val Phe Gly	Glu Thr Thr Asn Ser	Leu Ser Val	
2030		2035	2040	
Ala Trp	Asp His Ala Asp Gly	Pro Val Gln Gln Tyr	Arg Ile Ile	
2045		2050	2055	
Tyr Ser	Pro Thr Val Gly Asp	Pro Ile Asp Glu Tyr	Thr Thr Val	
2060		2065	2070	
Pro Gly	Arg Arg Asn Asn Val	Ile Leu Gln Pro Leu	Gln Pro Asp	
2075		2080	2085	
Thr Pro	Tyr Lys Ile Thr Val	Ile Ala Val Tyr Glu	Asp Gly Asp	
2090		2095	2100	

-continued

---

Gly	Gly	His	Leu	Thr	Gly	Asn	Gly	Arg	Thr	Val	Gly	Leu	Leu	Pro
2105						2110					2115			
Pro	Gln	Asn	Ile	His	Ile	Ser	Asp	Glu	Trp	Tyr	Thr	Arg	Phe	Arg
2120						2125					2130			
Val	Ser	Trp	Asp	Pro	Ser	Pro	Ser	Pro	Val	Leu	Gly	Tyr	Lys	Ile
2135						2140					2145			
Val	Tyr	Lys	Pro	Val	Gly	Ser	Asn	Glu	Pro	Met	Glu	Ala	Phe	Val
2150						2155					2160			
Gly	Glu	Met	Thr	Ser	Tyr	Thr	Leu	His	Asn	Leu	Asn	Pro	Ser	Thr
2165						2170					2175			
Thr	Tyr	Asp	Val	Asn	Val	Tyr	Ala	Gln	Tyr	Asp	Ser	Gly	Leu	Ser
2180						2185					2190			
Val	Pro	Leu	Thr	Asp	Gln	Gly	Thr	Thr	Leu	Tyr	Leu	Asn	Val	Thr
2195						2200					2205			
Asp	Leu	Lys	Thr	Tyr	Gln	Ile	Gly	Trp	Asp	Thr	Phe	Cys	Val	Lys
2210						2215					2220			
Trp	Ser	Pro	His	Arg	Ala	Ala	Thr	Ser	Tyr	Arg	Leu	Lys	Leu	Ser
2225						2230					2235			
Pro	Ala	Asp	Gly	Thr	Arg	Gly	Gln	Glu	Ile	Thr	Val	Arg	Gly	Ser
2240						2245					2250			
Glu	Thr	Ser	His	Cys	Phe	Thr	Gly	Leu	Ser	Pro	Asp	Thr	Asp	Tyr
2255						2260					2265			
Gly	Val	Thr	Val	Phe	Val	Gln	Thr	Pro	Asn	Leu	Glu	Gly	Pro	Gly
2270						2275					2280			
Val	Ser	Val	Lys	Glu	His	Thr	Thr	Val	Lys	Pro	Thr	Glu	Ala	Pro
2285						2290					2295			
Thr	Glu	Pro	Pro	Thr	Pro	Pro	Pro	Pro	Pro	Thr	Ile	Pro	Pro	Ala
2300						2305					2310			
Arg	Asp	Val	Cys	Lys	Gly	Ala	Lys	Ala	Asp	Ile	Val	Phe	Leu	Thr
2315						2320					2325			
Asp	Ala	Ser	Trp	Ser	Ile	Gly	Asp	Asp	Asn	Phe	Asn	Lys	Val	Val
2330						2335					2340			
Lys	Phe	Ile	Phe	Asn	Thr	Val	Gly	Gly	Phe	Asp	Glu	Ile	Ser	Pro
2345						2350					2355			
Ala	Gly	Ile	Gln	Val	Ser	Phe	Val	Gln	Tyr	Ser	Asp	Glu	Val	Lys
2360						2365					2370			
Ser	Glu	Phe	Lys	Leu	Asn	Thr	Tyr	Asn	Asp	Lys	Ala	Leu	Ala	Leu
2375						2380					2385			
Gly	Ala	Leu	Gln	Asn	Ile	Arg	Tyr	Arg	Gly	Gly	Asn	Thr	Arg	Thr
2390						2395					2400			
Gly	Lys	Ala	Leu	Thr	Phe	Ile	Lys	Glu	Lys	Val	Leu	Thr	Trp	Glu
2405						2410					2415			
Ser	Gly	Met	Arg	Lys	Asn	Val	Pro	Lys	Val	Leu	Val	Val	Val	Thr
2420						2425					2430			
Asp	Gly	Arg	Ser	Gln	Asp	Glu	Val	Lys	Lys	Ala	Ala	Leu	Val	Ile
2435						2440					2445			
Gln	Gln	Ser	Gly	Phe	Ser	Val	Phe	Val	Val	Gly	Val	Ala	Asp	Val
2450						2455					2460			
Asp	Tyr	Asn	Glu	Leu	Ala	Asn	Ile	Ala	Ser	Lys	Pro	Ser	Glu	Arg
2465						2470					2475			

-continued

---

His Val	Phe Ile Val Asp	Asp	Phe Glu Ser	Phe Glu	Lys Ile Glu
2480		2485		2490	
Asp Asn	Leu Ile Thr Phe	Val	Cys Glu Thr	Ala Thr	Ser Ser Cys
2495		2500		2505	
Pro Leu	Ile Tyr Leu Asp	Gly	Tyr Thr Ser	Pro Gly	Phe Lys Met
2510		2515		2520	
Leu Glu	Ala Tyr Asn Leu	Thr	Glu Lys Asn	Phe Ala	Ser Val Gln
2525		2530		2535	
Gly Val	Ser Leu Glu Ser	Gly	Ser Phe Pro	Ser Tyr	Ser Ala Tyr
2540		2545		2550	
Arg Ile	Gln Lys Asn Ala	Phe	Val Asn Gln	Pro Thr	Ala Asp Leu
2555		2560		2565	
His Pro	Asn Gly Leu Pro	Pro	Ser Tyr Thr	Ile Ile	Leu Leu Phe
2570		2575		2580	
Arg Leu	Leu Pro Glu Thr	Pro	Ser Asp Pro	Phe Ala	Ile Trp Gln
2585		2590		2595	
Ile Thr	Asp Arg Asp Tyr	Lys	Pro Gln Val	Gly Val	Ile Ala Asp
2600		2605		2610	
Pro Ser	Ser Lys Thr Leu	Ser	Phe Phe Asn	Lys Asp	Thr Arg Gly
2615		2620		2625	
Glu Val	Gln Thr Val Thr	Phe	Asp Thr Glu	Glu Val	Lys Thr Leu
2630		2635		2640	
Phe Tyr	Gly Ser Phe His	Lys	Val His Ile	Val Val	Thr Ser Lys
2645		2650		2655	
Ser Val	Lys Ile Tyr Ile	Asp	Cys Tyr Glu	Ile Ile	Glu Lys Asp
2660		2665		2670	
Ile Lys	Glu Ala Gly Asn	Ile	Thr Thr Asp	Gly Tyr	Glu Ile Leu
2675		2680		2685	
Gly Lys	Leu Leu Lys Gly	Glu	Arg Lys Ser	Ala Ala	Phe Gln Ile
2690		2695		2700	
Gln Ser	Phe Asp Ile Val	Cys	Ser Pro Val	Trp Thr	Ser Arg Asp
2705		2710		2715	
Arg Cys	Cys Asp Ile Pro	Ser	Arg Arg Asp	Glu Gly	Lys Cys Pro
2720		2725		2730	
Ala Phe	Pro Asn Ser Cys	Thr	Cys Thr Gln	Asp Ser	Val Gly Pro
2735		2740		2745	
Pro Gly	Pro Pro Gly Pro	Ala	Gly Gly Pro	Gly Ala	Lys Gly Pro
2750		2755		2760	
Arg Gly	Glu Arg Gly Ile	Ser	Gly Ala Ile	Gly Pro	Pro Gly Pro
2765		2770		2775	
Arg Gly	Asp Ile Gly Pro	Pro	Gly Pro Gln	Gly Pro	Pro Gly Pro
2780		2785		2790	
Gln Gly	Pro Asn Gly Leu	Ser	Ile Pro Gly	Glu Gln	Gly Arg Gln
2795		2800		2805	
Gly Met	Lys Gly Asp Ala	Gly	Glu Pro Gly	Leu Pro	Gly Arg Thr
2810		2815		2820	
Gly Thr	Pro Gly Leu Pro	Gly	Pro Pro Gly	Pro Met	Gly Pro Pro
2825		2830		2835	
Gly Asp	Arg Gly Phe Thr	Gly	Lys Asp Gly	Ala Met	Gly Pro Arg
2840		2845		2850	
Gly Pro	Pro Gly Pro Pro	Gly	Ser Pro Gly	Ser Pro	Gly Val Thr

-continued

---

2855	2860	2865
Gly Pro Ser Gly Lys Pro	Gly Lys Pro Gly Asp His	Gly Arg Pro
2870	2875	2880
Gly Pro Ser Gly Leu Lys	Gly Glu Lys Gly Asp Arg	Gly Asp Ile
2885	2890	2895
Ala Ser Gln Asn Met Met	Arg Ala Val Ala Arg Gln	Val Cys Glu
2900	2905	2910
Gln Leu Ile Ser Gly Gln	Met Asn Arg Phe Asn Gln	Met Leu Asn
2915	2920	2925
Gln Ile Pro Asn Asp Tyr	Gln Ser Ser Arg Asn Gln	Pro Gly Pro
2930	2935	2940
Pro Gly Pro Pro Gly Pro	Pro Gly Ser Ala Gly Ala	Arg Gly Glu
2945	2950	2955
Pro Gly Pro Gly Gly Arg	Pro Gly Phe Pro Gly Thr	Pro Gly Met
2960	2965	2970
Gln Gly Pro Pro Gly Glu	Arg Gly Leu Pro Gly Glu	Lys Gly Glu
2975	2980	2985
Arg Gly Thr Gly Ser Ser	Gly Pro Arg Gly Leu Pro	Gly Pro Pro
2990	2995	3000
Gly Pro Gln Gly Glu Ser	Arg Thr Gly Pro Pro Gly	Ser Thr Gly
3005	3010	3015
Ser Arg Gly Pro Pro Gly	Pro Pro Gly Arg Pro Gly	Asn Ser Gly
3020	3025	3030
Ile Arg Gly Pro Pro Gly	Pro Pro Gly Tyr Cys Asp	Ser Ser Gln
3035	3040	3045
Cys Ala Ser Ile Pro Tyr	Asn Gly Gln Gly Tyr Pro	Gly Ser Gly
3050	3055	3060

&lt;210&gt; SEQ ID NO 8

&lt;211&gt; LENGTH: 1796

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 8

Met Lys Ile Phe Gln Arg Lys Met Arg Tyr Trp Leu Leu Pro Pro Phe
1                    5                    10                    15
Leu Ala Ile Val Tyr Phe Cys Thr Ile Val Gln Gly Gln Val Ala Pro
20                    25                    30
Pro Thr Arg Leu Arg Tyr Asn Val Ile Ser His Asp Ser Ile Gln Ile
35                    40                    45
Ser Trp Lys Ala Pro Arg Gly Lys Phe Gly Gly Tyr Lys Leu Leu Val
50                    55                    60
Thr Pro Thr Ser Gly Gly Lys Thr Asn Gln Leu Asn Leu Gln Asn Thr
65                    70                    75                    80
Ala Thr Lys Ala Ile Ile Gln Gly Leu Met Pro Asp Gln Asn Tyr Thr
85                    90                    95
Val Gln Ile Ile Ala Tyr Asn Lys Asp Lys Glu Ser Lys Pro Ala Gln
100                    105                    110
Gly Gln Phe Arg Ile Lys Asp Leu Glu Lys Arg Lys Asp Pro Lys Pro
115                    120                    125
Arg Val Lys Val Val Asp Arg Gly Asn Gly Ser Arg Pro Ser Ser Pro
130                    135                    140

-continued

---

Glu Val Lys Phe Val Cys Gln Thr Pro Ala Ile Ala Asp Ile Val  
 145 150 155 160  
 Ile Leu Val Asp Gly Ser Trp Ser Ile Gly Arg Phe Asn Phe Arg Leu  
 165 170 175  
 Val Arg His Phe Leu Glu Asn Leu Val Thr Ala Phe Asp Val Gly Ser  
 180 185 190  
 Glu Lys Thr Arg Ile Gly Leu Ala Gln Tyr Ser Gly Asp Pro Arg Ile  
 195 200 205  
 Glu Trp His Leu Asn Ala Phe Ser Thr Lys Asp Glu Val Ile Glu Ala  
 210 215 220  
 Val Arg Asn Leu Pro Tyr Lys Gly Gly Asn Thr Leu Thr Gly Leu Ala  
 225 230 235 240  
 Leu Asn Tyr Ile Phe Glu Asn Ser Phe Lys Pro Glu Ala Gly Ser Arg  
 245 250 255  
 Thr Gly Val Ser Lys Ile Gly Ile Leu Ile Thr Asp Gly Lys Ser Gln  
 260 265 270  
 Asp Asp Ile Ile Pro Pro Ser Arg Asn Leu Arg Glu Ser Gly Val Glu  
 275 280 285  
 Leu Phe Ala Ile Gly Val Lys Asn Ala Asp Val Asn Glu Leu Gln Glu  
 290 295 300  
 Ile Ala Ser Glu Pro Asp Ser Thr His Val Tyr Asn Val Ala Glu Phe  
 305 310 315 320  
 Asp Leu Met His Thr Val Val Glu Ser Leu Thr Arg Thr Leu Cys Ser  
 325 330 335  
 Arg Val Glu Glu Gln Asp Arg Glu Ile Lys Ala Ser Ala His Ala Ile  
 340 345 350  
 Thr Gly Pro Pro Thr Glu Leu Ile Thr Ser Glu Val Thr Ala Arg Ser  
 355 360 365  
 Phe Met Val Asn Trp Thr His Ala Pro Gly Asn Val Glu Lys Tyr Arg  
 370 375 380  
 Val Val Tyr Tyr Pro Thr Arg Gly Gly Lys Pro Asp Glu Val Val Val  
 385 390 395 400  
 Asp Gly Thr Val Ser Ser Thr Val Leu Lys Asn Leu Met Ser Leu Thr  
 405 410 415  
 Glu Tyr Gln Ile Ala Val Phe Ala Ile Tyr Ala His Thr Ala Ser Glu  
 420 425 430  
 Gly Leu Arg Gly Thr Glu Thr Thr Leu Ala Leu Pro Met Ala Ser Asp  
 435 440 445  
 Leu Leu Leu Tyr Asp Val Thr Glu Asn Ser Met Arg Val Lys Trp Asp  
 450 455 460  
 Ala Val Pro Gly Ala Ser Gly Tyr Leu Ile Leu Tyr Ala Pro Leu Thr  
 465 470 475 480  
 Glu Gly Leu Ala Gly Asp Glu Lys Glu Met Lys Ile Gly Glu Thr His  
 485 490 495  
 Thr Asp Ile Glu Leu Ser Gly Leu Leu Pro Asn Thr Glu Tyr Thr Val  
 500 505 510  
 Thr Val Tyr Ala Met Phe Gly Glu Glu Ala Ser Asp Pro Val Thr Gly  
 515 520 525  
 Gln Glu Thr Thr Leu Ala Leu Ser Pro Pro Arg Asn Leu Arg Ile Ser  
 530 535 540  
 Asn Val Gly Ser Asn Ser Ala Arg Leu Thr Trp Asp Pro Thr Ser Arg

-continued

---

545		550		555		560
Gln Ile Asn Gly Tyr Arg Ile Val Tyr Asn Asn Ala Asp Gly Thr Glu						
		565		570		575
Ile Asn Glu Val Glu Val Asp Pro Ile Thr Thr Phe Pro Leu Lys Gly						
		580		585		590
Leu Thr Pro Leu Thr Glu Tyr Thr Ile Ala Ile Phe Ser Ile Tyr Asp						
		595		600		605
Glu Gly Gln Ser Glu Pro Leu Thr Gly Val Phe Thr Thr Glu Glu Val						
		610		615		620
Pro Ala Gln Gln Tyr Leu Glu Ile Asp Glu Val Thr Thr Asp Ser Phe						
		625		630		635
Arg Val Thr Trp His Pro Leu Ser Ala Asp Glu Gly Leu His Lys Leu						
		645		650		655
Met Trp Ile Pro Val Tyr Gly Gly Lys Thr Glu Glu Val Val Leu Lys						
		660		665		670
Glu Glu Gln Asp Ser His Val Ile Glu Gly Leu Glu Pro Gly Thr Glu						
		675		680		685
Tyr Glu Val Ser Leu Leu Ala Val Leu Asp Asp Gly Ser Glu Ser Glu						
		690		695		700
Val Val Thr Ala Val Gly Thr Thr Leu Asp Ser Phe Trp Thr Glu Pro						
		705		710		715
Ala Thr Thr Ile Val Pro Thr Thr Ser Val Thr Ser Val Phe Gln Thr						
		725		730		735
Gly Ile Arg Asn Leu Val Val Gly Asp Glu Thr Thr Ser Ser Leu Arg						
		740		745		750
Val Lys Trp Asp Ile Ser Asp Ser Asp Val Gln Gln Phe Arg Val Thr						
		755		760		765
Tyr Met Thr Ala Gln Gly Asp Pro Glu Glu Glu Val Ile Gly Thr Val						
		770		775		780
Met Val Pro Gly Ser Gln Asn Asn Leu Leu Leu Lys Pro Leu Leu Pro						
		785		790		795
Asp Thr Glu Tyr Lys Val Thr Val Thr Pro Ile Tyr Thr Asp Gly Glu						
		805		810		815
Gly Val Ser Val Ser Ala Pro Gly Lys Thr Leu Pro Ser Ser Gly Pro						
		820		825		830
Gln Asn Leu Arg Val Ser Glu Glu Trp Tyr Asn Arg Leu Arg Ile Thr						
		835		840		845
Trp Asp Pro Pro Ser Ser Pro Val Lys Gly Tyr Arg Ile Val Tyr Lys						
		850		855		860
Pro Val Ser Val Pro Gly Pro Thr Leu Glu Thr Phe Val Gly Ala Asp						
		865		870		875
Ile Asn Thr Ile Leu Ile Thr Asn Leu Leu Ser Gly Met Asp Tyr Asn						
		885		890		895
Val Lys Ile Phe Ala Ser Gln Ala Ser Gly Phe Ser Asp Ala Leu Thr						
		900		905		910
Gly Met Val Lys Thr Leu Phe Leu Gly Val Thr Asn Leu Gln Ala Lys						
		915		920		925
His Val Glu Met Thr Ser Leu Cys Ala His Trp Gln Val His Arg His						
		930		935		940
Ala Thr Ala Tyr Arg Val Val Ile Glu Ser Leu Gln Asp Arg Gln Lys						
		945		950		955
						960

-continued

---

Gln Glu Ser Thr Val Gly Gly Gly Thr Thr Arg His Cys Phe Tyr Gly  
                   965  970  975

Leu Gln Pro Asp Ser Glu Tyr Lys Ile Ser Val Tyr Thr Lys Leu Gln  
                   980  985  990

Glu Ile Glu Gly Pro Ser Val Ser Ile Met Glu Lys Thr Gln Ser Leu  
                   995  1000  1005

Pro Thr Arg Pro Pro Thr Phe Pro Pro Thr Ile Pro Pro Ala Lys  
                   1010  1015  1020

Glu Val Cys Lys Ala Ala Lys Ala Asp Leu Val Phe Met Val Asp  
                   1025  1030  1035

Gly Ser Trp Ser Ile Gly Asp Glu Asn Phe Asn Lys Ile Ile Ser  
                   1040  1045  1050

Phe Leu Tyr Ser Thr Val Gly Ala Leu Asn Lys Ile Gly Thr Asp  
                   1055  1060  1065

Gly Thr Gln Val Ala Met Val Gln Phe Thr Asp Asp Pro Arg Thr  
                   1070  1075  1080

Glu Phe Lys Leu Asn Ala Tyr Lys Thr Lys Glu Thr Leu Leu Asp  
                   1085  1090  1095

Ala Ile Lys His Ile Ser Tyr Lys Gly Gly Asn Thr Lys Thr Gly  
                   1100  1105  1110

Lys Ala Ile Lys Tyr Val Arg Asp Thr Leu Phe Thr Ala Glu Ser  
                   1115  1120  1125

Gly Thr Arg Arg Gly Ile Pro Lys Val Ile Val Val Ile Thr Asp  
                   1130  1135  1140

Gly Arg Ser Gln Asp Asp Val Asn Lys Ile Ser Arg Glu Met Gln  
                   1145  1150  1155

Leu Asp Gly Tyr Ser Ile Phe Ala Ile Gly Val Ala Asp Ala Asp  
                   1160  1165  1170

Tyr Ser Glu Leu Val Ser Ile Gly Ser Lys Pro Ser Ala Arg His  
                   1175  1180  1185

Val Phe Phe Val Asp Asp Phe Asp Ala Phe Lys Lys Ile Glu Asp  
                   1190  1195  1200

Glu Leu Ile Thr Phe Val Cys Glu Thr Ala Ser Ala Thr Cys Pro  
                   1205  1210  1215

Val Val His Lys Asp Gly Ile Asp Leu Ala Gly Phe Lys Met Met  
                   1220  1225  1230

Glu Met Phe Gly Leu Val Glu Lys Asp Phe Ser Ser Val Glu Gly  
                   1235  1240  1245

Val Ser Met Glu Pro Gly Thr Phe Asn Val Phe Pro Cys Tyr Gln  
                   1250  1255  1260

Leu His Lys Asp Ala Leu Val Ser Gln Pro Thr Arg Tyr Leu His  
                   1265  1270  1275

Pro Glu Gly Leu Pro Ser Asp Tyr Thr Ile Ser Phe Leu Phe Arg  
                   1280  1285  1290

Ile Leu Pro Asp Thr Pro Gln Glu Pro Phe Ala Leu Trp Glu Ile  
                   1295  1300  1305

Leu Asn Lys Asn Ser Asp Pro Leu Val Gly Val Ile Leu Asp Asn  
                   1310  1315  1320

Gly Gly Lys Thr Leu Thr Tyr Phe Asn Tyr Asp Gln Ser Gly Asp  
                   1325  1330  1335

-continued

---

Phe	Gln	Thr	Val	Thr	Phe	Glu	Gly	Pro	Glu	Ile	Arg	Lys	Ile	Phe
1340						1345						1350		
Tyr	Gly	Ser	Phe	His	Lys	Leu	His	Ile	Val	Val	Ser	Glu	Thr	Leu
1355						1360						1365		
Val	Lys	Val	Val	Ile	Asp	Cys	Lys	Gln	Val	Gly	Glu	Lys	Ala	Met
1370						1375						1380		
Asn	Ala	Ser	Ala	Asn	Ile	Thr	Ser	Asp	Gly	Val	Glu	Val	Leu	Gly
1385						1390						1395		
Lys	Met	Val	Arg	Ser	Arg	Gly	Pro	Gly	Gly	Asn	Ser	Ala	Pro	Phe
1400						1405						1410		
Gln	Leu	Gln	Met	Phe	Asp	Ile	Val	Cys	Ser	Thr	Ser	Trp	Ala	Asn
1415						1420						1425		
Thr	Asp	Lys	Cys	Cys	Glu	Leu	Pro	Gly	Leu	Arg	Asp	Asp	Glu	Ser
1430						1435						1440		
Cys	Pro	Asp	Leu	Pro	His	Ser	Cys	Ser	Cys	Ser	Glu	Thr	Asn	Glu
1445						1450						1455		
Val	Ala	Leu	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Gly	Pro	Gly	Leu	Arg
1460						1465						1470		
Gly	Pro	Lys	Gly	Gln	Gln	Gly	Glu	Pro	Gly	Pro	Lys	Gly	Pro	Asp
1475						1480						1485		
Gly	Pro	Arg	Gly	Glu	Ile	Gly	Leu	Pro	Gly	Pro	Gln	Gly	Pro	Pro
1490						1495						1500		
Gly	Pro	Gln	Gly	Pro	Ser	Gly	Leu	Ser	Ile	Gln	Gly	Met	Pro	Gly
1505						1510						1515		
Met	Pro	Gly	Glu	Lys	Gly	Glu	Lys	Gly	Asp	Thr	Gly	Leu	Pro	Gly
1520						1525						1530		
Pro	Gln	Gly	Ile	Pro	Gly	Gly	Val	Gly	Ser	Pro	Gly	Arg	Asp	Gly
1535						1540						1545		
Ser	Pro	Gly	Gln	Arg	Gly	Leu	Pro	Gly	Lys	Asp	Gly	Ser	Ser	Gly
1550						1555						1560		
Pro	Pro	Gly	Pro	Pro	Gly	Pro	Ile	Gly	Ile	Pro	Gly	Thr	Pro	Gly
1565						1570						1575		
Val	Pro	Gly	Ile	Thr	Gly	Ser	Met	Gly	Pro	Gln	Gly	Ala	Leu	Gly
1580						1585						1590		
Pro	Pro	Gly	Val	Pro	Gly	Ala	Lys	Gly	Glu	Arg	Gly	Glu	Arg	Gly
1595						1600						1605		
Asp	Leu	Gln	Ser	Gln	Ala	Met	Val	Arg	Ser	Val	Ala	Arg	Gln	Val
1610						1615						1620		
Cys	Glu	Gln	Leu	Ile	Gln	Ser	His	Met	Ala	Arg	Tyr	Thr	Ala	Ile
1625						1630						1635		
Leu	Asn	Gln	Ile	Pro	Ser	His	Ser	Ser	Ser	Ile	Arg	Thr	Val	Gln
1640						1645						1650		
Gly	Pro	Pro	Gly	Glu	Pro	Gly	Arg	Pro	Gly	Ser	Pro	Gly	Ala	Pro
1655						1660						1665		
Gly	Glu	Gln	Gly	Pro	Pro	Gly	Thr	Pro	Gly	Phe	Pro	Gly	Asn	Ala
1670						1675						1680		
Gly	Val	Pro	Gly	Thr	Pro	Gly	Glu	Arg	Gly	Leu	Thr	Gly	Ile	Lys
1685						1690						1695		
Gly	Glu	Lys	Gly	Asn	Pro	Gly	Val	Gly	Thr	Gln	Gly	Pro	Arg	Gly
1700						1705						1710		
Pro	Pro	Gly	Pro	Ala	Gly	Pro	Ser	Gly	Glu	Ser	Arg	Pro	Gly	Ser



-continued

---

Lys	Val	Glu	Pro	Ile	Asn	Thr	Pro	Pro	Thr	Pro	Ser	Ser	Pro	Phe	Glu
		275					280					285			
Asp	Met	Glu	Leu	Ser	Gly	Glu	Pro	Val	Pro	Glu	Gly	Thr	Leu	Glu	Thr
	290					295					300				
Thr	Asn	Met	Ser	Ile	Ile	Gln	His	Ser	Ser	Pro	Lys	Gln	Gly	Ser	Gly
305					310					315					320
Glu	Ile	Leu	Asn	Asp	Thr	Leu	Glu	Gly	Val	His	Ser	Val	Asp	Gly	Asp
				325					330					335	
Pro	Ile	Thr	Asp	Ser	Gly	Ser	Gly	Ala	Gly	Ala	Phe	Leu	Asp	Ile	Ala
			340					345					350		
Glu	Glu	Lys	Asn	Leu	Ala	Ala	Thr	Ala	Ala	Gly	Leu	Ala	Glu	Val	Pro
		355					360						365		
Ile	Ser	Thr	Ala	Gly	Glu	Ala	Glu	Ala	Ser	Ser	Val	Pro	Thr	Gly	Gly
	370					375						380			
Pro	Thr	Leu	Ser	Met	Ser	Thr	Glu	Asn	Pro	Glu	Glu	Gly	Val	Thr	Pro
385					390					395					400
Gly	Pro	Asp	Asn	Glu	Glu	Arg	Leu	Ala	Ala	Thr	Ala	Ala	Gly	Glu	Ala
				405					410					415	
Glu	Ala	Leu	Ala	Ser	Met	Pro	Gly	Glu	Val	Glu	Ala	Ser	Gly	Val	Ala
			420						425					430	
Pro	Gly	Glu	Leu	Asp	Leu	Ser	Met	Ser	Ala	Gln	Ser	Leu	Gly	Glu	Glu
		435					440						445		
Ala	Thr	Val	Gly	Pro	Ser	Ser	Glu	Asp	Ser	Leu	Thr	Thr	Ala	Ala	Ala
	450					455						460			
Ala	Thr	Glu	Val	Ser	Leu	Ser	Thr	Phe	Glu	Asp	Glu	Glu	Ala	Ser	Gly
465					470					475					480
Val	Pro	Thr	Asp	Gly	Leu	Ala	Pro	Leu	Thr	Ala	Thr	Met	Ala	Pro	Glu
				485					490					495	
Arg	Ala	Val	Thr	Ser	Gly	Pro	Gly	Asp	Glu	Glu	Asp	Leu	Ala	Ala	Ala
		500						505						510	
Thr	Thr	Glu	Glu	Pro	Leu	Ile	Thr	Ala	Gly	Gly	Glu	Glu	Ser	Gly	Ser
		515					520							525	
Pro	Pro	Pro	Asp	Gly	Pro	Pro	Leu	Pro	Leu	Pro	Thr	Val	Ala	Pro	Glu
		530				535						540			
Arg	Trp	Ile	Thr	Pro	Ala	Gln	Arg	Glu	His	Val	Gly	Met	Lys	Gly	Gln
545					550					555					560
Ala	Gly	Pro	Lys	Gly	Glu	Lys	Gly	Asp	Ala	Gly	Glu	Glu	Leu	Pro	Gly
				565					570					575	
Pro	Pro	Glu	Pro	Ser	Gly	Pro	Val	Gly	Pro	Thr	Ala	Gly	Ala	Glu	Ala
			580						585					590	
Glu	Gly	Ser	Gly	Leu	Gly	Trp	Gly	Ser	Asp	Val	Gly	Ser	Gly	Ser	Gly
		595					600					605			
Asp	Leu	Val	Gly	Ser	Glu	Gln	Leu	Leu	Arg	Gly	Pro	Pro	Gly	Pro	Pro
	610					615						620			
Gly	Pro	Pro	Gly	Leu	Pro	Gly	Ile	Pro	Gly	Lys	Pro	Gly	Thr	Asp	Val
				625		630				635					640
Phe	Met	Gly	Pro	Pro	Gly	Ser	Pro	Gly	Glu	Asp	Gly	Pro	Ala	Gly	Glu
				645					650					655	
Pro	Gly	Pro	Pro	Gly	Pro	Glu	Gly	Gln	Pro	Gly	Val	Asp	Gly	Ala	Thr
			660					665						670	
Gly	Leu	Pro	Gly	Met	Lys	Gly	Glu	Lys	Gly	Ala	Arg	Gly	Pro	Asn	Gly

-continued

675				680				685							
Ser	Val	Gly	Glu	Lys	Gly	Asp	Pro	Gly	Asn	Arg	Gly	Leu	Pro	Gly	Pro
690						695					700				
Pro	Gly	Lys	Lys	Gly	Gln	Ala	Gly	Pro	Pro	Gly	Val	Met	Gly	Pro	Pro
705					710					715					720
Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Gly	Cys	Thr	Met	Gly
			725						730					735	
Leu	Gly	Phe	Glu	Asp	Thr	Glu	Gly	Ser	Gly	Ser	Thr	Gln	Leu	Leu	Asn
			740						745					750	
Glu	Pro	Lys	Leu	Ser	Arg	Pro	Thr	Ala	Ala	Ile	Gly	Leu	Lys	Gly	Glu
		755					760							765	
Lys	Gly	Asp	Arg	Gly	Pro	Lys	Gly	Glu	Arg	Gly	Met	Asp	Gly	Ala	Ser
770						775					780				
Ile	Val	Gly	Pro	Pro	Gly	Pro	Arg	Gly	Pro	Pro	Gly	His	Ile	Lys	Val
785					790					795					800
Leu	Ser	Asn	Ser	Leu	Ile	Asn	Ile	Thr	His	Gly	Phe	Met	Asn	Phe	Ser
			805						810						815
Asp	Ile	Pro	Glu	Leu	Val	Gly	Pro	Pro	Gly	Pro	Asp	Gly	Leu	Pro	Gly
			820						825					830	
Leu	Pro	Gly	Phe	Pro	Gly	Pro	Arg	Gly	Pro	Lys	Gly	Asp	Thr	Gly	Leu
		835					840							845	
Pro	Gly	Phe	Pro	Gly	Leu	Lys	Gly	Glu	Gln	Gly	Glu	Lys	Gly	Glu	Pro
		850				855					860				
Gly	Ala	Ile	Leu	Thr	Glu	Asp	Ile	Pro	Leu	Glu	Arg	Leu	Met	Gly	Lys
865					870					875					880
Lys	Gly	Glu	Pro	Gly	Met	His	Gly	Ala	Pro	Gly	Pro	Met	Gly	Pro	Lys
			885						890					895	
Gly	Pro	Pro	Gly	His	Lys	Gly	Glu	Phe	Gly	Leu	Pro	Gly	Arg	Pro	Gly
			900						905					910	
Arg	Pro	Gly	Leu	Asn	Gly	Leu	Lys	Gly	Thr	Lys	Gly	Asp	Pro	Gly	Val
		915					920							925	
Ile	Met	Gln	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly
930						935					940				
Pro	Pro	Gly	Ala	Val	Ile	Asn	Ile	Lys	Gly	Ala	Ile	Phe	Pro	Ile	Pro
945						950				955					960
Val	Arg	Pro	His	Cys	Lys	Met	Pro	Val	Asp	Thr	Ala	His	Pro	Gly	Ser
			965						970					975	
Pro	Glu	Leu	Ile	Thr	Phe	His	Gly	Val	Lys	Gly	Glu	Lys	Gly	Ser	Trp
			980						985					990	
Gly	Leu	Pro	Gly	Ser	Lys	Gly	Glu	Lys	Gly	Asp	Gln	Gly	Ala	Gln	Gly
		995					1000							1005	
Pro	Pro	Gly	Pro	Pro	Leu	Asp	Leu	Ala	Tyr	Leu	Arg	His	Phe	Leu	
		1010					1015							1020	
Asn	Asn	Leu	Lys	Gly	Glu	Asn	Gly	Asp	Lys	Gly	Phe	Lys	Gly	Glu	
		1025					1030							1035	
Lys	Gly	Glu	Lys	Gly	Asp	Ile	Asn	Gly	Ser	Phe	Leu	Met	Ser	Gly	
		1040				1045								1050	
Pro	Pro	Gly	Leu	Pro	Gly	Asn	Pro	Gly	Pro	Ala	Gly	Gln	Lys	Gly	
		1055				1060								1065	
Glu	Thr	Val	Val	Gly	Pro	Gln	Gly	Pro	Pro	Gly	Ala	Pro	Gly	Leu	
		1070				1075								1080	

-continued

---

Pro Gly Pro Pro Gly Phe Gly Arg Pro Gly Asp Pro Gly Pro Pro  
 1085 1090 1095

Gly Pro Pro Gly Pro Pro Gly Pro Pro Ala Ile Leu Gly Ala Ala  
 1100 1105 1110

Val Ala Leu Pro Gly Pro Pro Gly Pro Pro Gly Gln Pro Gly Leu  
 1115 1120 1125

Pro Gly Ser Arg Asn Leu Val Thr Ala Phe Ser Asn Met Asp Asp  
 1130 1135 1140

Met Leu Gln Lys Ala His Leu Val Ile Glu Gly Thr Phe Ile Tyr  
 1145 1150 1155

Leu Arg Asp Ser Thr Glu Phe Phe Ile Arg Val Arg Asp Gly Trp  
 1160 1165 1170

Lys Lys Leu Gln Leu Gly Glu Leu Ile Pro Ile Pro Ala Asp Ser  
 1175 1180 1185

Pro Pro Pro Pro Ala Leu Ser Ser Asn Pro His Gln Leu Leu Pro  
 1190 1195 1200

Pro Pro Asn Pro Ile Ser Ser Ala Asn Tyr Glu Lys Pro Ala Leu  
 1205 1210 1215

His Leu Ala Ala Leu Asn Met Pro Phe Ser Gly Asp Ile Arg Ala  
 1220 1225 1230

Asp Phe Gln Cys Phe Lys Gln Ala Arg Ala Ala Gly Leu Leu Ser  
 1235 1240 1245

Thr Tyr Arg Ala Phe Leu Ser Ser His Leu Gln Asp Leu Ser Thr  
 1250 1255 1260

Ile Val Arg Lys Ala Glu Arg Tyr Ser Leu Pro Ile Val Asn Leu  
 1265 1270 1275

Lys Gly Gln Val Leu Phe Asn Asn Trp Asp Ser Ile Phe Ser Gly  
 1280 1285 1290

His Gly Gly Gln Phe Asn Met His Ile Pro Ile Tyr Ser Phe Asp  
 1295 1300 1305

Gly Arg Asp Ile Met Thr Asp Pro Ser Trp Pro Gln Lys Val Ile  
 1310 1315 1320

Trp His Gly Ser Ser Pro His Gly Val Arg Leu Val Asp Asn Tyr  
 1325 1330 1335

Cys Glu Ala Trp Arg Thr Ala Asp Thr Ala Val Thr Gly Leu Ala  
 1340 1345 1350

Ser Pro Leu Ser Thr Gly Lys Ile Leu Asp Gln Lys Ala Tyr Ser  
 1355 1360 1365

Cys Ala Asn Arg Leu Ile Val Leu Cys Ile Glu Asn Ser Phe Met  
 1370 1375 1380

Thr Asp Ala Arg Lys  
 1385

<210> SEQ ID NO 10  
 <211> LENGTH: 1751  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <400> SEQUENCE: 10

Met Ala Pro Tyr Pro Cys Gly Cys His Ile Leu Leu Leu Leu Phe Cys  
 1 5 10 15

Cys Leu Ala Ala Ala Arg Ala Asn Leu Leu Asn Leu Asn Trp Leu Trp

-continued

20					25					30					
Phe	Asn	Asn	Glu	Asp	Thr	Ser	His	Ala	Ala	Thr	Thr	Ile	Pro	Glu	Pro
	35						40					45			
Gln	Gly	Pro	Leu	Pro	Val	Gln	Pro	Thr	Ala	Asp	Thr	Thr	Thr	His	Val
	50					55					60				
Thr	Pro	Arg	Asn	Gly	Ser	Thr	Glu	Pro	Ala	Thr	Ala	Pro	Gly	Ser	Pro
65					70					75					80
Glu	Pro	Pro	Ser	Glu	Leu	Leu	Glu	Asp	Gly	Gln	Asp	Thr	Pro	Thr	Ser
				85					90						95
Ala	Glu	Ser	Pro	Asp	Ala	Pro	Glu	Glu	Asn	Ile	Ala	Gly	Val	Gly	Ala
			100					105					110		
Glu	Ile	Leu	Asn	Val	Ala	Lys	Gly	Ile	Arg	Ser	Phe	Val	Gln	Leu	Trp
	115						120					125			
Asn	Asp	Thr	Val	Pro	Thr	Glu	Ser	Leu	Ala	Arg	Ala	Glu	Thr	Leu	Val
	130					135					140				
Leu	Glu	Thr	Pro	Val	Gly	Pro	Leu	Ala	Leu	Ala	Gly	Pro	Ser	Ser	Thr
145					150					155					160
Pro	Gln	Glu	Asn	Gly	Thr	Thr	Leu	Trp	Pro	Ser	Arg	Gly	Ile	Pro	Ser
			165						170					175	
Ser	Pro	Gly	Ala	His	Thr	Thr	Glu	Ala	Gly	Thr	Leu	Pro	Ala	Pro	Thr
		180						185					190		
Pro	Ser	Pro	Pro	Ser	Leu	Gly	Arg	Pro	Trp	Ala	Pro	Leu	Thr	Gly	Pro
		195					200					205			
Ser	Val	Pro	Pro	Pro	Ser	Ser	Gly	Arg	Ala	Ser	Leu	Ser	Ser	Leu	Leu
	210					215					220				
Gly	Gly	Ala	Pro	Pro	Trp	Gly	Ser	Leu	Gln	Asp	Pro	Asp	Ser	Gln	Gly
225					230					235					240
Leu	Ser	Pro	Ala	Ala	Ala	Ala	Pro	Ser	Gln	Gln	Leu	Gln	Arg	Pro	Asp
			245						250					255	
Val	Arg	Leu	Arg	Thr	Pro	Leu	Leu	His	Pro	Leu	Val	Met	Gly	Ser	Leu
		260						265						270	
Gly	Lys	His	Ala	Ala	Pro	Ser	Ala	Phe	Ser	Ser	Gly	Leu	Pro	Gly	Ala
		275					280					285			
Leu	Ser	Gln	Val	Ala	Val	Thr	Thr	Leu	Thr	Arg	Asp	Ser	Gly	Ala	Trp
	290					295					300				
Val	Ser	His	Val	Ala	Asn	Ser	Val	Gly	Pro	Gly	Leu	Ala	Asn	Asn	Ser
305					310					315					320
Ala	Leu	Leu	Gly	Ala	Asp	Pro	Glu	Ala	Pro	Ala	Gly	Arg	Cys	Leu	Pro
			325						330					335	
Leu	Pro	Pro	Ser	Leu	Pro	Val	Cys	Gly	His	Leu	Gly	Ile	Ser	Arg	Phe
			340				345						350		
Trp	Leu	Pro	Asn	His	Leu	His	His	Glu	Ser	Gly	Glu	Gln	Val	Arg	Ala
	355						360					365			
Gly	Ala	Arg	Ala	Trp	Gly	Gly	Leu	Leu	Gln	Thr	His	Cys	His	Pro	Phe
	370					375						380			
Leu	Ala	Trp	Phe	Phe	Cys	Leu	Leu	Leu	Val	Pro	Pro	Cys	Gly	Ser	Val
385					390					395					400
Pro	Pro	Pro	Ala	Pro	Pro	Pro	Cys	Cys	Gln	Phe	Cys	Glu	Ala	Leu	Gln
			405						410					415	
Asp	Ala	Cys	Trp	Ser	Arg	Leu	Gly	Gly	Gly	Arg	Leu	Pro	Val	Ala	Cys
		420					425						430		

-continued

---

Ala Ser Leu Pro Thr Gln Glu Asp Gly Tyr Cys Val Leu Ile Gly Pro  
435 440 445

Ala Ala Glu Arg Ile Ser Glu Glu Val Gly Leu Leu Gln Leu Leu Gly  
450 455 460

Asp Pro Pro Pro Gln Gln Val Thr Gln Thr Asp Asp Pro Asp Val Gly  
465 470 475 480

Leu Ala Tyr Val Phe Gly Pro Asp Ala Asn Ser Gly Gln Val Ala Arg  
485 490 495

Tyr His Phe Pro Ser Leu Phe Phe Arg Asp Phe Ser Leu Leu Phe His  
500 505 510

Ile Arg Pro Ala Thr Glu Gly Pro Gly Val Leu Phe Ala Ile Thr Asp  
515 520 525

Ser Ala Gln Ala Met Val Leu Leu Gly Val Lys Leu Ser Gly Val Gln  
530 535 540

Asp Gly His Gln Asp Ile Ser Leu Leu Tyr Thr Glu Pro Gly Ala Gly  
545 550 555 560

Gln Thr His Thr Ala Ala Ser Phe Arg Leu Pro Ala Phe Val Gly Gln  
565 570 575

Trp Thr His Leu Ala Leu Ser Val Ala Gly Gly Phe Val Ala Leu Tyr  
580 585 590

Val Asp Cys Glu Glu Phe Gln Arg Met Pro Leu Ala Arg Ser Ser Arg  
595 600 605

Gly Leu Glu Leu Glu Pro Gly Ala Gly Leu Phe Val Ala Gln Ala Gly  
610 615 620

Gly Ala Asp Pro Asp Lys Phe Gln Gly Val Ile Ala Glu Leu Lys Val  
625 630 635 640

Arg Arg Asp Pro Gln Val Ser Pro Met His Cys Leu Asp Glu Glu Gly  
645 650 655

Asp Asp Ser Asp Gly Ala Ser Gly Asp Ser Gly Ser Gly Leu Gly Asp  
660 665 670

Ala Arg Glu Leu Leu Arg Glu Glu Thr Gly Ala Ala Leu Lys Pro Arg  
675 680 685

Leu Pro Ala Pro Pro Pro Val Thr Thr Pro Pro Leu Ala Gly Gly Ser  
690 695 700

Ser Thr Glu Asp Ser Arg Ser Glu Glu Val Glu Glu Gln Thr Thr Val  
705 710 715 720

Ala Ser Leu Gly Ala Gln Thr Leu Pro Gly Ser Asp Ser Val Ser Thr  
725 730 735

Trp Asp Gly Ser Val Arg Thr Pro Gly Gly Arg Val Lys Glu Gly Gly  
740 745 750

Leu Lys Gly Gln Lys Gly Glu Pro Gly Val Pro Gly Pro Pro Gly Arg  
755 760 765

Ala Gly Pro Pro Gly Ser Pro Cys Leu Pro Gly Pro Pro Gly Leu Pro  
770 775 780

Cys Pro Val Ser Pro Leu Gly Pro Ala Gly Pro Ala Leu Gln Thr Val  
785 790 795 800

Pro Gly Pro Gln Gly Pro Pro Gly Pro Pro Gly Arg Asp Gly Thr Pro  
805 810 815

Gly Arg Asp Gly Glu Pro Gly Asp Pro Gly Glu Asp Gly Lys Pro Gly  
820 825 830

-continued

---

Asp Thr Gly Pro Gln Gly Phe Pro Gly Thr Pro Gly Asp Val Gly Pro  
 835 840 845

Lys Gly Asp Lys Gly Asp Pro Gly Val Gly Glu Arg Gly Pro Pro Gly  
 850 855 860

Pro Gln Gly Pro Pro Gly Pro Pro Gly Pro Ser Phe Arg His Asp Lys  
 865 870 875 880

Leu Thr Phe Ile Asp Met Glu Gly Ser Gly Phe Gly Gly Asp Leu Glu  
 885 890 895

Ala Leu Arg Gly Pro Arg Gly Phe Pro Gly Pro Pro Gly Pro Pro Gly  
 900 905 910

Val Pro Gly Leu Pro Gly Glu Pro Gly Arg Phe Gly Val Asn Ser Ser  
 915 920 925

Asp Val Pro Gly Pro Ala Gly Leu Pro Gly Val Pro Gly Arg Glu Gly  
 930 935 940

Pro Pro Gly Phe Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Arg  
 945 950 955 960

Glu Gly Pro Pro Gly Arg Thr Gly Gln Lys Gly Ser Leu Gly Glu Ala  
 965 970 975

Gly Ala Pro Gly His Lys Gly Ser Lys Gly Ala Pro Gly Pro Ala Gly  
 980 985 990

Ala Arg Gly Glu Ser Gly Leu Ala Gly Ala Pro Gly Pro Ala Gly Pro  
 995 1000 1005

Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Gly Leu Pro  
 1010 1015 1020

Ala Gly Phe Asp Asp Met Glu Gly Ser Gly Gly Pro Phe Trp Ser  
 1025 1030 1035

Thr Ala Arg Ser Ala Asp Gly Pro Gln Gly Pro Pro Gly Leu Pro  
 1040 1045 1050

Gly Leu Lys Gly Asp Pro Gly Val Pro Gly Leu Pro Gly Ala Lys  
 1055 1060 1065

Gly Glu Val Gly Ala Asp Gly Val Pro Gly Phe Pro Gly Leu Pro  
 1070 1075 1080

Gly Arg Glu Gly Ile Ala Gly Pro Gln Gly Pro Lys Gly Asp Arg  
 1085 1090 1095

Gly Ser Arg Gly Glu Lys Gly Asp Pro Gly Lys Asp Gly Val Gly  
 1100 1105 1110

Gln Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Pro Val Val  
 1115 1120 1125

Tyr Val Ser Glu Gln Asp Gly Ser Val Leu Ser Val Pro Gly Pro  
 1130 1135 1140

Glu Gly Arg Pro Gly Phe Ala Gly Phe Pro Gly Pro Ala Gly Pro  
 1145 1150 1155

Lys Gly Asn Leu Gly Ser Lys Gly Glu Arg Gly Ser Pro Gly Pro  
 1160 1165 1170

Lys Gly Glu Lys Gly Glu Pro Gly Ser Ile Phe Ser Pro Asp Gly  
 1175 1180 1185

Gly Ala Leu Gly Pro Ala Gln Lys Gly Ala Lys Gly Glu Pro Gly  
 1190 1195 1200

Phe Arg Gly Pro Pro Gly Pro Tyr Gly Arg Pro Gly Tyr Lys Gly  
 1205 1210 1215

Glu Ile Gly Phe Pro Gly Arg Pro Gly Arg Pro Gly Met Asn Gly

-continued

---

1220	1225	1230
Leu Lys Gly Glu Lys Gly	Glu Pro Gly Asp Ala Ser	Leu Gly Phe
1235	1240	1245
Gly Met Arg Gly Met Pro	Gly Pro Pro Gly Pro Pro	Gly Pro Pro
1250	1255	1260
Gly Pro Pro Gly Thr Pro	Val Tyr Asp Ser Asn Val	Phe Ala Glu
1265	1270	1275
Ser Ser Arg Pro Gly Pro	Pro Gly Leu Pro Gly Asn	Gln Gly Pro
1280	1285	1290
Pro Gly Pro Lys Gly Ala	Lys Gly Glu Val Gly Pro	Pro Gly Pro
1295	1300	1305
Pro Gly Gln Phe Pro Phe	Asp Phe Leu Gln Leu Glu	Ala Glu Met
1310	1315	1320
Lys Gly Glu Lys Gly Asp	Arg Gly Asp Ala Gly Gln	Lys Gly Glu
1325	1330	1335
Arg Gly Glu Pro Gly Gly	Gly Phe Phe Gly Ser	Ser Leu Pro
1340	1345	1350
Gly Pro Pro Gly Pro Pro	Gly Pro Arg Gly Tyr Pro	Gly Ile Pro
1355	1360	1365
Gly Pro Lys Gly Glu Ser	Ile Arg Gly Gln Pro Gly	Pro Pro Gly
1370	1375	1380
Pro Gln Gly Pro Pro Gly	Ile Gly Tyr Glu Gly Arg	Gln Gly Pro
1385	1390	1395
Pro Gly Pro Pro Gly Pro	Pro Gly Pro Pro Ser Phe	Pro Gly Pro
1400	1405	1410
His Arg Gln Thr Ile Ser	Val Pro Gly Pro Pro Gly	Pro Pro Gly
1415	1420	1425
Pro Pro Gly Pro Pro Gly	Thr Met Gly Ala Ser Ser	Gly Val Arg
1430	1435	1440
Leu Trp Ala Thr Arg Gln	Ala Met Leu Gly Gln Val	His Glu Val
1445	1450	1455
Pro Glu Gly Trp Leu Ile	Phe Val Ala Glu Gln Glu	Glu Leu Tyr
1460	1465	1470
Val Arg Val Gln Asn Gly	Phe Arg Lys Val Gln Leu	Glu Ala Arg
1475	1480	1485
Thr Pro Leu Pro Arg Gly	Thr Asp Asn Glu Val Ala	Ala Leu Gln
1490	1495	1500
Pro Pro Val Val Gln Leu	His Asp Ser Asn Pro Tyr	Pro Arg Arg
1505	1510	1515
Glu His Pro His Pro Thr	Ala Arg Pro Trp Arg Ala	Asp Asp Ile
1520	1525	1530
Leu Ala Ser Pro Pro Arg	Leu Pro Glu Pro Gln Pro	Tyr Pro Gly
1535	1540	1545
Ala Pro His His Ser Ser	Tyr Val His Leu Arg Pro	Ala Arg Pro
1550	1555	1560
Thr Ser Pro Pro Ala His	Ser His Arg Asp Phe Gln	Pro Val Leu
1565	1570	1575
His Leu Val Ala Leu Asn	Ser Pro Leu Ser Gly Gly	Met Arg Gly
1580	1585	1590
Ile Arg Gly Ala Asp Phe	Gln Cys Phe Gln Gln Ala	Arg Ala Val
1595	1600	1605

-continued

---

Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser Ser Arg Leu Gln  
 1610 1615 1620  
 Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala Val Pro  
 1625 1630 1635  
 Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser Trp Glu Ala  
 1640 1645 1650  
 Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro Gly Ala Arg Ile  
 1655 1660 1665  
 Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr Trp Pro  
 1670 1675 1680  
 Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg Arg Leu  
 1685 1690 1695  
 Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser Ala  
 1700 1705 1710  
 Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln  
 1715 1720 1725  
 Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu  
 1730 1735 1740  
 Asn Ser Phe Met Thr Ala Ser Lys  
 1745 1750

<210> SEQ ID NO 11  
 <211> LENGTH: 1142  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

Met Arg Leu Thr Gly Pro Trp Lys Leu Trp Leu Trp Met Ser Ile Phe  
 1 5 10 15  
 Leu Leu Pro Ala Ser Thr Ser Val Thr Val Arg Asp Lys Thr Glu Glu  
 20 25 30  
 Ser Cys Pro Ile Leu Arg Ile Glu Gly His Gln Leu Thr Tyr Asp Asn  
 35 40 45  
 Ile Asn Lys Leu Glu Val Ser Gly Phe Asp Leu Gly Asp Ser Phe Ser  
 50 55 60  
 Leu Arg Arg Ala Phe Cys Glu Ser Asp Lys Thr Cys Phe Lys Leu Gly  
 65 70 75 80  
 Ser Ala Leu Leu Ile Arg Asp Thr Ile Lys Ile Phe Pro Lys Gly Leu  
 85 90 95  
 Pro Glu Glu Tyr Ser Val Ala Ala Met Phe Arg Val Arg Arg Asn Ala  
 100 105 110  
 Lys Lys Glu Arg Trp Phe Leu Trp Gln Val Leu Asn Gln Gln Asn Ile  
 115 120 125  
 Pro Gln Ile Ser Ile Val Val Asp Gly Gly Lys Lys Val Val Glu Phe  
 130 135 140  
 Met Phe Gln Ala Thr Glu Gly Asp Val Leu Asn Tyr Ile Phe Arg Asn  
 145 150 155 160  
 Arg Glu Leu Arg Pro Leu Phe Asp Arg Gln Trp His Lys Leu Gly Ile  
 165 170 175  
 Ser Ile Gln Ser Gln Val Ile Ser Leu Tyr Met Asp Cys Asn Leu Ile  
 180 185 190  
 Ala Arg Arg Gln Thr Asp Glu Lys Asp Thr Val Asp Phe His Gly Arg

-continued

195				200				205							
Thr	Val	Ile	Ala	Thr	Arg	Ala	Ser	Asp	Gly	Lys	Pro	Val	Asp	Ile	Glu
210						215					220				
Leu	His	Gln	Leu	Lys	Ile	Tyr	Cys	Ser	Ala	Asn	Leu	Ile	Ala	Gln	Glu
225					230					235					240
Thr	Cys	Cys	Glu	Ile	Ser	Asp	Thr	Lys	Cys	Pro	Glu	Gln	Asp	Gly	Phe
				245					250					255	
Gly	Asn	Ile	Ala	Ser	Ser	Trp	Val	Thr	Ala	His	Ala	Ser	Lys	Met	Ser
			260					265					270		
Ser	Tyr	Leu	Pro	Ala	Lys	Gln	Glu	Leu	Lys	Asp	Gln	Cys	Gln	Cys	Ile
		275						280				285			
Pro	Asn	Lys	Gly	Glu	Ala	Gly	Leu	Pro	Gly	Ala	Pro	Gly	Ser	Pro	Gly
		290				295					300				
Gln	Lys	Gly	His	Lys	Gly	Glu	Pro	Gly	Glu	Asn	Gly	Leu	His	Gly	Ala
305					310					315					320
Pro	Gly	Phe	Pro	Gly	Gln	Lys	Gly	Glu	Gln	Gly	Phe	Glu	Gly	Ser	Lys
				325					330					335	
Gly	Glu	Thr	Gly	Glu	Lys	Gly	Glu	Gln	Gly	Glu	Lys	Gly	Asp	Pro	Ala
			340					345					350		
Leu	Ala	Gly	Leu	Asn	Gly	Glu	Asn	Gly	Leu	Lys	Gly	Asp	Leu	Gly	Pro
		355				360						365			
His	Gly	Pro	Pro	Gly	Pro	Lys	Gly	Glu	Lys	Gly	Asp	Thr	Gly	Pro	Pro
	370					375					380				
Gly	Pro	Pro	Ala	Leu	Pro	Gly	Ser	Leu	Gly	Ile	Gln	Gly	Pro	Gln	Gly
385					390					395					400
Pro	Pro	Gly	Lys	Glu	Gly	Gln	Arg	Gly	Arg	Arg	Gly	Lys	Thr	Gly	Pro
			405					410					415		
Pro	Gly	Lys	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Ile	Gln
			420					425					430		
Gly	Ile	His	Gln	Thr	Leu	Gly	Gly	Tyr	Tyr	Asn	Lys	Asp	Asn	Lys	Gly
	435						440					445			
Asn	Asp	Glu	His	Glu	Ala	Gly	Gly	Leu	Lys	Gly	Asp	Lys	Gly	Glu	Thr
	450					455					460				
Gly	Leu	Pro	Gly	Phe	Pro	Gly	Ser	Val	Gly	Pro	Lys	Gly	Gln	Lys	Gly
465					470					475				480	
Glu	Pro	Gly	Glu	Pro	Phe	Thr	Lys	Gly	Glu	Lys	Gly	Asp	Arg	Gly	Glu
			485					490					495		
Pro	Gly	Val	Ile	Gly	Ser	Gln	Gly	Val	Lys	Gly	Glu	Pro	Gly	Asp	Pro
		500						505					510		
Gly	Pro	Pro	Gly	Leu	Ile	Gly	Ser	Pro	Gly	Leu	Lys	Gly	Gln	Gln	Gly
	515					520						525			
Ser	Ala	Gly	Ser	Met	Gly	Pro	Arg	Gly	Pro	Pro	Gly	Asp	Val	Gly	Leu
	530					535					540				
Pro	Gly	Glu	His	Gly	Ile	Pro	Gly	Lys	Gln	Gly	Ile	Lys	Gly	Glu	Lys
545					550					555					560
Gly	Asp	Pro	Gly	Gly	Ile	Ile	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Pro	Lys
			565					570						575	
Gly	Glu	Ala	Gly	Pro	Pro	Gly	Lys	Ser	Leu	Pro	Gly	Glu	Pro	Gly	Leu
		580						585					590		
Asp	Gly	Asn	Pro	Gly	Ala	Pro	Gly	Pro	Arg	Gly	Pro	Lys	Gly	Glu	Arg
	595					600						605			

-continued

---

Gly Leu Pro Gly Val His Gly Ser Pro Gly Asp Ile Gly Pro Gln Gly  
 610 615 620

Ile Gly Ile Pro Gly Arg Thr Gly Ala Gln Gly Pro Ala Gly Glu Pro  
 625 630 635 640

Gly Ile Gln Gly Pro Arg Gly Leu Pro Gly Leu Pro Gly Thr Pro Gly  
 645 650 655

Thr Pro Gly Asn Asp Gly Val Pro Gly Arg Asp Gly Lys Pro Gly Leu  
 660 665 670

Pro Gly Pro Pro Gly Asp Pro Ile Ala Leu Pro Leu Leu Gly Asp Ile  
 675 680 685

Gly Ala Leu Leu Lys Asn Phe Cys Gly Asn Cys Gln Ala Ser Val Pro  
 690 695 700

Gly Leu Lys Ser Asn Lys Gly Glu Glu Gly Gly Ala Gly Glu Pro Gly  
 705 710 715 720

Lys Tyr Asp Ser Met Ala Arg Lys Gly Asp Ile Gly Pro Arg Gly Pro  
 725 730 735

Pro Gly Ile Pro Gly Arg Glu Gly Pro Lys Gly Ser Lys Gly Glu Arg  
 740 745 750

Gly Tyr Pro Gly Ile Pro Gly Glu Lys Gly Asp Glu Gly Leu Gln Gly  
 755 760 765

Ile Pro Gly Ile Pro Gly Ala Pro Gly Pro Thr Gly Pro Pro Gly Leu  
 770 775 780

Met Gly Arg Thr Gly His Pro Gly Pro Thr Gly Ala Lys Gly Glu Lys  
 785 790 795 800

Gly Ser Asp Gly Pro Pro Gly Lys Pro Gly Pro Pro Gly Pro Pro Gly  
 805 810 815

Ile Pro Phe Asn Glu Arg Asn Gly Met Ser Ser Leu Tyr Lys Ile Lys  
 820 825 830

Gly Gly Val Asn Val Pro Ser Tyr Pro Gly Pro Pro Gly Pro Pro Gly  
 835 840 845

Pro Lys Gly Asp Pro Gly Pro Val Gly Glu Pro Gly Ala Met Gly Leu  
 850 855 860

Pro Gly Leu Glu Gly Phe Pro Gly Val Lys Gly Asp Arg Gly Pro Ala  
 865 870 875 880

Gly Pro Pro Gly Ile Ala Gly Met Ser Gly Lys Pro Gly Ala Pro Gly  
 885 890 895

Pro Pro Gly Val Pro Gly Glu Pro Gly Glu Arg Gly Pro Val Gly Asp  
 900 905 910

Ile Gly Phe Pro Gly Pro Glu Gly Pro Ser Gly Lys Pro Gly Ile Asn  
 915 920 925

Gly Lys Asp Gly Ile Pro Gly Ala Gln Gly Ile Met Gly Lys Pro Gly  
 930 935 940

Asp Arg Gly Pro Lys Gly Glu Arg Gly Asp Gln Gly Ile Pro Gly Asp  
 945 950 955 960

Arg Gly Ser Gln Gly Glu Arg Gly Lys Pro Gly Leu Thr Gly Met Lys  
 965 970 975

Gly Ala Ile Gly Pro Met Gly Pro Pro Gly Asn Lys Gly Ser Met Gly  
 980 985 990

Ser Pro Gly His Gln Gly Pro Pro Gly Ser Pro Gly Ile Pro Gly Ile  
 995 1000 1005

-continued

---

Pro Ala Asp Ala Val Ser Phe Glu Glu Ile Lys Lys Tyr Ile Asn  
 1010 1015 1020

Gln Glu Val Leu Arg Ile Phe Glu Glu Arg Met Ala Val Phe Leu  
 1025 1030 1035

Ser Gln Leu Lys Leu Pro Ala Ala Met Leu Ala Ala Gln Ala Tyr  
 1040 1045 1050

Gly Arg Pro Gly Pro Pro Gly Lys Asp Gly Leu Pro Gly Pro Pro  
 1055 1060 1065

Gly Asp Pro Gly Pro Gln Gly Tyr Arg Gly Gln Lys Gly Glu Arg  
 1070 1075 1080

Gly Glu Pro Gly Ile Gly Leu Pro Gly Ser Pro Gly Leu Pro Gly  
 1085 1090 1095

Thr Ser Ala Leu Gly Leu Pro Gly Ser Pro Gly Ala Pro Gly Pro  
 1100 1105 1110

Gln Gly Pro Pro Gly Pro Ser Gly Arg Cys Asn Pro Glu Asp Cys  
 1115 1120 1125

Leu Tyr Pro Val Ser His Ala His Gln Arg Thr Gly Gly Asn  
 1130 1135 1140

<210> SEQ ID NO 12  
 <211> LENGTH: 1366  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <400> SEQUENCE: 12

Met Leu Ser Phe Val Asp Thr Arg Thr Leu Leu Leu Leu Ala Val Thr  
 1 5 10 15

Leu Cys Leu Ala Thr Cys Gln Ser Leu Gln Glu Glu Thr Val Arg Lys  
 20 25 30

Gly Pro Ala Gly Asp Arg Gly Pro Arg Gly Glu Arg Gly Pro Pro Gly  
 35 40 45

Pro Pro Gly Arg Asp Gly Glu Asp Gly Pro Thr Gly Pro Pro Gly Pro  
 50 55 60

Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala Ala Gln  
 65 70 75 80

Tyr Asp Gly Lys Gly Val Gly Leu Gly Pro Gly Pro Met Gly Leu Met  
 85 90 95

Gly Pro Arg Gly Pro Pro Gly Ala Ala Gly Ala Pro Gly Pro Gln Gly  
 100 105 110

Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro  
 115 120 125

Ala Gly Ala Arg Gly Pro Ala Gly Pro Pro Gly Lys Ala Gly Glu Asp  
 130 135 140

Gly His Pro Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Val Val Gly  
 145 150 155 160

Pro Gln Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Phe  
 165 170 175

Lys Gly Ile Arg Gly His Asn Gly Leu Asp Gly Leu Lys Gly Gln Pro  
 180 185 190

Gly Ala Pro Gly Val Lys Gly Glu Pro Gly Ala Pro Gly Glu Asn Gly  
 195 200 205

Thr Pro Gly Gln Thr Gly Ala Arg Gly Leu Pro Gly Glu Arg Gly Arg  
 210 215 220

-continued

---

Val Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Ser Asp Gly Ser Val  
 225 230 235 240  
 Gly Pro Val Gly Pro Ala Gly Pro Ile Gly Ser Ala Gly Pro Pro Gly  
 245 250 255  
 Phe Pro Gly Ala Pro Gly Pro Lys Gly Glu Ile Gly Ala Val Gly Asn  
 260 265 270  
 Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg Gly Glu Val Gly Leu Pro  
 275 280 285  
 Gly Leu Ser Gly Pro Val Gly Pro Pro Gly Asn Pro Gly Ala Asn Gly  
 290 295 300  
 Leu Thr Gly Ala Lys Gly Ala Ala Gly Leu Pro Gly Val Ala Gly Ala  
 305 310 315 320  
 Pro Gly Leu Pro Gly Pro Arg Gly Ile Pro Gly Pro Val Gly Ala Ala  
 325 330 335  
 Gly Ala Thr Gly Ala Arg Gly Leu Val Gly Glu Pro Gly Pro Ala Gly  
 340 345 350  
 Ser Lys Gly Glu Ser Gly Asn Lys Gly Glu Pro Gly Ser Ala Gly Pro  
 355 360 365  
 Gln Gly Pro Pro Gly Pro Ser Gly Glu Glu Gly Lys Arg Gly Pro Asn  
 370 375 380  
 Gly Glu Ala Gly Ser Ala Gly Pro Pro Gly Pro Pro Gly Leu Arg Gly  
 385 390 395 400  
 Ser Pro Gly Ser Arg Gly Leu Pro Gly Ala Asp Gly Arg Ala Gly Val  
 405 410 415  
 Met Gly Pro Pro Gly Ser Arg Gly Ala Ser Gly Pro Ala Gly Val Arg  
 420 425 430  
 Gly Pro Asn Gly Asp Ala Gly Arg Pro Gly Glu Pro Gly Leu Met Gly  
 435 440 445  
 Pro Arg Gly Leu Pro Gly Ser Pro Gly Asn Ile Gly Pro Ala Gly Lys  
 450 455 460  
 Glu Gly Pro Val Gly Leu Pro Gly Ile Asp Gly Arg Pro Gly Pro Ile  
 465 470 475 480  
 Gly Pro Ala Gly Ala Arg Gly Glu Pro Gly Asn Ile Gly Phe Pro Gly  
 485 490 495  
 Pro Lys Gly Pro Thr Gly Asp Pro Gly Lys Asn Gly Asp Lys Gly His  
 500 505 510  
 Ala Gly Leu Ala Gly Ala Arg Gly Ala Pro Gly Pro Asp Gly Asn Asn  
 515 520 525  
 Gly Ala Gln Gly Pro Pro Gly Pro Gln Gly Val Gln Gly Gly Lys Gly  
 530 535 540  
 Glu Gln Gly Pro Pro Gly Pro Pro Gly Phe Gln Gly Leu Pro Gly Pro  
 545 550 555 560  
 Ser Gly Pro Ala Gly Glu Val Gly Lys Pro Gly Glu Arg Gly Leu His  
 565 570 575  
 Gly Glu Phe Gly Leu Pro Gly Pro Ala Gly Pro Arg Gly Glu Arg Gly  
 580 585 590  
 Pro Pro Gly Glu Ser Gly Ala Ala Gly Pro Thr Gly Pro Ile Gly Ser  
 595 600 605  
 Arg Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly Asn Lys Gly Glu Pro  
 610 615 620

-continued

---

Gly Val Val Gly Ala Val Gly Thr Ala Gly Pro Ser Gly Pro Ser Gly  
 625 630 635 640  
 Leu Pro Gly Glu Arg Gly Ala Ala Gly Ile Pro Gly Gly Lys Gly Glu  
 645 650 655  
 Lys Gly Glu Pro Gly Leu Arg Gly Glu Ile Gly Asn Pro Gly Arg Asp  
 660 665 670  
 Gly Ala Arg Gly Ala Pro Gly Ala Val Gly Ala Pro Gly Pro Ala Gly  
 675 680 685  
 Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala Ala Gly Pro Ala Gly Pro  
 690 695 700  
 Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg Gly Glu Val Gly Pro Ala  
 705 710 715 720  
 Gly Pro Asn Gly Phe Ala Gly Pro Ala Gly Ala Ala Gly Gln Pro Gly  
 725 730 735  
 Ala Lys Gly Glu Arg Gly Ala Lys Gly Pro Lys Gly Glu Asn Gly Val  
 740 745 750  
 Val Gly Pro Thr Gly Pro Val Gly Ala Ala Gly Pro Ala Gly Pro Asn  
 755 760 765  
 Gly Pro Pro Gly Pro Ala Gly Ser Arg Gly Asp Gly Gly Pro Pro Gly  
 770 775 780  
 Met Thr Gly Phe Pro Gly Ala Ala Gly Arg Thr Gly Pro Pro Gly Pro  
 785 790 795 800  
 Ser Gly Ile Ser Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu  
 805 810 815  
 Gly Leu Arg Gly Pro Arg Gly Asp Gln Gly Pro Val Gly Arg Thr Gly  
 820 825 830  
 Glu Val Gly Ala Val Gly Pro Pro Gly Phe Ala Gly Glu Lys Gly Pro  
 835 840 845  
 Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly Pro Gln  
 850 855 860  
 Gly Leu Leu Gly Ala Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg Gly  
 865 870 875 880  
 Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro  
 885 890 895  
 Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val  
 900 905 910  
 Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly  
 915 920 925  
 Asn Pro Gly Asn Asp Gly Pro Pro Gly Arg Asp Gly Gln Pro Gly His  
 930 935 940  
 Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala  
 945 950 955 960  
 Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly  
 965 970 975  
 Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala  
 980 985 990  
 Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys  
 995 1000 1005  
 Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Leu Lys  
 1010 1015 1020  
 Gly His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His

-continued

1025	1030	1035
Gly Asp Gln Gly Ala Pro	Gly Ser Val Gly Pro	Ala Gly Pro Arg
1040	1045	1050
Gly Pro Ala Gly Pro Ser	Gly Pro Ala Gly Lys Asp	Gly Arg Thr
1055	1060	1065
Gly His Pro Gly Thr Val	Gly Pro Ala Gly Ile Arg	Gly Pro Gln
1070	1075	1080
Gly His Gln Gly Pro Ala	Gly Pro Pro Gly Pro Pro	Gly Pro Pro
1085	1090	1095
Gly Pro Pro Gly Val Ser	Gly Gly Gly Tyr Asp Phe	Gly Tyr Asp
1100	1105	1110
Gly Asp Phe Tyr Arg Ala	Asp Gln Pro Arg Ser Ala	Pro Ser Leu
1115	1120	1125
Arg Pro Lys Asp Tyr Glu	Val Asp Ala Thr Leu Lys	Ser Leu Asn
1130	1135	1140
Asn Gln Ile Glu Thr Leu	Leu Thr Pro Glu Gly Ser	Arg Lys Asn
1145	1150	1155
Pro Ala Arg Thr Cys Arg	Asp Leu Arg Leu Ser His	Pro Glu Trp
1160	1165	1170
Ser Ser Gly Tyr Tyr Trp	Ile Asp Pro Asn Gln Gly	Cys Thr Met
1175	1180	1185
Asp Ala Ile Lys Val Tyr	Cys Asp Phe Ser Thr Gly	Glu Thr Cys
1190	1195	1200
Ile Arg Ala Gln Pro Glu	Asn Ile Pro Ala Lys Asn	Trp Tyr Arg
1205	1210	1215
Ser Ser Lys Asp Lys Lys	His Val Trp Leu Gly Glu	Thr Ile Asn
1220	1225	1230
Ala Gly Ser Gln Phe Glu	Tyr Asn Val Glu Gly Val	Thr Ser Lys
1235	1240	1245
Glu Met Ala Thr Gln Leu	Ala Phe Met Arg Leu Leu	Ala Asn Tyr
1250	1255	1260
Ala Ser Gln Asn Ile Thr	Tyr His Cys Lys Asn Ser	Ile Ala Tyr
1265	1270	1275
Met Asp Glu Glu Thr Gly	Asn Leu Lys Lys Ala Val	Ile Leu Gln
1280	1285	1290
Gly Ser Asn Asp Val Glu	Leu Val Ala Glu Gly Asn	Ser Arg Phe
1295	1300	1305
Thr Tyr Thr Val Leu Val	Asp Gly Cys Ser Lys Lys	Thr Asn Glu
1310	1315	1320
Trp Gly Lys Thr Ile Ile	Glu Tyr Lys Thr Asn Lys	Pro Ser Arg
1325	1330	1335
Leu Pro Phe Leu Asp Ile	Ala Pro Leu Asp Ile Gly	Gly Ala Asp
1340	1345	1350
Gln Glu Phe Phe Val Asp	Ile Gly Pro Val Cys Phe	Lys
1355	1360	1365

&lt;210&gt; SEQ ID NO 13

&lt;211&gt; LENGTH: 2386

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 13

-continued

---

Met Leu Arg Gly Pro Gly Pro Gly Leu Leu Leu Leu Ala Val Gln Cys  
 1 5 10 15  
 Leu Gly Thr Ala Val Pro Ser Thr Gly Ala Ser Lys Ser Lys Arg Gln  
 20 25 30  
 Ala Gln Gln Met Val Gln Pro Gln Ser Pro Val Ala Val Ser Gln Ser  
 35 40 45  
 Lys Pro Gly Cys Tyr Asp Asn Gly Lys His Tyr Gln Ile Asn Gln Gln  
 50 55 60  
 Trp Glu Arg Thr Tyr Leu Gly Asn Ala Leu Val Cys Thr Cys Tyr Gly  
 65 70 75 80  
 Gly Ser Arg Gly Phe Asn Cys Glu Ser Lys Pro Glu Ala Glu Glu Thr  
 85 90 95  
 Cys Phe Asp Lys Tyr Thr Gly Asn Thr Tyr Arg Val Gly Asp Thr Tyr  
 100 105 110  
 Glu Arg Pro Lys Asp Ser Met Ile Trp Asp Cys Thr Cys Ile Gly Ala  
 115 120 125  
 Gly Arg Gly Arg Ile Ser Cys Thr Ile Ala Asn Arg Cys His Glu Gly  
 130 135 140  
 Gly Gln Ser Tyr Lys Ile Gly Asp Thr Trp Arg Arg Pro His Glu Thr  
 145 150 155 160  
 Gly Gly Tyr Met Leu Glu Cys Val Cys Leu Gly Asn Gly Lys Gly Glu  
 165 170 175  
 Trp Thr Cys Lys Pro Ile Ala Glu Lys Cys Phe Asp His Ala Ala Gly  
 180 185 190  
 Thr Ser Tyr Val Val Gly Glu Thr Trp Glu Lys Pro Tyr Gln Gly Trp  
 195 200 205  
 Met Met Val Asp Cys Thr Cys Leu Gly Glu Gly Ser Gly Arg Ile Thr  
 210 215 220  
 Cys Thr Ser Arg Asn Arg Cys Asn Asp Gln Asp Thr Arg Thr Ser Tyr  
 225 230 235 240  
 Arg Ile Gly Asp Thr Trp Ser Lys Lys Asp Asn Arg Gly Asn Leu Leu  
 245 250 255  
 Gln Cys Ile Cys Thr Gly Asn Gly Arg Gly Glu Trp Lys Cys Glu Arg  
 260 265 270  
 His Thr Ser Val Gln Thr Thr Ser Ser Gly Ser Gly Pro Phe Thr Asp  
 275 280 285  
 Val Arg Ala Ala Val Tyr Gln Pro Gln Pro His Pro Gln Pro Pro Pro  
 290 295 300  
 Tyr Gly His Cys Val Thr Asp Ser Gly Val Val Tyr Ser Val Gly Met  
 305 310 315 320  
 Gln Trp Leu Lys Thr Gln Gly Asn Lys Gln Met Leu Cys Thr Cys Leu  
 325 330 335  
 Gly Asn Gly Val Ser Cys Gln Glu Thr Ala Val Thr Gln Thr Tyr Gly  
 340 345 350  
 Gly Asn Ser Asn Gly Glu Pro Cys Val Leu Pro Phe Thr Tyr Asn Gly  
 355 360 365  
 Arg Thr Phe Tyr Ser Cys Thr Thr Glu Gly Arg Gln Asp Gly His Leu  
 370 375 380  
 Trp Cys Ser Thr Thr Ser Asn Tyr Glu Gln Asp Gln Lys Tyr Ser Phe  
 385 390 395 400  
 Cys Thr Asp His Thr Val Leu Val Gln Thr Arg Gly Gly Asn Ser Asn



-continued

---

Thr Thr Val Asp Gln Val Asp Asp Thr Ser Ile Val Val Arg Trp Ser  
 820 825 830

Arg Pro Gln Ala Pro Ile Thr Gly Tyr Arg Ile Val Tyr Ser Pro Ser  
 835 840 845

Val Glu Gly Ser Ser Thr Glu Leu Asn Leu Pro Glu Thr Ala Asn Ser  
 850 855 860

Val Thr Leu Ser Asp Leu Gln Pro Gly Val Gln Tyr Asn Ile Thr Ile  
 865 870 875 880

Tyr Ala Val Glu Glu Asn Gln Glu Ser Thr Pro Val Val Ile Gln Gln  
 885 890 895

Glu Thr Thr Gly Thr Pro Arg Ser Asp Thr Val Pro Ser Pro Arg Asp  
 900 905 910

Leu Gln Phe Val Glu Val Thr Asp Val Lys Val Thr Ile Met Trp Thr  
 915 920 925

Pro Pro Glu Ser Ala Val Thr Gly Tyr Arg Val Asp Val Ile Pro Val  
 930 935 940

Asn Leu Pro Gly Glu His Gly Gln Arg Leu Pro Ile Ser Arg Asn Thr  
 945 950 955 960

Phe Ala Glu Val Thr Gly Leu Ser Pro Gly Val Thr Tyr Tyr Phe Lys  
 965 970 975

Val Phe Ala Val Ser His Gly Arg Glu Ser Lys Pro Leu Thr Ala Gln  
 980 985 990

Gln Thr Thr Lys Leu Asp Ala Pro Thr Asn Leu Gln Phe Val Asn Glu  
 995 1000 1005

Thr Asp Ser Thr Val Leu Val Arg Trp Thr Pro Pro Arg Ala Gln  
 1010 1015 1020

Ile Thr Gly Tyr Arg Leu Thr Val Gly Leu Thr Arg Arg Gly Gln  
 1025 1030 1035

Pro Arg Gln Tyr Asn Val Gly Pro Ser Val Ser Lys Tyr Pro Leu  
 1040 1045 1050

Arg Asn Leu Gln Pro Ala Ser Glu Tyr Thr Val Ser Leu Val Ala  
 1055 1060 1065

Ile Lys Gly Asn Gln Glu Ser Pro Lys Ala Thr Gly Val Phe Thr  
 1070 1075 1080

Thr Leu Gln Pro Gly Ser Ser Ile Pro Pro Tyr Asn Thr Glu Val  
 1085 1090 1095

Thr Glu Thr Thr Ile Val Ile Thr Trp Thr Pro Ala Pro Arg Ile  
 1100 1105 1110

Gly Phe Lys Leu Gly Val Arg Pro Ser Gln Gly Gly Glu Ala Pro  
 1115 1120 1125

Arg Glu Val Thr Ser Asp Ser Gly Ser Ile Val Val Ser Gly Leu  
 1130 1135 1140

Thr Pro Gly Val Glu Tyr Val Tyr Thr Ile Gln Val Leu Arg Asp  
 1145 1150 1155

Gly Gln Glu Arg Asp Ala Pro Ile Val Asn Lys Val Val Thr Pro  
 1160 1165 1170

Leu Ser Pro Pro Thr Asn Leu His Leu Glu Ala Asn Pro Asp Thr  
 1175 1180 1185

Gly Val Leu Thr Val Ser Trp Glu Arg Ser Thr Thr Pro Asp Ile  
 1190 1195 1200

-continued

Thr Gly	Tyr Arg Ile Thr	Thr	Thr Pro Thr Asn Gly	Gln Gln Gly
1205		1210		1215
Asn Ser	Leu Glu Glu Val	Val	His Ala Asp Gln Ser	Ser Cys Thr
1220		1225		1230
Phe Asp	Asn Leu Ser Pro	Gly	Leu Glu Tyr Asn Val	Ser Val Tyr
1235		1240		1245
Thr Val	Lys Asp Asp Lys	Glu	Ser Val Pro Ile Ser	Asp Thr Ile
1250		1255		1260
Ile Pro	Ala Val Pro Pro	Pro	Thr Asp Leu Arg Phe	Thr Asn Ile
1265		1270		1275
Gly Pro	Asp Thr Met Arg	Val	Thr Trp Ala Pro Pro	Pro Ser Ile
1280		1285		1290
Asp Leu	Thr Asn Phe Leu	Val	Arg Tyr Ser Pro Val	Lys Asn Glu
1295		1300		1305
Glu Asp	Val Ala Glu Leu	Ser	Ile Ser Pro Ser Asp	Asn Ala Val
1310		1315		1320
Val Leu	Thr Asn Leu Leu	Pro	Gly Thr Glu Tyr Val	Val Ser Val
1325		1330		1335
Ser Ser	Val Tyr Glu Gln	His	Glu Ser Thr Pro Leu	Arg Gly Arg
1340		1345		1350
Gln Lys	Thr Gly Leu Asp	Ser	Pro Thr Gly Ile Asp	Phe Ser Asp
1355		1360		1365
Ile Thr	Ala Asn Ser Phe	Thr	Val His Trp Ile Ala	Pro Arg Ala
1370		1375		1380
Thr Ile	Thr Gly Tyr Arg	Ile	Arg His His Pro Glu	His Phe Ser
1385		1390		1395
Gly Arg	Pro Arg Glu Asp	Arg	Val Pro His Ser Arg	Asn Ser Ile
1400		1405		1410
Thr Leu	Thr Asn Leu Thr	Pro	Gly Thr Glu Tyr Val	Val Ser Ile
1415		1420		1425
Val Ala	Leu Asn Gly Arg	Glu	Glu Ser Pro Leu Leu	Ile Gly Gln
1430		1435		1440
Gln Ser	Thr Val Ser Asp	Val	Pro Arg Asp Leu Glu	Val Val Ala
1445		1450		1455
Ala Thr	Pro Thr Ser Leu	Leu	Ile Ser Trp Asp Ala	Pro Ala Val
1460		1465		1470
Thr Val	Arg Tyr Tyr Arg	Ile	Thr Tyr Gly Glu Thr	Gly Gly Asn
1475		1480		1485
Ser Pro	Val Gln Glu Phe	Thr	Val Pro Gly Ser Lys	Ser Thr Ala
1490		1495		1500
Thr Ile	Ser Gly Leu Lys	Pro	Gly Val Asp Tyr Thr	Ile Thr Val
1505		1510		1515
Tyr Ala	Val Thr Gly Arg	Gly	Asp Ser Pro Ala Ser	Ser Lys Pro
1520		1525		1530
Ile Ser	Ile Asn Tyr Arg	Thr	Glu Ile Asp Lys Pro	Ser Gln Met
1535		1540		1545
Gln Val	Thr Asp Val Gln	Asp	Asn Ser Ile Ser Val	Lys Trp Leu
1550		1555		1560
Pro Ser	Ser Ser Pro Val	Thr	Gly Tyr Arg Val Thr	Thr Thr Pro
1565		1570		1575
Lys Asn	Gly Pro Gly Pro	Thr	Lys Thr Lys Thr Ala	Gly Pro Asp

-continued

---

1580	1585	1590
Gln Thr Glu Met Thr Ile	Glu Gly Leu Gln Pro	Thr Val Glu Tyr
1595	1600	1605
Val Val Ser Val Tyr Ala	Gln Asn Pro Ser Gly Glu	Ser Gln Pro
1610	1615	1620
Leu Val Gln Thr Ala Val	Thr Asn Ile Asp Arg Pro	Lys Gly Leu
1625	1630	1635
Ala Phe Thr Asp Val Asp	Val Asp Ser Ile Lys Ile	Ala Trp Glu
1640	1645	1650
Ser Pro Gln Gly Gln Val	Ser Arg Tyr Arg Val Thr	Tyr Ser Ser
1655	1660	1665
Pro Glu Asp Gly Ile His	Glu Leu Phe Pro Ala Pro	Asp Gly Glu
1670	1675	1680
Glu Asp Thr Ala Glu Leu	Gln Gly Leu Arg Pro Gly	Ser Glu Tyr
1685	1690	1695
Thr Val Ser Val Val Ala	Leu His Asp Asp Met Glu	Ser Gln Pro
1700	1705	1710
Leu Ile Gly Thr Gln Ser	Thr Ala Ile Pro Ala Pro	Thr Asp Leu
1715	1720	1725
Lys Phe Thr Gln Val Thr	Pro Thr Ser Leu Ser Ala	Gln Trp Thr
1730	1735	1740
Pro Pro Asn Val Gln Leu	Thr Gly Tyr Arg Val Arg	Val Thr Pro
1745	1750	1755
Lys Glu Lys Thr Gly Pro	Met Lys Glu Ile Asn Leu	Ala Pro Asp
1760	1765	1770
Ser Ser Ser Val Val Val	Ser Gly Leu Met Val Ala	Thr Lys Tyr
1775	1780	1785
Glu Val Ser Val Tyr Ala	Leu Lys Asp Thr Leu Thr	Ser Arg Pro
1790	1795	1800
Ala Gln Gly Val Val Thr	Thr Leu Glu Asn Val Ser	Pro Pro Arg
1805	1810	1815
Arg Ala Arg Val Thr Asp	Ala Thr Glu Thr Thr Ile	Thr Ile Ser
1820	1825	1830
Trp Arg Thr Lys Thr Glu	Thr Ile Thr Gly Phe Gln	Val Asp Ala
1835	1840	1845
Val Pro Ala Asn Gly Gln	Thr Pro Ile Gln Arg Thr	Ile Lys Pro
1850	1855	1860
Asp Val Arg Ser Tyr Thr	Ile Thr Gly Leu Gln Pro	Gly Thr Asp
1865	1870	1875
Tyr Lys Ile Tyr Leu Tyr	Thr Leu Asn Asp Asn Ala	Arg Ser Ser
1880	1885	1890
Pro Val Val Ile Asp Ala	Ser Thr Ala Ile Asp Ala	Pro Ser Asn
1895	1900	1905
Leu Arg Phe Leu Ala Thr	Thr Pro Asn Ser Leu Leu	Val Ser Trp
1910	1915	1920
Gln Pro Pro Arg Ala Arg	Ile Thr Gly Tyr Ile Ile	Lys Tyr Glu
1925	1930	1935
Lys Pro Gly Ser Pro Pro	Arg Glu Val Val Pro Arg	Pro Arg Pro
1940	1945	1950
Gly Val Thr Glu Ala Thr	Ile Thr Gly Leu Glu Pro	Gly Thr Glu
1955	1960	1965

-continued

---

Tyr	Thr	Ile	Tyr	Val	Ile	Ala	Leu	Lys	Asn	Asn	Gln	Lys	Ser	Glu
1970						1975					1980			
Pro	Leu	Ile	Gly	Arg	Lys	Lys	Thr	Asp	Glu	Leu	Pro	Gln	Leu	Val
1985						1990					1995			
Thr	Leu	Pro	His	Pro	Asn	Leu	His	Gly	Pro	Glu	Ile	Leu	Asp	Val
2000						2005					2010			
Pro	Ser	Thr	Val	Gln	Lys	Thr	Pro	Phe	Val	Thr	His	Pro	Gly	Tyr
2015						2020					2025			
Asp	Thr	Gly	Asn	Gly	Ile	Gln	Leu	Pro	Gly	Thr	Ser	Gly	Gln	Gln
2030						2035					2040			
Pro	Ser	Val	Gly	Gln	Gln	Met	Ile	Phe	Glu	Glu	His	Gly	Phe	Arg
2045						2050					2055			
Arg	Thr	Thr	Pro	Pro	Thr	Thr	Ala	Thr	Pro	Ile	Arg	His	Arg	Pro
2060						2065					2070			
Arg	Pro	Tyr	Pro	Pro	Asn	Val	Gly	Glu	Glu	Ile	Gln	Ile	Gly	His
2075						2080					2085			
Ile	Pro	Arg	Glu	Asp	Val	Asp	Tyr	His	Leu	Tyr	Pro	His	Gly	Pro
2090						2095					2100			
Gly	Leu	Asn	Pro	Asn	Ala	Ser	Thr	Gly	Gln	Glu	Ala	Leu	Ser	Gln
2105						2110					2115			
Thr	Thr	Ile	Ser	Trp	Ala	Pro	Phe	Gln	Asp	Thr	Ser	Glu	Tyr	Ile
2120						2125					2130			
Ile	Ser	Cys	His	Pro	Val	Gly	Thr	Asp	Glu	Glu	Pro	Leu	Gln	Phe
2135						2140					2145			
Arg	Val	Pro	Gly	Thr	Ser	Thr	Ser	Ala	Thr	Leu	Thr	Gly	Leu	Thr
2150						2155					2160			
Arg	Gly	Ala	Thr	Tyr	Asn	Val	Ile	Val	Glu	Ala	Leu	Lys	Asp	Gln
2165						2170					2175			
Gln	Arg	His	Lys	Val	Arg	Glu	Glu	Val	Val	Thr	Val	Gly	Asn	Ser
2180						2185					2190			
Val	Asn	Glu	Gly	Leu	Asn	Gln	Pro	Thr	Asp	Asp	Ser	Cys	Phe	Asp
2195						2200					2205			
Pro	Tyr	Thr	Val	Ser	His	Tyr	Ala	Val	Gly	Asp	Glu	Trp	Glu	Arg
2210						2215					2220			
Met	Ser	Glu	Ser	Gly	Phe	Lys	Leu	Leu	Cys	Gln	Cys	Leu	Gly	Phe
2225						2230					2235			
Gly	Ser	Gly	His	Phe	Arg	Cys	Asp	Ser	Ser	Arg	Trp	Cys	His	Asp
2240						2245					2250			
Asn	Gly	Val	Asn	Tyr	Lys	Ile	Gly	Glu	Lys	Trp	Asp	Arg	Gln	Gly
2255						2260					2265			
Glu	Asn	Gly	Gln	Met	Met	Ser	Cys	Thr	Cys	Leu	Gly	Asn	Gly	Lys
2270						2275					2280			
Gly	Glu	Phe	Lys	Cys	Asp	Pro	His	Glu	Ala	Thr	Cys	Tyr	Asp	Asp
2285						2290					2295			
Gly	Lys	Thr	Tyr	His	Val	Gly	Glu	Gln	Trp	Gln	Lys	Glu	Tyr	Leu
2300						2305					2310			
Gly	Ala	Ile	Cys	Ser	Cys	Thr	Cys	Phe	Gly	Gly	Gln	Arg	Gly	Trp
2315						2320					2325			
Arg	Cys	Asp	Asn	Cys	Arg	Arg	Pro	Gly	Gly	Glu	Pro	Ser	Pro	Glu
2330						2335					2340			

-continued

---

Gly Thr Thr Gly Gln Ser Tyr Asn Gln Tyr Ser Gln Arg Tyr His  
 2345 2350 2355

Gln Arg Thr Asn Thr Asn Val Asn Cys Pro Ile Glu Cys Phe Met  
 2360 2365 2370

Pro Leu Asp Val Gln Ala Asp Arg Glu Asp Ser Arg Glu  
 2375 2380 2385

<210> SEQ ID NO 14  
 <211> LENGTH: 2871  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

Met Arg Arg Gly Arg Leu Leu Glu Ile Ala Leu Gly Phe Thr Val Leu  
 1 5 10 15

Leu Ala Ser Tyr Thr Ser His Gly Ala Asp Ala Asn Leu Glu Ala Gly  
 20 25 30

Asn Val Lys Glu Thr Arg Ala Ser Arg Ala Lys Arg Arg Gly Gly Gly  
 35 40 45

Gly His Asp Ala Leu Lys Gly Pro Asn Val Cys Gly Ser Arg Tyr Asn  
 50 55 60

Ala Tyr Cys Cys Pro Gly Trp Lys Thr Leu Pro Gly Gly Asn Gln Cys  
 65 70 75 80

Ile Val Pro Ile Cys Arg His Ser Cys Gly Asp Gly Phe Cys Ser Arg  
 85 90 95

Pro Asn Met Cys Thr Cys Pro Ser Gly Gln Ile Ala Pro Ser Cys Gly  
 100 105 110

Ser Arg Ser Ile Gln His Cys Asn Ile Arg Cys Met Asn Gly Gly Ser  
 115 120 125

Cys Ser Asp Asp His Cys Leu Cys Gln Lys Gly Tyr Ile Gly Thr His  
 130 135 140

Cys Gly Gln Pro Val Cys Glu Ser Gly Cys Leu Asn Gly Gly Arg Cys  
 145 150 155 160

Val Ala Pro Asn Arg Cys Ala Cys Thr Tyr Gly Phe Thr Gly Pro Gln  
 165 170 175

Cys Glu Arg Asp Tyr Arg Thr Gly Pro Cys Phe Thr Val Ile Ser Asn  
 180 185 190

Gln Met Cys Gln Gly Gln Leu Ser Gly Ile Val Cys Thr Lys Thr Leu  
 195 200 205

Cys Cys Ala Thr Val Gly Arg Ala Trp Gly His Pro Cys Glu Met Cys  
 210 215 220

Pro Ala Gln Pro His Pro Cys Arg Arg Gly Phe Ile Pro Asn Ile Arg  
 225 230 235 240

Thr Gly Ala Cys Gln Asp Val Asp Glu Cys Gln Ala Ile Pro Gly Leu  
 245 250 255

Cys Gln Gly Gly Asn Cys Ile Asn Thr Val Gly Ser Phe Glu Cys Lys  
 260 265 270

Cys Pro Ala Gly His Lys Leu Asn Glu Val Ser Gln Lys Cys Glu Asp  
 275 280 285

Ile Asp Glu Cys Ser Thr Ile Pro Gly Ile Cys Glu Gly Gly Glu Cys  
 290 295 300

Thr Asn Thr Val Ser Ser Tyr Phe Cys Lys Cys Pro Pro Gly Phe Tyr  
 305 310 315 320

-continued

---

Thr Ser Pro Asp Gly Thr Arg Cys Ile Asp Val Arg Pro Gly Tyr Cys  
 325 330 335  
 Tyr Thr Ala Leu Thr Asn Gly Arg Cys Ser Asn Gln Leu Pro Gln Ser  
 340 345 350  
 Ile Thr Lys Met Gln Cys Cys Cys Asp Ala Gly Arg Cys Trp Ser Pro  
 355 360 365  
 Gly Val Thr Val Ala Pro Glu Met Cys Pro Ile Arg Ala Thr Glu Asp  
 370 375 380  
 Phe Asn Lys Leu Cys Ser Val Pro Met Val Ile Pro Gly Arg Pro Glu  
 385 390 395 400  
 Tyr Pro Pro Pro Pro Leu Gly Pro Ile Pro Pro Val Leu Pro Val Pro  
 405 410 415  
 Pro Gly Phe Pro Pro Gly Pro Gln Ile Pro Val Pro Arg Pro Pro Val  
 420 425 430  
 Glu Tyr Leu Tyr Pro Ser Arg Glu Pro Pro Arg Val Leu Pro Val Asn  
 435 440 445  
 Val Thr Asp Tyr Cys Gln Leu Val Arg Tyr Leu Cys Gln Asn Gly Arg  
 450 455 460  
 Cys Ile Pro Thr Pro Gly Ser Tyr Arg Cys Glu Cys Asn Lys Gly Phe  
 465 470 475 480  
 Gln Leu Asp Leu Arg Gly Glu Cys Ile Asp Val Asp Glu Cys Glu Lys  
 485 490 495  
 Asn Pro Cys Ala Gly Gly Glu Cys Ile Asn Asn Gln Gly Ser Tyr Thr  
 500 505 510  
 Cys Gln Cys Arg Ala Gly Tyr Gln Ser Thr Leu Thr Arg Thr Glu Cys  
 515 520 525  
 Arg Asp Ile Asp Glu Cys Leu Gln Asn Gly Arg Ile Cys Asn Asn Gly  
 530 535 540  
 Arg Cys Ile Asn Thr Asp Gly Ser Phe His Cys Val Cys Asn Ala Gly  
 545 550 555 560  
 Phe His Val Thr Arg Asp Gly Lys Asn Cys Glu Asp Met Asp Glu Cys  
 565 570 575  
 Ser Ile Arg Asn Met Cys Leu Asn Gly Met Cys Ile Asn Glu Asp Gly  
 580 585 590  
 Ser Phe Lys Cys Ile Cys Lys Pro Gly Phe Gln Leu Ala Ser Asp Gly  
 595 600 605  
 Arg Tyr Cys Lys Asp Ile Asn Glu Cys Glu Thr Pro Gly Ile Cys Met  
 610 615 620  
 Asn Gly Arg Cys Val Asn Thr Asp Gly Ser Tyr Arg Cys Glu Cys Phe  
 625 630 635 640  
 Pro Gly Leu Ala Val Gly Leu Asp Gly Arg Val Cys Val Asp Thr His  
 645 650 655  
 Met Arg Ser Thr Cys Tyr Gly Gly Tyr Lys Arg Gly Gln Cys Ile Lys  
 660 665 670  
 Pro Leu Phe Gly Ala Val Thr Lys Ser Glu Cys Cys Cys Ala Ser Thr  
 675 680 685  
 Glu Tyr Ala Phe Gly Glu Pro Cys Gln Pro Cys Pro Ala Gln Asn Ser  
 690 695 700  
 Ala Glu Tyr Gln Ala Leu Cys Ser Ser Gly Pro Gly Met Thr Ser Ala  
 705 710 715 720

-continued

---

Gly Ser Asp Ile Asn Glu Cys Ala Leu Asp Pro Asp Ile Cys Pro Asn  
 725 730 735

Gly Ile Cys Glu Asn Leu Arg Gly Thr Tyr Lys Cys Ile Cys Asn Ser  
 740 745 750

Gly Tyr Glu Val Asp Ser Thr Gly Lys Asn Cys Val Asp Ile Asn Glu  
 755 760 765

Cys Val Leu Asn Ser Leu Leu Cys Asp Asn Gly Gln Cys Arg Asn Thr  
 770 775 780

Pro Gly Ser Phe Val Cys Thr Cys Pro Lys Gly Phe Ile Tyr Lys Pro  
 785 790 795 800

Asp Leu Lys Thr Cys Glu Asp Ile Asp Glu Cys Glu Ser Ser Pro Cys  
 805 810 815

Ile Asn Gly Val Cys Lys Asn Ser Pro Gly Ser Phe Ile Cys Glu Cys  
 820 825 830

Ser Ser Glu Ser Thr Leu Asp Pro Thr Lys Thr Ile Cys Ile Glu Thr  
 835 840 845

Ile Lys Gly Thr Cys Trp Gln Thr Val Ile Asp Gly Arg Cys Glu Ile  
 850 855 860

Asn Ile Asn Gly Ala Thr Leu Lys Ser Gln Cys Cys Ser Ser Leu Gly  
 865 870 875 880

Ala Ala Trp Gly Ser Pro Cys Thr Leu Cys Gln Val Asp Pro Ile Cys  
 885 890 895

Gly Lys Gly Tyr Ser Arg Ile Lys Gly Thr Gln Cys Glu Asp Ile Asp  
 900 905 910

Glu Cys Glu Val Phe Pro Gly Val Cys Lys Asn Gly Leu Cys Val Asn  
 915 920 925

Thr Arg Gly Ser Phe Lys Cys Gln Cys Pro Ser Gly Met Thr Leu Asp  
 930 935 940

Ala Thr Gly Arg Ile Cys Leu Asp Ile Arg Leu Glu Thr Cys Phe Leu  
 945 950 955 960

Arg Tyr Glu Asp Glu Glu Cys Thr Leu Pro Ile Ala Gly Arg His Arg  
 965 970 975

Met Asp Ala Cys Cys Cys Ser Val Gly Ala Ala Trp Gly Thr Glu Glu  
 980 985 990

Cys Glu Glu Cys Pro Met Arg Asn Thr Pro Glu Tyr Glu Glu Leu Cys  
 995 1000 1005

Pro Arg Gly Pro Gly Phe Ala Thr Lys Glu Ile Thr Asn Gly Lys  
 1010 1015 1020

Pro Phe Phe Lys Asp Ile Asn Glu Cys Lys Met Ile Pro Ser Leu  
 1025 1030 1035

Cys Thr His Gly Lys Cys Arg Asn Thr Ile Gly Ser Phe Lys Cys  
 1040 1045 1050

Arg Cys Asp Ser Gly Phe Ala Leu Asp Ser Glu Glu Arg Asn Cys  
 1055 1060 1065

Thr Asp Ile Asp Glu Cys Arg Ile Ser Pro Asp Leu Cys Gly Arg  
 1070 1075 1080

Gly Gln Cys Val Asn Thr Pro Gly Asp Phe Glu Cys Lys Cys Asp  
 1085 1090 1095

Glu Gly Tyr Glu Ser Gly Phe Met Met Met Lys Asn Cys Met Asp  
 1100 1105 1110

Ile Asp Glu Cys Gln Arg Asp Pro Leu Leu Cys Arg Gly Gly Val

-continued

---

1115	1120	1125
Cys His Asn Thr Glu Gly Ser Tyr Arg Cys Glu Cys Pro Pro Gly 1130	1135	1140
His Gln Leu Ser Pro Asn Ile Ser Ala Cys Ile Asp Ile Asn Glu 1145	1150	1155
Cys Glu Leu Ser Ala His Leu Cys Pro Asn Gly Arg Cys Val Asn 1160	1165	1170
Leu Ile Gly Lys Tyr Gln Cys Ala Cys Asn Pro Gly Tyr His Ser 1175	1180	1185
Thr Pro Asp Arg Leu Phe Cys Val Asp Ile Asp Glu Cys Ser Ile 1190	1195	1200
Met Asn Gly Gly Cys Glu Thr Phe Cys Thr Asn Ser Glu Gly Ser 1205	1210	1215
Tyr Glu Cys Ser Cys Gln Pro Gly Phe Ala Leu Met Pro Asp Gln 1220	1225	1230
Arg Ser Cys Thr Asp Ile Asp Glu Cys Glu Asp Asn Pro Asn Ile 1235	1240	1245
Cys Asp Gly Gly Gln Cys Thr Asn Ile Pro Gly Glu Tyr Arg Cys 1250	1255	1260
Leu Cys Tyr Asp Gly Phe Met Ala Ser Glu Asp Met Lys Thr Cys 1265	1270	1275
Val Asp Val Asn Glu Cys Asp Leu Asn Pro Asn Ile Cys Leu Ser 1280	1285	1290
Gly Thr Cys Glu Asn Thr Lys Gly Ser Phe Ile Cys His Cys Asp 1295	1300	1305
Met Gly Tyr Ser Gly Lys Lys Gly Lys Thr Gly Cys Thr Asp Ile 1310	1315	1320
Asn Glu Cys Glu Ile Gly Ala His Asn Cys Gly Lys His Ala Val 1325	1330	1335
Cys Thr Asn Thr Ala Gly Ser Phe Lys Cys Ser Cys Ser Pro Gly 1340	1345	1350
Trp Ile Gly Asp Gly Ile Lys Cys Thr Asp Leu Asp Glu Cys Ser 1355	1360	1365
Asn Gly Thr His Met Cys Ser Gln His Ala Asp Cys Lys Asn Thr 1370	1375	1380
Met Gly Ser Tyr Arg Cys Leu Cys Lys Glu Gly Tyr Thr Gly Asp 1385	1390	1395
Gly Phe Thr Cys Thr Asp Leu Asp Glu Cys Ser Glu Asn Leu Asn 1400	1405	1410
Leu Cys Gly Asn Gly Gln Cys Leu Asn Ala Pro Gly Gly Tyr Arg 1415	1420	1425
Cys Glu Cys Asp Met Gly Phe Val Pro Ser Ala Asp Gly Lys Ala 1430	1435	1440
Cys Glu Asp Ile Asp Glu Cys Ser Leu Pro Asn Ile Cys Val Phe 1445	1450	1455
Gly Thr Cys His Asn Leu Pro Gly Leu Phe Arg Cys Glu Cys Glu 1460	1465	1470
Ile Gly Tyr Glu Leu Asp Arg Ser Gly Gly Asn Cys Thr Asp Val 1475	1480	1485
Asn Glu Cys Leu Asp Pro Thr Thr Cys Ile Ser Gly Asn Cys Val 1490	1495	1500

-continued

---

Asn Thr	Pro Gly Ser Tyr	Ile	Cys Asp Cys Pro	Pro	Asp Phe Glu
1505		1510		1515	
Leu Asn	Pro Thr Arg Val	Gly	Cys Val Asp Thr Arg	Ser Gly Asn	
1520		1525		1530	
Cys Tyr	Leu Asp Ile Arg	Pro	Arg Gly Asp Asn Gly	Asp Thr Ala	
1535		1540		1545	
Cys Ser	Asn Glu Ile Gly	Val	Gly Val Ser Lys Ala	Ser Cys Cys	
1550		1555		1560	
Cys Ser	Leu Gly Lys Ala	Trp	Gly Thr Pro Cys Glu	Met Cys Pro	
1565		1570		1575	
Ala Val	Asn Thr Ser Glu	Tyr	Lys Ile Leu Cys Pro	Gly Gly Glu	
1580		1585		1590	
Gly Phe	Arg Pro Asn Pro	Ile	Thr Val Ile Leu Glu	Asp Ile Asp	
1595		1600		1605	
Glu Cys	Gln Glu Leu Pro	Gly	Leu Cys Gln Gly Gly	Lys Cys Ile	
1610		1615		1620	
Asn Thr	Phe Gly Ser Phe	Gln	Cys Arg Cys Pro Thr	Gly Tyr Tyr	
1625		1630		1635	
Leu Asn	Glu Asp Thr Arg	Val	Cys Asp Asp Val Asn	Glu Cys Glu	
1640		1645		1650	
Thr Pro	Gly Ile Cys Gly	Pro	Gly Thr Cys Tyr Asn	Thr Val Gly	
1655		1660		1665	
Asn Tyr	Thr Cys Ile Cys	Pro	Pro Asp Tyr Met Gln	Val Asn Gly	
1670		1675		1680	
Gly Asn	Asn Cys Met Asp	Met	Arg Arg Ser Leu Cys	Tyr Arg Asn	
1685		1690		1695	
Tyr Tyr	Ala Asp Asn Gln	Thr	Cys Asp Gly Glu Leu	Leu Phe Asn	
1700		1705		1710	
Met Thr	Lys Lys Met Cys	Cys	Cys Ser Tyr Asn Ile	Gly Arg Ala	
1715		1720		1725	
Trp Asn	Lys Pro Cys Glu	Gln	Cys Pro Ile Pro Ser	Thr Asp Glu	
1730		1735		1740	
Phe Ala	Thr Leu Cys Gly	Ser	Gln Arg Pro Gly Phe	Val Ile Asp	
1745		1750		1755	
Ile Tyr	Thr Gly Leu Pro	Val	Asp Ile Asp Glu Cys	Arg Glu Ile	
1760		1765		1770	
Pro Gly	Val Cys Glu Asn	Gly	Val Cys Ile Asn Met	Val Gly Ser	
1775		1780		1785	
Phe Arg	Cys Glu Cys Pro	Val	Gly Phe Phe Tyr Asn	Asp Lys Leu	
1790		1795		1800	
Leu Val	Cys Glu Asp Ile	Asp	Glu Cys Gln Asn Gly	Pro Val Cys	
1805		1810		1815	
Gln Arg	Asn Ala Glu Cys	Ile	Asn Thr Ala Gly Ser	Tyr Arg Cys	
1820		1825		1830	
Asp Cys	Lys Pro Gly Tyr	Arg	Phe Thr Ser Thr Gly	Gln Cys Asn	
1835		1840		1845	
Asp Arg	Asn Glu Cys Gln	Glu	Ile Pro Asn Ile Cys	Ser His Gly	
1850		1855		1860	
Gln Cys	Ile Asp Thr Val	Gly	Ser Phe Tyr Cys Leu	Cys His Thr	
1865		1870		1875	

-continued

---

Gly	Phe	Lys	Thr	Asn	Asp	Asp	Gln	Thr	Met	Cys	Leu	Asp	Ile	Asn
1880						1885					1890			
Glu	Cys	Glu	Arg	Asp	Ala	Cys	Gly	Asn	Gly	Thr	Cys	Arg	Asn	Thr
1895						1900					1905			
Ile	Gly	Ser	Phe	Asn	Cys	Arg	Cys	Asn	His	Gly	Phe	Ile	Leu	Ser
1910						1915					1920			
His	Asn	Asn	Asp	Cys	Ile	Asp	Val	Asp	Glu	Cys	Ala	Ser	Gly	Asn
1925						1930					1935			
Gly	Asn	Leu	Cys	Arg	Asn	Gly	Gln	Cys	Ile	Asn	Thr	Val	Gly	Ser
1940						1945					1950			
Phe	Gln	Cys	Gln	Cys	Asn	Glu	Gly	Tyr	Glu	Val	Ala	Pro	Asp	Gly
1955						1960					1965			
Arg	Thr	Cys	Val	Asp	Ile	Asn	Glu	Cys	Leu	Leu	Glu	Pro	Arg	Lys
1970						1975					1980			
Cys	Ala	Pro	Gly	Thr	Cys	Gln	Asn	Leu	Asp	Gly	Ser	Tyr	Arg	Cys
1985						1990					1995			
Ile	Cys	Pro	Pro	Gly	Tyr	Ser	Leu	Gln	Asn	Glu	Lys	Cys	Glu	Asp
2000						2005					2010			
Ile	Asp	Glu	Cys	Val	Glu	Glu	Pro	Glu	Ile	Cys	Ala	Leu	Gly	Thr
2015						2020					2025			
Cys	Ser	Asn	Thr	Glu	Gly	Ser	Phe	Lys	Cys	Leu	Cys	Pro	Glu	Gly
2030						2035					2040			
Phe	Ser	Leu	Ser	Ser	Ser	Gly	Arg	Arg	Cys	Gln	Asp	Leu	Arg	Met
2045						2050					2055			
Ser	Tyr	Cys	Tyr	Ala	Lys	Phe	Glu	Gly	Gly	Lys	Cys	Ser	Ser	Pro
2060						2065					2070			
Lys	Ser	Arg	Asn	His	Ser	Lys	Gln	Glu	Cys	Cys	Cys	Ala	Leu	Lys
2075						2080					2085			
Gly	Glu	Gly	Trp	Gly	Asp	Pro	Cys	Glu	Leu	Cys	Pro	Thr	Glu	Pro
2090						2095					2100			
Asp	Glu	Ala	Phe	Arg	Gln	Ile	Cys	Pro	Tyr	Gly	Ser	Gly	Ile	Ile
2105						2110					2115			
Val	Gly	Pro	Asp	Asp	Ser	Ala	Val	Asp	Met	Asp	Glu	Cys	Lys	Glu
2120						2125					2130			
Pro	Asp	Val	Cys	Lys	His	Gly	Gln	Cys	Ile	Asn	Thr	Asp	Gly	Ser
2135						2140					2145			
Tyr	Arg	Cys	Glu	Cys	Pro	Phe	Gly	Tyr	Ile	Leu	Ala	Gly	Asn	Glu
2150						2155					2160			
Cys	Val	Asp	Thr	Asp	Glu	Cys	Ser	Val	Gly	Asn	Pro	Cys	Gly	Asn
2165						2170					2175			
Gly	Thr	Cys	Lys	Asn	Val	Ile	Gly	Gly	Phe	Glu	Cys	Thr	Cys	Glu
2180						2185					2190			
Glu	Gly	Phe	Glu	Pro	Gly	Pro	Met	Met	Thr	Cys	Glu	Asp	Ile	Asn
2195						2200					2205			
Glu	Cys	Ala	Gln	Asn	Pro	Leu	Leu	Cys	Ala	Phe	Arg	Cys	Val	Asn
2210						2215					2220			
Thr	Tyr	Gly	Ser	Tyr	Glu	Cys	Lys	Cys	Pro	Val	Gly	Tyr	Val	Leu
2225						2230					2235			
Arg	Glu	Asp	Arg	Arg	Met	Cys	Lys	Asp	Glu	Asp	Glu	Cys	Glu	Glu
2240						2245					2250			
Gly	Lys	His	Asp	Cys	Thr	Glu	Lys	Gln	Met	Glu	Cys	Lys	Asn	Leu

-continued

---

2255	2260	2265
Ile Gly Thr Tyr Met Cys	Ile Cys Gly Pro Gly Tyr	Gln Arg Arg
2270	2275	2280
Pro Asp Gly Glu Gly Cys	Val Asp Glu Asn Glu Cys	Gln Thr Lys
2285	2290	2295
Pro Gly Ile Cys Glu Asn	Gly Arg Cys Leu Asn Thr	Arg Gly Ser
2300	2305	2310
Tyr Thr Cys Glu Cys Asn	Asp Gly Phe Thr Ala Ser	Pro Asn Gln
2315	2320	2325
Asp Glu Cys Leu Asp Asn	Arg Glu Gly Tyr Cys Phe	Thr Glu Val
2330	2335	2340
Leu Gln Asn Met Cys Gln	Ile Gly Ser Ser Asn Arg	Asn Pro Val
2345	2350	2355
Thr Lys Ser Glu Cys Cys	Cys Asp Gly Gly Arg Gly	Trp Gly Pro
2360	2365	2370
His Cys Glu Ile Cys Pro	Phe Gln Gly Thr Val Ala	Phe Lys Lys
2375	2380	2385
Leu Cys Pro His Gly Arg	Gly Phe Met Thr Asn Gly	Ala Asp Ile
2390	2395	2400
Asp Glu Cys Lys Val Ile	His Asp Val Cys Arg Asn	Gly Glu Cys
2405	2410	2415
Val Asn Asp Arg Gly Ser	Tyr His Cys Ile Cys Lys	Thr Gly Tyr
2420	2425	2430
Thr Pro Asp Ile Thr Gly	Thr Ser Cys Val Asp Leu	Asn Glu Cys
2435	2440	2445
Asn Gln Ala Pro Lys Pro	Cys Asn Phe Ile Cys Lys	Asn Thr Glu
2450	2455	2460
Gly Ser Tyr Gln Cys Ser	Cys Pro Lys Gly Tyr Ile	Leu Gln Glu
2465	2470	2475
Asp Gly Arg Ser Cys Lys	Asp Leu Asp Glu Cys Ala	Thr Lys Gln
2480	2485	2490
His Asn Cys Gln Phe Leu	Cys Val Asn Thr Ile Gly	Gly Phe Thr
2495	2500	2505
Cys Lys Cys Pro Pro Gly	Phe Thr Gln His His Thr	Ser Cys Ile
2510	2515	2520
Asp Asn Asn Glu Cys Thr	Ser Asp Ile Asn Leu Cys	Gly Ser Lys
2525	2530	2535
Gly Ile Cys Gln Asn Thr	Pro Gly Ser Phe Thr Cys	Glu Cys Gln
2540	2545	2550
Arg Gly Phe Ser Leu Asp	Gln Thr Gly Ser Ser Cys	Glu Asp Val
2555	2560	2565
Asp Glu Cys Glu Gly Asn	His Arg Cys Gln His Gly	Cys Gln Asn
2570	2575	2580
Ile Ile Gly Gly Tyr Arg	Cys Ser Cys Pro Gln Gly	Tyr Leu Gln
2585	2590	2595
His Tyr Gln Trp Asn Gln	Cys Val Asp Glu Asn Glu	Cys Leu Ser
2600	2605	2610
Ala His Ile Cys Gly Gly	Ala Ser Cys His Asn Thr	Leu Gly Ser
2615	2620	2625
Tyr Lys Cys Met Cys Pro	Ala Gly Phe Gln Tyr Glu	Gln Phe Ser
2630	2635	2640

-continued

---

Gly Gly Cys Gln Asp Ile Asn Glu Cys Gly Ser Ala Gln Ala Pro  
 2645 2650 2655

Cys Ser Tyr Gly Cys Ser Asn Thr Glu Gly Gly Tyr Leu Cys Gly  
 2660 2665 2670

Cys Pro Pro Gly Tyr Phe Arg Ile Gly Gln Gly His Cys Val Ser  
 2675 2680 2685

Gly Met Gly Met Gly Arg Gly Asn Pro Glu Pro Pro Val Ser Gly  
 2690 2695 2700

Glu Met Asp Asp Asn Ser Leu Ser Pro Glu Ala Cys Tyr Glu Cys  
 2705 2710 2715

Lys Ile Asn Gly Tyr Pro Lys Arg Gly Arg Lys Arg Arg Ser Thr  
 2720 2725 2730

Asn Glu Thr Asp Ala Ser Asn Ile Glu Asp Gln Ser Glu Thr Glu  
 2735 2740 2745

Ala Asn Val Ser Leu Ala Ser Trp Asp Val Glu Lys Thr Ala Ile  
 2750 2755 2760

Phe Ala Phe Asn Ile Ser His Val Ser Asn Lys Val Arg Ile Leu  
 2765 2770 2775

Glu Leu Leu Pro Ala Leu Thr Thr Leu Thr Asn His Asn Arg Tyr  
 2780 2785 2790

Leu Ile Glu Ser Gly Asn Glu Asp Gly Phe Phe Lys Ile Asn Gln  
 2795 2800 2805

Lys Glu Gly Ile Ser Tyr Leu His Phe Thr Lys Lys Lys Pro Val  
 2810 2815 2820

Ala Gly Thr Tyr Ser Leu Gln Ile Ser Ser Thr Pro Leu Tyr Lys  
 2825 2830 2835

Lys Lys Glu Leu Asn Gln Leu Glu Asp Lys Tyr Asp Lys Asp Tyr  
 2840 2845 2850

Leu Ser Gly Glu Leu Gly Asp Asn Leu Lys Met Lys Ile Gln Val  
 2855 2860 2865

Leu Leu His  
 2870

<210> SEQ ID NO 15  
 <211> LENGTH: 201  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

Met Asp Leu Ser Leu Leu Trp Val Leu Met Pro Leu Val Thr Met Ala  
 1 5 10 15

Trp Gly Gln Tyr Gly Asp Tyr Gly Tyr Pro Tyr Gln Gln Tyr His Asp  
 20 25 30

Tyr Ser Asp Asp Gly Trp Val Asn Leu Asn Arg Gln Gly Phe Ser Tyr  
 35 40 45

Gln Cys Pro Gln Gly Gln Val Ile Val Ala Val Arg Ser Ile Phe Ser  
 50 55 60

Lys Lys Glu Gly Ser Asp Arg Gln Trp Asn Tyr Ala Cys Met Pro Thr  
 65 70 75 80

Pro Gln Ser Leu Gly Glu Pro Thr Glu Cys Trp Trp Glu Glu Ile Asn  
 85 90 95

Arg Ala Gly Met Glu Trp Tyr Gln Thr Cys Ser Asn Asn Gly Leu Val

-continued

---

	100							105							110
Ala	Gly	Phe	Gln	Ser	Arg	Tyr	Phe	Glu	Ser	Val	Leu	Asp	Arg	Glu	Trp
	115						120					125			
Gln	Phe	Tyr	Cys	Cys	Arg	Tyr	Ser	Lys	Arg	Cys	Pro	Tyr	Ser	Cys	Trp
	130					135					140				
Leu	Thr	Thr	Glu	Tyr	Pro	Gly	His	Tyr	Gly	Glu	Glu	Met	Asp	Met	Ile
145					150					155					160
Ser	Tyr	Asn	Tyr	Asp	Tyr	Tyr	Ile	Arg	Gly	Ala	Thr	Thr	Thr	Phe	Ser
				165					170						175
Ala	Val	Glu	Arg	Asp	Arg	Gln	Trp	Lys	Phe	Ile	Met	Cys	Arg	Met	Thr
			180					185						190	
Glu	Tyr	Asp	Cys	Glu	Phe	Ala	Asn	Val							
	195						200								

<210> SEQ ID NO 16  
 <211> LENGTH: 207  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

Met	Ala	Pro	Phe	Glu	Pro	Leu	Ala	Ser	Gly	Ile	Leu	Leu	Leu	Leu	Trp
1				5					10						15
Leu	Ile	Ala	Pro	Ser	Arg	Ala	Cys	Thr	Cys	Val	Pro	Pro	His	Pro	Gln
			20					25					30		
Thr	Ala	Phe	Cys	Asn	Ser	Asp	Leu	Val	Ile	Arg	Ala	Lys	Phe	Val	Gly
		35					40					45			
Thr	Pro	Glu	Val	Asn	Gln	Thr	Thr	Leu	Tyr	Gln	Arg	Tyr	Glu	Ile	Lys
	50					55					60				
Met	Thr	Lys	Met	Tyr	Lys	Gly	Phe	Gln	Ala	Leu	Gly	Asp	Ala	Ala	Asp
65					70					75					80
Ile	Arg	Phe	Val	Tyr	Thr	Pro	Ala	Met	Glu	Ser	Val	Cys	Gly	Tyr	Phe
				85					90					95	
His	Arg	Ser	His	Asn	Arg	Ser	Glu	Glu	Phe	Leu	Ile	Ala	Gly	Lys	Leu
			100				105						110		
Gln	Asp	Gly	Leu	Leu	His	Ile	Thr	Thr	Cys	Ser	Phe	Val	Ala	Pro	Trp
	115						120					125			
Asn	Ser	Leu	Ser	Leu	Ala	Gln	Arg	Arg	Gly	Phe	Thr	Lys	Thr	Tyr	Thr
	130					135						140			
Val	Gly	Cys	Glu	Glu	Cys	Thr	Val	Phe	Pro	Cys	Leu	Ser	Ile	Pro	Cys
145					150					155					160
Lys	Leu	Gln	Ser	Gly	Thr	His	Cys	Leu	Trp	Thr	Asp	Gln	Leu	Leu	Gln
				165					170						175
Gly	Ser	Glu	Lys	Gly	Phe	Gln	Ser	Arg	His	Leu	Ala	Cys	Leu	Pro	Arg
			180					185						190	
Glu	Pro	Gly	Leu	Cys	Thr	Trp	Gln	Ser	Leu	Arg	Ser	Gln	Ile	Ala	
	195						200					205			

<210> SEQ ID NO 17  
 <211> LENGTH: 135  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Met	Ala	Cys	Gly	Leu	Val	Ala	Ser	Asn	Leu	Asn	Leu	Lys	Pro	Gly	Glu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

-continued

---

```

1           5           10           15
Cys Leu Arg Val Arg Gly Glu Val Ala Pro Asp Ala Lys Ser Phe Val
      20           25           30
Leu Asn Leu Gly Lys Asp Ser Asn Asn Leu Cys Leu His Phe Asn Pro
      35           40           45
Arg Phe Asn Ala His Gly Asp Ala Asn Thr Ile Val Cys Asn Ser Lys
      50           55           60
Asp Gly Gly Ala Trp Gly Thr Glu Gln Arg Glu Ala Val Phe Pro Phe
      65           70           75           80
Gln Pro Gly Ser Val Ala Glu Val Cys Ile Thr Phe Asp Gln Ala Asn
      85           90           95
Leu Thr Val Lys Leu Pro Asp Gly Tyr Glu Phe Lys Phe Pro Asn Arg
      100           105           110
Leu Asn Leu Glu Ala Ile Asn Tyr Met Ala Ala Asp Gly Asp Phe Lys
      115           120           125
Ile Lys Cys Val Ala Phe Asp
      130           135

```

```

<210> SEQ ID NO 18
<211> LENGTH: 338
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 18

```

```

Met Ser Leu Ser Ala Phe Thr Leu Phe Leu Ala Leu Ile Gly Gly Thr
1           5           10           15
Ser Gly Gln Tyr Tyr Asp Tyr Asp Phe Pro Pro Ser Ile Tyr Gly Gln
      20           25           30
Ser Ser Pro Asn Cys Ala Pro Glu Cys Asn Cys Pro Glu Ser Tyr Pro
      35           40           45
Ser Ala Met Tyr Cys Asp Glu Leu Lys Leu Lys Ser Val Pro Met Val
      50           55           60
Pro Pro Gly Ile Lys Tyr Leu Tyr Leu Arg Asn Asn Gln Ile Asp His
      65           70           75           80
Ile Asp Glu Lys Ala Phe Glu Asn Val Thr Asp Leu Gln Trp Leu Ile
      85           90           95
Leu Asp His Asn Val Leu Glu Asn Ser Lys Ile Lys Gly Arg Val Phe
      100           105           110
Ser Lys Leu Lys Gln Leu Lys Lys Leu His Ile Asn His Asn Asn Leu
      115           120           125
Thr Glu Ser Val Gly Pro Leu Pro Lys Ser Leu Glu Asp Leu Gln Leu
      130           135           140
Thr His Asn Lys Ile Thr Lys Leu Gly Ser Phe Glu Gly Leu Val Asn
      145           150           155           160
Leu Thr Phe Ile His Leu Gln His Asn Arg Leu Lys Glu Asp Ala Val
      165           170           175
Ser Ala Ala Phe Lys Gly Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser
      180           185           190
Phe Asn Gln Ile Ala Arg Leu Pro Ser Gly Leu Pro Val Ser Leu Leu
      195           200           205
Thr Leu Tyr Leu Asp Asn Asn Lys Ile Ser Asn Ile Pro Asp Glu Tyr
      210           215           220

```

-continued

---

Phe Lys Arg Phe Asn Ala Leu Gln Tyr Leu Arg Leu Ser His Asn Glu  
 225 230 235 240  
 Leu Ala Asp Ser Gly Ile Pro Gly Asn Ser Phe Asn Val Ser Ser Leu  
 245 250 255  
 Val Glu Leu Asp Leu Ser Tyr Asn Lys Leu Lys Asn Ile Pro Thr Val  
 260 265 270  
 Asn Glu Asn Leu Glu Asn Tyr Tyr Leu Glu Val Asn Gln Leu Glu Lys  
 275 280 285  
 Phe Asp Ile Lys Ser Phe Cys Lys Ile Leu Gly Pro Leu Ser Tyr Ser  
 290 295 300  
 Lys Ile Lys His Leu Arg Leu Asp Gly Asn Arg Ile Ser Glu Thr Ser  
 305 310 315 320  
 Leu Pro Pro Asp Met Tyr Glu Cys Leu Arg Val Ala Asn Glu Val Thr  
 325 330 335  
 Leu Asn  
 <210> SEQ ID NO 19  
 <211> LENGTH: 382  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <400> SEQUENCE: 19  
 Met Arg Ser Pro Leu Cys Trp Leu Leu Pro Leu Leu Ile Leu Ala Ser  
 1 5 10 15  
 Val Ala Gln Gly Gln Pro Thr Arg Arg Pro Arg Pro Gly Thr Gly Pro  
 20 25 30  
 Gly Arg Arg Pro Arg Pro Arg Pro Arg Pro Thr Pro Ser Phe Pro Gln  
 35 40 45  
 Pro Asp Glu Pro Ala Glu Pro Thr Asp Leu Pro Pro Pro Leu Pro Pro  
 50 55 60  
 Gly Pro Pro Ser Ile Phe Pro Asp Cys Pro Arg Glu Cys Tyr Cys Pro  
 65 70 75 80  
 Pro Asp Phe Pro Ser Ala Leu Tyr Cys Asp Ser Arg Asn Leu Arg Lys  
 85 90 95  
 Val Pro Val Ile Pro Pro Arg Ile His Tyr Leu Tyr Leu Gln Asn Asn  
 100 105 110  
 Phe Ile Thr Glu Leu Pro Val Glu Ser Phe Gln Asn Ala Thr Gly Leu  
 115 120 125  
 Arg Trp Ile Asn Leu Asp Asn Asn Arg Ile Arg Lys Ile Asp Gln Arg  
 130 135 140  
 Val Leu Glu Lys Leu Pro Gly Leu Val Phe Leu Tyr Met Glu Lys Asn  
 145 150 155 160  
 Gln Leu Glu Glu Val Pro Ser Ala Leu Pro Arg Asn Leu Glu Gln Leu  
 165 170 175  
 Arg Leu Ser Gln Asn His Ile Ser Arg Ile Pro Pro Gly Val Phe Ser  
 180 185 190  
 Lys Leu Glu Asn Leu Leu Leu Leu Asp Leu Gln His Asn Arg Leu Ser  
 195 200 205  
 Asp Gly Val Phe Lys Pro Asp Thr Phe His Gly Leu Lys Asn Leu Met  
 210 215 220  
 Gln Leu Asn Leu Ala His Asn Ile Leu Arg Lys Met Pro Pro Arg Val  
 225 230 235 240

-continued

---

```

Pro Thr Ala Ile His Gln Leu Tyr Leu Asp Ser Asn Lys Ile Glu Thr
      245                250                255

Ile Pro Asn Gly Tyr Phe Lys Ser Phe Pro Asn Leu Ala Phe Ile Arg
      260                265                270

Leu Asn Tyr Asn Lys Leu Thr Asp Arg Gly Leu Pro Lys Asn Ser Phe
      275                280                285

Asn Ile Ser Asn Leu Leu Val Leu His Leu Ser His Asn Arg Ile Ser
      290                295                300

Ser Val Pro Ala Ile Asn Asn Arg Leu Glu His Leu Tyr Leu Asn Asn
      305                310                315                320

Asn Ser Ile Glu Lys Ile Asn Gly Thr Gln Ile Cys Pro Asn Asp Leu
      325                330                335

Val Ala Phe His Asp Phe Ser Ser Asp Leu Glu Asn Val Pro His Leu
      340                345                350

Arg Tyr Leu Arg Leu Asp Gly Asn Tyr Leu Lys Pro Pro Ile Pro Leu
      355                360                365

Asp Leu Met Met Cys Phe Arg Leu Leu Gln Ser Val Val Ile
      370                375                380

```

```

<210> SEQ ID NO 20
<211> LENGTH: 2201
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 20

```

```

Met Gly Ala Met Thr Gln Leu Leu Ala Gly Val Phe Leu Ala Phe Leu
1      5      10      15

Ala Leu Ala Thr Glu Gly Gly Val Leu Lys Lys Val Ile Arg His Lys
      20      25      30

Arg Gln Ser Gly Val Asn Ala Thr Leu Pro Glu Glu Asn Gln Pro Val
      35      40      45

Val Phe Asn His Val Tyr Asn Ile Lys Leu Pro Val Gly Ser Gln Cys
      50      55      60

Ser Val Asp Leu Glu Ser Ala Ser Gly Glu Lys Asp Leu Ala Pro Pro
      65      70      75      80

Ser Glu Pro Ser Glu Ser Phe Gln Glu His Thr Val Asp Gly Glu Asn
      85      90      95

Gln Ile Val Phe Thr His Arg Ile Asn Ile Pro Arg Arg Ala Cys Gly
      100     105     110

Cys Ala Ala Ala Pro Asp Val Lys Glu Leu Leu Ser Arg Leu Glu Glu
      115     120     125

Leu Glu Asn Leu Val Ser Ser Leu Arg Glu Gln Cys Thr Ala Gly Ala
      130     135     140

Gly Cys Cys Leu Gln Pro Ala Thr Gly Arg Leu Asp Thr Arg Pro Phe
      145     150     155     160

Cys Ser Gly Arg Gly Asn Phe Ser Thr Glu Gly Cys Gly Cys Val Cys
      165     170     175

Glu Pro Gly Trp Lys Gly Pro Asn Cys Ser Glu Pro Glu Cys Pro Gly
      180     185     190

Asn Cys His Leu Arg Gly Arg Cys Ile Asp Gly Gln Cys Ile Cys Asp
      195     200     205

Asp Gly Phe Thr Gly Glu Asp Cys Ser Gln Leu Ala Cys Pro Ser Asp
      210     215     220

```

-continued

---

Cys Asn Asp Gln Gly Lys Cys Val Asn Gly Val Cys Ile Cys Phe Glu  
 225 230 235 240  
 Gly Tyr Ala Gly Ala Asp Cys Ser Arg Glu Ile Cys Pro Val Pro Cys  
 245 250 255  
 Ser Glu Glu His Gly Thr Cys Val Asp Gly Leu Cys Val Cys His Asp  
 260 265 270  
 Gly Phe Ala Gly Asp Asp Cys Asn Lys Pro Leu Cys Leu Asn Asn Cys  
 275 280 285  
 Tyr Asn Arg Gly Arg Cys Val Glu Asn Glu Cys Val Cys Asp Glu Gly  
 290 295 300  
 Phe Thr Gly Glu Asp Cys Ser Glu Leu Ile Cys Pro Asn Asp Cys Phe  
 305 310 315 320  
 Asp Arg Gly Arg Cys Ile Asn Gly Thr Cys Tyr Cys Glu Glu Gly Phe  
 325 330 335  
 Thr Gly Glu Asp Cys Gly Lys Pro Thr Cys Pro His Ala Cys His Thr  
 340 345 350  
 Gln Gly Arg Cys Glu Glu Gly Gln Cys Val Cys Asp Glu Gly Phe Ala  
 355 360 365  
 Gly Val Asp Cys Ser Glu Lys Arg Cys Pro Ala Asp Cys His Asn Arg  
 370 375 380  
 Gly Arg Cys Val Asp Gly Arg Cys Glu Cys Asp Asp Gly Phe Thr Gly  
 385 390 395 400  
 Ala Asp Cys Gly Glu Leu Lys Cys Pro Asn Gly Cys Ser Gly His Gly  
 405 410 415  
 Arg Cys Val Asn Gly Gln Cys Val Cys Asp Glu Gly Tyr Thr Gly Glu  
 420 425 430  
 Asp Cys Ser Gln Leu Arg Cys Pro Asn Asp Cys His Ser Arg Gly Arg  
 435 440 445  
 Cys Val Glu Gly Lys Cys Val Cys Glu Gln Gly Phe Lys Gly Tyr Asp  
 450 455 460  
 Cys Ser Asp Met Ser Cys Pro Asn Asp Cys His Gln His Gly Arg Cys  
 465 470 475 480  
 Val Asn Gly Met Cys Val Cys Asp Asp Gly Tyr Thr Gly Glu Asp Cys  
 485 490 495  
 Arg Asp Arg Gln Cys Pro Arg Asp Cys Ser Asn Arg Gly Leu Cys Val  
 500 505 510  
 Asp Gly Gln Cys Val Cys Glu Asp Gly Phe Thr Gly Pro Asp Cys Ala  
 515 520 525  
 Glu Leu Ser Cys Pro Asn Asp Cys His Gly Gln Gly Arg Cys Val Asn  
 530 535 540  
 Gly Gln Cys Val Cys His Glu Gly Phe Met Gly Lys Asp Cys Lys Glu  
 545 550 555 560  
 Gln Arg Cys Pro Ser Asp Cys His Gly Gln Gly Arg Cys Val Asp Gly  
 565 570 575  
 Gln Cys Ile Cys His Glu Gly Phe Thr Gly Leu Asp Cys Gly Gln His  
 580 585 590  
 Ser Cys Pro Ser Asp Cys Asn Asn Leu Gly Gln Cys Val Ser Gly Arg  
 595 600 605  
 Cys Ile Cys Asn Glu Gly Tyr Ser Gly Glu Asp Cys Ser Glu Val Ser  
 610 615 620

-continued

---

Pro	Pro	Lys	Asp	Leu	Val	Val	Thr	Glu	Val	Thr	Glu	Glu	Thr	Val	Asn
625					630					635					640
Leu	Ala	Trp	Asp	Asn	Glu	Met	Arg	Val	Thr	Glu	Tyr	Leu	Val	Val	Tyr
				645						650				655	
Thr	Pro	Thr	His	Glu	Gly	Gly	Leu	Glu	Met	Gln	Phe	Arg	Val	Pro	Gly
			660						665					670	
Asp	Gln	Thr	Ser	Thr	Ile	Ile	Gln	Glu	Leu	Glu	Pro	Gly	Val	Glu	Tyr
		675					680						685		
Phe	Ile	Arg	Val	Phe	Ala	Ile	Leu	Glu	Asn	Lys	Lys	Ser	Ile	Pro	Val
	690					695					700				
Ser	Ala	Arg	Val	Ala	Thr	Tyr	Leu	Pro	Ala	Pro	Glu	Gly	Leu	Lys	Phe
	705				710					715					720
Lys	Ser	Ile	Lys	Glu	Thr	Ser	Val	Glu	Val	Glu	Trp	Asp	Pro	Leu	Asp
			725						730					735	
Ile	Ala	Phe	Glu	Thr	Trp	Glu	Ile	Ile	Phe	Arg	Asn	Met	Asn	Lys	Glu
			740						745					750	
Asp	Glu	Gly	Glu	Ile	Thr	Lys	Ser	Leu	Arg	Arg	Pro	Glu	Thr	Ser	Tyr
		755					760						765		
Arg	Gln	Thr	Gly	Leu	Ala	Pro	Gly	Gln	Glu	Tyr	Glu	Ile	Ser	Leu	His
		770					775					780			
Ile	Val	Lys	Asn	Asn	Thr	Arg	Gly	Pro	Gly	Leu	Lys	Arg	Val	Thr	Thr
	785				790						795				800
Thr	Arg	Leu	Asp	Ala	Pro	Ser	Gln	Ile	Glu	Val	Lys	Asp	Val	Thr	Asp
				805						810				815	
Thr	Thr	Ala	Leu	Ile	Thr	Trp	Phe	Lys	Pro	Leu	Ala	Glu	Ile	Asp	Gly
			820					825						830	
Ile	Glu	Leu	Thr	Tyr	Gly	Ile	Lys	Asp	Val	Pro	Gly	Asp	Arg	Thr	Thr
		835					840						845		
Ile	Asp	Leu	Thr	Glu	Asp	Glu	Asn	Gln	Tyr	Ser	Ile	Gly	Asn	Leu	Lys
	850					855							860		
Pro	Asp	Thr	Glu	Tyr	Glu	Val	Ser	Leu	Ile	Ser	Arg	Arg	Gly	Asp	Met
	865				870						875				880
Ser	Ser	Asn	Pro	Ala	Lys	Glu	Thr	Phe	Thr	Thr	Gly	Leu	Asp	Ala	Pro
				885					890					895	
Arg	Asn	Leu	Arg	Arg	Val	Ser	Gln	Thr	Asp	Asn	Ser	Ile	Thr	Leu	Glu
			900						905					910	
Trp	Arg	Asn	Gly	Lys	Ala	Ala	Ile	Asp	Ser	Tyr	Arg	Ile	Lys	Tyr	Ala
		915						920						925	
Pro	Ile	Ser	Gly	Gly	Asp	His	Ala	Glu	Val	Asp	Val	Pro	Lys	Ser	Gln
	930					935						940			
Gln	Ala	Thr	Thr	Lys	Thr	Thr	Leu	Thr	Gly	Leu	Arg	Pro	Gly	Thr	Glu
	945				950						955				960
Tyr	Gly	Ile	Gly	Val	Ser	Ala	Val	Lys	Glu	Asp	Lys	Glu	Ser	Asn	Pro
			965							970					975
Ala	Thr	Ile	Asn	Ala	Ala	Thr	Glu	Leu	Asp	Thr	Pro	Lys	Asp	Leu	Gln
			980						985					990	
Val	Ser	Glu	Thr	Ala	Glu	Thr	Ser	Leu	Thr	Leu	Leu	Trp	Lys	Thr	Pro
		995					1000						1005		
Leu	Ala	Lys	Phe	Asp	Arg	Tyr	Arg	Leu	Asn	Tyr	Ser	Leu	Pro	Thr	
	1010					1015						1020			
Gly	Gln	Trp	Val	Gly	Val	Gln	Leu	Pro	Arg	Asn	Thr	Thr	Ser	Tyr	

-continued

---

1025						1030						1035
Val Leu	Arg Gly	Leu Glu	Pro	Gly Gln	Glu Tyr	Asn	Val Leu	Leu				
1040			1045			1050						
Thr Ala	Glu Lys	Gly Arg	His	Lys Ser	Lys Pro	Ala	Arg Val	Lys				
1055			1060			1065						
Ala Ser	Thr Glu	Gln Ala	Pro	Glu Leu	Glu Asn	Leu	Thr Val	Thr				
1070			1075			1080						
Glu Val	Gly Trp	Asp Gly	Leu	Arg Leu	Asn Trp	Thr	Ala Ala	Asp				
1085			1090			1095						
Gln Ala	Tyr Glu	His Phe	Ile	Ile Gln	Val Gln	Glu	Ala Asn	Lys				
1100			1105			1110						
Val Glu	Ala Ala	Arg Asn	Leu	Thr Val	Pro Gly	Ser	Leu Arg	Ala				
1115			1120			1125						
Val Asp	Ile Pro	Gly Leu	Lys	Ala Ala	Thr Pro	Tyr	Thr Val	Ser				
1130			1135			1140						
Ile Tyr	Gly Val	Ile Gln	Gly	Tyr Arg	Thr Pro	Val	Leu Ser	Ala				
1145			1150			1155						
Glu Ala	Ser Thr	Gly Glu	Thr	Pro Asn	Leu Gly	Glu	Val Val	Val				
1160			1165			1170						
Ala Glu	Val Gly	Trp Asp	Ala	Leu Lys	Leu Asn	Trp	Thr Ala	Pro				
1175			1180			1185						
Glu Gly	Ala Tyr	Glu Tyr	Phe	Phe Ile	Gln Val	Gln	Glu Ala	Asp				
1190			1195			1200						
Thr Val	Glu Ala	Ala Gln	Asn	Leu Thr	Val Pro	Gly	Gly Leu	Arg				
1205			1210			1215						
Ser Thr	Asp Leu	Pro Gly	Leu	Lys Ala	Ala Thr	His	Tyr Thr	Ile				
1220			1225			1230						
Thr Ile	Arg Gly	Val Thr	Gln	Asp Phe	Ser Thr	Thr	Pro Leu	Ser				
1235			1240			1245						
Val Glu	Val Leu	Thr Glu	Glu	Val Pro	Asp Met	Gly	Asn Leu	Thr				
1250			1255			1260						
Val Thr	Glu Val	Ser Trp	Asp	Ala Leu	Arg Leu	Asn	Trp Thr	Thr				
1265			1270			1275						
Pro Asp	Gly Thr	Tyr Asp	Gln	Phe Thr	Ile Gln	Val	Gln Glu	Ala				
1280			1285			1290						
Asp Gln	Val Glu	Glu Ala	His	Asn Leu	Thr Val	Pro	Gly Ser	Leu				
1295			1300			1305						
Arg Ser	Met Glu	Ile Pro	Gly	Leu Arg	Ala Gly	Thr	Pro Tyr	Thr				
1310			1315			1320						
Val Thr	Leu His	Gly Glu	Val	Arg Gly	His Ser	Thr	Arg Pro	Leu				
1325			1330			1335						
Ala Val	Glu Val	Val Thr	Glu	Asp Leu	Pro Gln	Leu	Gly Asp	Leu				
1340			1345			1350						
Ala Val	Ser Glu	Val Gly	Trp	Asp Gly	Leu Arg	Leu	Asn Trp	Thr				
1355			1360			1365						
Ala Ala	Asp Asn	Ala Tyr	Glu	His Phe	Val Ile	Gln	Val Gln	Glu				
1370			1375			1380						
Val Asn	Lys Val	Glu Ala	Ala	Gln Asn	Leu Thr	Leu	Pro Gly	Ser				
1385			1390			1395						
Leu Arg	Ala Val	Asp Ile	Pro	Gly Leu	Glu Ala	Ala	Thr Pro	Tyr				
1400			1405			1410						

-continued

---

Arg Val	Ser Ile Tyr Gly	Val Ile Arg Gly Tyr Arg	Thr Pro Val
1415		1420	1425
Leu Ser	Ala Glu Ala Ser	Thr Ala Lys Glu Pro Glu	Ile Gly Asn
1430		1435	1440
Leu Asn	Val Ser Asp Ile	Thr Pro Glu Ser Phe Asn	Leu Ser Trp
1445		1450	1455
Met Ala	Thr Asp Gly Ile	Phe Glu Thr Phe Thr Ile	Glu Ile Ile
1460		1465	1470
Asp Ser	Asn Arg Leu Leu	Glu Thr Val Glu Tyr Asn	Ile Ser Gly
1475		1480	1485
Ala Glu	Arg Thr Ala His	Ile Ser Gly Leu Pro Pro	Ser Thr Asp
1490		1495	1500
Phe Ile	Val Tyr Leu Ser	Gly Leu Ala Pro Ser Ile	Arg Thr Lys
1505		1510	1515
Thr Ile	Ser Ala Thr Ala	Thr Thr Glu Ala Leu Pro	Leu Leu Glu
1520		1525	1530
Asn Leu	Thr Ile Ser Asp	Ile Asn Pro Tyr Gly Phe	Thr Val Ser
1535		1540	1545
Trp Met	Ala Ser Glu Asn	Ala Phe Asp Ser Phe Leu	Val Thr Val
1550		1555	1560
Val Asp	Ser Gly Lys Leu	Leu Asp Pro Gln Glu Phe	Thr Leu Ser
1565		1570	1575
Gly Thr	Gln Arg Lys Leu	Glu Leu Arg Gly Leu Ile	Thr Gly Ile
1580		1585	1590
Gly Tyr	Glu Val Met Val	Ser Gly Phe Thr Gln Gly	His Gln Thr
1595		1600	1605
Lys Pro	Leu Arg Ala Glu	Ile Val Thr Glu Ala Glu	Pro Glu Val
1610		1615	1620
Asp Asn	Leu Leu Val Ser	Asp Ala Thr Pro Asp Gly	Phe Arg Leu
1625		1630	1635
Ser Trp	Thr Ala Asp Glu	Gly Val Phe Asp Asn Phe	Val Leu Lys
1640		1645	1650
Ile Arg	Asp Thr Lys Lys	Gln Ser Glu Pro Leu Glu	Ile Thr Leu
1655		1660	1665
Leu Ala	Pro Glu Arg Thr	Arg Asp Ile Thr Gly Leu	Arg Glu Ala
1670		1675	1680
Thr Glu	Tyr Glu Ile Glu	Leu Tyr Gly Ile Ser Lys	Gly Arg Arg
1685		1690	1695
Ser Gln	Thr Val Ser Ala	Ile Ala Thr Thr Ala Met	Gly Ser Pro
1700		1705	1710
Lys Glu	Val Ile Phe Ser	Asp Ile Thr Glu Asn Ser	Ala Thr Val
1715		1720	1725
Ser Trp	Arg Ala Pro Thr	Ala Gln Val Glu Ser Phe	Arg Ile Thr
1730		1735	1740
Tyr Val	Pro Ile Thr Gly	Gly Thr Pro Ser Met Val	Thr Val Asp
1745		1750	1755
Gly Thr	Lys Thr Gln Thr	Arg Leu Val Lys Leu Ile	Pro Gly Val
1760		1765	1770
Glu Tyr	Leu Val Ser Ile	Ile Ala Met Lys Gly Phe	Glu Glu Ser
1775		1780	1785

-continued

---

Glu	Pro	Val	Ser	Gly	Ser	Phe	Thr	Thr	Ala	Leu	Asp	Gly	Pro	Ser
1790						1795					1800			
Gly	Leu	Val	Thr	Ala	Asn	Ile	Thr	Asp	Ser	Glu	Ala	Leu	Ala	Arg
1805						1810					1815			
Trp	Gln	Pro	Ala	Ile	Ala	Thr	Val	Asp	Ser	Tyr	Val	Ile	Ser	Tyr
1820						1825					1830			
Thr	Gly	Glu	Lys	Val	Pro	Glu	Ile	Thr	Arg	Thr	Val	Ser	Gly	Asn
1835						1840					1845			
Thr	Val	Glu	Tyr	Ala	Leu	Thr	Asp	Leu	Glu	Pro	Ala	Thr	Glu	Tyr
1850						1855					1860			
Thr	Leu	Arg	Ile	Phe	Ala	Glu	Lys	Gly	Pro	Gln	Lys	Ser	Ser	Thr
1865						1870					1875			
Ile	Thr	Ala	Lys	Phe	Thr	Thr	Asp	Leu	Asp	Ser	Pro	Arg	Asp	Leu
1880						1885					1890			
Thr	Ala	Thr	Glu	Val	Gln	Ser	Glu	Thr	Ala	Leu	Leu	Thr	Trp	Arg
1895						1900					1905			
Pro	Pro	Arg	Ala	Ser	Val	Thr	Gly	Tyr	Leu	Leu	Val	Tyr	Glu	Ser
1910						1915					1920			
Val	Asp	Gly	Thr	Val	Lys	Glu	Val	Ile	Val	Gly	Pro	Asp	Thr	Thr
1925						1930					1935			
Ser	Tyr	Ser	Leu	Ala	Asp	Leu	Ser	Pro	Ser	Thr	His	Tyr	Thr	Ala
1940						1945					1950			
Lys	Ile	Gln	Ala	Leu	Asn	Gly	Pro	Leu	Arg	Ser	Asn	Met	Ile	Gln
1955						1960					1965			
Thr	Ile	Phe	Thr	Thr	Ile	Gly	Leu	Leu	Tyr	Pro	Phe	Pro	Lys	Asp
1970						1975					1980			
Cys	Ser	Gln	Ala	Met	Leu	Asn	Gly	Asp	Thr	Thr	Ser	Gly	Leu	Tyr
1985						1990					1995			
Thr	Ile	Tyr	Leu	Asn	Gly	Asp	Lys	Ala	Glu	Ala	Leu	Glu	Val	Phe
2000						2005					2010			
Cys	Asp	Met	Thr	Ser	Asp	Gly	Gly	Gly	Trp	Ile	Val	Phe	Leu	Arg
2015						2020					2025			
Arg	Lys	Asn	Gly	Arg	Glu	Asn	Phe	Tyr	Gln	Asn	Trp	Lys	Ala	Tyr
2030						2035					2040			
Ala	Ala	Gly	Phe	Gly	Asp	Arg	Arg	Glu	Glu	Phe	Trp	Leu	Gly	Leu
2045						2050					2055			
Asp	Asn	Leu	Asn	Lys	Ile	Thr	Ala	Gln	Gly	Gln	Tyr	Glu	Leu	Arg
2060						2065					2070			
Val	Asp	Leu	Arg	Asp	His	Gly	Glu	Thr	Ala	Phe	Ala	Val	Tyr	Asp
2075						2080					2085			
Lys	Phe	Ser	Val	Gly	Asp	Ala	Lys	Thr	Arg	Tyr	Lys	Leu	Lys	Val
2090						2095					2100			
Glu	Gly	Tyr	Ser	Gly	Thr	Ala	Gly	Asp	Ser	Met	Ala	Tyr	His	Asn
2105						2110					2115			
Gly	Arg	Ser	Phe	Ser	Thr	Phe	Asp	Lys	Asp	Thr	Asp	Ser	Ala	Ile
2120						2125					2130			
Thr	Asn	Cys	Ala	Leu	Ser	Tyr	Lys	Gly	Ala	Phe	Trp	Tyr	Arg	Asn
2135						2140					2145			
Cys	His	Arg	Val	Asn	Leu	Met	Gly	Arg	Tyr	Gly	Asp	Asn	Asn	His
2150						2155					2160			
Ser	Gln	Gly	Val	Asn	Trp	Phe	His	Trp	Lys	Gly	His	Glu	His	Ser

-continued

---

```

2165          2170          2175
Ile Gln Phe Ala Glu Met Lys Leu Arg Pro Ser Asn Phe Arg Asn
2180          2185          2190

Leu Glu Gly Arg Arg Lys Arg Ala
2195          2200

<210> SEQ ID NO 21
<211> LENGTH: 478
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

Met Ala Pro Leu Arg Pro Leu Leu Ile Leu Ala Leu Leu Ala Trp Val
1          5          10          15
Ala Leu Ala Asp Gln Glu Ser Cys Lys Gly Arg Cys Thr Glu Gly Phe
20         25         30
Asn Val Asp Lys Lys Cys Gln Cys Asp Glu Leu Cys Ser Tyr Tyr Gln
35         40         45
Ser Cys Cys Thr Asp Tyr Thr Ala Glu Cys Lys Pro Gln Val Thr Arg
50         55         60
Gly Asp Val Phe Thr Met Pro Glu Asp Glu Tyr Thr Val Tyr Asp Asp
65         70         75         80
Gly Glu Glu Lys Asn Asn Ala Thr Val His Glu Gln Val Gly Gly Pro
85         90         95
Ser Leu Thr Ser Asp Leu Gln Ala Gln Ser Lys Gly Asn Pro Glu Gln
100        105        110
Thr Pro Val Leu Lys Pro Glu Glu Glu Ala Pro Ala Pro Glu Val Gly
115        120        125
Ala Ser Lys Pro Glu Gly Ile Asp Ser Arg Pro Glu Thr Leu His Pro
130        135        140
Gly Arg Pro Gln Pro Pro Ala Glu Glu Glu Leu Cys Ser Gly Lys Pro
145        150        155        160
Phe Asp Ala Phe Thr Asp Leu Lys Asn Gly Ser Leu Phe Ala Phe Arg
165        170        175
Gly Gln Tyr Cys Tyr Glu Leu Asp Glu Lys Ala Val Arg Pro Gly Tyr
180        185        190
Pro Lys Leu Ile Arg Asp Val Trp Gly Ile Glu Gly Pro Ile Asp Ala
195        200        205
Ala Phe Thr Arg Ile Asn Cys Gln Gly Lys Thr Tyr Leu Phe Lys Gly
210        215        220
Ser Gln Tyr Trp Arg Phe Glu Asp Gly Val Leu Asp Pro Asp Tyr Pro
225        230        235        240
Arg Asn Ile Ser Asp Gly Phe Asp Gly Ile Pro Asp Asn Val Asp Ala
245        250        255
Ala Leu Ala Leu Pro Ala His Ser Tyr Ser Gly Arg Glu Arg Val Tyr
260        265        270
Phe Phe Lys Gly Lys Gln Tyr Trp Glu Tyr Gln Phe Gln His Gln Pro
275        280        285
Ser Gln Glu Glu Cys Glu Gly Ser Ser Leu Ser Ala Val Phe Glu His
290        295        300
Phe Ala Met Met Gln Arg Asp Ser Trp Glu Asp Ile Phe Glu Leu Leu
305        310        315        320

```

-continued

---

Phe Trp Gly Arg Thr Ser Ala Gly Thr Arg Gln Pro Gln Phe Ile Ser  
 325 330 335  
 Arg Asp Trp His Gly Val Pro Gly Gln Val Asp Ala Ala Met Ala Gly  
 340 345 350  
 Arg Ile Tyr Ile Ser Gly Met Ala Pro Arg Pro Ser Leu Ala Lys Lys  
 355 360 365  
 Gln Arg Phe Arg His Arg Asn Arg Lys Gly Tyr Arg Ser Gln Arg Gly  
 370 375 380  
 His Ser Arg Gly Arg Asn Gln Asn Ser Arg Arg Pro Ser Arg Ala Thr  
 385 390 395 400  
 Trp Leu Ser Leu Phe Ser Ser Glu Glu Ser Asn Leu Gly Ala Asn Asn  
 405 410 415  
 Tyr Asp Asp Tyr Arg Met Asp Trp Leu Val Pro Ala Thr Cys Glu Pro  
 420 425 430  
 Ile Gln Ser Val Phe Phe Phe Ser Gly Asp Lys Tyr Tyr Arg Val Asn  
 435 440 445  
 Leu Arg Thr Arg Arg Val Asp Thr Val Asp Pro Pro Tyr Pro Arg Ser  
 450 455 460  
 Ile Ala Gln Tyr Trp Leu Gly Cys Pro Ala Pro Gly His Leu  
 465 470 475  
  
 <210> SEQ ID NO 22  
 <211> LENGTH: 4289  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
  
 <400> SEQUENCE: 22  
 Met Met Pro Ala Gln Tyr Ala Leu Thr Ser Ser Leu Val Leu Leu Val  
 1 5 10 15  
 Leu Leu Ser Thr Ala Arg Ala Gly Pro Phe Ser Ser Arg Ser Asn Val  
 20 25 30  
 Thr Leu Pro Ala Pro Arg Pro Pro Pro Gln Pro Gly Gly His Thr Val  
 35 40 45  
 Gly Ala Gly Val Gly Ser Pro Ser Ser Gln Leu Tyr Glu His Thr Val  
 50 55 60  
 Glu Gly Gly Glu Lys Gln Val Val Phe Thr His Arg Ile Asn Leu Pro  
 65 70 75 80  
 Pro Ser Thr Gly Cys Gly Cys Pro Pro Gly Thr Glu Pro Pro Val Leu  
 85 90 95  
 Ala Ser Glu Val Gln Ala Leu Arg Val Arg Leu Glu Ile Leu Glu Glu  
 100 105 110  
 Leu Val Lys Gly Leu Lys Glu Gln Cys Thr Gly Gly Cys Cys Pro Ala  
 115 120 125  
 Ser Ala Gln Ala Gly Thr Gly Gln Thr Asp Val Arg Thr Leu Cys Ser  
 130 135 140  
 Leu His Gly Val Phe Asp Leu Ser Arg Cys Thr Cys Ser Cys Glu Pro  
 145 150 155 160  
 Gly Trp Gly Gly Pro Thr Cys Ser Asp Pro Thr Asp Ala Glu Ile Pro  
 165 170 175  
 Pro Ser Ser Pro Pro Ser Ala Ser Gly Ser Cys Pro Asp Asp Cys Asn  
 180 185 190  
 Asp Gln Gly Arg Cys Val Arg Gly Arg Cys Val Cys Phe Pro Gly Tyr  
 195 200 205

-continued

---

Thr Gly Pro Ser Cys Gly Trp Pro Ser Cys Pro Gly Asp Cys Gln Gly  
 210 215 220  
 Arg Gly Arg Cys Val Gln Gly Val Cys Val Cys Arg Ala Gly Phe Ser  
 225 230 235 240  
 Gly Pro Asp Cys Ser Gln Arg Ser Cys Pro Arg Gly Cys Ser Gln Arg  
 245 250 255  
 Gly Arg Cys Glu Gly Gly Arg Cys Val Cys Asp Pro Gly Tyr Thr Gly  
 260 265 270  
 Asp Asp Cys Gly Met Arg Ser Cys Pro Arg Gly Cys Ser Gln Arg Gly  
 275 280 285  
 Arg Cys Glu Asn Gly Arg Cys Val Cys Asn Pro Gly Tyr Thr Gly Glu  
 290 295 300  
 Asp Cys Gly Val Arg Ser Cys Pro Arg Gly Cys Ser Gln Arg Gly Arg  
 305 310 315 320  
 Cys Lys Asp Gly Arg Cys Val Cys Asp Pro Gly Tyr Thr Gly Glu Asp  
 325 330 335  
 Cys Gly Thr Arg Ser Cys Pro Trp Asp Cys Gly Glu Gly Gly Arg Cys  
 340 345 350  
 Val Asp Gly Arg Cys Val Cys Trp Pro Gly Tyr Thr Gly Glu Asp Cys  
 355 360 365  
 Ser Thr Arg Thr Cys Pro Arg Asp Cys Arg Gly Arg Gly Arg Cys Glu  
 370 375 380  
 Asp Gly Glu Cys Ile Cys Asp Thr Gly Tyr Ser Gly Asp Asp Cys Gly  
 385 390 395 400  
 Val Arg Ser Cys Pro Gly Asp Cys Asn Gln Arg Gly Arg Cys Glu Asp  
 405 410 415  
 Gly Arg Cys Val Cys Trp Pro Gly Tyr Thr Gly Thr Asp Cys Gly Ser  
 420 425 430  
 Arg Ala Cys Pro Arg Asp Cys Arg Gly Arg Gly Arg Cys Glu Asn Gly  
 435 440 445  
 Val Cys Val Cys Asn Ala Gly Tyr Ser Gly Glu Asp Cys Gly Val Arg  
 450 455 460  
 Ser Cys Pro Gly Asp Cys Arg Gly Arg Gly Arg Cys Glu Ser Gly Arg  
 465 470 475 480  
 Cys Met Cys Trp Pro Gly Tyr Thr Gly Arg Asp Cys Gly Thr Arg Ala  
 485 490 495  
 Cys Pro Gly Asp Cys Arg Gly Arg Gly Arg Cys Val Asp Gly Arg Cys  
 500 505 510  
 Val Cys Asn Pro Gly Phe Thr Gly Glu Asp Cys Gly Ser Arg Arg Cys  
 515 520 525  
 Pro Gly Asp Cys Arg Gly His Gly Leu Cys Glu Asp Gly Val Cys Val  
 530 535 540  
 Cys Asp Ala Gly Tyr Ser Gly Glu Asp Cys Ser Thr Arg Ser Cys Pro  
 545 550 555 560  
 Gly Gly Cys Arg Gly Arg Gly Gln Cys Leu Asp Gly Arg Cys Val Cys  
 565 570 575  
 Glu Asp Gly Tyr Ser Gly Glu Asp Cys Gly Val Arg Gln Cys Pro Asn  
 580 585 590  
 Asp Cys Ser Gln His Gly Val Cys Gln Asp Gly Val Cys Ile Cys Trp  
 595 600 605

-continued

---

Glu Gly Tyr Val Ser Glu Asp Cys Ser Ile Arg Thr Cys Pro Ser Asn  
 610 615 620  
 Cys His Gly Arg Gly Arg Cys Glu Glu Gly Arg Cys Leu Cys Asp Pro  
 625 630 635 640  
 Gly Tyr Thr Gly Pro Thr Cys Ala Thr Arg Met Cys Pro Ala Asp Cys  
 645 650 655  
 Arg Gly Arg Gly Arg Cys Val Gln Gly Val Cys Leu Cys His Val Gly  
 660 665 670  
 Tyr Gly Gly Glu Asp Cys Gly Gln Glu Glu Pro Pro Ala Ser Ala Cys  
 675 680 685  
 Pro Gly Gly Cys Gly Pro Arg Glu Leu Cys Arg Ala Gly Gln Cys Val  
 690 695 700  
 Cys Val Glu Gly Phe Arg Gly Pro Asp Cys Ala Ile Gln Thr Cys Pro  
 705 710 715 720  
 Gly Asp Cys Arg Gly Arg Gly Glu Cys His Asp Gly Ser Cys Val Cys  
 725 730 735  
 Lys Asp Gly Tyr Ala Gly Glu Asp Cys Gly Glu Ala Arg Val Pro Ser  
 740 745 750  
 Ser Ala Ser Ala Tyr Asp Gln Arg Gly Leu Ala Pro Gly Gln Glu Tyr  
 755 760 765  
 Gln Val Thr Val Arg Ala Leu Arg Gly Thr Ser Trp Gly Leu Pro Ala  
 770 775 780  
 Ser Lys Thr Ile Thr Thr Met Ile Asp Gly Pro Gln Asp Leu Arg Val  
 785 790 795 800  
 Val Ala Val Thr Pro Thr Thr Leu Glu Leu Gly Trp Leu Arg Pro Gln  
 805 810 815  
 Ala Glu Val Asp Arg Phe Val Val Ser Tyr Val Ser Ala Gly Asn Gln  
 820 825 830  
 Arg Val Arg Leu Glu Val Pro Pro Glu Ala Asp Gly Thr Leu Leu Thr  
 835 840 845  
 Asp Leu Met Pro Gly Val Glu Tyr Val Val Thr Val Thr Ala Glu Arg  
 850 855 860  
 Gly Arg Ala Val Ser Tyr Pro Ala Ser Val Arg Ala Asn Thr Glu Glu  
 865 870 875 880  
 Arg Glu Glu Glu Ser Pro Pro Arg Pro Ser Leu Ser Gln Pro Pro Arg  
 885 890 895  
 Arg Pro Trp Gly Asn Leu Thr Ala Glu Leu Ser Arg Phe Arg Gly Thr  
 900 905 910  
 Val Gln Asp Leu Glu Arg His Leu Arg Ala His Gly Tyr Pro Leu Arg  
 915 920 925  
 Ala Asn Gln Thr Tyr Thr Ser Val Ala Arg His Ile His Glu Tyr Leu  
 930 935 940  
 Gln Arg Gln Val Leu Gly Ser Ser Ala Asp Gly Ala Leu Leu Val Ser  
 945 950 955 960  
 Leu Asp Gly Leu Arg Gly Gln Phe Glu Arg Val Val Leu Arg Trp Arg  
 965 970 975  
 Pro Gln Pro Pro Ala Glu Gly Pro Gly Gly Glu Leu Thr Val Pro Gly  
 980 985 990  
 Thr Thr Arg Thr Val Ser Leu Pro Asp Leu Arg Pro Gly Thr Thr Tyr  
 995 1000 1005  
 His Val Glu Val His Gly Val Arg Ala Gly Gln Thr Ser Lys Ser

-continued

---

1010	1015	1020
Tyr Ala Phe Ile Thr Thr Thr Gly Pro Ser Thr Thr Gln Gly Ala		
1025	1030	1035
Gln Ala Pro Leu Leu Gln Gln Arg Pro Gln Glu Leu Gly Glu Leu		
1040	1045	1050
Arg Val Leu Gly Arg Asp Glu Thr Gly Arg Leu Arg Val Val Trp		
1055	1060	1065
Thr Ala Gln Pro Asp Thr Phe Ala Tyr Phe Gln Leu Arg Met Arg		
1070	1075	1080
Val Pro Glu Gly Pro Gly Ala His Glu Glu Val Leu Pro Gly Asp		
1085	1090	1095
Val Arg Gln Ala Leu Val Pro Pro Pro Pro Pro Gly Thr Pro Tyr		
1100	1105	1110
Glu Leu Ser Leu His Gly Val Pro Pro Gly Gly Lys Pro Ser Asp		
1115	1120	1125
Pro Ile Ile Tyr Gln Gly Ile Met Asp Lys Asp Glu Glu Lys Pro		
1130	1135	1140
Gly Lys Ser Ser Gly Pro Pro Arg Leu Gly Glu Leu Thr Val Thr		
1145	1150	1155
Asp Arg Thr Ser Asp Ser Leu Leu Leu Arg Trp Thr Val Pro Glu		
1160	1165	1170
Gly Glu Phe Asp Ser Phe Val Ile Gln Tyr Lys Asp Arg Asp Gly		
1175	1180	1185
Gln Pro Gln Val Val Pro Val Glu Gly Pro Gln Arg Ser Ala Val		
1190	1195	1200
Ile Thr Ser Leu Asp Pro Gly Arg Lys Tyr Lys Phe Val Leu Tyr		
1205	1210	1215
Gly Phe Val Gly Lys Lys Arg His Gly Pro Leu Val Ala Glu Ala		
1220	1225	1230
Lys Ile Leu Pro Gln Ser Asp Pro Ser Pro Gly Thr Pro Pro His		
1235	1240	1245
Leu Gly Asn Leu Trp Val Thr Asp Pro Thr Pro Asp Ser Leu His		
1250	1255	1260
Leu Ser Trp Thr Val Pro Glu Gly Gln Phe Asp Thr Phe Met Val		
1265	1270	1275
Gln Tyr Arg Asp Arg Asp Gly Arg Pro Gln Val Val Pro Val Glu		
1280	1285	1290
Gly Pro Glu Arg Ser Phe Val Val Ser Ser Leu Asp Pro Asp His		
1295	1300	1305
Lys Tyr Arg Phe Thr Leu Phe Gly Ile Ala Asn Lys Lys Arg Tyr		
1310	1315	1320
Gly Pro Leu Thr Ala Asp Gly Thr Thr Ala Pro Glu Arg Lys Glu		
1325	1330	1335
Glu Pro Pro Arg Pro Glu Phe Leu Glu Gln Pro Leu Leu Gly Glu		
1340	1345	1350
Leu Thr Val Thr Gly Val Thr Pro Asp Ser Leu Arg Leu Ser Trp		
1355	1360	1365
Thr Val Ala Gln Gly Pro Phe Asp Ser Phe Met Val Gln Tyr Lys		
1370	1375	1380
Asp Ala Gln Gly Gln Pro Gln Ala Val Pro Val Ala Gly Asp Glu		
1385	1390	1395

-continued

---

Asn	Glu	Val	Thr	Val	Pro	Gly	Leu	Asp	Pro	Asp	Arg	Lys	Tyr	Lys
1400						1405					1410			
Met	Asn	Leu	Tyr	Gly	Leu	Arg	Gly	Arg	Gln	Arg	Val	Gly	Pro	Glu
1415						1420					1425			
Ser	Val	Val	Ala	Lys	Thr	Ala	Pro	Gln	Glu	Asp	Val	Asp	Glu	Thr
1430						1435					1440			
Pro	Ser	Pro	Thr	Glu	Leu	Gly	Thr	Glu	Ala	Pro	Glu	Ser	Pro	Glu
1445						1450					1455			
Glu	Pro	Leu	Leu	Gly	Glu	Leu	Thr	Val	Thr	Gly	Ser	Ser	Pro	Asp
1460						1465					1470			
Ser	Leu	Ser	Leu	Phe	Trp	Thr	Val	Pro	Gln	Gly	Ser	Phe	Asp	Ser
1475						1480					1485			
Phe	Thr	Val	Gln	Tyr	Lys	Asp	Arg	Asp	Gly	Arg	Pro	Arg	Ala	Val
1490						1495					1500			
Arg	Val	Gly	Gly	Lys	Glu	Ser	Glu	Val	Thr	Val	Gly	Gly	Leu	Glu
1505						1510					1515			
Pro	Gly	His	Lys	Tyr	Lys	Met	His	Leu	Tyr	Gly	Leu	His	Glu	Gly
1520						1525					1530			
Gln	Arg	Val	Gly	Pro	Val	Ser	Ala	Val	Gly	Val	Thr	Ala	Pro	Gln
1535						1540					1545			
Gln	Glu	Glu	Thr	Pro	Pro	Ala	Thr	Glu	Ser	Pro	Leu	Glu	Pro	Arg
1550						1555					1560			
Leu	Gly	Glu	Leu	Thr	Val	Thr	Asp	Val	Thr	Pro	Asn	Ser	Val	Gly
1565						1570					1575			
Leu	Ser	Trp	Thr	Val	Pro	Glu	Gly	Gln	Phe	Asp	Ser	Phe	Ile	Val
1580						1585					1590			
Gln	Tyr	Lys	Asp	Lys	Asp	Gly	Gln	Pro	Gln	Val	Val	Pro	Val	Ala
1595						1600					1605			
Ala	Asp	Gln	Arg	Glu	Val	Thr	Val	Tyr	Asn	Leu	Glu	Pro	Glu	Arg
1610						1615					1620			
Lys	Tyr	Lys	Met	Asn	Met	Tyr	Gly	Leu	His	Asp	Gly	Gln	Arg	Met
1625						1630					1635			
Gly	Pro	Leu	Ser	Val	Val	Ile	Val	Thr	Ala	Pro	Ala	Thr	Glu	Ala
1640						1645					1650			
Ser	Lys	Pro	Pro	Leu	Glu	Pro	Arg	Leu	Gly	Glu	Leu	Thr	Val	Thr
1655						1660					1665			
Asp	Ile	Thr	Pro	Asp	Ser	Val	Gly	Leu	Ser	Trp	Thr	Val	Pro	Glu
1670						1675					1680			
Gly	Glu	Phe	Asp	Ser	Phe	Val	Val	Gln	Tyr	Lys	Asp	Arg	Asp	Gly
1685						1690					1695			
Gln	Pro	Gln	Val	Val	Pro	Val	Ala	Ala	Asp	Gln	Arg	Glu	Val	Thr
1700						1705					1710			
Ile	Pro	Asp	Leu	Glu	Pro	Ser	Arg	Lys	Tyr	Lys	Phe	Leu	Leu	Phe
1715						1720					1725			
Gly	Ile	Gln	Asp	Gly	Lys	Arg	Arg	Ser	Pro	Val	Ser	Val	Glu	Ala
1730						1735					1740			
Lys	Thr	Val	Ala	Arg	Gly	Asp	Ala	Ser	Pro	Gly	Ala	Pro	Pro	Arg
1745						1750					1755			
Leu	Gly	Glu	Leu	Trp	Val	Thr	Asp	Pro	Thr	Pro	Asp	Ser	Leu	Arg
1760						1765					1770			

-continued

---

Leu	Ser	Trp	Thr	Val	Pro	Glu	Gly	Gln	Phe	Asp	Ser	Phe	Val	Val
1775						1780					1785			
Gln	Phe	Lys	Asp	Lys	Asp	Gly	Pro	Gln	Val	Val	Pro	Val	Glu	Gly
1790						1795					1800			
His	Glu	Arg	Ser	Val	Thr	Val	Thr	Pro	Leu	Asp	Ala	Gly	Arg	Lys
1805						1810					1815			
Tyr	Arg	Phe	Leu	Leu	Tyr	Gly	Leu	Leu	Gly	Lys	Lys	Arg	His	Gly
1820						1825					1830			
Pro	Leu	Thr	Ala	Asp	Gly	Thr	Thr	Glu	Ala	Arg	Ser	Ala	Met	Asp
1835						1840					1845			
Asp	Thr	Gly	Thr	Lys	Arg	Pro	Pro	Lys	Pro	Arg	Leu	Gly	Glu	Glu
1850						1855					1860			
Leu	Gln	Val	Thr	Thr	Val	Thr	Gln	Asn	Ser	Val	Gly	Leu	Ser	Trp
1865						1870					1875			
Thr	Val	Pro	Glu	Gly	Gln	Phe	Asp	Ser	Phe	Val	Val	Gln	Tyr	Lys
1880						1885					1890			
Asp	Arg	Asp	Gly	Gln	Pro	Gln	Val	Val	Pro	Val	Glu	Gly	Ser	Leu
1895						1900					1905			
Arg	Glu	Val	Ser	Val	Pro	Gly	Leu	Asp	Pro	Ala	His	Arg	Tyr	Lys
1910						1915					1920			
Leu	Leu	Leu	Tyr	Gly	Leu	His	His	Gly	Lys	Arg	Val	Gly	Pro	Ile
1925						1930					1935			
Ser	Ala	Val	Ala	Ile	Thr	Ala	Gly	Arg	Glu	Glu	Thr	Glu	Thr	Glu
1940						1945					1950			
Thr	Thr	Ala	Pro	Thr	Pro	Pro	Ala	Pro	Glu	Pro	His	Leu	Gly	Glu
1955						1960					1965			
Leu	Thr	Val	Glu	Glu	Ala	Thr	Ser	His	Thr	Leu	His	Leu	Ser	Trp
1970						1975					1980			
Met	Val	Thr	Glu	Gly	Glu	Phe	Asp	Ser	Phe	Glu	Ile	Gln	Tyr	Thr
1985						1990					1995			
Asp	Arg	Asp	Gly	Gln	Leu	Gln	Met	Val	Arg	Ile	Gly	Gly	Asp	Arg
2000						2005					2010			
Asn	Asp	Ile	Thr	Leu	Ser	Gly	Leu	Glu	Ser	Asp	His	Arg	Tyr	Leu
2015						2020					2025			
Val	Thr	Leu	Tyr	Gly	Phe	Ser	Asp	Gly	Lys	His	Val	Gly	Pro	Val
2030						2035					2040			
His	Val	Glu	Ala	Leu	Thr	Val	Pro	Glu	Glu	Glu	Lys	Pro	Ser	Glu
2045						2050					2055			
Pro	Pro	Thr	Ala	Thr	Pro	Glu	Pro	Pro	Ile	Lys	Pro	Arg	Leu	Gly
2060						2065					2070			
Glu	Leu	Thr	Val	Thr	Asp	Ala	Thr	Pro	Asp	Ser	Leu	Ser	Leu	Ser
2075						2080					2085			
Trp	Thr	Val	Pro	Glu	Gly	Gln	Phe	Asp	His	Phe	Leu	Val	Gln	Tyr
2090						2095					2100			
Arg	Asn	Gly	Asp	Gly	Gln	Pro	Lys	Ala	Val	Arg	Val	Pro	Gly	His
2105						2110					2115			
Glu	Glu	Gly	Val	Thr	Ile	Ser	Gly	Leu	Glu	Pro	Asp	His	Lys	Tyr
2120						2125					2130			
Lys	Met	Asn	Leu	Tyr	Gly	Phe	His	Gly	Gly	Gln	Arg	Met	Gly	Pro
2135						2140					2145			
Val	Ser	Val	Val	Gly	Val	Thr	Glu	Pro	Ser	Met	Glu	Ala	Pro	Glu

-continued

---

2150	2155	2160
Pro Ala Glu Glu Pro Leu	Leu Gly Glu Leu Thr Val	Thr Gly Ser
2165	2170	2175
Ser Pro Asp Ser Leu Ser	Leu Ser Trp Thr Val Pro	Gln Gly Arg
2180	2185	2190
Phe Asp Ser Phe Thr Val	Gln Tyr Lys Asp Arg Asp	Gly Arg Pro
2195	2200	2205
Gln Val Val Arg Val Gly	Gly Glu Glu Ser Glu Val	Thr Val Gly
2210	2215	2220
Gly Leu Glu Pro Gly Arg	Lys Tyr Lys Met His Leu	Tyr Gly Leu
2225	2230	2235
His Glu Gly Arg Arg Val	Gly Pro Val Ser Ala Val	Gly Val Thr
2240	2245	2250
Ala Pro Glu Glu Glu Ser	Pro Asp Ala Pro Leu Ala	Lys Leu Arg
2255	2260	2265
Leu Gly Gln Met Thr Val	Arg Asp Ile Thr Ser Asp	Ser Leu Ser
2270	2275	2280
Leu Ser Trp Thr Val Pro	Glu Gly Gln Phe Asp His	Phe Leu Val
2285	2290	2295
Gln Phe Lys Asn Gly Asp	Gly Gln Pro Lys Ala Val	Arg Val Pro
2300	2305	2310
Gly His Glu Asp Gly Val	Thr Ile Ser Gly Leu Glu	Pro Asp His
2315	2320	2325
Lys Tyr Lys Met Asn Leu	Tyr Gly Phe His Gly Gly	Gln Arg Val
2330	2335	2340
Gly Pro Val Ser Ala Val	Gly Leu Thr Ala Ser Thr	Glu Pro Pro
2345	2350	2355
Thr Pro Glu Pro Pro Ile	Lys Pro Arg Leu Glu Glu	Leu Thr Val
2360	2365	2370
Thr Asp Ala Thr Pro Asp	Ser Leu Ser Leu Ser Trp	Thr Val Pro
2375	2380	2385
Glu Gly Gln Phe Asp His	Phe Leu Val Gln Tyr Lys	Asn Gly Asp
2390	2395	2400
Gly Gln Pro Lys Ala Thr	Arg Val Pro Gly His Glu	Asp Arg Val
2405	2410	2415
Thr Ile Ser Gly Leu Glu	Pro Asp Asn Lys Tyr Lys	Met Asn Leu
2420	2425	2430
Tyr Gly Phe His Gly Gly	Gln Arg Val Gly Pro Val	Ser Ala Ile
2435	2440	2445
Gly Val Thr Glu Glu Glu	Thr Pro Ser Pro Thr Glu	Pro Ser Met
2450	2455	2460
Glu Ala Pro Glu Pro Pro	Glu Glu Pro Leu Leu Gly	Glu Leu Thr
2465	2470	2475
Val Thr Gly Ser Ser Pro	Asp Ser Leu Ser Leu Ser	Trp Thr Val
2480	2485	2490
Pro Gln Gly Arg Phe Asp	Ser Phe Thr Val Gln Tyr	Lys Asp Arg
2495	2500	2505
Asp Gly Arg Pro Gln Val	Val Arg Val Gly Gly Glu	Glu Ser Glu
2510	2515	2520
Val Thr Val Gly Gly Leu	Glu Pro Gly Arg Lys Tyr	Lys Met His
2525	2530	2535

-continued

---

Leu	Tyr	Gly	Leu	His	Glu	Gly	Arg	Arg	Val	Gly	Pro	Val	Ser	Thr
2540						2545					2550			
Val	Gly	Val	Thr	Ala	Pro	Gln	Glu	Asp	Val	Asp	Glu	Thr	Pro	Ser
2555						2560					2565			
Pro	Thr	Glu	Pro	Gly	Thr	Glu	Ala	Pro	Gly	Pro	Pro	Glu	Glu	Pro
2570						2575					2580			
Leu	Leu	Gly	Glu	Leu	Thr	Val	Thr	Gly	Ser	Ser	Pro	Asp	Ser	Leu
2585						2590					2595			
Ser	Leu	Ser	Trp	Thr	Val	Pro	Gln	Gly	Arg	Phe	Asp	Ser	Phe	Thr
2600						2605					2610			
Val	Gln	Tyr	Lys	Asp	Arg	Asp	Gly	Arg	Pro	Gln	Ala	Val	Arg	Val
2615						2620					2625			
Gly	Gly	Gln	Glu	Ser	Lys	Val	Thr	Val	Arg	Gly	Leu	Glu	Pro	Gly
2630						2635					2640			
Arg	Lys	Tyr	Lys	Met	His	Leu	Tyr	Gly	Leu	His	Glu	Gly	Arg	Arg
2645						2650					2655			
Leu	Gly	Pro	Val	Ser	Ala	Val	Gly	Val	Thr	Glu	Asp	Glu	Ala	Glu
2660						2665					2670			
Thr	Thr	Gln	Ala	Val	Pro	Thr	Met	Thr	Pro	Glu	Pro	Pro	Ile	Lys
2675						2680					2685			
Pro	Arg	Leu	Gly	Glu	Leu	Thr	Met	Thr	Asp	Ala	Thr	Pro	Asp	Ser
2690						2695					2700			
Leu	Ser	Leu	Ser	Trp	Thr	Val	Pro	Glu	Gly	Gln	Phe	Asp	His	Phe
2705						2710					2715			
Leu	Val	Gln	Tyr	Arg	Asn	Gly	Asp	Gly	Gln	Pro	Lys	Ala	Val	Arg
2720						2725					2730			
Val	Pro	Gly	His	Glu	Asp	Gly	Val	Thr	Ile	Ser	Gly	Leu	Glu	Pro
2735						2740					2745			
Asp	His	Lys	Tyr	Lys	Met	Asn	Leu	Tyr	Gly	Phe	His	Gly	Gly	Gln
2750						2755					2760			
Arg	Val	Gly	Pro	Ile	Ser	Val	Ile	Gly	Val	Thr	Glu	Glu	Glu	Thr
2765						2770					2775			
Pro	Ser	Pro	Thr	Glu	Leu	Ser	Thr	Glu	Ala	Pro	Glu	Pro	Pro	Glu
2780						2785					2790			
Glu	Pro	Leu	Leu	Gly	Glu	Leu	Thr	Val	Thr	Gly	Ser	Ser	Pro	Asp
2795						2800					2805			
Ser	Leu	Ser	Leu	Ser	Trp	Thr	Ile	Pro	Gln	Gly	His	Phe	Asp	Ser
2810						2815					2820			
Phe	Thr	Val	Gln	Tyr	Lys	Asp	Arg	Asp	Gly	Arg	Pro	Gln	Val	Met
2825						2830					2835			
Arg	Val	Arg	Gly	Glu	Glu	Ser	Glu	Val	Thr	Val	Gly	Gly	Leu	Glu
2840						2845					2850			
Pro	Gly	Arg	Lys	Tyr	Lys	Met	His	Leu	Tyr	Gly	Leu	His	Glu	Gly
2855						2860					2865			
Arg	Arg	Val	Gly	Pro	Val	Ser	Thr	Val	Gly	Val	Thr	Val	Pro	Thr
2870						2875					2880			
Thr	Thr	Pro	Glu	Pro	Pro	Asn	Lys	Pro	Arg	Leu	Gly	Glu	Leu	Thr
2885						2890					2895			
Val	Thr	Asp	Ala	Thr	Pro	Asp	Ser	Leu	Ser	Leu	Ser	Trp	Met	Val
2900						2905					2910			

-continued

Pro 2915	Glu	Gly	Gln	Phe	Asp	His 2920	Phe	Leu	Val	Gln	Tyr 2925	Arg	Asn	Gly
Asp 2930	Gly	Gln	Pro	Lys	Val	Val 2935	Arg	Val	Pro	Gly	His 2940	Glu	Asp	Gly
Val 2945	Thr	Ile	Ser	Gly	Leu	Glu 2950	Pro	Asp	His	Lys	Tyr 2955	Lys	Met	Asn
Leu 2960	Tyr	Gly	Phe	His	Gly	Gly 2965	Gln	Arg	Val	Gly	Pro 2970	Ile	Ser	Val
Ile 2975	Gly	Val	Thr	Glu	Glu	Glu 2980	Thr	Pro	Ala	Pro	Thr 2985	Glu	Pro	Ser
Thr 2990	Glu	Ala	Pro	Glu	Pro	Pro 2995	Glu	Glu	Pro	Leu	Leu 3000	Gly	Glu	Leu
Thr 3005	Val	Thr	Gly	Ser	Ser	Pro 3010	Asp	Ser	Leu	Ser	Leu 3015	Ser	Trp	Thr
Ile 3020	Pro	Gln	Gly	Arg	Phe	Asp 3025	Ser	Phe	Thr	Val	Gln 3030	Tyr	Lys	Asp
Arg 3035	Asp	Gly	Arg	Pro	Gln	Val 3040	Val	Arg	Val	Arg	Gly 3045	Glu	Glu	Ser
Glu 3050	Val	Thr	Val	Gly	Gly	Leu 3055	Glu	Pro	Gly	Cys	Lys 3060	Tyr	Lys	Met
His 3065	Leu	Tyr	Gly	Leu	His	Glu 3070	Gly	Gln	Arg	Val	Gly 3075	Pro	Val	Ser
Ala 3080	Val	Gly	Val	Thr	Ala	Pro 3085	Lys	Asp	Glu	Ala	Glu 3090	Thr	Thr	Gln
Ala 3095	Val	Pro	Thr	Met	Thr	Pro 3100	Glu	Pro	Pro	Ile	Lys 3105	Pro	Arg	Leu
Gly 3110	Glu	Leu	Thr	Val	Thr	Asp 3115	Ala	Thr	Pro	Asp	Ser 3120	Leu	Ser	Leu
Ser 3125	Trp	Met	Val	Pro	Glu	Gly 3130	Gln	Phe	Asp	His	Phe 3135	Leu	Val	Gln
Tyr 3140	Arg	Asn	Gly	Asp	Gly	Gln 3145	Pro	Lys	Ala	Val	Arg 3150	Val	Pro	Gly
His 3155	Glu	Asp	Gly	Val	Thr	Ile 3160	Ser	Gly	Leu	Glu	Pro 3165	Asp	His	Lys
Tyr 3170	Lys	Met	Asn	Leu	Tyr	Gly 3175	Phe	His	Gly	Gly	Gln 3180	Arg	Val	Gly
Pro 3185	Val	Ser	Ala	Ile	Gly	Val 3190	Thr	Glu	Glu	Glu	Thr 3195	Pro	Ser	Pro
Thr 3200	Glu	Pro	Ser	Thr	Glu	Ala 3205	Pro	Glu	Ala	Pro	Glu 3210	Glu	Pro	Leu
Leu 3215	Gly	Glu	Leu	Thr	Val	Thr 3220	Gly	Ser	Ser	Pro	Asp 3225	Ser	Leu	Ser
Leu 3230	Ser	Trp	Thr	Val	Pro	Gln 3235	Gly	Arg	Phe	Asp	Ser 3240	Phe	Thr	Val
Gln 3245	Tyr	Lys	Asp	Arg	Asp	Gly 3250	Gln	Pro	Gln	Val	Val 3255	Arg	Val	Arg
Gly 3260	Glu	Glu	Ser	Glu	Val	Thr 3265	Val	Gly	Gly	Leu	Glu 3270	Pro	Gly	Arg
Lys 3275	Tyr	Lys	Met	His	Leu	Tyr 3280	Gly	Leu	His	Glu	Gly 3285	Gln	Arg	Val
Gly 3290	Pro	Val	Ser	Thr	Val	Gly 3295	Ile	Thr	Ala	Pro	Leu 3300	Pro	Thr	Pro

-continued

---

3290	3295	3300
Leu Pro Val Glu Pro Arg 3305	Leu Gly Glu Leu Ala Val 3310	Ala Ala Val 3315
Thr Ser Asp Ser Val Gly 3320	Leu Ser Trp Thr Val Ala 3325	Gln Gly Pro 3330
Phe Asp Ser Phe Leu Val 3335	Gln Tyr Arg Asp Ala Gln 3340	Gly Gln Pro 3345
Gln Ala Val Pro Val Ser 3350	Gly Asp Leu Arg Ala Val 3355	Ala Val Ser 3360
Gly Leu Asp Pro Ala Arg 3365	Lys Tyr Lys Phe Leu Leu 3370	Phe Gly Leu 3375
Gln Asn Gly Lys Arg His 3380	Gly Pro Val Pro Val Glu 3385	Ala Arg Thr 3390
Ala Pro Asp Thr Lys Pro 3395	Ser Pro Arg Leu Gly Glu 3400	Leu Thr Val 3405
Thr Asp Ala Thr Pro Asp 3410	Ser Val Gly Leu Ser Trp 3415	Thr Val Pro 3420
Glu Gly Glu Phe Asp Ser 3425	Phe Val Val Gln Tyr Lys 3430	Asp Lys Asp 3435
Gly Arg Leu Gln Val Val 3440	Pro Val Ala Ala Asn Gln 3445	Arg Glu Val 3450
Thr Val Gln Gly Leu Glu 3455	Pro Ser Arg Lys Tyr Arg 3460	Phe Leu Leu 3465
Tyr Gly Leu Ser Gly Arg 3470	Lys Arg Leu Gly Pro Ile 3475	Ser Ala Asp 3480
Ser Thr Thr Ala Pro Leu 3485	Glu Lys Glu Leu Pro Pro 3490	His Leu Gly 3495
Glu Leu Thr Val Ala Glu 3500	Glu Thr Ser Ser Ser Leu 3505	Arg Leu Ser 3510
Trp Thr Val Ala Gln Gly 3515	Pro Phe Asp Ser Phe Val 3520	Val Gln Tyr 3525
Arg Asp Thr Asp Gly Gln 3530	Pro Arg Ala Val Pro Val 3535	Ala Ala Asp 3540
Gln Arg Thr Val Thr Val 3545	Glu Asp Leu Glu Pro Gly 3550	Lys Lys Tyr 3555
Lys Phe Leu Leu Tyr Gly 3560	Leu Leu Gly Gly Lys Arg 3565	Leu Gly Pro 3570
Val Ser Ala Leu Gly Met 3575	Thr Ala Pro Glu Glu Asp 3580	Thr Pro Ala 3585
Pro Glu Leu Ala Pro Glu 3590	Ala Pro Glu Pro Pro Glu 3595	Glu Pro Arg 3600
Leu Gly Val Leu Thr Val 3605	Thr Asp Thr Thr Pro Asp 3610	Ser Met Arg 3615
Leu Ser Trp Ser Val Ala 3620	Gln Gly Pro Phe Asp Ser 3625	Phe Val Val 3630
Gln Tyr Glu Asp Thr Asn 3635	Gly Gln Pro Gln Ala Leu 3640	Leu Val Asp 3645
Gly Asp Gln Ser Lys Ile 3650	Leu Ile Ser Gly Leu Glu 3655	Pro Ser Thr 3660
Pro Tyr Arg Phe Leu Leu 3665	Tyr Gly Leu His Glu Gly 3670	Lys Arg Leu 3675

-continued

---

Gly 3680	Pro	Leu	Ser	Ala	Glu	Gly 3685	Thr	Thr	Gly	Leu	Ala 3690	Pro	Ala	Gly
Gln 3695	Thr	Ser	Glu	Glu	Ser	Arg 3700	Pro	Arg	Leu	Ser	Gln 3705	Leu	Ser	Val
Thr 3710	Asp	Val	Thr	Thr	Ser	Ser 3715	Leu	Arg	Leu	Asn	Trp 3720	Glu	Ala	Pro
Pro 3725	Gly	Ala	Phe	Asp	Ser	Phe 3730	Leu	Leu	Arg	Phe	Gly 3735	Val	Pro	Ser
Pro 3740	Ser	Thr	Leu	Glu	Pro	His 3745	Pro	Arg	Pro	Leu	Leu 3750	Gln	Arg	Glu
Leu 3755	Met	Val	Pro	Gly	Thr	Arg 3760	His	Ser	Ala	Val	Leu 3765	Arg	Asp	Leu
Arg 3770	Ser	Gly	Thr	Leu	Tyr	Ser 3775	Leu	Thr	Leu	Tyr	Gly 3780	Leu	Arg	Gly
Pro 3785	His	Lys	Ala	Asp	Ser	Ile 3790	Gln	Gly	Thr	Ala	Arg 3795	Thr	Leu	Ser
Pro 3800	Val	Leu	Glu	Ser	Pro	Arg 3805	Asp	Leu	Gln	Phe	Ser 3810	Glu	Ile	Arg
Glu 3815	Thr	Ser	Ala	Lys	Val	Asn 3820	Trp	Met	Pro	Pro	Pro 3825	Ser	Arg	Ala
Asp 3830	Ser	Phe	Lys	Val	Ser	Tyr 3835	Gln	Leu	Ala	Asp	Gly 3840	Gly	Glu	Pro
Gln 3845	Ser	Val	Gln	Val	Asp	Gly 3850	Gln	Ala	Arg	Thr	Gln 3855	Lys	Leu	Gln
Gly 3860	Leu	Ile	Pro	Gly	Ala	Arg 3865	Tyr	Glu	Val	Thr	Val 3870	Val	Ser	Val
Arg 3875	Gly	Phe	Glu	Glu	Ser	Glu 3880	Pro	Leu	Thr	Gly	Phe 3885	Leu	Thr	Thr
Val 3890	Pro	Asp	Gly	Pro	Thr	Gln 3895	Leu	Arg	Ala	Leu	Asn 3900	Leu	Thr	Glu
Gly 3905	Phe	Ala	Val	Leu	His	Trp 3910	Lys	Pro	Pro	Gln	Asn 3915	Pro	Val	Asp
Thr 3920	Tyr	Asp	Val	Gln	Val	Thr 3925	Ala	Pro	Gly	Ala	Pro 3930	Pro	Leu	Gln
Ala 3935	Glu	Thr	Pro	Gly	Ser	Ala 3940	Val	Asp	Tyr	Pro	Leu 3945	His	Asp	Leu
Val 3950	Leu	His	Thr	Asn	Tyr	Thr 3955	Ala	Thr	Val	Arg	Gly 3960	Leu	Arg	Gly
Pro 3965	Asn	Leu	Thr	Ser	Pro	Ala 3970	Ser	Ile	Thr	Phe	Thr 3975	Thr	Gly	Leu
Glu 3980	Ala	Pro	Arg	Asp	Leu	Glu 3985	Ala	Lys	Glu	Val	Thr 3990	Pro	Arg	Thr
Ala 3995	Leu	Leu	Thr	Trp	Thr	Glu 4000	Pro	Pro	Val	Arg	Pro 4005	Ala	Gly	Tyr
Leu 4010	Leu	Ser	Phe	His	Thr	Pro 4015	Gly	Gly	Gln	Asn	Gln 4020	Glu	Ile	Leu
Leu 4025	Pro	Gly	Gly	Ile	Thr	Ser 4030	His	Gln	Leu	Leu	Gly 4035	Leu	Phe	Pro
Ser 4040	Thr	Ser	Tyr	Asn	Ala	Arg 4045	Leu	Gln	Ala	Met	Trp 4050	Gly	Gln	Ser

-continued

---

Leu Leu Pro Pro Val Ser Thr Ser Phe Thr Thr Gly Gly Leu Arg  
 4055 4060 4065

Ile Pro Phe Pro Arg Asp Cys Gly Glu Glu Met Gln Asn Gly Ala  
 4070 4075 4080

Gly Ala Ser Arg Thr Ser Thr Ile Phe Leu Asn Gly Asn Arg Glu  
 4085 4090 4095

Arg Pro Leu Asn Val Phe Cys Asp Met Glu Thr Asp Gly Gly Gly  
 4100 4105 4110

Trp Leu Val Phe Gln Arg Arg Met Asp Gly Gln Thr Asp Phe Trp  
 4115 4120 4125

Arg Asp Trp Glu Asp Tyr Ala His Gly Phe Gly Asn Ile Ser Gly  
 4130 4135 4140

Glu Phe Trp Leu Gly Asn Glu Ala Leu His Ser Leu Thr Gln Ala  
 4145 4150 4155

Gly Asp Tyr Ser Met Arg Val Asp Leu Arg Ala Gly Asp Glu Ala  
 4160 4165 4170

Val Phe Ala Gln Tyr Asp Ser Phe His Val Asp Ser Ala Ala Glu  
 4175 4180 4185

Tyr Tyr Arg Leu His Leu Glu Gly Tyr His Gly Thr Ala Gly Asp  
 4190 4195 4200

Ser Met Ser Tyr His Ser Gly Ser Val Phe Ser Ala Arg Asp Arg  
 4205 4210 4215

Asp Pro Asn Ser Leu Leu Ile Ser Cys Ala Val Ser Tyr Arg Gly  
 4220 4225 4230

Ala Trp Trp Tyr Arg Asn Cys His Tyr Ala Asn Leu Asn Gly Leu  
 4235 4240 4245

Tyr Gly Ser Thr Val Asp His Gln Gly Val Ser Trp Tyr His Trp  
 4250 4255 4260

Lys Gly Phe Glu Phe Ser Val Pro Phe Thr Glu Met Lys Leu Arg  
 4265 4270 4275

Pro Arg Asn Phe Arg Ser Pro Ala Gly Gly Gly  
 4280 4285

<210> SEQ ID NO 23  
 <211> LENGTH: 1712  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 23

Met Gly Arg Asp Gln Arg Ala Val Ala Gly Pro Ala Leu Arg Arg Trp  
 1 5 10 15

Leu Leu Leu Gly Thr Val Thr Val Gly Phe Leu Ala Gln Ser Val Leu  
 20 25 30

Ala Gly Val Lys Lys Phe Asp Val Pro Cys Gly Gly Arg Asp Cys Ser  
 35 40 45

Gly Gly Cys Gln Cys Tyr Pro Glu Lys Gly Gly Arg Gly Gln Pro Gly  
 50 55 60

Pro Val Gly Pro Gln Gly Tyr Asn Gly Pro Pro Gly Leu Gln Gly Phe  
 65 70 75 80

Pro Gly Leu Gln Gly Arg Lys Gly Asp Lys Gly Glu Arg Gly Ala Pro  
 85 90 95

Gly Val Thr Gly Pro Lys Gly Asp Val Gly Ala Arg Gly Val Ser Gly  
 100 105 110

-continued

---

Phe Pro Gly Ala Asp Gly Ile Pro Gly His Pro Gly Gln Gly Gly Pro  
 115 120 125  
 Arg Gly Arg Pro Gly Tyr Asp Gly Cys Asn Gly Thr Gln Gly Asp Ser  
 130 135 140  
 Gly Pro Gln Gly Pro Pro Gly Ser Glu Gly Phe Thr Gly Pro Pro Gly  
 145 150 155 160  
 Pro Gln Gly Pro Lys Gly Gln Lys Gly Glu Pro Tyr Ala Leu Pro Lys  
 165 170 175  
 Glu Glu Arg Asp Arg Tyr Arg Gly Glu Pro Gly Glu Pro Gly Leu Val  
 180 185 190  
 Gly Phe Gln Gly Pro Pro Gly Arg Pro Gly His Val Gly Gln Met Gly  
 195 200 205  
 Pro Val Gly Ala Pro Gly Arg Pro Gly Pro Pro Gly Pro Pro Gly Pro  
 210 215 220  
 Lys Gly Gln Gln Gly Asn Arg Gly Leu Gly Phe Tyr Gly Val Lys Gly  
 225 230 235 240  
 Glu Lys Gly Asp Val Gly Gln Pro Gly Pro Asn Gly Ile Pro Ser Asp  
 245 250 255  
 Thr Leu His Pro Ile Ile Ala Pro Thr Gly Val Thr Phe His Pro Asp  
 260 265 270  
 Gln Tyr Lys Gly Glu Lys Gly Ser Glu Gly Glu Pro Gly Ile Arg Gly  
 275 280 285  
 Ile Ser Leu Lys Gly Glu Glu Gly Ile Met Gly Phe Pro Gly Leu Arg  
 290 295 300  
 Gly Tyr Pro Gly Leu Ser Gly Glu Lys Gly Ser Pro Gly Gln Lys Gly  
 305 310 315 320  
 Ser Arg Gly Leu Asp Gly Tyr Gln Gly Pro Asp Gly Pro Arg Gly Pro  
 325 330 335  
 Lys Gly Glu Ala Gly Asp Pro Gly Pro Pro Gly Leu Pro Ala Tyr Ser  
 340 345 350  
 Pro His Pro Ser Leu Ala Lys Gly Ala Arg Gly Asp Pro Gly Phe Pro  
 355 360 365  
 Gly Ala Gln Gly Glu Pro Gly Ser Gln Gly Glu Pro Gly Asp Pro Gly  
 370 375 380  
 Leu Pro Gly Pro Pro Gly Leu Ser Ile Gly Asp Gly Asp Gln Arg Arg  
 385 390 395 400  
 Gly Leu Pro Gly Glu Met Gly Pro Lys Gly Phe Ile Gly Asp Pro Gly  
 405 410 415  
 Ile Pro Ala Leu Tyr Gly Gly Pro Pro Gly Pro Asp Gly Lys Arg Gly  
 420 425 430  
 Pro Pro Gly Pro Pro Gly Leu Pro Gly Pro Pro Gly Pro Asp Gly Phe  
 435 440 445  
 Leu Phe Gly Leu Lys Gly Ala Lys Gly Arg Ala Gly Phe Pro Gly Leu  
 450 455 460  
 Pro Gly Ser Pro Gly Ala Arg Gly Pro Lys Gly Trp Lys Gly Asp Ala  
 465 470 475 480  
 Gly Glu Cys Arg Cys Thr Glu Gly Asp Glu Ala Ile Lys Gly Leu Pro  
 485 490 495  
 Gly Leu Pro Gly Pro Lys Gly Phe Ala Gly Ile Asn Gly Glu Pro Gly  
 500 505 510

-continued

---

Arg Lys Gly Asp Arg Gly Asp Pro Gly Gln His Gly Leu Pro Gly Phe  
 515 520 525  
 Pro Gly Leu Lys Gly Val Pro Gly Asn Ile Gly Ala Pro Gly Pro Lys  
 530 535 540  
 Gly Ala Lys Gly Asp Ser Arg Thr Ile Thr Thr Lys Gly Glu Arg Gly  
 545 550 555 560  
 Gln Pro Gly Val Pro Gly Val Pro Gly Met Lys Gly Asp Asp Gly Ser  
 565 570 575  
 Pro Gly Arg Asp Gly Leu Asp Gly Phe Pro Gly Leu Pro Gly Pro Pro  
 580 585 590  
 Gly Asp Gly Ile Lys Gly Pro Pro Gly Asp Pro Gly Tyr Pro Gly Ile  
 595 600 605  
 Pro Gly Thr Lys Gly Thr Pro Gly Glu Met Gly Pro Pro Gly Leu Gly  
 610 615 620  
 Leu Pro Gly Leu Lys Gly Gln Arg Gly Phe Pro Gly Asp Ala Gly Leu  
 625 630 635 640  
 Pro Gly Pro Pro Gly Phe Leu Gly Pro Pro Gly Pro Ala Gly Thr Pro  
 645 650 655  
 Gly Gln Ile Asp Cys Asp Thr Asp Val Lys Arg Ala Val Gly Gly Asp  
 660 665 670  
 Arg Gln Glu Ala Ile Gln Pro Gly Cys Ile Gly Gly Pro Lys Gly Leu  
 675 680 685  
 Pro Gly Leu Pro Gly Pro Pro Gly Pro Thr Gly Ala Lys Gly Leu Arg  
 690 695 700  
 Gly Ile Pro Gly Phe Ala Gly Ala Asp Gly Gly Pro Gly Pro Arg Gly  
 705 710 715 720  
 Leu Pro Gly Asp Ala Gly Arg Glu Gly Phe Pro Gly Pro Pro Gly Phe  
 725 730 735  
 Ile Gly Pro Arg Gly Ser Lys Gly Ala Val Gly Leu Pro Gly Pro Asp  
 740 745 750  
 Gly Ser Pro Gly Pro Ile Gly Leu Pro Gly Pro Asp Gly Pro Pro Gly  
 755 760 765  
 Glu Arg Gly Leu Pro Gly Glu Val Leu Gly Ala Gln Pro Gly Pro Arg  
 770 775 780  
 Gly Asp Ala Gly Val Pro Gly Gln Pro Gly Leu Lys Gly Leu Pro Gly  
 785 790 795 800  
 Asp Arg Gly Pro Pro Gly Phe Arg Gly Ser Gln Gly Met Pro Gly Met  
 805 810 815  
 Pro Gly Leu Lys Gly Gln Pro Gly Leu Pro Gly Pro Ser Gly Gln Pro  
 820 825 830  
 Gly Leu Tyr Gly Pro Pro Gly Leu His Gly Phe Pro Gly Ala Pro Gly  
 835 840 845  
 Gln Glu Gly Pro Leu Gly Leu Pro Gly Ile Pro Gly Arg Glu Gly Leu  
 850 855 860  
 Pro Gly Asp Arg Gly Asp Pro Gly Asp Thr Gly Ala Pro Gly Pro Val  
 865 870 875 880  
 Gly Met Lys Gly Leu Ser Gly Asp Arg Gly Asp Ala Gly Phe Thr Gly  
 885 890 895  
 Glu Gln Gly His Pro Gly Ser Pro Gly Phe Lys Gly Ile Asp Gly Met  
 900 905 910  
 Pro Gly Thr Pro Gly Leu Lys Gly Asp Arg Gly Ser Pro Gly Met Asp

-continued

915				920				925							
Gly	Phe	Gln	Gly	Met	Pro	Gly	Leu	Lys	Gly	Arg	Pro	Gly	Phe	Pro	Gly
930						935					940				
Ser	Lys	Gly	Glu	Ala	Gly	Phe	Phe	Gly	Ile	Pro	Gly	Leu	Lys	Gly	Leu
945					950					955				960	
Ala	Gly	Glu	Pro	Gly	Phe	Lys	Gly	Ser	Arg	Gly	Asp	Pro	Gly	Pro	Pro
				965						970				975	
Gly	Pro	Pro	Pro	Val	Ile	Leu	Pro	Gly	Met	Lys	Asp	Ile	Lys	Gly	Glu
				980					985				990		
Lys	Gly	Asp	Glu	Gly	Pro	Met	Gly	Leu	Lys	Gly	Tyr	Leu	Gly	Ala	Lys
		995					1000						1005		
Gly	Ile	Gln	Gly	Met	Pro	Gly	Ile	Pro	Gly	Leu	Ser	Gly	Ile	Pro	
1010						1015						1020			
Gly	Leu	Pro	Gly	Arg	Pro	Gly	His	Ile	Lys	Gly	Val	Lys	Gly	Asp	
1025						1030						1035			
Ile	Gly	Val	Pro	Gly	Ile	Pro	Gly	Leu	Pro	Gly	Phe	Pro	Gly	Val	
1040						1045						1050			
Ala	Gly	Pro	Pro	Gly	Ile	Thr	Gly	Phe	Pro	Gly	Phe	Ile	Gly	Ser	
1055						1060						1065			
Arg	Gly	Asp	Lys	Gly	Ala	Pro	Gly	Arg	Ala	Gly	Leu	Tyr	Gly	Glu	
1070						1075						1080			
Ile	Gly	Ala	Thr	Gly	Asp	Phe	Gly	Asp	Ile	Gly	Asp	Thr	Ile	Asn	
1085						1090						1095			
Leu	Pro	Gly	Arg	Pro	Gly	Leu	Lys	Gly	Glu	Arg	Gly	Thr	Thr	Gly	
1100						1105						1110			
Ile	Pro	Gly	Leu	Lys	Gly	Phe	Phe	Gly	Glu	Lys	Gly	Thr	Glu	Gly	
1115						1120						1125			
Asp	Ile	Gly	Phe	Pro	Gly	Ile	Thr	Gly	Val	Thr	Gly	Val	Gln	Gly	
1130						1135						1140			
Pro	Pro	Gly	Leu	Lys	Gly	Gln	Thr	Gly	Phe	Pro	Gly	Leu	Thr	Gly	
1145						1150						1155			
Pro	Pro	Gly	Ser	Gln	Gly	Glu	Leu	Gly	Arg	Ile	Gly	Leu	Pro	Gly	
1160						1165						1170			
Gly	Lys	Gly	Asp	Asp	Gly	Trp	Pro	Gly	Ala	Pro	Gly	Leu	Pro	Gly	
1175						1180						1185			
Phe	Pro	Gly	Leu	Arg	Gly	Ile	Arg	Gly	Leu	His	Gly	Leu	Pro	Gly	
1190						1195						1200			
Thr	Lys	Gly	Phe	Pro	Gly	Ser	Pro	Gly	Ser	Asp	Ile	His	Gly	Asp	
1205						1210						1215			
Pro	Gly	Phe	Pro	Gly	Pro	Pro	Gly	Glu	Arg	Gly	Asp	Pro	Gly	Glu	
1220						1225						1230			
Ala	Asn	Thr	Leu	Pro	Gly	Pro	Val	Gly	Val	Pro	Gly	Gln	Lys	Gly	
1235						1240						1245			
Asp	Gln	Gly	Ala	Pro	Gly	Glu	Arg	Gly	Pro	Pro	Gly	Ser	Pro	Gly	
1250						1255						1260			
Leu	Gln	Gly	Phe	Pro	Gly	Ile	Thr	Pro	Pro	Ser	Asn	Ile	Ser	Gly	
1265						1270						1275			
Ala	Pro	Gly	Asp	Lys	Gly	Ala	Pro	Gly	Ile	Phe	Gly	Leu	Lys	Gly	
1280						1285						1290			
Tyr	Arg	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Ser	Ala	Ala	Leu	Pro	Gly	
1295						1300						1305			

-continued

---

Ser	Lys	Gly	Asp	Thr	Gly	Asn	Pro	Gly	Ala	Pro	Gly	Thr	Pro	Gly
1310						1315					1320			
Thr	Lys	Gly	Trp	Ala	Gly	Asp	Ser	Gly	Pro	Gln	Gly	Arg	Pro	Gly
1325						1330					1335			
Val	Phe	Gly	Leu	Pro	Gly	Glu	Lys	Gly	Pro	Arg	Gly	Glu	Gln	Gly
1340						1345					1350			
Phe	Met	Gly	Asn	Thr	Gly	Pro	Thr	Gly	Ala	Val	Gly	Asp	Arg	Gly
1355						1360					1365			
Pro	Lys	Gly	Pro	Lys	Gly	Asp	Pro	Gly	Phe	Pro	Gly	Ala	Pro	Gly
1370						1375					1380			
Thr	Val	Gly	Ala	Pro	Gly	Ile	Ala	Gly	Ile	Pro	Gln	Lys	Ile	Ala
1385						1390					1395			
Val	Gln	Pro	Gly	Thr	Val	Gly	Pro	Gln	Gly	Arg	Arg	Gly	Pro	Pro
1400						1405					1410			
Gly	Ala	Pro	Gly	Glu	Met	Gly	Pro	Gln	Gly	Pro	Pro	Gly	Glu	Pro
1415						1420					1425			
Gly	Phe	Arg	Gly	Ala	Pro	Gly	Lys	Ala	Gly	Pro	Gln	Gly	Arg	Gly
1430						1435					1440			
Gly	Val	Ser	Ala	Val	Pro	Gly	Phe	Arg	Gly	Asp	Glu	Gly	Pro	Ile
1445						1450					1455			
Gly	His	Gln	Gly	Pro	Ile	Gly	Gln	Glu	Gly	Ala	Pro	Gly	Arg	Pro
1460						1465					1470			
Gly	Ser	Pro	Gly	Leu	Pro	Gly	Met	Pro	Gly	Arg	Ser	Val	Ser	Ile
1475						1480					1485			
Gly	Tyr	Leu	Leu	Val	Lys	His	Ser	Gln	Thr	Asp	Gln	Glu	Pro	Met
1490						1495					1500			
Cys	Pro	Val	Gly	Met	Asn	Lys	Leu	Trp	Ser	Gly	Tyr	Ser	Leu	Leu
1505						1510					1515			
Tyr	Phe	Glu	Gly	Gln	Glu	Lys	Ala	His	Asn	Gln	Asp	Leu	Gly	Leu
1520						1525					1530			
Ala	Gly	Ser	Cys	Leu	Ala	Arg	Phe	Ser	Thr	Met	Pro	Phe	Leu	Tyr
1535						1540					1545			
Cys	Asn	Pro	Gly	Asp	Val	Cys	Tyr	Tyr	Ala	Ser	Arg	Asn	Asp	Lys
1550						1555					1560			
Ser	Tyr	Trp	Leu	Ser	Thr	Thr	Ala	Pro	Leu	Pro	Met	Met	Pro	Val
1565						1570					1575			
Ala	Glu	Asp	Glu	Ile	Lys	Pro	Tyr	Ile	Ser	Arg	Cys	Ser	Val	Cys
1580						1585					1590			
Glu	Ala	Pro	Ala	Ile	Ala	Ile	Ala	Val	His	Ser	Gln	Asp	Val	Ser
1595						1600					1605			
Ile	Pro	His	Cys	Pro	Ala	Gly	Trp	Arg	Ser	Leu	Trp	Ile	Gly	Tyr
1610						1615					1620			
Ser	Phe	Leu	Met	His	Thr	Ala	Ala	Gly	Asp	Glu	Gly	Gly	Gly	Gln
1625						1630					1635			
Ser	Leu	Val	Ser	Pro	Gly	Ser	Cys	Leu	Glu	Asp	Phe	Arg	Ala	Thr
1640						1645					1650			
Pro	Phe	Ile	Glu	Cys	Asn	Gly	Gly	Arg	Gly	Thr	Cys	His	Tyr	Tyr
1655						1660					1665			
Ala	Asn	Lys	Tyr	Ser	Phe	Trp	Leu	Thr	Thr	Ile	Pro	Glu	Gln	Ser
1670						1675					1680			

-continued

---

Phe Gln Gly Ser Pro Ser Ala Asp Thr Leu Lys Ala Gly Leu Ile  
 1685 1690 1695  
 Arg Thr His Ile Ser Arg Cys Gln Val Cys Met Lys Asn Leu  
 1700 1705 1710

<210> SEQ ID NO 24  
 <211> LENGTH: 1691  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

Met Lys Leu Arg Gly Val Ser Leu Ala Ala Gly Leu Phe Leu Leu Ala  
 1 5 10 15  
 Leu Ser Leu Trp Gly Gln Pro Ala Glu Ala Ala Ala Cys Tyr Gly Cys  
 20 25 30  
 Ser Pro Gly Ser Lys Cys Asp Cys Ser Gly Ile Lys Gly Glu Lys Gly  
 35 40 45  
 Glu Arg Gly Phe Pro Gly Leu Glu Gly His Pro Gly Leu Pro Gly Phe  
 50 55 60  
 Pro Gly Pro Glu Gly Pro Pro Gly Pro Arg Gly Gln Lys Gly Asp Asp  
 65 70 75 80  
 Gly Ile Pro Gly Pro Gly Pro Lys Gly Ile Arg Gly Pro Pro Gly  
 85 90 95  
 Leu Pro Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Met Pro Gly His  
 100 105 110  
 Asp Gly Ala Pro Gly Pro Gln Gly Ile Pro Gly Cys Asn Gly Thr Lys  
 115 120 125  
 Gly Glu Arg Gly Phe Pro Gly Ser Pro Gly Phe Pro Gly Leu Gln Gly  
 130 135 140  
 Pro Pro Gly Pro Pro Gly Ile Pro Gly Met Lys Gly Glu Pro Gly Ser  
 145 150 155 160  
 Ile Ile Met Ser Ser Leu Pro Gly Pro Lys Gly Asn Pro Gly Tyr Pro  
 165 170 175  
 Gly Pro Pro Gly Ile Gln Gly Leu Pro Gly Pro Thr Gly Ile Pro Gly  
 180 185 190  
 Pro Ile Gly Pro Pro Gly Pro Pro Gly Leu Met Gly Pro Pro Gly Pro  
 195 200 205  
 Pro Gly Leu Pro Gly Pro Lys Gly Asn Met Gly Leu Asn Phe Gln Gly  
 210 215 220  
 Pro Lys Gly Glu Lys Gly Glu Gln Gly Leu Gln Gly Pro Pro Gly Pro  
 225 230 235 240  
 Pro Gly Gln Ile Ser Glu Gln Lys Arg Pro Ile Asp Val Glu Phe Gln  
 245 250 255  
 Lys Gly Asp Gln Gly Leu Pro Gly Asp Arg Gly Pro Pro Gly Pro Pro  
 260 265 270  
 Gly Ile Arg Gly Pro Pro Gly Pro Pro Gly Gly Glu Lys Gly Glu Lys  
 275 280 285  
 Gly Glu Gln Gly Glu Pro Gly Lys Arg Gly Lys Pro Gly Lys Asp Gly  
 290 295 300  
 Glu Asn Gly Gln Pro Gly Ile Pro Gly Leu Pro Gly Asp Pro Gly Tyr  
 305 310 315 320  
 Pro Gly Glu Pro Gly Arg Asp Gly Glu Lys Gly Gln Lys Gly Asp Thr  
 325 330 335

-continued

---

Gly Pro Pro Gly Pro Pro Gly Leu Val Ile Pro Arg Pro Gly Thr Gly  
                   340                                  345                                  350

Ile Thr Ile Gly Glu Lys Gly Asn Ile Gly Leu Pro Gly Leu Pro Gly  
                   355                                  360                                  365

Glu Lys Gly Glu Arg Gly Phe Pro Gly Ile Gln Gly Pro Pro Gly Leu  
                   370                                  375                                  380

Pro Gly Pro Pro Gly Ala Ala Val Met Gly Pro Pro Gly Pro Pro Gly  
 385                                  390                                  395                                  400

Phe Pro Gly Glu Arg Gly Gln Lys Gly Asp Glu Gly Pro Pro Gly Ile  
                   405                                  410                                  415

Ser Ile Pro Gly Pro Pro Gly Leu Asp Gly Gln Pro Gly Ala Pro Gly  
                   420                                  425                                  430

Leu Pro Gly Pro Pro Gly Pro Ala Gly Pro His Ile Pro Pro Ser Asp  
                   435                                  440                                  445

Glu Ile Cys Glu Pro Gly Pro Pro Gly Pro Pro Gly Ser Pro Gly Asp  
                   450                                  455                                  460

Lys Gly Leu Gln Gly Glu Gln Gly Val Lys Gly Asp Lys Gly Asp Thr  
 465                                  470                                  475                                  480

Cys Phe Asn Cys Ile Gly Thr Gly Ile Ser Gly Pro Pro Gly Gln Pro  
                   485                                  490                                  495

Gly Leu Pro Gly Leu Pro Gly Pro Pro Gly Ser Leu Gly Phe Pro Gly  
                   500                                  505                                  510

Gln Lys Gly Glu Lys Gly Gln Ala Gly Ala Thr Gly Pro Lys Gly Leu  
                   515                                  520                                  525

Pro Gly Ile Pro Gly Ala Pro Gly Ala Pro Gly Phe Pro Gly Ser Lys  
                   530                                  535                                  540

Gly Glu Pro Gly Asp Ile Leu Thr Phe Pro Gly Met Lys Gly Asp Lys  
 545                                  550                                  555                                  560

Gly Glu Leu Gly Ser Pro Gly Ala Pro Gly Leu Pro Gly Leu Pro Gly  
                   565                                  570                                  575

Thr Pro Gly Gln Asp Gly Leu Pro Gly Leu Pro Gly Pro Lys Gly Glu  
                   580                                  585                                  590

Pro Gly Gly Ile Thr Phe Lys Gly Glu Arg Gly Pro Pro Gly Asn Pro  
                   595                                  600                                  605

Gly Leu Pro Gly Leu Pro Gly Asn Ile Gly Pro Met Gly Pro Pro Gly  
                   610                                  615                                  620

Phe Gly Pro Pro Gly Pro Val Gly Glu Lys Gly Ile Gln Gly Val Ala  
 625                                  630                                  635                                  640

Gly Asn Pro Gly Gln Pro Gly Ile Pro Gly Pro Lys Gly Asp Pro Gly  
                   645                                  650                                  655

Gln Thr Ile Thr Gln Pro Gly Lys Pro Gly Leu Pro Gly Asn Pro Gly  
                   660                                  665                                  670

Arg Asp Gly Asp Val Gly Leu Pro Gly Asp Pro Gly Leu Pro Gly Gln  
                   675                                  680                                  685

Pro Gly Leu Pro Gly Ile Pro Gly Ser Lys Gly Glu Pro Gly Ile Pro  
                   690                                  695                                  700

Gly Ile Gly Leu Pro Gly Pro Pro Gly Pro Lys Gly Phe Pro Gly Ile  
 705                                  710                                  715                                  720

Pro Gly Pro Pro Gly Ala Pro Gly Thr Pro Gly Arg Ile Gly Leu Glu  
                   725                                  730                                  735

-continued

---

Gly Pro Pro Gly Pro Pro Gly Phe Pro Gly Pro Lys Gly Glu Pro Gly  
 740 745 750

Phe Ala Leu Pro Gly Pro Pro Gly Pro Pro Gly Leu Pro Gly Phe Lys  
 755 760 765

Gly Ala Leu Gly Pro Lys Gly Asp Arg Gly Phe Pro Gly Pro Pro Gly  
 770 775 780

Pro Pro Gly Arg Thr Gly Leu Asp Gly Leu Pro Gly Pro Lys Gly Asp  
 785 790 795 800

Val Gly Pro Asn Gly Gln Pro Gly Pro Met Gly Pro Pro Gly Leu Pro  
 805 810 815

Gly Ile Gly Val Gln Gly Pro Pro Gly Pro Pro Gly Ile Pro Gly Pro  
 820 825 830

Ile Gly Gln Pro Gly Leu His Gly Ile Pro Gly Glu Lys Gly Asp Pro  
 835 840 845

Gly Pro Pro Gly Leu Asp Val Pro Gly Pro Pro Gly Glu Arg Gly Ser  
 850 855 860

Pro Gly Ile Pro Gly Ala Pro Gly Pro Ile Gly Pro Pro Gly Ser Pro  
 865 870 875 880

Gly Leu Pro Gly Lys Ala Gly Ala Ser Gly Phe Pro Gly Thr Lys Gly  
 885 890 895

Glu Met Gly Met Met Gly Pro Pro Gly Pro Pro Gly Pro Leu Gly Ile  
 900 905 910

Pro Gly Arg Ser Gly Val Pro Gly Leu Lys Gly Asp Asp Gly Leu Gln  
 915 920 925

Gly Gln Pro Gly Leu Pro Gly Pro Thr Gly Glu Lys Gly Ser Lys Gly  
 930 935 940

Glu Pro Gly Leu Pro Gly Pro Pro Gly Pro Met Asp Pro Asn Leu Leu  
 945 950 955 960

Gly Ser Lys Gly Glu Lys Gly Glu Pro Gly Leu Pro Gly Ile Pro Gly  
 965 970 975

Val Ser Gly Pro Lys Gly Tyr Gln Gly Leu Pro Gly Asp Pro Gly Gln  
 980 985 990

Pro Gly Leu Ser Gly Gln Pro Gly Leu Pro Gly Pro Pro Gly Pro Lys  
 995 1000 1005

Gly Asn Pro Gly Leu Pro Gly Gln Pro Gly Leu Ile Gly Pro Pro  
 1010 1015 1020

Gly Leu Lys Gly Thr Ile Gly Asp Met Gly Phe Pro Gly Pro Gln  
 1025 1030 1035

Gly Val Glu Gly Pro Pro Gly Pro Ser Gly Val Pro Gly Gln Pro  
 1040 1045 1050

Gly Ser Pro Gly Leu Pro Gly Gln Lys Gly Asp Lys Gly Asp Pro  
 1055 1060 1065

Gly Ile Ser Ser Ile Gly Leu Pro Gly Leu Pro Gly Pro Lys Gly  
 1070 1075 1080

Glu Pro Gly Leu Pro Gly Tyr Pro Gly Asn Pro Gly Ile Lys Gly  
 1085 1090 1095

Ser Val Gly Asp Pro Gly Leu Pro Gly Leu Pro Gly Thr Pro Gly  
 1100 1105 1110

Ala Lys Gly Gln Pro Gly Leu Pro Gly Phe Pro Gly Thr Pro Gly  
 1115 1120 1125

Pro Pro Gly Pro Lys Gly Ile Ser Gly Pro Pro Gly Asn Pro Gly

-continued

---

1130	1135	1140
Leu Pro Gly Glu Pro Gly 1145	Pro Val Gly Gly Gly 1150	Gly Gly His Pro Gly 1155
Gln Pro Gly Pro Pro Gly 1160	Glu Lys Gly Lys Pro 1165	Gly Gln Asp Gly 1170
Ile Pro Gly Pro Ala Gly 1175	Gln Lys Gly Glu Pro 1180	Gly Gln Pro Gly 1185
Phe Gly Asn Pro Gly Pro 1190	Pro Gly Leu Pro Gly 1195	Leu Ser Gly Gln 1200
Lys Gly Asp Gly Gly Leu 1205	Pro Gly Ile Pro Gly 1210	Asn Pro Gly Leu 1215
Pro Gly Pro Lys Gly Glu 1220	Pro Gly Phe His Gly 1225	Phe Pro Gly Val 1230
Gln Gly Pro Pro Gly Pro 1235	Pro Gly Ser Pro Gly 1240	Pro Ala Leu Glu 1245
Gly Pro Lys Gly Asn Pro 1250	Gly Pro Gln Gly Pro 1255	Pro Gly Arg Pro 1260
Gly Pro Thr Gly Phe Gln 1265	Gly Leu Pro Gly Pro 1270	Glu Gly Pro Pro 1275
Gly Leu Pro Gly Asn Gly 1280	Gly Ile Lys Gly Glu 1285	Lys Gly Asn Pro 1290
Gly Gln Pro Gly Leu Pro 1295	Gly Leu Pro Gly Leu 1300	Lys Gly Asp Gln 1305
Gly Pro Pro Gly Leu Gln 1310	Gly Asn Pro Gly Arg 1315	Pro Gly Leu Asn 1320
Gly Met Lys Gly Asp Pro 1325	Gly Leu Pro Gly Val 1330	Pro Gly Phe Pro 1335
Gly Met Lys Gly Pro Ser 1340	Gly Val Pro Gly Ser 1345	Ala Gly Pro Glu 1350
Gly Glu Pro Gly Leu Ile 1355	Gly Pro Pro Gly Pro 1360	Pro Gly Leu Pro 1365
Gly Pro Ser Gly Gln Ser 1370	Ile Ile Ile Lys Gly 1375	Asp Ala Gly Pro 1380
Pro Gly Ile Pro Gly Gln 1385	Pro Gly Leu Lys Gly 1390	Leu Pro Gly Pro 1395
Gln Gly Pro Gln Gly Leu 1400	Pro Gly Pro Thr Gly 1405	Pro Gly Asp 1410
Pro Gly Arg Asn Gly Leu 1415	Pro Gly Phe Asp Gly 1420	Ala Gly Gly Arg 1425
Lys Gly Asp Pro Gly Leu 1430	Pro Gly Gln Pro Gly 1435	Thr Arg Gly Leu 1440
Asp Gly Pro Pro Gly Pro 1445	Asp Gly Leu Gln Gly 1450	Pro Gly Pro 1455
Pro Gly Thr Ser Ser Val 1460	Ala His Gly Phe Leu 1465	Ile Thr Arg His 1470
Ser Gln Thr Thr Asp Ala 1475	Pro Gln Cys Pro Gln 1480	Gly Thr Leu Gln 1485
Val Tyr Glu Gly Phe Ser 1490	Leu Leu Tyr Val Gln 1495	Gly Asn Lys Arg 1500
Ala His Gly Gln Asp Leu 1505	Gly Thr Ala Gly Ser 1510	Cys Leu Arg Arg 1515

-continued

---

Phe Ser Thr Met Pro Phe Met Phe Cys Asn Ile Asn Asn Val Cys  
 1520 1525 1530  
 Asn Phe Ala Ser Arg Asn Asp Tyr Ser Tyr Trp Leu Ser Thr Pro  
 1535 1540 1545  
 Glu Pro Met Pro Met Ser Met Gln Pro Leu Lys Gly Gln Ser Ile  
 1550 1555 1560  
 Gln Pro Phe Ile Ser Arg Cys Ala Val Cys Glu Ala Pro Ala Val  
 1565 1570 1575  
 Val Ile Ala Val His Ser Gln Thr Ile Gln Ile Pro His Cys Pro  
 1580 1585 1590  
 Gln Gly Trp Asp Ser Leu Trp Ile Gly Tyr Ser Phe Met Met His  
 1595 1600 1605  
 Thr Ser Ala Gly Ala Glu Gly Ser Gly Gln Ala Leu Ala Ser Pro  
 1610 1615 1620  
 Gly Ser Cys Leu Glu Glu Phe Arg Ser Ala Pro Phe Ile Glu Cys  
 1625 1630 1635  
 His Gly Arg Gly Thr Cys Asn Tyr Tyr Ala Asn Ser Tyr Ser Phe  
 1640 1645 1650  
 Trp Leu Ala Thr Val Asp Val Ser Asp Met Phe Ser Lys Pro Gln  
 1655 1660 1665  
 Ser Glu Thr Leu Lys Ala Gly Asp Leu Arg Thr Arg Ile Ser Arg  
 1670 1675 1680  
 Cys Gln Val Cys Met Lys Arg Thr  
 1685 1690

<210> SEQ ID NO 25  
 <211> LENGTH: 730  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Met Ala Gly Leu Thr Ala Ala Ala Pro Arg Pro Gly Val Leu Leu Leu  
 1 5 10 15  
 Leu Leu Ser Ile Leu His Pro Ser Arg Pro Gly Gly Val Pro Gly Ala  
 20 25 30  
 Ile Pro Gly Gly Val Pro Gly Gly Val Phe Tyr Pro Gly Ala Gly Leu  
 35 40 45  
 Gly Ala Leu Gly Gly Gly Ala Leu Gly Pro Gly Gly Lys Pro Leu Lys  
 50 55 60  
 Pro Val Pro Gly Gly Leu Ala Gly Ala Gly Leu Gly Ala Gly Leu Gly  
 65 70 75 80  
 Ala Phe Pro Ala Val Thr Phe Pro Gly Ala Leu Val Pro Gly Gly Val  
 85 90 95  
 Ala Asp Ala Ala Ala Tyr Lys Ala Ala Lys Ala Gly Ala Gly Leu  
 100 105 110  
 Gly Gly Val Pro Gly Val Gly Gly Leu Gly Val Ser Ala Gly Ala Val  
 115 120 125  
 Val Pro Gln Pro Gly Ala Gly Val Lys Pro Gly Lys Val Pro Gly Val  
 130 135 140  
 Gly Leu Pro Gly Val Tyr Pro Gly Gly Val Leu Pro Gly Ala Arg Phe  
 145 150 155 160  
 Pro Gly Val Gly Val Leu Pro Gly Val Pro Thr Gly Ala Gly Val Lys

-continued

165					170					175					
Pro	Lys	Ala	Pro	Gly	Val	Gly	Gly	Ala	Phe	Ala	Gly	Ile	Pro	Gly	Val
			180					185					190		
Gly	Pro	Phe	Gly	Gly	Pro	Gln	Pro	Gly	Val	Pro	Leu	Gly	Tyr	Pro	Ile
		195					200					205			
Lys	Ala	Pro	Lys	Leu	Pro	Gly	Gly	Tyr	Gly	Leu	Pro	Tyr	Thr	Thr	Gly
	210					215					220				
Lys	Leu	Pro	Tyr	Gly	Tyr	Gly	Pro	Gly	Gly	Val	Ala	Gly	Ala	Ala	Gly
	225					230					235				240
Lys	Ala	Gly	Tyr	Pro	Thr	Gly	Thr	Gly	Val	Gly	Pro	Gln	Ala	Ala	Ala
			245						250					255	
Ala	Ala	Ala	Ala	Lys	Ala	Ala	Ala	Lys	Phe	Gly	Ala	Gly	Ala	Ala	Gly
			260					265					270		
Val	Leu	Pro	Gly	Val	Gly	Gly	Ala	Gly	Val	Pro	Gly	Val	Pro	Gly	Ala
		275					280					285			
Ile	Pro	Gly	Ile	Gly	Gly	Ile	Ala	Gly	Val	Gly	Thr	Pro	Ala	Ala	Ala
	290					295					300				
Ala	Ala	Ala	Ala	Ala	Ala	Ala	Lys	Ala	Ala	Lys	Tyr	Gly	Ala	Ala	Ala
	305					310					315				320
Gly	Leu	Val	Pro	Gly	Gly	Pro	Gly	Phe	Gly	Pro	Gly	Val	Val	Gly	Val
			325					330						335	
Pro	Gly	Ala	Gly	Val	Pro	Gly	Val	Gly	Val	Pro	Gly	Ala	Gly	Ile	Pro
		340					345					350			
Val	Val	Pro	Gly	Ala	Gly	Ile	Pro	Gly	Ala	Ala	Val	Pro	Gly	Val	Val
		355					360					365			
Ser	Pro	Glu	Ala	Ala	Ala	Lys	Ala	Ala	Ala	Lys	Ala	Ala	Lys	Tyr	Gly
	370					375					380				
Ala	Arg	Pro	Gly	Val	Gly	Val	Gly	Gly	Ile	Pro	Thr	Tyr	Gly	Val	Gly
	385					390					395				400
Ala	Gly	Gly	Phe	Pro	Gly	Phe	Gly	Val	Gly	Val	Gly	Gly	Ile	Pro	Gly
			405					410						415	
Val	Ala	Gly	Val	Pro	Ser	Val	Gly	Gly	Val	Pro	Gly	Val	Gly	Gly	Val
		420						425					430		
Pro	Gly	Val	Gly	Ile	Ser	Pro	Glu	Ala	Gln	Ala	Ala	Ala	Ala	Ala	Lys
		435					440					445			
Ala	Ala	Lys	Tyr	Gly	Val	Gly	Thr	Pro	Ala	Ala	Ala	Ala	Ala	Lys	Ala
	450					455					460				
Ala	Ala	Lys	Ala	Ala	Gln	Phe	Ala	Leu	Leu	Asn	Leu	Ala	Gly	Leu	Val
	465					470					475				480
Pro	Gly	Val	Gly	Val	Ala	Pro	Gly	Val	Gly	Val	Ala	Pro	Gly	Val	Gly
			485					490						495	
Val	Ala	Pro	Gly	Val	Gly	Leu	Ala	Pro	Gly	Val	Gly	Val	Ala	Pro	Gly
		500						505					510		
Val	Gly	Val	Ala	Pro	Gly	Val	Gly	Val	Ala	Pro	Gly	Ile	Gly	Pro	Gly
		515					520					525			
Gly	Val	Ala	Ala	Ala	Ala	Lys	Ser	Ala	Ala	Lys	Val	Ala	Ala	Lys	Ala
	530					535					540				
Gln	Leu	Arg	Ala	Ala	Ala	Gly	Leu	Gly	Ala	Gly	Ile	Pro	Gly	Leu	Gly
	545					550					555				560
Val	Gly	Val	Gly	Val	Pro	Gly	Leu	Gly	Val	Gly	Ala	Gly	Val	Pro	Gly
			565					570						575	

-continued

Leu Gly Val Gly Ala Gly Val Pro Gly Phe Gly Ala Val Pro Gly Ala  
 580 585 590

Leu Ala Ala Ala Lys Ala Ala Lys Tyr Gly Ala Ala Val Pro Gly Val  
 595 600 605

Leu Gly Gly Leu Gly Ala Leu Gly Gly Val Gly Ile Pro Gly Gly Val  
 610 615 620

Val Gly Ala Gly Pro Ala Ala Ala Ala Ala Ala Lys Ala Ala Ala  
 625 630 635 640

Lys Ala Ala Gln Phe Gly Leu Val Gly Ala Ala Gly Leu Gly Gly Leu  
 645 650 655

Gly Val Gly Gly Leu Gly Val Pro Gly Val Gly Gly Leu Gly Gly Ile  
 660 665 670

Pro Pro Ala Ala Ala Ala Lys Ala Ala Lys Tyr Gly Ala Ala Gly Leu  
 675 680 685

Gly Gly Val Leu Gly Gly Ala Gly Gln Phe Pro Leu Gly Gly Val Ala  
 690 695 700

Ala Arg Pro Gly Phe Gly Leu Ser Pro Ile Phe Pro Gly Gly Ala Cys  
 705 710 715 720

Leu Gly Lys Ala Cys Gly Arg Lys Arg Lys  
 725 730

<210> SEQ ID NO 26  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence  
 <400> SEQUENCE: 26

Thr Gly Gly Ile Ser Val Pro Gly Pro Met Gly Pro Ser Gly Pro Arg  
 1 5 10 15

<210> SEQ ID NO 27  
 <211> LENGTH: 13  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence  
 <400> SEQUENCE: 27

Gly Leu Pro Gly Pro Pro Gly Ala Pro Gly Pro Gln Gly  
 1 5 10

<210> SEQ ID NO 28  
 <211> LENGTH: 14  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence  
 <400> SEQUENCE: 28

Gly Leu Pro Gly Pro Pro Gly Ala Pro Gly Pro Gln Gly Phe  
 1 5 10

<210> SEQ ID NO 29  
 <211> LENGTH: 24  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:

-continued

---

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 29

Pro Gly Glu Pro Gly Glu Pro Gly Ala Ser Gly Pro Met Gly Pro Arg  
1                   5                   10                   15

Gly Pro Pro Gly Pro Pro Gly Lys  
                  20

<210> SEQ ID NO 30  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 30

Gly Ala Ser Gly Pro Met Gly Pro Arg Gly Pro Pro Gly Pro Pro Gly  
1                   5                   10                   15

Lys

<210> SEQ ID NO 31  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 31

Lys Pro Gly Arg Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala  
1                   5                   10                   15

Arg

<210> SEQ ID NO 32  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 32

Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Leu Pro Gly Thr Ala Gly  
1                   5                   10                   15

Leu Pro Gly Met  
                  20

<210> SEQ ID NO 33  
<211> LENGTH: 7  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 33

Ala Gly Pro Gln Gly Pro Arg  
1                   5

<210> SEQ ID NO 34  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

-continued

---

<400> SEQUENCE: 34

Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly Phe Pro Gly Ala Arg  
1 5 10 15

<210> SEQ ID NO 35

<211> LENGTH: 28

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 35

Pro Gly Ile Ala Gly Ala Pro Gly Phe Pro Gly Ala Arg Gly Pro Ser  
1 5 10 15

Gly Pro Gln Gly Pro Gly Gly Pro Pro Gly Pro Lys  
20 25

<210> SEQ ID NO 36

<211> LENGTH: 26

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 36

Ile Ala Gly Ala Pro Gly Phe Pro Gly Ala Arg Gly Pro Ser Gly Pro  
1 5 10 15

Gln Gly Pro Gly Gly Pro Pro Gly Pro Lys  
20 25

<210> SEQ ID NO 37

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 37

Gly Phe Pro Gly Ala Arg Gly Pro Ser Gly Pro Gln Gly Pro Gly Gly  
1 5 10 15

Pro Pro Gly Pro Lys  
20

<210> SEQ ID NO 38

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 38

Gly Pro Ser Gly Pro Gln Gly Pro Gly Gly  
1 5 10

<210> SEQ ID NO 39

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 39

-continued

---

Gly Asp Thr Gly Ala Lys Gly Glu Pro  
1 5

<210> SEQ ID NO 40  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 40

Val Gln Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys  
1 5 10

<210> SEQ ID NO 41  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 41

Gly Glu Pro Gly Pro Thr Gly Leu Pro Gly Pro Pro Gly  
1 5 10

<210> SEQ ID NO 42  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 42

Gly Glu Pro Gly Pro Thr Gly Leu Pro Gly Pro Pro Gly Glu Arg Gly  
1 5 10 15

Gly Pro Gly Ser  
20

<210> SEQ ID NO 43  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 43

Thr Gly Leu Pro Gly Pro Pro Gly Glu Arg  
1 5 10

<210> SEQ ID NO 44  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 44

Leu Pro Gly Pro Pro Gly Glu Arg  
1 5

<210> SEQ ID NO 45  
<211> LENGTH: 10  
<212> TYPE: PRT

-continued

---

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 45

Ala Gly Pro Lys Gly Pro Ala Gly Glu Arg  
1 5 10

<210> SEQ ID NO 46

<211> LENGTH: 22

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 46

Gly Ser Pro Gly Pro Ala Gly Pro Lys Gly Ser Pro Gly Glu Ala Gly  
1 5 10 15

Arg Pro Gly Glu Ala Gly  
20

<210> SEQ ID NO 47

<211> LENGTH: 30

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 47

Pro Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro Gly Ala Lys  
1 5 10 15

Gly Leu Thr Gly Ser Pro Gly Ser Pro Gly Pro Asp Gly Lys  
20 25 30

<210> SEQ ID NO 48

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 48

Leu Thr Gly Ser Pro Gly Ser Pro Gly Pro Asp Gly Lys  
1 5 10

<210> SEQ ID NO 49

<211> LENGTH: 23

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 49

Thr Gly Pro Pro Gly Pro Ala Gly Gln Asp Gly Arg Pro Gly Pro Pro  
1 5 10 15

Gly Pro Pro Gly Ala Arg Gly  
20

<210> SEQ ID NO 50

<211> LENGTH: 28

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

-continued

---

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 50

Pro Gly Ala Val Gly Pro Ala Gly Lys Asp Gly Glu Ala Gly Ala Gln  
1                   5                   10                   15

Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly Glu Arg  
                  20                   25

<210> SEQ ID NO 51  
<211> LENGTH: 18  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 51

Gly Glu Ala Gly Ala Gln Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly  
1                   5                   10                   15

Glu Arg

<210> SEQ ID NO 52  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 52

Glu Ala Gly Ala Gln Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly Glu  
1                   5                   10                   15

Arg

<210> SEQ ID NO 53  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 53

Val Gln Gly Pro Pro Gly Pro Ala Gly Pro Arg  
1                   5                   10

<210> SEQ ID NO 54  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 54

Gln Gly Pro Pro Gly Pro Ala Gly Pro Arg  
1                   5                   10

<210> SEQ ID NO 55  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 55

-continued

---

Gly Pro Pro Gly Pro Ala Gly Pro Arg  
1 5

<210> SEQ ID NO 56  
 <211> LENGTH: 35  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 56

Ala Asn Gly Ala Pro Gly Asn Asp Gly Ala Lys Gly Asp Ala Gly Ala  
1 5 10 15

Pro Gly Ala Pro Gly Ser Gln Gly Ala Pro Gly Leu Gln Gly Met Pro  
20 25 30

Gly Glu Arg  
35

<210> SEQ ID NO 57  
 <211> LENGTH: 8  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 57

Leu Gln Gly Met Pro Gly Glu Arg  
1 5

<210> SEQ ID NO 58  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 58

Leu Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly Asp  
1 5 10 15

Lys

<210> SEQ ID NO 59  
 <211> LENGTH: 13  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 59

Ile Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly Asp Lys  
1 5 10

<210> SEQ ID NO 60  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 60

Lys Gly Glu Ser Gly Pro Ser Gly Pro Ala Gly Pro Thr Gly Ala Arg  
1 5 10 15

-continued

---

<210> SEQ ID NO 61  
<211> LENGTH: 28  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 61  
  
Pro Gly Asp Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Phe Ala  
1 5 10 15  
  
Gly Pro Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys  
20 25

<210> SEQ ID NO 62  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 62

Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Phe  
1 5 10

<210> SEQ ID NO 63  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 63

Phe Ala Gly Pro Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys  
1 5 10

<210> SEQ ID NO 64  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 64

Ala Gly Pro Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys  
1 5 10

<210> SEQ ID NO 65  
<211> LENGTH: 22  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 65

Arg Val Gly Pro Pro Gly Pro Ser Gly Asn Ala Gly Pro Pro Gly Pro  
1 5 10 15  
  
Pro Gly Pro Ala Gly Lys  
20

<210> SEQ ID NO 66  
<211> LENGTH: 24  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence

-continued

---

<220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 66

Val Gly Pro Pro Gly Pro Ser Gly Asn Ala Gly Pro Pro Gly Pro Pro  
 1           5                   10                   15

Gly Pro Ala Gly Lys Glu Gly Gly  
 20

<210> SEQ ID NO 67  
 <211> LENGTH: 38  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 67

Glu Val Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Glu Lys Gly Ser  
 1           5                   10                   15

Pro Gly Ala Asp Gly Pro Ala Gly Ala Pro Gly Thr Pro Gly Pro Gln  
 20                   25                   30

Gly Ile Ala Gly Gln Arg  
 35

<210> SEQ ID NO 68  
 <211> LENGTH: 34  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 68

Pro Gly Pro Pro Gly Pro Ala Gly Glu Lys Gly Ser Pro Gly Ala Asp  
 1           5                   10                   15

Gly Pro Ala Gly Ala Pro Gly Thr Pro Gly Pro Gln Gly Ile Ala Gly  
 20                   25                   30

Gln Arg

<210> SEQ ID NO 69  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 69

Gly Ser Pro Gly Ala Asp Gly Pro Ala Gly Ala Pro Gly Thr Pro Gly  
 1           5                   10                   15

Pro Gln Gly

<210> SEQ ID NO 70  
 <211> LENGTH: 18  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 70

Gly Pro Ala Gly Ala Pro Gly Thr Pro Gly Pro Gln Gly Ile Ala Gly  
 1           5                   10                   15

-continued

---

Gln Arg

<210> SEQ ID NO 71  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 71

Val Val Gly Leu Pro Gly Gln Arg  
1 5

<210> SEQ ID NO 72  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 72

Leu Ala Gly Pro Pro Gly Glu Ser Gly Arg  
1 5 10

<210> SEQ ID NO 73  
<211> LENGTH: 29  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 73

Glu Thr Gly Pro Ala Gly Pro Pro Gly Ala Pro Gly Ala Pro Gly Ala  
1 5 10 15

Pro Gly Pro Val Gly Pro Ala Gly Lys Ser Gly Asp Arg  
20 25

<210> SEQ ID NO 74  
<211> LENGTH: 19  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 74

Arg Gly Glu Thr Gly Pro Ala Gly Pro Ala Gly Pro Val Gly Pro Val  
1 5 10 15

Gly Ala Arg

<210> SEQ ID NO 75  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 75

Pro Ala Gly Pro Val Gly Pro Val Gly Ala Arg  
1 5 10

<210> SEQ ID NO 76  
<211> LENGTH: 8  
<212> TYPE: PRT

-continued

---

<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 76

Pro Val Gly Pro Val Gly Ala Arg  
1 5

<210> SEQ ID NO 77  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 77

Ser Pro Gly Glu Gln Gly Pro Ser Gly Ala Ser Gly Pro Ala Gly Pro  
1 5 10 15

Arg

<210> SEQ ID NO 78  
<211> LENGTH: 16  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 78

Pro Gly Glu Gln Gly Pro Ser Gly Ala Ser Gly Pro Ala Gly Pro Arg  
1 5 10 15

<210> SEQ ID NO 79  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 79

Gly Pro Ser Gly Ala Ser Gly Pro Ala Gly Pro Arg  
1 5 10

<210> SEQ ID NO 80  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 80

Ala Ser Gly Pro Ala Gly Pro Arg  
1 5

<210> SEQ ID NO 81  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 81

Gly Pro Pro Gly Ser Ala Gly Ala Pro Gly Lys Asp  
1 5 10

-continued

---

<210> SEQ ID NO 82  
 <211> LENGTH: 26  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 82

Pro Pro Gly Ser Ala Gly Ala Pro Gly Lys Asp Gly Leu Asn Gly Leu  
 1 5 10 15

Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg  
 20 25

<210> SEQ ID NO 83  
 <211> LENGTH: 8  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 83

Leu Pro Gln Pro Pro Gln Glu Lys  
 1 5

<210> SEQ ID NO 84  
 <211> LENGTH: 39  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 84

Gly Leu Met Gly Pro Arg Gly Pro Pro Gly Ala Ala Gly Ala Pro Gly  
 1 5 10 15

Pro Gln Gly Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln  
 20 25 30

Thr Gly Pro Ala Gly Ala Arg  
 35

<210> SEQ ID NO 85  
 <211> LENGTH: 20  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 85

Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro  
 1 5 10 15

Ala Gly Ala Arg  
 20

<210> SEQ ID NO 86  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 86

Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro Ala  
 1 5 10 15

-continued

---

Gly Ala Arg

<210> SEQ ID NO 87  
<211> LENGTH: 23  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 87

Glu Asp Gly His Pro Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Val  
1 5 10 15

Val Gly Pro Gln Gly Ala Arg  
20

<210> SEQ ID NO 88  
<211> LENGTH: 35  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 88

Pro Ala Gly Ala Arg Gly Ser Asp Gly Ser Val Gly Pro Val Gly Pro  
1 5 10 15

Ala Gly Pro Ile Gly Ser Ala Gly Pro Pro Gly Phe Pro Gly Ala Pro  
20 25 30

Gly Pro Lys  
35

<210> SEQ ID NO 89  
<211> LENGTH: 28  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 89

Asp Gly Ser Val Gly Pro Val Gly Pro Ala Gly Pro Ile Gly Ser Ala  
1 5 10 15

Gly Pro Pro Gly Phe Pro Gly Ala Pro Gly Pro Lys  
20 25

<210> SEQ ID NO 90  
<211> LENGTH: 25  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 90

Pro Gly Ala Pro Gly Pro Lys Gly Glu Ile Gly Ala Val Gly Asn Ala  
1 5 10 15

Gly Pro Ala Gly Pro Ala Gly Pro Arg  
20 25

<210> SEQ ID NO 91  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:

-continued

---

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 91

Gly Pro Ala Gly Pro Ala Gly Pro Arg  
1 5

<210> SEQ ID NO 92

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 92

Pro Ala Gly Pro Ala Gly Pro Arg  
1 5

<210> SEQ ID NO 93

<211> LENGTH: 28

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 93

Arg Gly Glu Val Gly Leu Pro Gly Leu Ser Gly Pro Val Gly Pro Pro  
1 5 10 15

Gly Asn Pro Gly Ala Asn Gly Leu Thr Gly Ala Lys  
20 25

<210> SEQ ID NO 94

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 94

Gly Ala Pro Gly Leu Pro Gly Pro Arg  
1 5

<210> SEQ ID NO 95

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 95

Pro Asn Gly Glu Ala Gly Ser Ala Gly Pro Pro Gly Pro Pro Gly Leu  
1 5 10 15

Arg

<210> SEQ ID NO 96

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 96

Gly Pro Arg Gly Leu Pro Gly Ser Pro Gly Asn Ile Gly Pro Ala Gly  
1 5 10 15

-continued

---

Lys

<210> SEQ ID NO 97  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 97

Gly Arg Pro Gly Pro Ile Gly Pro Ala Gly Ala Arg  
1 5 10

<210> SEQ ID NO 98  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 98

Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly  
1 5 10

<210> SEQ ID NO 99  
<211> LENGTH: 27  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 99

Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly Asn Lys Gly Glu Pro Gly  
1 5 10 15

Val Val Gly Ala Val Gly Thr Ala Gly Pro Ser  
20 25

<210> SEQ ID NO 100  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 100

Gly Pro Ser Gly Leu Pro Gly Glu Arg  
1 5

<210> SEQ ID NO 101  
<211> LENGTH: 30  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 101

Gly Ala Val Gly Ala Pro Gly Pro Ala Gly Ala Thr Gly Asp Arg Gly  
1 5 10 15

Glu Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg  
20 25 30

<210> SEQ ID NO 102

-continued

---

<211> LENGTH: 28  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 102

Val Gly Ala Pro Gly Pro Ala Gly Ala Thr Gly Asp Arg Gly Glu Ala  
1 5 10 15

Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg  
20 25

<210> SEQ ID NO 103  
<211> LENGTH: 25  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 103

Pro Gly Pro Ala Gly Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala Ala  
1 5 10 15

Gly Pro Ala Gly Pro Ala Gly Pro Arg  
20 25

<210> SEQ ID NO 104  
<211> LENGTH: 28  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 104

Asn Gly Val Val Gly Pro Thr Gly Pro Val Gly Ala Ala Gly Pro Ala  
1 5 10 15

Gly Pro Asn Gly Pro Pro Gly Pro Ala Gly Ser Arg  
20 25

<210> SEQ ID NO 105  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 105

Gly Pro Pro Gly Pro Ala Gly Ser Arg  
1 5

<210> SEQ ID NO 106  
<211> LENGTH: 24  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 106

Pro Gly Pro Ala Gly Ser Arg Gly Asp Gly Gly Pro Pro Gly Met Thr  
1 5 10 15

Gly Phe Pro Gly Ala Ala Gly Arg  
20

-continued

---

<210> SEQ ID NO 107  
<211> LENGTH: 36  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 107  
  
Gly Asp Gly Gly Pro Pro Gly Met Thr Gly Phe Pro Gly Ala Ala Gly  
1 5 10 15  
  
Arg Thr Gly Pro Pro Gly Pro Ser Gly Ile Ser Gly Pro Pro Gly Pro  
20 25 30  
  
Pro Gly Pro Ala  
35

<210> SEQ ID NO 108  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 108

Ile Ser Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys  
1 5 10

<210> SEQ ID NO 109  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 109

Gly Pro Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly  
1 5 10 15  
  
Pro Gln Gly Leu  
20

<210> SEQ ID NO 110  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 110

Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg  
1 5 10

<210> SEQ ID NO 111  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 111

Ile Ala Gly Pro Pro Gly Ala Arg  
1 5

<210> SEQ ID NO 112  
<211> LENGTH: 28

-continued

---

<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 112

Pro Gly Asn Ile Gly Pro Val Gly Ala Ala Gly Ala Pro Gly Pro His  
1                   5                   10                   15

Gly Pro Val Gly Pro Ala Gly Lys His Gly Asn Arg  
                  20                   25

<210> SEQ ID NO 113  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 113

Val Gly Pro Ala Gly Ala Val Gly Pro Arg  
1                   5                   10

<210> SEQ ID NO 114  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 114

Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg  
1                   5                   10

<210> SEQ ID NO 115  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 115

Gly Pro Ala Gly Pro Ser Gly Pro Ala Gly Lys Asp  
1                   5                   10

<210> SEQ ID NO 116  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 116

Gly Thr Val Gly Pro Ala Gly Ile Arg  
1                   5

<210> SEQ ID NO 117  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 117

Gly Pro Gln Gly Pro Lys Gly Asp Pro Gly Pro Pro Gly Ile Pro Gly

-continued

---

1                    5                    10                    15

Arg

<210> SEQ ID NO 118  
 <211> LENGTH: 45  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 118

Pro Gly Thr Ser Gly His Pro Gly Ser Pro Gly Ser Pro Gly Tyr Gln  
 1                    5                    10                    15

Gly Pro Pro Gly Glu Pro Gly Gln Ala Gly Pro Ser Gly Pro Pro Gly  
                   20                    25                    30

Pro Pro Gly Ala Ile Gly Pro Ser Gly Pro Ala Gly Lys  
                   35                    40                    45

<210> SEQ ID NO 119  
 <211> LENGTH: 13  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 119

Gly Leu Pro Gly Pro Pro Gly Ile Lys Gly Pro Ala Gly  
 1                    5                    10

<210> SEQ ID NO 120  
 <211> LENGTH: 28  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 120

Gly Glu Val Gly Pro Ala Gly Ser Pro Gly Ser Asn Gly Ala Pro Gly  
 1                    5                    10                    15

Gln Arg Gly Glu Pro Gly Pro Gln Gly His Ala Gly  
                   20                    25

<210> SEQ ID NO 121  
 <211> LENGTH: 37  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 121

Gly Glu Pro Gly Pro Gln Gly His Ala Gly Ala Gln Gly Pro Pro Gly  
 1                    5                    10                    15

Pro Pro Gly Ile Asn Gly Ser Pro Gly Gly Lys Gly Glu Met Gly Pro  
                   20                    25                    30

Ala Gly Ile Pro Gly  
                   35

<210> SEQ ID NO 122  
 <211> LENGTH: 25  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence

-continued

---

<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 122

Gly Glu Met Gly Pro Ala Gly Ile Pro Gly Ala Pro Gly Leu Met Gly  
1           5                   10                   15

Ala Arg Gly Pro Pro Gly Pro Ala Gly  
          20                   25

<210> SEQ ID NO 123  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 123

Gly Ile Pro Gly Ala Pro Gly Leu Met Gly Ala Arg  
1           5                   10

<210> SEQ ID NO 124  
<211> LENGTH: 24  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 124

Gly Ala Pro Gly Leu Met Gly Ala Arg Gly Pro Pro Gly Pro Ala Gly  
1           5                   10                   15

Ala Asn Gly Ala Pro Gly Leu Arg  
          20

<210> SEQ ID NO 125  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 125

Pro Ala Gly Glu Arg Gly Ala Pro Gly Pro Ala Gly Pro Arg  
1           5                   10

<210> SEQ ID NO 126  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 126

Gly Ala Pro Gly Pro Ala Gly Pro Arg Gly Ala Ala Gly Glu Pro  
1           5                   10                   15

<210> SEQ ID NO 127  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 127

-continued

---

Gly Glu Pro Gly Arg Asp Gly Val Pro Gly Gly Pro Gly Met Arg  
1 5 10 15

<210> SEQ ID NO 128  
 <211> LENGTH: 25  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 128

Asp Gly Lys Pro Gly Pro Pro Gly Ser Gln Gly Glu Ser Gly Arg Pro  
1 5 10 15

Gly Pro Pro Gly Pro Ser Gly Pro Arg  
20 25

<210> SEQ ID NO 129  
 <211> LENGTH: 24  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 129

Gly Lys Pro Gly Pro Pro Gly Ser Gln Gly Glu Ser Gly Arg Pro Gly  
1 5 10 15

Pro Pro Gly Pro Ser Gly Pro Arg  
20

<210> SEQ ID NO 130  
 <211> LENGTH: 12  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 130

Gly Arg Pro Gly Pro Pro Gly Pro Ser Gly Pro Arg  
1 5 10

<210> SEQ ID NO 131  
 <211> LENGTH: 9  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 131

Gly Pro Pro Gly Pro Ser Gly Pro Arg  
1 5

<210> SEQ ID NO 132  
 <211> LENGTH: 25  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 132

Gln Gly Pro Pro Gly Lys Asn Gly Glu Thr Gly Pro Gln Gly Pro Pro  
1 5 10 15

Gly Pro Thr Gly Pro Gly Gly Asp Lys  
20 25

-continued

---

<210> SEQ ID NO 133  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 133

Gly Asp Ala Gly Ala Pro Gly Glu Arg Gly Pro  
1                    5                    10

<210> SEQ ID NO 134  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 134

Leu Gln Gly Met Pro Gly Glu Arg  
1                    5

<210> SEQ ID NO 135  
<211> LENGTH: 26  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 135

Gly Glu Gly Gly Pro Pro Gly Val Ala Gly Pro Pro Gly Gly Ser Gly  
1                    5                    10                    15

Pro Ala Gly Pro Pro Gly Pro Gln Gly Val  
20                    25

<210> SEQ ID NO 136  
<211> LENGTH: 39  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 136

Gly Ser Asn Gly Asn Pro Gly Pro Pro Gly Pro Ser Gly Ser Pro Gly  
1                    5                    10                    15

Lys Asp Gly Pro Pro Gly Pro Ala Gly Asn Thr Gly Ala Pro Gly Ser  
20                    25                    30

Pro Gly Val Ser Gly Pro Lys  
35

<210> SEQ ID NO 137  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 137

Asn Gly Asn Pro Gly Pro Pro Gly Pro Ser Gly Ser Pro Gly Lys  
1                    5                    10                    15

-continued

---

<210> SEQ ID NO 138  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 138

Gly Ser Pro Gly Ala Gln Gly Pro Pro  
1 5

<210> SEQ ID NO 139  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 139

Gly Asn Pro Gly Ser Asp Gly Leu Pro Gly Arg  
1 5 10

<210> SEQ ID NO 140  
<211> LENGTH: 25  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 140

Glu Asn Gly Ser Pro Gly Ala Pro Gly Ala Pro Gly His Pro Gly Pro  
1 5 10 15

Pro Gly Pro Val Gly Pro Ala Gly Lys  
20 25

<210> SEQ ID NO 141  
<211> LENGTH: 21  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 141

Pro Gly Ala Pro Gly Ala Pro Gly His Pro Gly Pro Pro Gly Pro Val  
1 5 10 15

Gly Pro Ala Gly Lys  
20

<210> SEQ ID NO 142  
<211> LENGTH: 19  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 142

Arg Gly Glu Ser Gly Pro Ala Gly Pro Ala Gly Ala Pro Gly Pro Ala  
1 5 10 15

Gly Ser Arg

<210> SEQ ID NO 143  
<211> LENGTH: 12  
<212> TYPE: PRT

-continued

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 143

Gly Glu Ser Gly Pro Ala Gly Pro Ala Gly Ala Pro  
 1                    5                    10

&lt;210&gt; SEQ ID NO 144

&lt;211&gt; LENGTH: 25

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 144

Pro Gly Ala Pro Gly Ser Pro Gly Pro Ala Gly Gln Gln Gly Ala Ile  
 1                    5                    10                    15

Gly Ser Pro Gly Pro Ala Gly Pro Arg  
                   20                    25

&lt;210&gt; SEQ ID NO 145

&lt;211&gt; LENGTH: 26

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 145

Gly Gln Gln Gly Ala Ile Gly Ser Pro Gly Pro Ala Gly Pro Arg Gly  
 1                    5                    10                    15

Pro Val Gly Pro Ser Gly Pro Pro Gly Lys  
                   20                    25

&lt;210&gt; SEQ ID NO 146

&lt;211&gt; LENGTH: 13

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 146

Gln Gly Ala Ile Gly Ser Pro Gly Pro Ala Gly Pro Arg  
 1                    5                    10

&lt;210&gt; SEQ ID NO 147

&lt;211&gt; LENGTH: 49

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 147

Gly Ser Glu Gly Ser Pro Gly His Pro Gly Gln Pro Gly Pro Pro Gly  
 1                    5                    10                    15

Pro Pro Gly Ala Pro Gly Pro Cys Cys Gly Gly Val Gly Ala Ala Ala  
                   20                    25                    30

Ile Ala Gly Ile Gly Gly Glu Lys Ala Gly Gly Phe Ala Pro Tyr Tyr  
                   35                    40                    45

Gly

-continued

---

<210> SEQ ID NO 148  
<211> LENGTH: 44  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 148

Gly Pro Gln Gly Phe Gln Gly Asn Pro Gly Glu Pro Gly Glu Pro Gly  
1 5 10 15  
Val Ser Gly Pro Met Gly Pro Arg Gly Pro Pro Gly Pro Pro Gly Lys  
20 25 30  
Pro Gly Asp Asp Gly Glu Ala Gly Lys Pro Gly Lys  
35 40

<210> SEQ ID NO 149  
<211> LENGTH: 36  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 149

Gly Ala Ala Gly Ala Arg Gly Asn Asp Gly Gln Pro Gly Pro Ala Gly  
1 5 10 15  
Pro Pro Gly Pro Val Gly Pro Ala Gly Gly Pro Gly Phe Pro Gly Ala  
20 25 30  
Pro Gly Ala Lys  
35

<210> SEQ ID NO 150  
<211> LENGTH: 35  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 150

Ala Ala Gly Ala Arg Gly Asn Asp Gly Gln Pro Gly Pro Ala Gly Pro  
1 5 10 15  
Pro Gly Pro Val Gly Pro Ala Gly Gly Pro Gly Phe Pro Gly Ala Pro  
20 25 30  
Gly Ala Lys  
35

<210> SEQ ID NO 151  
<211> LENGTH: 22  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 151

Pro Gly Ala Lys Gly Ser Ala Gly Ala Pro Gly Ile Ala Gly Ala Pro  
1 5 10 15  
Gly Phe Pro Gly Pro Arg  
20

<210> SEQ ID NO 152  
<211> LENGTH: 18  
<212> TYPE: PRT

-continued

---

<213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 152

Gly Pro Arg Gly Pro Pro Gly Pro Gln Gly Ala Thr Gly Pro Leu Gly  
 1                   5                   10                   15

Pro Lys

<210> SEQ ID NO 153  
 <211> LENGTH: 7  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 153

Asp Gly Leu Ala Gly Pro Lys  
 1                   5

<210> SEQ ID NO 154  
 <211> LENGTH: 26  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 154

Pro Gln Gly Lys Val Gly Pro Ser Gly Ala Pro Gly Glu Asp Gly Arg  
 1                   5                   10                   15

Pro Gly Pro Pro Gly Pro Gln Gly Ala Arg  
 20                   25

<210> SEQ ID NO 155  
 <211> LENGTH: 14  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 155

Gly Phe Pro Gly Pro Lys Gly Ala Asn Gly Glu Pro Gly Lys  
 1                   5                   10

<210> SEQ ID NO 156  
 <211> LENGTH: 33  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 156

Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Glu Gly Gly Lys Pro Gly  
 1                   5                   10                   15

Asp Gln Gly Val Pro Gly Glu Ala Gly Ala Pro Gly Leu Val Gly Pro  
 20                   25                   30

Arg

<210> SEQ ID NO 157  
 <211> LENGTH: 27  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence

-continued

---

<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 157

Gly Pro Pro Gly Glu Gly Gly Lys Pro Gly Asp Gln Gly Val Pro Gly  
1           5                   10                   15

Glu Ala Gly Ala Pro Gly Leu Val Gly Pro Arg  
          20                   25

<210> SEQ ID NO 158  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 158

Leu Gln Gly Met Pro Gly Glu Arg  
1                   5

<210> SEQ ID NO 159  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 159

Gly Arg Gly Leu Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala Gly Ala  
1           5                   10                   15

Asn Gly Glu Lys  
          20

<210> SEQ ID NO 160  
<211> LENGTH: 24  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 160

Gly Leu Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala Gly Ala Asn Gly  
1           5                   10                   15

Glu Lys Gly Glu Val Gly Pro Pro  
          20

<210> SEQ ID NO 161  
<211> LENGTH: 31  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 161

Gly Leu Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala Gly Ala Asn Gly  
1           5                   10                   15

Glu Lys Gly Glu Val Gly Pro Pro Gly Pro Ala Gly Ser Ala Gly  
          20                   25                   30

<210> SEQ ID NO 162  
<211> LENGTH: 32  
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 162

Leu Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala Gly Ala Asn Gly Glu  
1 5 10 15

Lys Gly Glu Val Gly Pro Pro Gly Pro Ala Gly Ser Ala Gly Ala Arg  
20 25 30

<210> SEQ ID NO 163

<211> LENGTH: 31

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 163

Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala Gly Ala Asn Gly Glu Lys  
1 5 10 15

Gly Glu Val Gly Pro Pro Gly Pro Ala Gly Ser Ala Gly Ala Arg  
20 25 30

<210> SEQ ID NO 164

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 164

Phe Ala Gly Pro Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys  
1 5 10

<210> SEQ ID NO 165

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 165

Ala Gly Pro Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys  
1 5 10

<210> SEQ ID NO 166

<211> LENGTH: 22

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 166

Ser Gly Pro Pro Gly Arg Ala Gly Glu Pro Gly Leu Gln Gly Pro Ala  
1 5 10 15

Gly Pro Pro Gly Glu Lys  
20

<210> SEQ ID NO 167

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

-continued

---

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 167

Gly Pro Pro Gly Arg Ala Gly Glu Pro Gly Leu Gln Gly Pro Ala Gly  
1 5 10 15

Pro Pro Gly Glu Lys  
20

<210> SEQ ID NO 168  
<211> LENGTH: 25  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 168

Pro Pro Gly Leu Thr Gly Pro Ala Gly Glu Pro Gly Arg Glu Gly Ser  
1 5 10 15

Pro Gly Ala Asp Gly Pro Pro Gly Arg  
20 25

<210> SEQ ID NO 169  
<211> LENGTH: 18  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 169

Pro Gly Pro Gly Ile Asp Met Ser Ala Phe Ala Gly Leu Gly Pro Arg  
1 5 10 15

Glu Lys

<210> SEQ ID NO 170  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 170

Ile Glu Trp His Leu Asn Ala Phe  
1 5

<210> SEQ ID NO 171  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 171

Ala Ile Thr Gly Pro Pro Thr Glu Leu Ile Thr Ser Glu Val Thr Ala  
1 5 10 15

Arg

<210> SEQ ID NO 172  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

---

-continued

---

<400> SEQUENCE: 172

Ala Ile Tyr Ala His Thr Ala Ser Glu Gly Leu Arg  
1                   5                   10

<210> SEQ ID NO 173

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 173

Leu Tyr Asp Val Thr Glu Asn Ser Met Arg  
1                   5                   10

<210> SEQ ID NO 174

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 174

Tyr Leu Ile Leu Tyr Ala Pro Leu Thr Glu Gly Leu Ala Gly Asp Glu  
1                   5                   10                   15

Lys Glu Met Lys  
                  20

<210> SEQ ID NO 175

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 175

Tyr Ala Pro Leu Thr Glu Gly Leu Ala Gly Asp Glu Lys  
1                   5                   10

<210> SEQ ID NO 176

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 176

His Val Glu Met Thr Ser Leu Cys Ala His  
1                   5                   10

<210> SEQ ID NO 177

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 177

Ser Ile Gln Gly Met Pro Gly Met Pro Gly Glu Lys Gly Glu Lys  
1                   5                   10                   15

<210> SEQ ID NO 178

-continued

---

<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 178

Gln Val Cys Glu Gln Leu Ile Gln Ser His  
1                  5                          10

<210> SEQ ID NO 179  
<211> LENGTH: 35  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 179

Glu Pro Gly Arg Pro Gly Ser Pro Gly Ala Pro Gly Glu Gln Gly Pro  
1                  5                          10                          15

Pro Gly Thr Pro Gly Phe Pro Gly Asn Ala Gly Val Pro Gly Thr Pro  
                  20                          25                          30

Gly Glu Arg  
                  35

<210> SEQ ID NO 180  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 180

Gly Gly Ser Thr Asn Thr Gly Lys Ala Met Thr Tyr Val Arg Glu  
1                  5                          10                          15

<210> SEQ ID NO 181  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 181

Pro Lys Val Met Ile Leu Ile Thr Asp Gly Lys  
1                  5                          10

<210> SEQ ID NO 182  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 182

Pro Asp Asp Thr His Ala Tyr Asn Val Ala Asp Phe Glu Ser Leu Ser  
1                  5                          10                          15

Arg

<210> SEQ ID NO 183  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 183

Ser Val Val Glu Asp Glu Tyr Ser Glu Pro Leu Lys  
1           5                   10

<210> SEQ ID NO 184

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 184

Ser Glu Thr Ser Thr Ser Leu Lys Asp  
1           5

<210> SEQ ID NO 185

<211> LENGTH: 25

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 185

Leu Lys Pro Asp Thr Pro Tyr Thr Ile Thr Val Ser Ser Leu Tyr Pro  
1           5                   10                   15

Asp Gly Glu Gly Gly Arg Met Thr Gly  
          20                   25

<210> SEQ ID NO 186

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 186

Pro Gly Pro Ala Gly Gly Pro Gly Ala Lys  
1           5                   10

<210> SEQ ID NO 187

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 187

Gly Arg Thr Gly Thr Pro Gly Leu Pro Gly Pro Pro Gly Pro Met Gly  
1           5                   10                   15

Pro Pro Gly Asp Arg  
          20

<210> SEQ ID NO 188

<211> LENGTH: 22

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 188

-continued

---

Thr Pro Gly Leu Pro Gly Pro Pro Gly Pro Met Gly Pro Pro Gly Asp  
1 5 10 15

Arg Gly Phe Thr Gly Lys  
20

<210> SEQ ID NO 189  
<211> LENGTH: 21  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 189

Gly Phe Pro Gly Thr Pro Gly Met Gln Gly Pro Pro Gly Glu Arg Gly  
1 5 10 15

Leu Pro Gly Glu Lys  
20

<210> SEQ ID NO 190  
<211> LENGTH: 7  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 190

Gln Gly Pro Pro Gly Glu Arg  
1 5

<210> SEQ ID NO 191  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 191

Pro Arg Gly Leu Pro Gly Pro Pro Gly Pro Gln Gly Glu Ser Arg  
1 5 10 15

<210> SEQ ID NO 192  
<211> LENGTH: 23  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 192

Pro Pro Ser Leu Gly Arg Pro Trp Ala Pro Leu Thr Gly Pro Ser Val  
1 5 10 15

Pro Pro Pro Ser Ser Gly Arg  
20

<210> SEQ ID NO 193  
<211> LENGTH: 28  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 193

Pro Gly Glu Asp Gly Lys Pro Gly Asp Thr Gly Pro Gln Gly Phe Pro  
1 5 10 15

-continued

---

Gly Thr Pro Gly Asp Val Gly Pro Lys Gly Asp Lys  
                   20                                  25

<210> SEQ ID NO 194  
 <211> LENGTH: 9  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 194

Pro Gly Leu Pro Gly Glu Pro Gly Arg  
 1                                  5

<210> SEQ ID NO 195  
 <211> LENGTH: 20  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 195

Gly Arg Glu Gly Pro Pro Gly Phe Pro Gly Leu Pro Gly Pro Pro Gly  
 1                                  5                                  10                                  15

Pro Pro Gly Arg  
                   20

<210> SEQ ID NO 196  
 <211> LENGTH: 33  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 196

Gln Asp Gly Ser Val Leu Ser Val Pro Gly Pro Glu Gly Arg Pro Gly  
 1                                  5                                  10                                  15

Phe Ala Gly Phe Pro Gly Pro Ala Gly Pro Lys Gly Asn Leu Gly Ser  
                   20                                  25                                  30

Lys

<210> SEQ ID NO 197  
 <211> LENGTH: 21  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 197

Ala Glu Ser Ser Arg Pro Gly Pro Pro Gly Leu Pro Gly Asn Gln Gly  
 1                                  5                                  10                                  15

Pro Pro Gly Pro Lys  
                   20

<210> SEQ ID NO 198  
 <211> LENGTH: 9  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 198

-continued

Gly Pro Pro Gly Pro Lys Gly Ala Lys  
1 5

<210> SEQ ID NO 199  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 199

Pro Gly Pro Pro Gly Pro Pro Gly Thr Met Gly Ala Ser Ser Gly Val  
1 5 10 15

Arg

<210> SEQ ID NO 200  
<211> LENGTH: 34  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 200

Arg Leu Pro Glu Pro Gln Pro Tyr Pro Gly Ala Pro His His Ser Ser  
1 5 10 15

Tyr Val His Leu Arg Pro Ala Arg Pro Thr Ser Pro Pro Ala His Ser  
20 25 30

His Arg

<210> SEQ ID NO 201  
<211> LENGTH: 16  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 201

Leu Pro Glu Pro Gln Pro Tyr Pro Gly Ala Pro His His Ser Ser Tyr  
1 5 10 15

<210> SEQ ID NO 202  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 202

Asn Ser Pro Leu Ser Gly Gly Met Arg  
1 5

<210> SEQ ID NO 203  
<211> LENGTH: 22  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 203

Pro Ser Leu Gly Arg Pro Trp Ala Pro Leu Thr Gly Pro Ser Val Pro  
1 5 10 15

-continued

---

Pro Pro Ser Ser Glu Arg  
20

<210> SEQ ID NO 204  
 <211> LENGTH: 24  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 204

Gly Ala Arg Gly Val Ser Gly Phe Pro Gly Ala Asp Gly Ile Pro Gly  
1 5 10 15

His Pro Gly Gln Gly Gly Pro Arg  
20

<210> SEQ ID NO 205  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 205

Gly Gly Pro Lys Gly Leu Pro Gly Leu Pro Gly Pro Pro Gly Pro Thr  
1 5 10 15

Gly Ala Lys

<210> SEQ ID NO 206  
 <211> LENGTH: 33  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 206

Gly Pro Pro Gly Leu His Gly Phe Pro Gly Ala Pro Gly Gln Glu Gly  
1 5 10 15

Pro Leu Gly Leu Pro Gly Ile Pro Gly Arg Glu Gly Leu Pro Gly Asp  
20 25 30

Arg

<210> SEQ ID NO 207  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 207

Ala Pro Gly Arg Pro Gly Ser Pro Gly Leu Pro Gly Met Pro Gly Arg  
1 5 10 15

<210> SEQ ID NO 208  
 <211> LENGTH: 14  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 208

Leu Tyr Cys Asn Pro Gly Asp Val Cys Tyr Tyr Ala Ser Arg

-continued

---

1                    5                    10

<210> SEQ ID NO 209  
 <211> LENGTH: 26  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 209

Leu Met His Thr Ala Ala Gly Asp Glu Gly Gly Gly Gln Ser Leu Val  
 1                    5                    10                    15

Ser Pro Gly Ser Cys Leu Glu Asp Phe Arg  
                   20                    25

<210> SEQ ID NO 210  
 <211> LENGTH: 25  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 210

Glu Pro Gly Pro Pro Gly Leu Pro Gly Ser Val Gly Ser Pro Gly Val  
 1                    5                    10                    15

Pro Gly Ile Gly Pro Pro Gly Ala Arg  
                   20                    25

<210> SEQ ID NO 211  
 <211> LENGTH: 30  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 211

Pro Gly Val Pro Gly Ile Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly  
 1                    5                    10                    15

Gly Gln Gly Pro Pro Gly Leu Ser Gly Pro Pro Gly Ile Lys  
                   20                    25                    30

<210> SEQ ID NO 212  
 <211> LENGTH: 20  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 212

Pro Pro Gly Gly Gln Gly Pro Pro Gly Leu Ser Gly Pro Pro Gly Ile  
 1                    5                    10                    15

Lys Gly Glu Lys  
                   20

<210> SEQ ID NO 213  
 <211> LENGTH: 20  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 213

-continued

---

Asp Pro Gly Phe Gln Gly Met Pro Gly Ile Gly Gly Ser Pro Gly Ile  
1 5 10 15

Thr Gly Ser Lys  
20

<210> SEQ ID NO 214  
<211> LENGTH: 28  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 214

Lys Gly Gln Gln Gly Val Thr Gly Leu Val Gly Ile Pro Gly Pro Pro  
1 5 10 15

Gly Ile Pro Gly Phe Asp Gly Ala Pro Gly Gln Lys  
20 25

<210> SEQ ID NO 215  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 215

Ser Leu Leu Tyr Val Gln Gly Asn Glu Arg  
1 5 10

<210> SEQ ID NO 216  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 216

Leu Phe Cys Asn Ile Asn Asn Val Cys Asn Phe Ala Ser Arg  
1 5 10

<210> SEQ ID NO 217  
<211> LENGTH: 26  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 217

Val Met His Thr Ser Ala Gly Ala Glu Gly Ser Gly Gln Ala Leu Ala  
1 5 10 15

Ser Pro Gly Ser Cys Leu Glu Glu Phe Arg  
20 25

<210> SEQ ID NO 218  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 218

Arg Ser Ala Pro Phe Ile Glu Cys His Gly Arg  
1 5 10

-continued

---

<210> SEQ ID NO 219  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 219

Ser Phe Trp Leu Ala Thr Ile Glu Arg  
1 5

<210> SEQ ID NO 220  
<211> LENGTH: 7  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 220

Trp Leu Ala Thr Ile Glu Arg  
1 5

<210> SEQ ID NO 221  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 221

Asp Gly Ile Pro Gly Pro Pro Gly Pro Lys  
1 5 10

<210> SEQ ID NO 222  
<211> LENGTH: 46  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 222

Lys Gly Asn Pro Gly Tyr Pro Gly Pro Pro Gly Ile Gln Gly Leu Pro  
1 5 10 15

Gly Pro Thr Gly Ile Pro Gly Pro Ile Gly Pro Pro Gly Pro Pro Gly  
20 25 30

Leu Met Gly Pro Pro Gly Pro Pro Gly Leu Pro Gly Pro Lys  
35 40 45

<210> SEQ ID NO 223  
<211> LENGTH: 24  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 223

Pro His Ile Pro Pro Ser Asp Glu Ile Cys Glu Pro Gly Pro Pro Gly  
1 5 10 15

Pro Pro Gly Ser Pro Gly Asp Lys  
20

-continued

---

<210> SEQ ID NO 224  
<211> LENGTH: 18  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 224  
  
Gly Leu Pro Gly Leu Pro Gly Pro Pro Gly Ser Leu Gly Phe Pro Gly  
1 5 10 15

Gln Lys

<210> SEQ ID NO 225  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 225

Pro Lys Gly Glu Pro Gly Gly Ile Thr Phe Lys  
1 5 10

<210> SEQ ID NO 226  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 226

Thr Pro Gly Arg Ile Gly Leu Glu Gly Pro Pro Gly Pro Pro Gly Phe  
1 5 10 15

Pro Gly Pro Lys  
20

<210> SEQ ID NO 227  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 227

Gly Pro Pro Gly Arg Thr Gly Leu Asp Gly Leu Pro Gly Pro Lys  
1 5 10 15

<210> SEQ ID NO 228  
<211> LENGTH: 16  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 228

Ala Pro Gly Pro Ile Gly Pro Pro Gly Ser Pro Gly Leu Pro Gly Lys  
1 5 10 15

<210> SEQ ID NO 229  
<211> LENGTH: 21  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

-continued

&lt;400&gt; SEQUENCE: 229

Lys Gly Glu Pro Gly Leu Pro Gly Pro Pro Gly Pro Met Asp Pro Asn  
 1 5 10 15  
 Leu Leu Gly Ser Lys  
 20

&lt;210&gt; SEQ ID NO 230

&lt;211&gt; LENGTH: 22

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 230

Pro Gly Glu Pro Gly Pro Val Gly Gly Gly Gly His Pro Gly Gln Pro  
 1 5 10 15  
 Gly Pro Pro Gly Glu Lys  
 20

&lt;210&gt; SEQ ID NO 231

&lt;211&gt; LENGTH: 43

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 231

Pro Ala Leu Glu Gly Pro Lys Gly Asn Pro Gly Pro Gln Gly Pro Pro  
 1 5 10 15  
 Gly Arg Pro Gly Pro Thr Gly Phe Gln Gly Leu Pro Gly Pro Glu Gly  
 20 25 30  
 Pro Pro Gly Leu Pro Gly Asn Gly Gly Ile Lys  
 35 40

&lt;210&gt; SEQ ID NO 232

&lt;211&gt; LENGTH: 19

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 232

Gly Pro Pro Gly Pro Pro Gly Leu Pro Gly Pro Ser Gly Gln Ser Ile  
 1 5 10 15  
 Ile Ile Lys

&lt;210&gt; SEQ ID NO 233

&lt;211&gt; LENGTH: 11

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic amino acid sequence

&lt;400&gt; SEQUENCE: 233

Val Asp Gly Ala Thr Gly Leu Pro Gly Met Lys  
 1 5 10

&lt;210&gt; SEQ ID NO 234

&lt;211&gt; LENGTH: 34

&lt;212&gt; TYPE: PRT

-continued

---

<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 234

Lys Gly Gln Ala Gly Pro Pro Gly Val Met Gly Pro Pro Gly Pro Pro  
1 5 10 15

Gly Pro Pro Gly Pro Pro Gly Pro Gly Cys Thr Met Gly Leu Gly Phe  
20 25 30

Glu Asp

<210> SEQ ID NO 235  
<211> LENGTH: 18  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 235

Lys Leu Gln Leu Gly Glu Leu Ile Pro Ile Pro Ala Asp Ser Pro Pro  
1 5 10 15

Pro Pro

<210> SEQ ID NO 236  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 236

Ala Trp Arg Thr Ala Asp Thr Ala Val Thr Gly Leu Ala Ser Pro Leu  
1 5 10 15

Ser Thr Gly Lys  
20

<210> SEQ ID NO 237  
<211> LENGTH: 18  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 237

Ala Val Thr Gly Leu Ala Ser Pro Leu Ser Thr Gly Lys Ile Leu Asp  
1 5 10 15

Gln Lys

<210> SEQ ID NO 238  
<211> LENGTH: 50  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 238

Gly Val Glu Asp Ala Asp Glu Gly Ala Leu Lys Glu Ile Ala Ser Glu  
1 5 10 15

Pro Leu Asn Met His Met Phe Asn Leu Glu Asn Phe Thr Ser Leu His  
20 25 30

-continued

---

Asp Ile Val Gly Asn Leu Val Ser Cys Val His Ser Ser Val Ser Pro  
                   35                                  40                                  45

Glu Arg  
       50

<210> SEQ ID NO 239  
 <211> LENGTH: 11  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 239

Asn Asn Leu Phe Thr Ser Ser Ala Gly Tyr Arg  
 1                  5                                  10

<210> SEQ ID NO 240  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 240

Ala Ala Pro Leu Gln Gly Met Leu Pro Gly Leu Leu Ala Pro Leu Arg  
 1                  5                                  10                                  15

<210> SEQ ID NO 241  
 <211> LENGTH: 10  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 241

Ile Gly Asp Leu His Pro Gln Ile Val Asn  
 1                  5                                  10

<210> SEQ ID NO 242  
 <211> LENGTH: 8  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 242

Gly Pro Gln Gly Asp Gln Gly Arg  
 1                  5

<210> SEQ ID NO 243  
 <211> LENGTH: 8  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 243

Thr Asp Pro Ala His Asp Val Arg  
 1                  5

<210> SEQ ID NO 244  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence

-continued

---

<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 244  
  
Phe Ser Asp Gly Asn Ser Gln Gly Ala Thr Pro Ala Ala Ile Glu Lys  
1           5                   10                   15

<210> SEQ ID NO 245  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 245

Gln Val Asn Glu Pro His Ile Arg  
1           5

<210> SEQ ID NO 246  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 246

Gly Val Phe His Gln Thr Val Ser Arg  
1           5

<210> SEQ ID NO 247  
<211> LENGTH: 23  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 247

Gly Pro Gly Leu Leu Leu Ala Val Gln Cys Leu Gly Thr Ala Val  
1           5                   10                   15  
  
Pro Ser Thr Gly Ala Ser Lys  
          20

<210> SEQ ID NO 248  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 248

Ala Leu Val Cys Thr Cys Tyr Gly Gly Ser Arg  
1           5                   10

<210> SEQ ID NO 249  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 249

Met Val Asp Cys Thr Cys Leu Gly Glu Gly Ser Gly Arg  
1           5                   10

-continued

---

<210> SEQ ID NO 250  
<211> LENGTH: 16  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 250

Ala Ala His Glu Glu Ile Cys Thr Thr Asn Glu Gly Val Met Tyr Arg  
1 5 10 15

<210> SEQ ID NO 251  
<211> LENGTH: 16  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 251

Ser His Pro Ile Gln Trp Asn Ala Pro Gln Pro Ser His Ile Ser Lys  
1 5 10 15

<210> SEQ ID NO 252  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 252

Val Val Ser Trp Val Ser Ala Ser Asp Thr Val Ser Gly Phe Arg  
1 5 10 15

<210> SEQ ID NO 253  
<211> LENGTH: 19  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 253

Ser Asp Thr Val Pro Ser Pro Arg Asp Leu Gln Phe Val Glu Val Thr  
1 5 10 15

Asp Val Lys

<210> SEQ ID NO 254  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 254

Val Asp Val Ile Pro Val Asn Leu Pro Gly Glu His Gly Gln Arg  
1 5 10 15

<210> SEQ ID NO 255  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 255

-continued

---

Val Phe Ala Val Ser His Gly Arg Glu Ser Lys Pro Leu Thr Ala Gln  
1 5 10 15

Gln Thr Thr Lys  
20

<210> SEQ ID NO 256  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 256

Leu Gly Val Arg Pro Ser Gln Gly Gly Glu Ala Pro Arg  
1 5 10

<210> SEQ ID NO 257  
<211> LENGTH: 19  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 257

Asp Ala Pro Ile Val Asn Lys Val Val Thr Pro Leu Ser Pro Pro Thr  
1 5 10 15

Asn Leu His

<210> SEQ ID NO 258  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 258

Thr Pro Asp Ile Thr Gly Tyr Arg  
1 5

<210> SEQ ID NO 259  
<211> LENGTH: 22  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 259

Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln His  
1 5 10 15

Glu Ser Thr Pro Leu Arg  
20

<210> SEQ ID NO 260  
<211> LENGTH: 22  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 260

Thr Gly Leu Asp Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala  
1 5 10 15

-continued

---

Asn Ser Phe Thr Val His  
20

<210> SEQ ID NO 261  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 261

Thr Val His Trp Ile Ala Pro Arg  
1 5

<210> SEQ ID NO 262  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 262

Ser Pro Val Gln Glu Phe Thr Val Pro Gly Ser Lys  
1 5 10

<210> SEQ ID NO 263  
<211> LENGTH: 28  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 263

Val Val Ser Val Tyr Ala Gln Asn Pro Ser Gly Glu Ser Gln Pro Leu  
1 5 10 15

Val Gln Thr Ala Val Thr Asn Ile Asp Arg Pro Lys  
20 25

<210> SEQ ID NO 264  
<211> LENGTH: 37  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 264

Arg Pro Gly Ser Glu Tyr Thr Val Ser Val Val Ala Leu His Asp Asp  
1 5 10 15

Met Glu Ser Gln Pro Leu Ile Gly Thr Gln Ser Thr Ala Ile Pro Ala  
20 25 30

Pro Thr Asp Leu Lys  
35

<210> SEQ ID NO 265  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 265

Tyr Glu Val Ser Val Tyr Ala Leu Lys

-continued

---

1 5

<210> SEQ ID NO 266  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 266

Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg  
1 5 10

<210> SEQ ID NO 267  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 267

Ser Leu Leu Val Ser Trp Gln Pro Pro Arg  
1 5 10

<210> SEQ ID NO 268  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 268

Tyr Glu Lys Pro Gly Ser Pro Pro Arg  
1 5

<210> SEQ ID NO 269  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 269

Thr Pro Phe Val Thr His Pro Gly  
1 5

<210> SEQ ID NO 270  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 270

Thr Pro Phe Val Thr His Pro Gly Tyr Asp Thr  
1 5 10

<210> SEQ ID NO 271  
<211> LENGTH: 31  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 271

-continued

Thr Pro Phe Val Thr His Pro Gly Tyr Asp Thr Gly Asn Gly Ile Gln  
1 5 10 15

Leu Pro Gly Thr Ser Gly Gln Gln Pro Ser Val Gly Gln Gln Met  
20 25 30

<210> SEQ ID NO 272  
<211> LENGTH: 23  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 272

Gln Asp Thr Ser Glu Tyr Ile Ile Ser Cys His Pro Val Gly Thr Asp  
1 5 10 15

Glu Glu Pro Leu Gln Phe Arg  
20

<210> SEQ ID NO 273  
<211> LENGTH: 27  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 273

Val Pro Gly Thr Ser Thr Ser Ala Thr Leu Thr Gly Leu Thr Arg Gly  
1 5 10 15

Ala Thr Tyr Asn Ile Ile Val Glu Ala Leu Lys  
20 25

<210> SEQ ID NO 274  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 274

Val Arg Glu Glu Val Val Thr Val Gly Asn  
1 5 10

<210> SEQ ID NO 275  
<211> LENGTH: 31  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 275

Ser Val Asn Glu Gly Leu Asn Gln Pro Thr Asp Asp Ser Cys Phe Asp  
1 5 10 15

Pro Tyr Thr Val Ser His Tyr Ala Val Gly Asp Glu Trp Glu Arg  
20 25 30

<210> SEQ ID NO 276  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

-continued

---

<400> SEQUENCE: 276

Leu Gly Phe Gly Ser Gly His Phe Arg  
1 5

<210> SEQ ID NO 277

<211> LENGTH: 27

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 277

Ala Cys Glu Asp Ile Asp Glu Cys Ser Leu Pro Asn Ile Cys Val Phe  
1 5 10 15

Gly Thr Cys His Asn Leu Pro Gly Leu Phe Arg  
20 25

<210> SEQ ID NO 278

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 278

Thr Gly Leu Pro Val Asp Ile Asp Glu Cys Arg  
1 5 10

<210> SEQ ID NO 279

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 279

Pro Val Asp Ile Asp Glu Cys Arg  
1 5

<210> SEQ ID NO 280

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 280

Glu Ile Pro Gly Val Cys Asn Gly Val Cys Ile Asn His Val Gly Ser  
1 5 10 15

Phe Arg

<210> SEQ ID NO 281

<211> LENGTH: 19

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 281

Glu Ile Pro Gly Val Cys Glu Asn Gly Val Cys Ile Asn Met Val Gly  
1 5 10 15

Ser Phe Arg

-continued

---

<210> SEQ ID NO 282  
<211> LENGTH: 18  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 282

Leu Leu Val Cys Glu Asp Ile Asp Glu Cys Gln Asn Gly Pro Val Cys  
1 5 10 15

Gln Arg

<210> SEQ ID NO 283  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 283

Thr Cys Val Asp Ile Asn Glu Cys Leu Leu Glu Pro Arg  
1 5 10

<210> SEQ ID NO 284  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 284

Gly Glu Gly Trp Gly Asp Pro Cys Glu Leu Cys Pro Thr Glu Pro Asp  
1 5 10 15

Glu Ala Phe Arg  
20

<210> SEQ ID NO 285  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 285

Cys Thr Asp Tyr Thr Ala Glu Cys Lys Pro Gln Val Thr Arg  
1 5 10

<210> SEQ ID NO 286  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 286

Ile Tyr Ile Ser Gly Met Ala Pro Arg Pro Ser  
1 5 10

<210> SEQ ID NO 287  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence

-continued

---

<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 287  
  
Thr Cys Glu Pro Ile Gln Ser Val Phe Phe Phe Ser Gly Asp Lys  
1           5                   10                   15

<210> SEQ ID NO 288  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 288

Ser Ile Ala Gln Tyr Trp Leu Gly Cys Pro Ala Pro Gly His  
1           5                   10

<210> SEQ ID NO 289  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 289

Trp Leu Gly Cys Pro Ala Pro Gly His Leu  
1           5                   10

<210> SEQ ID NO 290  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 290

Cys Asn Ser Asp Leu Val Ile Arg  
1           5

<210> SEQ ID NO 291  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 291

Leu Gln Asp Gly Leu Leu His Ile Thr Thr Cys  
1           5                   10

<210> SEQ ID NO 292  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 292

Ser Phe Val Ala Pro Trp Asn Ser Leu Ser Leu Ala Gln Arg  
1           5                   10

<210> SEQ ID NO 293  
<211> LENGTH: 10

-continued

---

<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 293

Ser Asp Asp Gly Trp Val Asn Leu Asn Arg  
1            5                    10

<210> SEQ ID NO 294  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 294

Ser Tyr Gln Cys Pro Gln Gly Gln Val Ile Val Ala Val Arg  
1            5                    10

<210> SEQ ID NO 295  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 295

Ser Leu Gly Glu Pro Thr Glu Cys Trp Trp Glu Glu Ile Asn Arg  
1            5                    10                    15

<210> SEQ ID NO 296  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 296

Ser Asn Asn Gly Leu Val Ala Gly Phe Gln Ser Arg  
1            5                    10

<210> SEQ ID NO 297  
<211> LENGTH: 14  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 297

Val Ala Ser Asn Leu Asn Leu Lys Pro Gly Glu Cys Leu Arg  
1            5                    10

<210> SEQ ID NO 298  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 298

Gly Asp Ala Asn Thr Ile Val Cys Asn Ser Lys  
1            5                    10

-continued

---

<210> SEQ ID NO 299  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 299

Met Ala Ala Asp Gly Asp Phe Lys  
1 5

<210> SEQ ID NO 300  
<211> LENGTH: 21  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 300

Cys Ala Pro Glu Cys Asn Cys Pro Glu Ser Tyr Pro Ser Ala Met Tyr  
1 5 10 15

Cys Asp Glu Leu Lys  
20

<210> SEQ ID NO 301  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 301

Arg Asn Asn Gln Ile Asp His Ile Asp Glu Lys  
1 5 10

<210> SEQ ID NO 302  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 302

Asn Asn Gln Ile Asp His Ile Asp Glu  
1 5

<210> SEQ ID NO 303  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 303

Ile Leu Asp His Asn Leu Leu Glu Asn Ser Lys  
1 5 10

<210> SEQ ID NO 304  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 304

-continued

---

Ser Leu Glu Asp Leu Gln Leu Thr His  
1 5

<210> SEQ ID NO 305  
<211> LENGTH: 7  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 305

Ile His Leu Gln His Asn Arg  
1 5

<210> SEQ ID NO 306  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 306

Cys Lys Ile Leu Gly Pro Leu Ser Tyr Ser Lys  
1 5 10

<210> SEQ ID NO 307  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 307

Glu Val Pro Ser Ala Leu Pro Arg  
1 5

<210> SEQ ID NO 308  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 308

Arg Leu Ser Gln Asn His Ile Ser Arg  
1 5

<210> SEQ ID NO 309  
<211> LENGTH: 17  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 309

Arg Leu Ser Gln Asn His Ile Ser Arg Ile Pro Pro Gly Val Phe Ser  
1 5 10 15

Lys

<210> SEQ ID NO 310  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence

-continued

---

<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 310

Leu Ser Asp Gly Val Phe Lys Pro Asp Thr  
1           5                   10

<210> SEQ ID NO 311  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 311

Asn Leu Ala His Asn Ile Leu Arg  
1           5

<210> SEQ ID NO 312  
<211> LENGTH: 7  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 312

Leu Ala His Asn Ile Leu Arg  
1           5

<210> SEQ ID NO 313  
<211> LENGTH: 24  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 313

Leu Asp Ser Asn Lys Ile Glu Thr Ile Pro Asn Gly Tyr Phe Lys Ser  
1           5                   10                   15

Phe Pro Asn Leu Ala Phe Ile Arg  
          20

<210> SEQ ID NO 314  
<211> LENGTH: 16  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 314

Ile Glu Thr Ile Pro Asn Gly Tyr Phe Lys Ser Phe Pro Asn Leu Ala  
1           5                   10                   15

<210> SEQ ID NO 315  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 315

Ser Phe Pro Asn Leu Ala Phe Ile Arg Leu Asn Tyr Asn  
1           5                   10

-continued

---

<210> SEQ ID NO 316  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 316

Leu Asn Asn Asn Ser Ile Glu Lys  
1 5

<210> SEQ ID NO 317  
<211> LENGTH: 19  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 317

Asp Leu Val Ala Phe His Asp Phe Ser Ser Asp Leu Glu Asn Val Pro  
1 5 10 15

His Leu Arg

<210> SEQ ID NO 318  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 318

Glu Leu Glu Pro Gly Val Glu Tyr Phe Ile Arg  
1 5 10

<210> SEQ ID NO 319  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 319

Thr Val Ser Ile Tyr Gly Val Ile Gln Gly Tyr Arg  
1 5 10

<210> SEQ ID NO 320  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 320

Thr Val Thr Leu His Gly Glu Val Arg  
1 5

<210> SEQ ID NO 321  
<211> LENGTH: 22  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 321

-continued

---

Phe Arg Ile Thr Tyr Val Pro Ile Thr Gly Gly Thr Pro Ser Met Val  
1 5 10 15

Thr Val Asp Gly Thr Lys  
20

<210> SEQ ID NO 322  
<211> LENGTH: 24  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 322

Trp Arg Pro Gln Pro Pro Ala Glu Gly Pro Gly Gly Glu Leu Thr Val  
1 5 10 15

Pro Gly Thr Thr Arg Thr Val Ser  
20

<210> SEQ ID NO 323  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 323

Phe Asp Ser Phe Thr Val Gln Tyr Lys  
1 5

<210> SEQ ID NO 324  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 324

Gly Glu Glu Ser Glu Val Thr Val Gly Gly Leu Glu Pro Gly Arg  
1 5 10 15

<210> SEQ ID NO 325  
<211> LENGTH: 7  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 325

Glu Pro Pro Asn Lys Pro Arg  
1 5

<210> SEQ ID NO 326  
<211> LENGTH: 21  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 326

Gly Phe Glu Glu Ser Glu Pro Leu Thr Gly Phe Leu Thr Thr Val Pro  
1 5 10 15

Asp Gly Pro Thr Gln

-continued

20

<210> SEQ ID NO 327  
<211> LENGTH: 8  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 327

Ile Ser Cys Thr Ile Ala Asn Arg  
1 5

<210> SEQ ID NO 328  
<211> LENGTH: 18  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 328

Leu Phe Ser Asp Gly Asn Ser Gln Gly Ala Thr Pro Ala Ala Ile Glu  
1 5 10 15

Lys Ala

<210> SEQ ID NO 329  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 329

Arg Gly Val Phe His Gln Thr Val Ser Arg Lys  
1 5 10

<210> SEQ ID NO 330  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 330

Arg Gln Val Asn Glu Pro His Ile Arg Val  
1 5 10

<210> SEQ ID NO 331  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 331

Arg Thr Asp Pro Ala His Asp Val Arg Val  
1 5 10

<210> SEQ ID NO 332  
<211> LENGTH: 7  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

---

-continued

---

<400> SEQUENCE: 332

Asp Ala Pro Ile Val Asn Lys  
1 5

<210> SEQ ID NO 333

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 333

Ser Glu Pro Leu Ile Gly Arg  
1 5

<210> SEQ ID NO 334

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 334

Ala Thr Ile Thr Gly Tyr Arg  
1 5

<210> SEQ ID NO 335

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 335

Ala Gln Ile Thr Gly Tyr Arg  
1 5

<210> SEQ ID NO 336

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 336

Ser Asp Thr Val Pro Ser Pro Arg  
1 5

<210> SEQ ID NO 337

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 337

Val Phe Ala Val Ser His Gly Arg  
1 5

<210> SEQ ID NO 338

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

-continued

---

<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 338

Ile Ser Cys Thr Ile Ala Asn Arg Cys  
1 5

<210> SEQ ID NO 339  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 339

Pro Leu Thr Ala Gln Gln Thr Thr Lys  
1 5

<210> SEQ ID NO 340  
<211> LENGTH: 9  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 340

Tyr Glu Val Ser Val Tyr Ala Leu Lys  
1 5

<210> SEQ ID NO 341  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 341

Gln Tyr Asn Val Gly Pro Ser Val Ser Lys  
1 5 10

<210> SEQ ID NO 342  
<211> LENGTH: 12  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 342

Gly Ala Thr Tyr Asn Ile Ile Val Glu Ala Leu Lys  
1 5 10

<210> SEQ ID NO 343  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 343

Asp Leu Gln Phe Val Glu Val Thr Asp Val Lys  
1 5 10

<210> SEQ ID NO 344  
<211> LENGTH: 13

-continued

---

<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 344  
  
Leu Gly Val Arg Pro Ser Gln Gly Gly Glu Ala Pro Arg  
1                   5                   10  
  
<210> SEQ ID NO 345  
<211> LENGTH: 11  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 345  
  
Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg  
1                   5                   10  
  
<210> SEQ ID NO 346  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 346  
  
Val Pro Gly Thr Ser Thr Ser Ala Thr Leu Thr Gly Leu Thr Arg  
1                   5                   10                   15  
  
<210> SEQ ID NO 347  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 347  
  
Val Asp Val Ile Pro Val Asn Leu Pro Gly Glu His Gly Gln Arg  
1                   5                   10                   15  
  
<210> SEQ ID NO 348  
<211> LENGTH: 29  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 348  
  
Lys Ala Cys Glu Asp Ile Asp Glu Cys Ser Leu Pro Asn Ile Cys Val  
1                   5                   10                   15  
  
Phe Gly Thr Cys His Asn Leu Pro Gly Leu Phe Arg Cys  
                  20                   25  
  
<210> SEQ ID NO 349  
<211> LENGTH: 13  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence  
  
<400> SEQUENCE: 349  
  
Tyr Thr Gly Leu Pro Val Asp Ile Asp Glu Cys Arg Glu

-continued

---

1                    5                    10

<210> SEQ ID NO 350  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 350

Leu Pro Val Asp Ile Asp Glu Cys Arg Glu  
1                    5                    10

<210> SEQ ID NO 351  
<211> LENGTH: 21  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 351

Arg Glu Ile Pro Gly Val Cys Glu Asn Gly Val Cys Ile Asn Met Val  
1                    5                    10                    15

Gly Ser Phe Arg Cys  
                         20

<210> SEQ ID NO 352  
<211> LENGTH: 20  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 352

Lys Leu Leu Val Cys Glu Asp Ile Asp Glu Cys Gln Asn Gly Pro Val  
1                    5                    10                    15

Cys Gln Arg Asn  
                         20

<210> SEQ ID NO 353  
<211> LENGTH: 15  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 353

Arg Thr Cys Val Asp Ile Asn Glu Cys Leu Leu Glu Pro Arg Lys  
1                    5                    10                    15

<210> SEQ ID NO 354  
<211> LENGTH: 22  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 354

Lys Gly Glu Gly Trp Gly Asp Pro Cys Glu Leu Cys Pro Thr Glu Pro  
1                    5                    10                    15

Asp Glu Ala Phe Arg Gln  
                         20

-continued

<210> SEQ ID NO 355  
 <211> LENGTH: 8  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic amino acid sequence

<400> SEQUENCE: 355

Asn Pro Gly Ala Pro Gly Pro Arg  
 1 5

What is claimed is:

1. A method for detecting an unstable arteriosclerotic plaque in an individual, the method comprising detecting in a biological sample from the individual an enzymatic cleavage product of a protein component of an arteriosclerotic plaque.

2. The method of claim 1, wherein the protein component is a structural protein.

3. The method of claim 1, wherein the protein component is a non-enzymatic protein.

4. The method of claim 1, wherein the individual is asymptomatic with respect to an arterial occlusive event.

5. The method of claim 1, wherein the subject is an apparently healthy human subject.

6. The method of claim 1, wherein the individual has experienced one or more typical symptoms of cardiovascular disease.

7. The method of claim 1, wherein the individual has experienced an atypical symptom of cardiovascular disease.

8. The method of claim 1, wherein the biological sample is blood or a blood fraction.

9. The method of claim 6, wherein the blood fraction is serum or plasma.

10. The method of claim 1, wherein the level of the one or more enzymatic cleavage products is determined by an immunological method.

11. The method of claim 1, wherein the protein component is fibrillin, vitronectin, fibronectin, tenascin, prolargin, dermatopontin, vascular collagen, metalloproteinase inhibitor-1, galectin-1, or tenascin-X.

12. The method of claim 11, where the collagen is collagen alpha-1 (I) chain, collagen alpha-1 (II) chain, collagen alpha-1 (IV) chain, collagen alpha-1 (VI) chain, collagen alpha-1 (XII), collagen alpha-1 (XIV) chain, collagen alpha-1 (XV) chain, collagen alpha-1 (XVIII), collagen alpha-1 (XIX), collagen alpha-2 (I) chain, collagen alpha-3 (VI), collagen alpha-2 (IV), or collagen alpha-5 (IV).

13. The method of claim 1, wherein the enzymatic cleavage product has a molecular weight in a range of from about 0.5 kDa to about 50 kDa.

14. The method of claim 1, wherein the enzymatic cleavage product has a length in a range of from about 5 amino acids to about 500 amino acids.

15. The method of claim 1, wherein said detecting further comprises processing the enzymatic cleavage product in vitro.

16. The method of claim 15, wherein said processing comprises trypsin digestion.

17. The method of claim 1, wherein the enzymatic cleavage product is a cleavage product of a matrix metalloproteinase (MMP).

18. The method of claim 17, wherein the MMP is secreted by a macrophage.

19. The method of claim 17, wherein the MMP is MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, or MMP13.

20. The method of claim 1, wherein the enzymatic cleavage product is a cleavage product of a cathepsin.

21. The method of claim 1, wherein the method comprises generating a report providing an indication of the risk that the individual will experience an occlusive vascular event.

22. A method for determining a risk that an individual will develop an occlusive vascular event, the method comprising:

a) assaying the level, in a biological sample from the individual, of an enzymatic cleavage product of a protein component of an arteriosclerotic plaque;

b) identifying the individual as being at risk of developing an occlusive vascular event when the level of the enzymatic cleavage product is higher than a normal control level.

23. The method of claim 22, wherein the protein component is fibrillin, vitronectin, fibronectin, tenascin, prolargin, dermatopontin, vascular collagen, metalloproteinase inhibitor-1, galectin-1, or tenascin-X.

24. The method of claim 22, wherein the level of the one or more enzymatic cleavage products is determined by an immunological method.

25. The method of claim 22, wherein the biological sample is blood, serum, or plasma.

26. The method of claim 22, wherein the subject is an apparently healthy human subject.

27. The method of claim 22, wherein the individual does not have a history of having an occlusive vascular event.

28. The method of claim 22, further comprising outputting a report indicating a risk assessment based on said identifying to facilitate a treatment decision by a clinician.

29. A kit for detecting an unstable arteriosclerotic plaque in an individual, the kit comprising:

a) a binding reagent that specifically binds an enzymatic cleavage product of a protein component of an arteriosclerotic plaque;

b) a control that provides for quantitation of the enzymatic product.

30. The kit of claim 29, wherein the reagent that specifically binds an enzymatic cleavage product of a protein component of an arteriosclerotic plaque is an antibody.

31. The kit of claim 30, wherein the antibody is a monoclonal antibody, or an antigen-binding fragment.

32. The kit of claim 29, wherein the antibody is immobilized on an insoluble support.

**33.** The kit of claim **29**, wherein the antibody comprises a detectable label.

**34.** The kit of claim **29**, further comprising one or more reagents for developing a detectable label.

**35.** An assay device for use in detecting, in a liquid biological sample obtained from an individual, an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, the device comprising a matrix defining an axial flow path, the matrix comprising:

- i) a sample receiving zone at an upstream end of the flow path that receives the liquid sample;
- ii) one or more test zones positioned within the flow path and downstream from the sample receiving zone, each of said one or more test zones comprising an antibody specific for an enzymatic cleavage product of a protein component of an arteriosclerotic plaque immobilized in each of said test zones, wherein each of said immobilized antibodies is capable of binding different enzymatic cleavage product present in said liquid sample, to form an immobilized antibody/enzymatic cleavage product complex; and
- iii) one or more control zones positioned within the flow path and downstream from the sample receiving zone.

**36.** The assay device of claim **35**, wherein the one or more control zones are positioned between the test zones when two or more test zones are present.

**37.** The assay device of claim **35**, wherein the test zones and control zones are positioned in an alternating format within the flow path beginning with a test zone positioned upstream of any control zone.

**38.** The assay device of claim **35**, further comprising a label zone positioned upstream of a test zone, wherein the label zone comprises a labeled antibody specific for an enzymatic cleavage product of a protein component of an arteriosclerotic plaque, wherein the labeled antibody is capable of bind-

ing an enzymatic cleavage product present in an immobilized antibody/enzymatic cleavage product complex to form a labeled immobilized antibody/enzymatic cleavage product complex, and wherein the labeled antibody is mobilizable in the presence of the liquid sample.

**39.** The assay device of claim **38**, wherein the labeled antibody comprises a label component selected from the group consisting of a chemiluminescent agent, a particulate label, a colorimetric agent, an energy transfer agent, an enzyme, a fluorescent agent, and a radioisotope.

**40.** The assay device of claim **35**, wherein the matrix is positioned within a housing comprising a support and optionally a cover, wherein the housing contains an application aperture and one or more observation ports.

**41.** The assay device of claim **35**, wherein the device is a test strip.

**42.** The assay device of claim **35**, wherein the device is a dipstick assay device.

**43.** The assay device of claim **35**, wherein the liquid sample is blood, serum, or plasma.

**44.** A panel of purified enzymatic cleavage products of a protein component of an arteriosclerotic plaque.

**45.** The panel of claim **44**, wherein the panel comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, or more than 50, different enzymatic cleavage products.

**46.** The panel of claim **44**, wherein the protein component is fibrillin, vitronectin, fibronectin, tenascin, prolargin, dermatopontin, vascular collagen, metalloproteinase inhibitor-1, galectin-1, or tenascin-X.

**47.** The panel of claim **44**, wherein each enzymatic cleavage product has a length in a range of from about 5 amino acids to about 500 amino acids.

\* \* \* \* \*

专利名称(译)	用于检测不稳定动脉硬化斑块的组合物和方法		
公开(公告)号	<a href="#">US20150160201A1</a>	公开(公告)日	2015-06-11
申请号	US14/391153	申请日	2013-03-06
[标]申请(专利权)人(译)	加利福尼亚大学董事会		
申请(专利权)人(译)	加利福尼亚大学董事会		
当前申请(专利权)人(译)	加利福尼亚大学董事会		
[标]发明人	KANE JOHN P CHALKLEY ROBERT J MIROSHNYCHENKO OLGA		
发明人	KANE, JOHN P. CHALKLEY, ROBERT J. MIROSHNYCHENKO, OLGA		
IPC分类号	G01N33/53		
CPC分类号	G01N2800/323 G01N33/5308 G01N33/6893 G01N2800/324 G01N2800/50		
优先权	61/635645 2012-04-19 US		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

本公开内容提供了检测个体中不稳定的动脉硬化斑块的方法，包括在来自个体的生物样品中检测动脉硬化斑块的蛋白质组分的酶促裂解产物。本公开提供了评估个体发生闭塞性血管事件的风险的方法。本公开还提供了用于实施主题方法的试剂盒。

Figure 1A

*Homo sapiens*  
Alpha-1 (I) collagen (1464 aa)  
GenBank AAB94054

```

1 mfsfvdlrll lllaataltt hgqeeqgveg qdedippitc vqnglryhdx dwvkpepcrri
61 cvcdngkvlc ddvicdetkn cpgaevpege ccvpcpdgae sptdgettgv egpkgtgpr
121 gprgpagppg rdgipgqpl pggppppppp gppglgnfa pqlsygydek stggisvppg
181 mpspsgrglp gppgagppg fgppppppge pgaagpmgpr gppppppkng ddgeagkppr
241 pgergppgq garglpqtag lpgmkghrgf sgl dgakgda gpaqkgepg spgeagppg
301 mprglpger grpgagppa argndgatga agppgptgpa gppgfgavq akgeagppg
361 rseegppqvr gepgpppaa aagpagnpa dqppgakgan gapqiaqavq fpgargppg
421 qpppppppk qnsgeppap skgdtgakge pppvvgppp ppaageekrg argeppptgl
481 ppppppppp qsrfgpdaq vaqpkpape rgsppgagpk gspgeagrp eaglpgakgl
541 tpsppppppd gktgpppaa qdgrppppp pgarqqaqvm gfpqkgaag epkagergv
601 ppppavvpa kkdgeaagq ppgpapage rgeqppagp gfgllppag ppeagkpe
661 qvppdlgap ppsargerg fpgergvpp ppaagprgan gapndgak dagapagpa
721 qaapglqmp gergaaglp pkdrgdagg kgaqspgkd gvrlltppig pppagapgd
781 kgesppsgpa gptgargap drgeppppp agfagppgad gppgakgepg dagakdagg
841 pppagpppp ppiqnvapq akargpagg ppatgfpгаа гrvppppps nagpppppp
901 akkeggkpr getpparpq evppppppp agekspgad gpaagpptp pgiagqrv
961 vllppqger gfgllppps epkpppppa sgerppppm gppglaqpp esgregappa
1021 eqspgrdgp gakdrgetg pagpppaga ppaagppvpa kksgrgetg pagpavvpp
1081 vgarppagp gprdkgetg eqgdrkikh rfgslqgpp gpppppgeq psasgppag
1141 rpppsagap gkdglnglp pigpppprr tqdagvppp gpppppppp ppsagdfsf

```